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An investigation of the intestinal epithelial damage response to cytokines produced 
during inflammatory bowel disease and sepsis. 
 
Felix Irewole Ikuomola 
 
Sepsis is a life-threatening host response to severe systemic infection that can result 
in multi-organ dysfunction syndrome (MODS) and organ failure. Globally, there are 
around 30 million cases of and 6 million deaths from sepsis annually. The intestine 
is one of the first organs to be damaged during the sepsis-induced proinflammatory 
cytokine production and hyperinflammatory responses. Similar processes occur in 
the intestinal mucosa during active inflammatory bowel disease (IBD). Under normal 
physiological conditions, the intestinal epithelium promotes gut homeostasis via 
mechanical protection and maintenance of structural integrity, and provides a 
physical barrier comprised of a continuous single cell layer of intestinal epithelial 
cells. Intestinal barrier dysfunction or compromised intestinal integrity potentially 
facilitates the passage of intestinal bacteria into the gut mucosa and blood circulation. 
Compromised intestinal barrier function occurs as a result of excessive epithelial cell 
shedding and apoptosis resulting from the direct effects of pro-inflammatory 
cytokines such as tumour necrosis factor (TNF) on intestinal epithelia. Understanding 
the mechanisms responsible for intestinal barrier function break down will potentially 
enable future prevention and treatment of sepsis, IBD and other conditions 
associated with intestinal barrier disruption. Recent advances in intestinal stem cell 
culture have enabled the generation of three-dimensional organoid cultures of the 
intestinal epithelium (termed enteroids) which can auto-propagate, auto-renew and 
contain similar cell populations to those found in the intestinal epithelium in vivo. This 
culture system represents a more physiological model of the intestinal epithelium 
than has previously been achievable using standard tissue culture techniques. It 
enabled investigation of tissue-level dynamics and the importance of NFκB signalling 
specifically in the intestinal epithelium in response to TNF (chapter 3). TNF treatment 
was associated with asynchronous expansions and contractions, increased motility, 
claudin-7 remodelling, reduced epithelial thickness and early increased surface area 
of enteroids. The alternative NFκB signalling pathway was demonstrated to regulate 
the intestinal epithelial response to injury and further exploration of other cytokines 
known to activate alternative pathway NFκB signalling was undertaken. We identified 
that other activators of NFκB signalling that are upregulated in the serum of patients 
with inflammatory conditions, such as TWEAK and LIGHT, were also capable of 
initiating the enteroid damage response and that Nfκb2-/- enteroids were resistant to 
these stimuli (chapter 4). Proteomic analyses were used to identify potential 
mechanisms responsible for altered intestinal epithelial dynamics in response to TNF 
including TNFaip3 and saa3. Proteomics elucidated the potential mechanistic drivers 
of the intestinal damage response during perturbed NFκB signalling (chapter 5). The 
enteroid inflammatory model was finally tested with corticosteroids, a non-steroidal 
anti-inflammatory drug and a natural anti-inflammatory compound found in the diet 
known to modulate NFκB signalling to determine whether this newly established in 
vitro model could be used to assess novel putative therapeutic interventions for 
sepsis and IBD (chapter 6). Further investigation is now warranted to determine the 
importance of TNF, other pro-inflammatory cytokines and alternative pathway NFκB 
signalling in regulating intestinal tissue level dynamics during health and disease and 
how these parameters may be modulated therapeutically to ameliorate the severity 
of IBD and sepsis. 
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Sepsis is an infection-induced systemic syndrome of physiologic, pathologic, and 
biochemical abnormalities (Singer et al, 2016). It is a life-threatening infection-host 
response dysregulation resulting in multi-organ dysfunction syndrome (MODS) 
including cognitive dysfunction and organ damage (Singer et al., 2016; Williams et 
al., 2013). One of the first body organs to undergo pathophysiologic derangements 
due to an abrupt onset and dramatic progression of sepsis is the intestine (Doig et 
al., 1998; Julian et al., 2011). Intestinal homeostasis is ensured by the protective, 
structural, and functional barrier of the intestinal epithelium (Gasbarrini & Montalto, 
1999; Ley et a.l, 2006; O’Hara et al., 2006). There are about 100 trillion bacteria which 
live symbiotically in the gut (Turnbaugh et al., 2007). However, any intestinal barrier 
dysfunction or compromised intestinal integrity could facilitate the passage of 
intestinal bacteria into the blood circulation (Blikslager et al., 2007; Cani et al., 2008). 
This potentially, results in increased bacterial load and subsequent sepsis 
progression and intestinal failure (Kiesslich et al., 2012; Piton et al., 2011; Shinoda 
et al., 2016). Sepsis causes increased intestinal permeability with associated multi-
systemic organ dysfunction in critically ill patients. (Doig et al., 1998). Globally, every 
year about 30 million cases of sepsis including 19.4 million severe cases are reported 
(Reinhart et al., 2017) and the mortality rate due to sepsis is about 6 million cases 
globally per year (Reinhart et al., 2017). Globally, about 3 million newborns and 1.2 
million children contract sepsis respectively each year (Fleischmann-Struzek et al., 
2018). Sepsis is also responsible for about 30% of cancer deaths in hospitalised 
patients (Mayr et al., 2014). The estimated economic burden of sepsis in the US is 
around $20 billion per annum (Singer et al., 2016), while in the UK the economic 
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burden totals about £2.7 billion annually (Tsertsvadze et al., 2015) resulting in 
considerable cost to the National Health Service (NHS).  
People at the early and late extremes of life are more susceptible to developing the 
severe complications of sepsis. Other vulnerable groups include pregnant women, 
hospitalised patients, asplenic individuals, and patients with autoimmune diseases, 
cancer, HIV/AIDS, kidney disease, and liver cirrhosis (Say et al., 2014). Key 
diagnostic factors of systemic inflammatory response syndrome (SIRS) include high 
(>38°C) or low (<36°C) temperature, tachycardia, and tachypnoea. Other clinical 
manifestations of sepsis include ileus, purpura fulminans, jaundice, hypotension, 
altered sensorium, oliguria, and dyspnoea (Dellinger et al., 2004). In sepsis, the 
intestine is among the first tissues to be affected with disruption of intestinal 
homeostasis that results in intestinal failure. Positive blood cultures observed in 
patients with sepsis, severe sepsis, and septic shock are respectively 17%, 25%, and 
69% (Fink & Heard, 1990). The classification of sepsis has changed recently and no 
longer includes SIRS which can occur without sepsis or the presence of infection.  
Unfortunately, there are no molecularly targeted sepsis-specific therapeutics or 
validated standard diagnostics, the only current treatment is supportive or 
symptomatic care (Singer et al., 2016). Thus, an in-depth study of sepsis that will aid 
in understanding the cascades of mechanism of actions and discovery of any novel 
therapeutic targets with potential ability to enhance intestinal protective barrier 
integrity and prevent intestinal barrier dysfunction should be investigated. 
1.1.1 Clinical course of sepsis 
Early clinical manifestations of sepsis may be subtle and difficult to diagnose, so, a 
high index of suspicion is paramount. In general, a patient may present with fever 
which is the commonest presentation of sepsis. However, patients at the extremes 
of life (early and late) and patients with debilitating conditions, a history of chronic 
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alcohol abuse or uraemia are likely to present with sepsis-induced hypothermia and 
an absence of fever (Hotchkiss & Karl, 2003).  
Intestinal features of sepsis include abdominal pain, vomiting, bloody or non-bloody 
diarrhoea, distension, rigidity, guarding, reduced or absent bowel sounds, and upper 
gastrointestinal tract blood loss. Early clinical presentations of sepsis include 
increased pulse rate, increased respiratory rate, warm and dry extremities, 
restlessness, slight confusion, reduced urine output, and high cardiac output. Other 
features include low systemic vascular resistance due to the vasodilatory effect of 
released mediators. However, blood pressure maybe normal or slightly reduced 
during the early stages of sepsis. Clinical features of late sepsis include a decreased 
level of consciousness, coma, markedly reduced urine output, tachypnoea, 
tachycardia, hypotension, reduced cardiac output, and cold extremities. 
Investigations in the diagnosis of sepsis include serum lactate, full blood count 
(especially white blood cells - total and differential), blood culture, urea, electrolytes, 
creatinine, C-reactive protein, procalcitonin, and liver function tests. Adequate 
administration of antibiotics within one hour of suspected sepsis (which is considered 
as the ‘golden hour’) is very important in increasing the survival of patients (Dellinger 
et al., 2008). When this ‘golden hour’ opportunity is missed, each hour delay of 
administration of antibiotics, decreases patient survival by about 8% (Kumar et al., 
2006). The prognosis in sepsis is based on early recognition, prompt diagnosis, early 
administration of appropriate antibiotics, and early adequate reversal of the shock 
state.  
1.1.2 Pathogenesis of sepsis  
The pathogenesis of sepsis is not only complex, but complicated and broad (figure 
1.1). It includes dysregulated inflammatory responses, a dysfunctional clotting 
system, imbalanced immunomodulation, autophagy, endoplasmic reticulum stress, 
disrupted mitochondrial organelles, and other altered pathophysiological processes. 
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The cascades of dysfunctional cellular and molecular responses to sepsis cumulate 
in multiple organ dysfunction syndrome (MODS) and eventual multiple organ failure. 
Pathogens such as bacteria, viruses, parasites, and fungi invade endothelial cells 
and elicit the host’s responses of cytokine-mediated pro- and anti-inflammatory 
activations. The first line of defence is migration of neutrophils to the site and these 
recognise and phagocytose invading pathogens through the release of proteolytic 
enzymes and other active host defense factors. This results in activation of 
mononuclear/macrophage cells via the stimulation of granulocyte-macrophage 
colony-stimulating factor (GM-CSF), immune complexes, pathogenic 
microorganisms, chemical mediators, and others (Shen et al., 2017). Pro-
inflammatory cytokines can trigger a cytokine storm and modulate pattern-recognition 
receptors (PRRs) to activate the innate immune system through the detection of 
damage-associated molecular patterns (DAMPs) or pathogen-associated molecular 
patterns (PAMPs) (Takeuchi & Akira, 2010). PRRs such as Toll-like receptors (TLRs), 
retinoic acid-inducible gene (RIG)-I-like receptors (RLRs), C-type lectin receptors 
(CLRs), and nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs) 
mediate stimulation of the innate immune system resulting in overexpression of 
associated inflammatory target genes (Raymond et al., 2017). Toll/interleukin-1 
receptor (TIR) homology domains induce TLRs to interact with their ligands to 
activate c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase 
(MAPK), extracellular signal-regulated kinase 1/2 (ERK1/2), and nuclear factor-κB 
(NF-κB) signaling pathways via the myeloid differentiation factor 88-dependent 
(MyD88) pathway (Kawai & Akira, 2010). These cascades of reactions result in the 
synthesis of inflammatory cytokines, including tumor necrosis factor (TNF), 
interleukin (IL)-1, IL-6, interferon (IFN) regulatory factor 7 (IRF7), and adaptor 
proteins (AP) (most especially AP-1 and AP-3) (Kawai & Akira, 2010). In response to 
the activation of the immune system by PAMPs and DAMPs, intracellular cytosolic 
protein complexes of inflammasomes are assembled. Inflammasomes initiate the 
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cleaving of caspase-1 precursor to cause activation of caspase-1, which results in 
activated caspase-1 cleaving IL-1β and IL-18 precursors thus leading to release of 
the proinflammatory cytokines IL-1β and IL-18 (Lamkanfi, 2011; Qiu et al., 2019). IL-
1 modulates the thermoregulatory centre of the hypothalamus to increase body 
temperature during sepsis, thus it is known as an endogenous pyrogen. IL-1 also 
induces vasodilation, hypotension, and hyperalgesia. IL-6 mediates the production of 
acute phase proteins such as albumin, transthyretin, transferrin, and retinol-binding 
protein (Huang, Cai, & Su, 2019). It is also involved in the proliferation of B-
lymphocytes and neutrophils in sepsis. The interferon (IFN) regulatory factor 7 
controls the tissue-damaging apoptotic effects of interferon and interferon-mediated 
production of reactive oxygen species (ROS) (Arens et al., 2016). Adaptor proteins 
are involved in coordinating protein-binding site interaction with ligands to facilitate 
the generation of multiple signalling complexes especially T cell receptor (TCR) and 
other immunomodulatory activities (Flynn, 2001; Peterson et al., 1998). The immune 
dysfunction in sepsis includes reduction in HLA-DR, increase in lymphocyte 
replication, induction of apoptosis, and increase in anti-inflammatory molecules 
expression (Venet & Monneret, 2018). In sepsis, there is a coordinated interaction 
between the inflammatory process and coagulation through which inflammation can 
activate the coagulation reaction resulting in an inflammatory response. Systemic 
responses to sepsis range from shock, hypotension, confusion, coma, disseminated 
intravascular coagulopathy, carbon dioxide, increased and lactic acid concentrations 
and, autodigestion to multiple organ dysfunction and failure (De Backer et al., 2002; 





Figure 1.1 Microbes attached to surface cell receptors trigger immune responses 
that result in the activation of cascades of reactions including inflammation, 
vasodilatation, complement pathways, coagulopathy, endothelial cell damage, and 
MODS thus worsening the condition of sepsis. Modified from Arens et al., 2016; 
Kawai & Akira, 2010; Takeuchi & Akira, 2010. 
 
1.1.3 Intestinal manifestation of sepsis 
Sepsis disrupts intestinal epithelial homeostasis, including its protective and 
absorptive functions, and structural integrity. It also affects intestinal epithelial 
perfusion, enzymatic response, coagulation function, and the mucosal immune 
system (MIS) (Mowat & Agace, 2014). PRRs are present in intestinal epithelial cells 
(IECs) and intestinal macrophages and other immune cells such as neutrophils and 
dendritic cells (DCs). During sepsis, the presence of PAMPs such as 
lipopolysaccharide (LPS), bacterial DNA, and cytosine-phosphate-guanine (CpG) of 
bacterial microorganisms on the surface of IECs are detected by PRRs (Cerovic et 
al., 2014). The MIS comprises of intestinal macrophages and DCs that recognise 
luminal PAMPs through transepithelial dendrites (TEDs) (Cerovic et al., 2014; 
Haussner et al., 2019). The interaction between PAMPs and the host’s PRRs and 
MIS results in a cytokine storm of pro-inflammatory mediators with subsequent 
release of reactive oxygen species (ROS), overexpression of endothelial adhesion 
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molecules, and additional neutrophil recruitment. The sequelae of sepsis resulting 
from the association of a PAMP with a PRR can provoke a cascade of reactions, 
including translocation of transcription factors such as nuclear factor-kappa B and 
activator protein-1 resulting in mediation of further increased production of pro-
inflammatory proteins that can cause adverse events both locally and systemically 
(Wang, Bastarache & Ware, 2008). Local cellular responses to sepsis include 
disrupted IEC barrier functions, aggravated vasodilatation, enhanced capillary 
leakage, increased interstitial oedema, increased hypoxia, and necrosis of IECs, 
suppressed intestinal regeneration, compromised IEC repair, and facilitated bacterial 
translocation (Amalakuhan et al., 2016; Stadnyk, 2002). Other local effects of sepsis 
include compromised gut integrity, increased apoptosis, reduced proliferation, and 
shortened villus length (Clark et al., 2008; Dominguez et al., 2013; Williams et al., 
2013).  
 
1.2 Therapeutic approaches for sepsis 
1.2.1 General measures 
Supportive and symptomatic measures are among the mainstream treatments in the 
management of sepsis. Intravenous fluids are given for resuscitation and to ensure 
adequate hydration and enhance systemic function. Sufficient oxygenation is very 
important for maintenance of vital organ function. Intubation and mechanical support 
are sometimes given to patients with respiratory compromise, while dialysis ensures 
optimal kidney function in patients who have renal failure. Vasopressors such as 
norepinephrine, phenylephrine, or dopamine are given to correct sepsis-induced 
hypotension. The indication for vasopressor therapy in sepsis is to maintain a 
patient’s mean arterial pressure at or higher than 65 mmHg. Where enteral feeding 
is impossible parenteral nutrition is sometimes administered to patients. Central 
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venous catheter placement can also be conducted for continuous hemodynamic 
monitoring of patients with sepsis. 
NSAIDs are used in mild sepsis to inhibit cyclooxygenase enzymes. Legras and 
colleagues investigated whether there was any association between NSAIDs 
treatment during evolving bacterial community-acquired infection in adults and 
development of severe sepsis or septic shock (Legras et al., 2009). They concluded 
that the use of NSAIDs was not associated with severe sepsis or septic shock except 
that NSAID users had a longer median time to prescription of effective antibiotic 
therapy (Legras et al., 2009). Examples of NSAIDs are aspirin, ibuprofen, celecoxib, 
flunixin meglumine (not currently used in humans), and others that are used as 
antipyretic and analgesic. 
1.2.2 Specific measures  
Various types of therapeutics have been used in the past to treat sepsis; some have 
been effect while some are not. There are some that are experimental and have not 
been tested in humans yet. 
1.2.2.1 Antimicrobial antibiotics 
Empirical antibiotics are given to patients with sepsis while awaiting the results of the 
microscopy, culture, and sensitivity tests. Based on these laboratory results specific 
antibiotics can also be given against causative organisms. Usually, combinations of 
two or three antibiotics are administered. Examples of antibiotics that work against 
Gram-negative and Gram-positive bacteria are ceftriaxone, ampicillin, piperacillin 
and tazobactam, levofloxacin, and others. In the case of resistance against the 
antibiotics, vancomycin may be given to treat methicillin-resistant Staphylococcus 
aureus (MRSA). In the case of viral-, fungal, or parasitic-mediated sepsis, 
therapeutics are directed against the aetiologic agents. Cutuli and colleagues 
conducted analysis of a multicenter registry of patients with sepsis that were treated 
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with polymyxin B hemoperfusion (PMX-HP) and reported that early administration of 
PMX-HP demonstrated improved hemodynamics and lung oxygenation and 
decreased mortality in a septic shock clinical trial (Cutuli et al., 2016). However, 
Iwagami and colleagues reported that PMX-HP failed to demonstrate any 
improvement in survival of patients with septic shock and reduction in mortality in a 
randomised controlled trial (Iwagami et al., 2014).  
1.2.2.2 Corticosteroids  
Use of corticosteroids in sepsis is attributed to how they attenuate the fulminant and 
dysfunctional pro-inflammatory response, regulate anti-inflammatory response as 
they ensure preservation of innate immune system (Keh et al., 2003; Marik et al., 
2008). Corticosteroids mediate anti-inflammatory responses in sepsis via mitogen-
activated protein kinase phosphatase-1 which inhibits the mitogen-activated protein 
kinase signalling pathway thus inhibiting inflammatory transcription gene target in the 
nucleus. Other anti-inflammatory responses include activating histone acetylation 
and antiprotease secretory leukoprotease inhibitor (SLPI) and inhibiting increased 
expression of kinins, chemokines, adhesion molecules and inducible cyclooxygenase 
and nitric oxide synthase (Barnes et al., 2006; Ito, Barnes & Adcock, 2000). 
Prednisolone modulates the immune response to ameliorate allergic, oedema, 
redness, and pruritus (Bunte et al., 2018). The corticosteroids that are commonly 
used in sepsis include hydrocortisone, prednisolone, and dexamethasone.  All of 
these corticosteroids are known to modulate NFκB signalling. Corticosteroids 
mediate induction of IκBα inhibitory protein, which sequesters activated NFκB in 
inactive cytosolic complexes thereby hindering release of a free NFκB and preventing 
its translocation to nucleus where it effects transcriptional activation of inflammatory 




1.2.2.3 PRR Antagonist 
Eritoran is a potent inhibitor of TLR4 which is one of the signal transduction surface 
cell receptors for bacterial LPS. Eritoran is used to prevent released endotoxins from 
bacteria from binding to TLR4. In mice, Eritoran protected mice from lethal infection 
caused by influenza superimposed by bacteria (Shirey et al., 2013). However, 
Eritoran could not proceed beyond a clinical phase III trial for failure to improve 
survival of patients with sepsis (Opal et al., 2013). Resatorvid (TAK-242), a 
cyclohexen derivative, is a potent antagonist of TLR4 by selectively binding to the 
TIR domain of TLR4. In LPS-induced sepsis in mice, Resatorvid ameliorated organ 
dysfunction and prolonged survival. When Resatorvid was combined with imipenem, 
there was decreased mortality and inhibition of cytokine production in CLP-induced 
septic mice (Sha et al., 2011), not yet tested in humans. 
1.2.2.4 HMGB-1 inhibitors  
In experimental cell cultures and animal models of sepsis, HMGB-1 inhibitors 
especially ethyl pyruvate, chloroquine, stearoyl lysophosphatidylcholine, nicotine, 
persicarin and isorhamnetin-3-O-galactoside demonstrated antagonism against 
HMGB-1 (Shukla et al., 2014). However, the efficacies of these HMGB-1 inhibitors 
are yet to be shown in humans. 
1.2.2.5 NFκB inhibitors 
Lestaurtinib, a tyrosine kinase inhibitor, is a potent NFκB inhibitor that blocks the 
phosphorylation of IκBα (Tickenbrock et al., 2006). Various studies with parthenolide, 
a sesquiterpene lactone, have shown that it induces alkylation and inactivation of a 
cysteine residue in the p65 subunit that is very important for DNA binding (Lyss et 
al., 1998). Other studies with parthenolide have shown that it can alkylate a cysteine 
residue in IKK, thus deterring phosphorylation and biodegradation of IκB-α and 
preventing availability of NFκB for translocation to nucleus and participation in the 
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transcription of inflammatory target genes (Hehner et al., 1999; Mazor et al., 2000). 
Sheehan and colleagues conducted a sepsis-induced study in rats and reported that 
administration of parthenolide reduced the serum levels of NF-κB for up to 6 hours 
while the reduction in the serum levels of TNF and IL-6 lasted up to 18 hours 
(Sheehan et al., 2003). Other potential inhibitors of NFκB are Sunitinib malate, 
Narasin, Sorafenib tosylate, Bithionol, Emetine, tribromsalan, fluorosalan, and 
lestaurtinib (Miller et al., 2010). They also prevent IκBα phosphorylation, however, 
are not routinely used in humans. 
1.2.2.6 Immunosuppressants 
Lv and colleagues conducted a meta-analysis on seventeen studies that contained 
8971 patients that investigated the efficacy of TNF antagonist treatment against 
placebo in patients with severe sepsis or septic shock (Lv et al., 2014). They reported 
that TNF antagonists significantly reduced mortality in sepsis when compared with 
the placebo group and improved survival in patients who had high levels of IL-6 
(>1000 pg/ml) and patients with shock (Lv et al., 2014). The main TNF inhibitors are 
infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol. 
Afelimomab treatment was also reported to significantly lower serum concentrations 
of TNF-α and IL-6 for three consecutive days, reduce mortality, and improve organ 
dysfunction in patients with severe sepsis (Conrad et al., 2011). 
1.2.2.7 Stem cell therapy 
Studies have reported the various inherent properties of stem cells such as anti-
apoptotic, antimicrobial, anti-inflammatory, and cytoprotective. These properties 
could be very important in improving the prognosis of patients with sepsis and MODS. 
Mesenchymal stem cells (MSCs) have been reported to play major roles in the 
secretion of anti-inflammatory cytokines against TNF-stimulated genes that interact 
with macrophages’ CD44 receptors to reduce TNF expression through down-
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regulation of NFκB signalling pathways. In response to LPS, MSCs secreted 
cathelicidin LL-37 peptide which exhibited antimicrobial effects by attacking bacterial 
membranes (Wannemuehler et al., 2012). Krasnodembskaya and colleagues 
administered human MSCs to septic mice and reported that MSCs decreased 
mortality, enhanced bacterial clearance, and improved phagocytic activity of the body 
defense (monocytes) (Krasnodembskaya et al., 2012). 
1.2.2.8 Natural products 
Pourdast and colleagues investigated the potential anti-inflammatory effects of 
Septimeb, a herb, in a randomised clinical trial of 51 patients with sepsis in intensive 
care (Pourdast et al., 2017). They reported that Septimeb treatment caused a 
significant reduction in sequential organ failure assessment (SOFA) score, 
improvement in Glasgow coma scale (GCS), and reduction in severity of sepsis in 
the experimental group in comparison with the control group (Pourdast et al., 2017). 
They also reported that the elevated concentrations of lactate, blood sugar, and white 
blood cells (WBC) were significantly reduced post-treatment. Although levels of ESR 
and CRP were reduced, they were not significantly decreased when compared with 
the control group. Another natural product is Chromomycin A3, an antibiotic isolated 
from S. griseus that possesses NFκB inhibiting properties (Calabresi, 1996), has not 
been tested in humans. Kukoamine B, a natural alkaloid herb that inhibits LPS and 
CpG DNA and reduces the release of TNF and IL-6 during sepsis and improves 
patient survival (Liu et al., 2011). The potential use of Curcumin, an active ingredient 
in turmeric, in this setting is extensively discussed in chapter 6 of this thesis. 
1.2.2.9 Surgery  
Surgery may be required to drain abscesses, remove the source of infection, or 
amputate limbs to reduce bacterial load. More information on management and 
treatment of sepsis are available at www.nhs.uk. 
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1.3 Inflammatory bowel diseases 
Inflammatory bowel diseases (IBD) are generally localised to the intestine, however 
there are similarities between IBD and the intestinal manifestations of sepsis and 
clues can be drawn from both conditions that will enhance scientific knowledge and 
research in both areas.  IBD results from an immunological imbalance in response to 
many environmental stimuli in both genetically and non-genetically susceptible 
individuals (Baumgart & Carding, 2007). The postulated aetiological factors for IBD 
are epidemiological (diet, seasonal variation, drugs, and smoking), gut/environmental 
interface (gut bacteria, biofilms, epithelial barrier integrity, and immune/epithelial 
interactions), and inflammation (Xavier & Podolsky, 2007). There are two main sub-
types of IBDs which are Crohn’s disease (CD) and ulcerative colitis (UC). Prevalence 
and incidence of CD are 1.0% and 24.3 per 100,000 person-years respectively while 
in UC they are respectively 0.5% and 12.7 per 100,000 person-years in Europe 
(Loddo & Romano, 2015; Ventham et al., 2013). 
The implicated genetic factors include mutations of NOD2/caspase recruitment 
domain-containing protein 15 (CARD15) or IBD protein 1 (IBD1) located on 
chromosome 16, organic cation transporter novel type 1/2 (OCTN1/2) on 
chromosome 5, discs large MAGUK scaffold protein 5 (DLG5) on chromosome 10, 
and IL23R (Ardizzone & Porro, 2002; Becker et al., 2003; Ogura et al., 2001 ). Other 
genes include immunity-related GTPase family M (IRGM), autophagy related 16 like 
1 (ATG16L1), interleukin 23 receptor (IL23R), and protein tyrosine phosphatase non-
receptor type 2 (PTPN2) (Baumgart & Sandborn, 2012; Loddo & Romano, 2015). 
Genetic predispositions include 15% of patients with CD have a family member who 
suffered from IBD, while in twin studies for CD there have been 50% concordance in 
monozygotic twins and less than 10% in dizygotics (Cho & Brant, 2011; Loddo & 
Romano, 2015). Genome-wide association (GWA) studies of over 75,000 IBD 
patients and controls have identified and confirmed 163 susceptibility loci for IBDs 
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(Baumgart & Sandborn, 2012). Shared genetic risk of IBD was confirmed based on 
trans-ethnic analysis of over 20,000 individuals of European and non-European 
ancestry of which an additional 38 new IBD loci were identified (McGovern, 
Kugathasan, & Cho, 2015; Liu et al., 2015). In all, contributions of identified genetic 
factors to pathogenesis in CD and UC are respectively 13.1% and 8.2% (Liu et al., 
2015; Uhlig, 2013). Principally, CD and UC are associated respectively with type 1 
helper T cells (Th-1) and Th-2 lymphocytes that are differentiated by the cytokines. 
The signal transduction pathways mediating IBD inflammatory processes include 
P38 MAPK, JNK MAPK, PI3K/Akt, NF-κB, and TLR pathways (Wei & Feng, 2010). 
 
1.4 Similarities between sepsis and inflammatory bowel 
diseases 
Both sepsis and IBD have dysregulated inflammatory responses, imbalanced 
immunomodulation and local and systemic involvements. The signal transduction 
pathways via P38 MAPK, JNK MAPK, PI3K/Akt, NF-κB, and TLR that play prominent 
roles in IBD are also implicated in sepsis (Kawai & Akira, 2010; Wei & Feng, 2010). 
The role played by the activation of proinflammatory cytokines such as TNF, IFNγ 
and IL-6 and in particular TNF has been associated with a damaging effect on 
intestinal barrier integrity. The disruption of intestinal epithelial barrier function that 
results in gut leakage, bacterial translocation, interstitial oedema, and loss of mucosal 
protection are hallmarks of local effects of the various mechanisms mediating IBD 
and sepsis (Kiesslich, 2012; Michielan & D'Inca, 2015; Salim & Soderholm, 2011). 
Poorly controlled IBD can also sometimes result in sepsis.  
Colbert and colleagues analysed 92,296 visits of patients with sepsis (severe or 
septic) in the 2012 national inpatient sample (NIS) database in USA and adjusted for 
possible confounders (Colbert et al., 2016). They reported that when compared with 
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controls, patients with UC had markedly worsened sepsis related outcomes, 
including mortality (odds ratio [OR] 1.61, 95%CI 1.35-1.93) while CD had a lower 
mortality rate (OR 0.78, 95%CI 0.63-0.97) (Colbert et al., 2016). However, Goren and 
colleagues in the analysis of a nine-year observational cohort of 5522 hospitalised 
patients with IBD (aged 16 - 80 years) showed that 1.3% of the cases had 
bacteraemia and a bacteraemia-associated mortality rate of 13.7% at 30 days (Goren 
et al., 2020). Longer hospitalisations (P < 0.0001) and older age (P < 0.0001) were 
significantly associated with an increased risk of bacteraemia (Goren et al., 2020). 
Antibiotics are used to treat both sepsis and IBD to mitigate bacterial load, reduce 
tissue invasion, and eradicate virulent bacterial species (Song et al., 2015). Other 
common therapeutics that are used in sepsis and IBD are corticosteroids, biologics 
(agents made from a living organism or its products including monoclonal or 
polyclonal antibodies) (such as infliximab and adalimumab), and immunomodulatory 
drugs (azathioprine, 6-mercaptopurine, methotrexate and cyclosporine) (Sartor, 
2004; Targan et al., 1997). Immunomodulatory drugs function by modifying the 
response of immune system either by decreasing (immunosuppressives) or 
increasing (immuno-stimulators) the synthesis of serum antibodies. 
 
1.5 Anatomy and physiology of the small intestine  
The small intestine is an internal organ that is located within the gastrointestinal tract. 
It commences from the pylorus of the stomach to the ileocecal junction, where it 
meets the large intestine (Buckley & Turner, 2018). The small intestine is located 
around the center of the abdomen, while the large intestine is located peripherally 
except for the transverse colon that lies from the right colic flexure to the left colic 
flexure to join ascending and descending components of the colon respectively 
(Sinnatamby, 2013). Superiorly and laterally, the small intestine is surrounded by the 
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large bowel, while it is related anteriorly to the greater omentum (Driscoll, 2006). 
Posteriorly, the small intestine is related to the posterior wall of the peritoneal cavity. 
The small intestine is an intraperitoneal structure while some parts of the colon are 
retroperitoneal, and others are intraperitoneal. The mesentery is formed from a 
membranous fold (Driscoll, 2006). The intestine assists in the digestion and 
absorption of ingested food. In humans, the small intestine is about 6 m (20 ft) long, 
while the colon is about 1.5 m (5 ft) long. However, in mouse the small intestine is 
about 35 cm (13.8 in) long and the average length of the large bowel of C57BL/6J 
mice is just 10 cm (Cook, 1965). 
Histologically, the small intestine consists of four layers, including the mucosa 
(innermost layer containing epithelium, lamina propria, and muscularis mucosae) and 
submucosa (connective tissue layer containing blood vessels, lymphatics, and the 
submucosal plexus). The remaining two layers are the muscularis externa or 
muscularis propria (outer longitudinal layer and inner circular layer) and the adventitia 
(outermost layer containing loosely arranged fibroblasts and collagen and 
neurovascular structures). The serosa (mesothelium) covers most of the small 
intestine adventitia (figure 1.2). 
The superior and inferior mesenteric arteries and veins that supply the intestine are 
contained within the mesentery (Driscoll, 2006). The intestinal lymphatic drainage 
system consists of the mesenteric lymphatic vessels, gut-associated lymphoid tissue 
(GALT) (Peyer's patches), and the lacteals (Trevaskis et al., 2015). The intestinal 
nervous system terminates at the myenteric plexus (Auerbach's plexus) and 
submucosal plexus (Meissner's plexus) (Driscoll, 2006). The Auerbach's plexus is 
located between the outer longitudinal and inner circular layers of the muscularis 
externa (Buckley & Turner, 2018). It innervates the motor layers and provides 
secretomotor innervation to the mucosa (Driscoll, 2006). It possesses both 
sympathetic and parasympathetic fibres (Buckley & Turner, 2018). The Meissner's 
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plexus possesses only parasympathetic fibres and provides innervation for the 
smooth muscle of the muscularis mucosae (Driscoll, 2006). The gastrointestinal tract 
smooth muscle has interstitial cells of Cajal (ICC) within it, which act as the electrical 
pacemaker cells. The ICC are responsible for the basal (slow waves) rhythm 
necessary for peristaltic movements and contraction (Burns et al., 2009). 
   
Figure 1.2 Anatomy of the small intestine showing various layers from the outer 
serosa to the mucosa that has an interface with the intestinal lumen and microbiota 
(A). The enlarged section of the small intestine depicts the structure of a villus 
covered in microvilli and, capillary network (B). Modified from McKinley & O'Loughlin, 
2008; Mescher, 2018. 
 
1.6 Intestinal mucosal epithelium 
The intestine is lined by a single layer of columnar epithelial cells that provide a 
protective and functional barrier between the luminal contents and the body through 
the tight junction architectural structure of sealing strands (Buckley & Turner, 2018; 
Last & McMinn, 1994; Williams et al., 2013). It is one of the first organs to undergo 
pathophysiological changes during the rapid onset and progression of sepsis (Doig 
et al., 1998; Julian et al., 2011). LPS induces intestinal epithelial cell shedding by 
stimulating the release of cytokines such as tumour necrosis factor (TNF) that are 
known to remodel tight junctional components (Williams et al., 2013). 
40 
 
Functionally, the intestinal epithelium helps in nutrient absorption while structurally it 
provides a barrier against any invading harmful substances (Ebnet et al., 2004). It is 
involved in a diverse range of functions, such as providing a functional barrier 
between the intestinal luminal contents and underlying tissue microorganisms, 
nutrients’ absorption regulation and waste excretion, paracrine hormonal secretion, 
and endocrine signalling (Furness, Kunze, & Clerc, 1999; Sato et al., 2009). Intestinal 
epithelial cells are polarised structures. The apical surface of epithelial cells is 
towards the lumen while the basal surface lies towards the basement membrane 
(Tsukita et al., 2008; Buckley & Turner, 2018; Williams et al., 2013). This polarity of 
epithelial cells determines their biochemical responses (Ebnet et al., 2004). The 
epithelial cells are joined by tight junction proteins which maintain the selective 
functional and structural barrier integrity of the epithelial surface. 
1.6.1 Intestinal tight junctions  
Tight junctions are one of the four junctional complexes that exist between adjacent 
cell plasma membranes and are commonly found in vertebrates (figure 1.3). Others 
junctional complexes include adherens junctions, gap junctions, and desmosomes. 
The role of tight junctions in regulating intestinal epithelia is unique, thus a deeper 
understanding of how they contribute to barrier function, epithelial structure, and 
regulation mechanisms might hold a key to the discovery of innovative therapeutics 
to prevent the breakdown of intestinal barrier function (Gasbarrini & Montalto, 1999; 
Zihni et al., 2016) in sepsis and IBD. The intestinal epithelial tight junction consists of 
strand-constituting integral membrane proteins (Schneeberger, 2004; Tsukita et al., 
2008; Williams et al., 2013). The tight junction forms a continuous intercellular 
junctional barrier between intestinal epithelial cells and over 40 different component 
proteins have been identified (Schneeberger et al., 2004; Yamazaki et al., 2008). The 
tight junction proteins include claudins, occludin, tricellulin, junctional adhesion 
molecules (JAMs), endothelial cell-selective adhesion molecule (ESAM) (Nasdala et 
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al., 2002), coxsackie- and adenovirus receptor (CAR) (Cohen et al., 2001) and 
others. It is often considered that tight junctions create kissing points between 
adjacent plasma membranes (Van Itallie, 2006). The tight junctions are mostly found 
at the apical surface of the epithelium (Tsukita et al., 2008). They regulate the size of 
the apical intercellular spaces and are often described as the paracellular pathway 
“gatekeepers” (figure 1.3). Tight junctions help to regulate internal homeostasis of 
ions and solutes in the body and the epithelial microenvironment and they are 
involved in the selective permeability of solutes and solvents (Tsukita et al., 2008; 
Ulluwishewa et al., 2011). Activation of NF-κB results in redistribution of tight junction 
proteins including an increase in the expressions of claudin-4, -6, -7, and -9 
(Chavarría-Velazquez et al., 2018). 
   
Figure 1.3 Diagram of junctional protein complexes showing different types of 
proteins involved in maintaining intestinal epithelial integrity including tight junctions, 
adherens junctions, desmosomes, and gap junctions. Tight junctions play a major 
prominent role in maintaining intestinal epithelial barrier function and protecting the 
gut against invading sepsis-inducing microbes. Modified from Williams et al., 2015. 
 
1.6.1.1 Claudins 
Claudins are tetraspan, integral membrane proteins of the tight junctional complex 
(Furuse et al., 1998) with small molecular masses of between 21 - 28 kDa (Van Itallie, 
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2006). Currently there are about 31 known members of the claudin family (Tipsmark 
et al., 2008). The claudin family can be broadly divided into two main classes; pore-
forming claudins which include claudins 2 and 15 as the major members of this group 
(Furuse et a.l, 1998; Shinoda et al., 2016; Tamura et al., 2008; Van Itallie, 2006) and 
seal- or barrier-forming claudins which prominently comprise claudins 1, 4, 7, and 10 
(Ding et al., 2012; Lal-Nag & Morin, 2009; Mineta et al., 2011). The seal-forming 
claudins are more abundant in nature than the pore-forming ones. In some layers or 
tissues, the pore-forming claudins may be less abundant or absent (Shinoda et al., 
2016). Claudin 1 is found in most tissues (Zhu et al., 2006). Most of the claudins are 
charge-selective and often tend to be either up- or down-regulated during disease 
states (Gunzel et al., 2013). There are some claudins that can both occur as up- and 
down-regulated proteins in different disease states in comparison to the normal state 
(Amoozadeh et al., 2015; Calpado et al., 2014). Under- or overexpression of claudins 
has been implicated in a number of pathological conditions (appendix A). 
Inflammatory mediators, most especially TNF, activate transcriptional regulation, 
enhance endocytic trafficking, and the remodelling of claudins in epithelial tight 
junction (Matsuda et al., 2004). Intestinal inflammatory dysregulation induces 
upregulation of intestinal epithelial claudins-1, -2, and -18 and downregulation of 
intestinal epithelial claudins -3, -4, -5, -7, -8, and -12 (Shen, Weber, & Turner, 2008). 
The therapeutic target of the transcriptional regulatory effects of inflammatory 
mediators on the claudin family may hold a breakthrough to containing intestinal 
epithelial dysfunction and gut leakage. In the same vein, therapeutics that can 
augment the effect of intestinal epithelial integrity of the upregulated claudins may be 
worthy of study.  
1.6.1.2 Occludin 
Occludin is one of the major proteins in the tight junctions of intestinal epithelial cells 
and was first described in 1993. Occludin has a molecular weight of 65 kDa, is 
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comprised of 522 amino acids, and is encoded by the OCLN gene which is found on 
chromosome 5q in humans (Ando-Akatsuka et al., 1996; Furuse et al., 1993). 
Structurally, its C-terminal domain comprises of 257 amino acids and this is involved 
in ensuring the proper assembly and functional integrity of the tight junction barrier 
and has been reported to be a key mediator in cell survival (Chen et al., 1997). The 
N-terminal domain contains 66 amino acids and it promotes the adequate sealing of 
the tight junction barrier function (Feldman, Mullin & Ryan, 2005). Yoseph and 
colleagues experimented with caecal ligation and puncture (CLP), a model of 
polymicrobial intra-abdominal sepsis, to investigate the effects of sepsis, including 
intestinal barrier dysfunction on the tight junctions of mice (Yoseph et al., 2016). They 
reported that 12 hours after the onset of induced sepsis, occludin protein expression 
was statistically significantly decreased by Western blotting (Yoseph et al., 2016). On 
the histomicrograph, occludin expression in the lower villus was observed to be 
decreased (Yoseph et al., 2016). A decreased amount of occludin has also been 
reported to be associated with increased intestinal permeability (Li et al., 2009; 
Yoseph et al., 2016). Therapeutic enhancement of occludin expression may therefore 
potentially prevent increased intestinal permeability and a leaky gut. 
1.6.1.3 Junctional adhesion molecule A (JAM-A) 
Junctional adhesion molecule A (JAM-A) is a protein of the F11R gene and a member 
of the immunoglobulin superfamily with 299 amino acids and 32.58 kDa molecular 
weight that is present in many cells including epithelial cells, endothelial cells and 
platelets (Itoh et al., 2001). It has a PDZ (an abbreviation formed from post-synaptic 
density protein, Drosophila disc large tumour suppressor (Dlg1), and Zonula 
occludens-1 protein) binding domain that modulates common structural protein 
interactions of about 80-90 amino acids and targets other proteins’ C-terminal short 
amino acids region (Izumi et al., 1998). The PDZ also coordinates the signalling 
functions of some proteins in organisms and enhances attachment of membranous 
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receptor proteins to the cytoplasmic and cytoskeletal counterparts to facilitate 
transduction organisation and complex formation. JAM-A forms cell-to-cell adhesions 
that protects and promotes tight junction barrier function in epithelial cells and, acts 
as a receptor for platelets and reovirus and a ligand for leucocyte ligand (Lee & 
Zheng, 2010; Ostermann et al., 2002). Yoseph and colleagues conducted a CLP 
experiment in mice and reported a significant increase in JAM-A (p<0.05) by western 
blot 12 hours after the onset of sepsis (Yoseph et al., 2016). On the histomicrographs, 
the amount of JAM-A in the villus and crypt of CLP-mice was observed to be 
increased in comparison with the controls (Yoseph et al., 2016). Therapeutic 
modulation to promote the effect of JAM-A on intestinal epithelial integrity during 
sepsis may therefore potentially alter the sepsis-induced intestinal epithelial 
dysfunction that results in increased intestinal permeability, bacterial translocation, 
and other complications. 
1.6.1.4 ZO-1 
Zona occludens-1 (ZO-1) is a transmembrane protein encoded by the TJP1 gene 
with 1748 amino acids, 220-kDa molecular weight, and PDZ domains containing 80 
- 100 amino acid residues that allow it to interact with other tight junction proteins 
(Balda & Matter, 2008; Willott et al., 1993). ZO-1 plays key roles in the structural and 
functional integrity of tight junctions, cell-to-cell transduction signalling, and 
regulatory transcription of the protective barrier function of tight junctions (Bauer et 
al., 2010). A structural complex occludin-ZO-1 regulatory protein interaction interface 
is usually formed between occludin and ZO-1 and this is very important in the 
assembly and disassembly of the tight junction (Nomme et al., 2011). ZO-1 serves 
as a scaffold protein with the provision of anchoring cross-links for the strand proteins 
of the tight junction to communicate with cytoskeletal proteins. Yoseph and 
colleagues in the septic mice model using CLP, reported that both western blot and 
histomicrographs at 12 hours following sepsis induction did not show significant 
45 
 
changes in the levels of ZO-1 when compared with sham mice (Yoseph et al., 2016). 
However, serum concentrations of ZO-1, have been demonstrated to be elevated in 
sepsis in other studies (Aslan et al., 2017; Zhao et al., 2016). Marchiando and 
colleagues reported that treatment of wild-type and transgenic mice with 7.5µg TNF 
intraperitoneally resulted in redistribution of intestinal epithelial tight junction including 
ZO-1 following TNF-induced shedding and apoptosis (Marchiando et al., 2011). 
 
1.7 Cell dynamics of the small intestinal epithelium 
1.7.1 Stem cells and epithelial cell turnover 
Physiologically, intestinal homeostasis is maintained by an equilibrium between the 
rate of generation of the epithelia in the crypts of Lieberkühn and the rate of loss of 
epithelial cells from the villus tip (figure 1.4). The stem cell zone is located within the 
intestinal crypt and is now thought to consists of crypt base columnar cells (CBC) 
which express the active cycling stem cell marker leucine-rich repeat-containing G 
protein–coupled receptor 5 (Lgr5) (Barker et al., 2007). The CBC structures intermix 
among the Paneth cells at the crypt base and generate transit-amplifying (TA) 
daughter cells located at higher cell positions within the crypt. TA daughter cells 
usually differentiate into other cells such as goblet, neuroendocrine, and absorptive 
enterocytes as they migrate along the crypt-villus axis, thus completing the stem cell-
transit cell-mature cell profile (Potten, 1990; Williams et al., 2015). At the crypt base, 
Lgr5-positive CBCs in the centre specifically maintain position while Lgr5-negative 
CBC cells at the peripheral positions of the crypt base can be displaced into the TA 
daughter cell population (Ritsma et al., 2014). Lgr5-positive cells possess a long 
survival tendency, multipotency, and self-renewal ability and usually divide once 
every 24 hours (Schepers et al., 2011). Lgr5 is a G-protein coupled receptor and is 
activated by R-spondins. Every 2-6 days, the functional epithelial villus in most adult 
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mammals is rapidly and almost completely renewed by the production of new cells 
by the stem cells within the crypt domains (Barker, 2014; Cheng & Leblond, 1974; 
Mayhew et al., 1999). This makes intestinal epithelial cells the cell type in the body 
with the highest turnover rate (Stalker, 2007). Based on mathematical mouse 
modelling, about 1400 mature absorptive enterocytes are thought to be shed from 
the extrusion zone of a single villus tip daily (Potten, 1990). Respectively, in mouse 
and human the rates of turnover of small intestinal epithelial cells are about 2 x 108 
and 1011 in 24 hours (Potten & Loeffler, 1990). The intestinal stem cell population 
gives rise to two cell lineages which consist of five cell types. The absorptive cell 
lineage comprises absorptive enterocytes, while the secretory cell lineages consists 
of goblet, enteroendocrine, Paneth cells, and tuft cells. In certain pathological states, 
intestinal homeostasis could be, disrupted, leading to an intestinal disequilibrium as 
a result of might set in, thus resulting in greater loss of epithelial cells from the villus 
tip than the production of new epithelial cells in the crypts (Williams et al., 2015). This 
condition of intestinal homeostasis disturbance could further lead to more intestinal 
epithelial cell shedding and apoptosis, resulting in a dysfunctional intestinal barrier 
and increased intestinal permeability. If this is untreated and unabated, intestinal 
failure could then potentially occur. Pathologically-mediated intestinal disequilibrium 
could be caused by inflammatory agents (cytokines such as TNF), sepsis, trauma, 
and microorganisms such as Gram-negative bacteria (especially E. coli through 




Figure 1.4 Diagrammatic representation of the small intestinal epithelium depicting 
the villus, crypt, intestinal stem cells, transit amplifying cells, Paneth cells, goblet, 
enteroendocrine cells, tuft cells, and enterocytes. The synthesised undifferentiated 
cells in the crypt domain migrate through the crypt-villus axis and they become 
differentiated, perform different cell lineage functions, and undergo shedding at the 




Enterocytes are simple columnar epithelial cells saddled with specialised 
responsibilities of absorption, digestion, protection, and transportation of nutrient 
from the intestinal lumen into inner connective tissues and blood circulation (figure 
1.4). Enterocytes live for about 2-6 days and can also play an endocrine role by 
secreting the hormone leptin (Mayhew et al., 1999). About 80% of the small intestinal 
mucosa consists of absorptive enterocytes in humans (Chen et al., 2018; Pearce et 
al., 2018). Although the intestinal lumen is internally located, it contacts directly with 
external environmental agents that are ingested. Apically, enterocytes are composed 
of microvilli that increase the absorptive surface area to facilitate movement of micro-
molecules from the intestinal lumen to enterocytes (Knutson, 2017). The microvilli 
are like folds of finger-like projections occupying the intestinal epithelial brush border 
of the lumen (Crawley, Mooseker & Tyska, 2014). Basolaterally, enterocytes form 
cell-to-cell adhesions which allow communication with other cell types and 
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transportation of nutrients out of the enterocytes into blood vessels (Crawley, 
Mooseker & Tyska, 2014). This apical and basolateral domain polarisation of 
enterocytes is due to structural and architectural arrangements of their cytoskeletons, 
especially actin monofilaments and the proper development of vascular traffic that 
ensures differential distributions of molecules between the two domains (Giammanco 
et al., 2015; Knutson, 2017). Ultra-structurally, absorptive enterocytes consist of a 
supra-nuclear Golgi complex, lysosomes, ribosomes, secretory granules, rough 
endoplasmic reticulum, mitochondria, and heterochromatic nuclei (Sohma, 1983). 
The transcellular, paracellular, or endocytosis/transcytosis pathways ensure 
movement of small molecules from the intestinal lumen into and out of enterocytes. 
The transcellular pathway is coordinated by free passive diffusion, facilitated passive 
diffusion, or active carrier mediated transport (Collins et al., 1993). The transcellular 
pathway involves movement of nutrients from the intestinal lumen into the 
enterocytes through the cell membrane, while paracellular passage is via the 
intercellular space. Endocytosis or transcytosis is another form of transcellular 
pathway that facilitates movement of nutrients through a process by which vesicles 
engulf macromolecules at one end of the cell, draw it across the cell, and then eject 
it out at the other end (Shifrin et al., 2012). Free passive diffusion is a process of 
transportation of molecules across the cell membrane without any requirement for 
cellular energy input, whereas active mediated transport requires cellular energy 
input. Non-polar, small molecules such as carbon dioxide and oxygen are examples 
of molecules that undergo free passive diffusion. Facilitated passive diffusion is a 
process devoid of any need of cellular energy of ATP hydrolysis; it transports 
macromolecules across the cell membrane through the help of transmembrane 
carrier proteins such as permeases. Large molecules including glucose and amino 
acids and poorly soluble non-polar molecules such as fatty acids and retinol can only 
be transported through facilitated diffusion (Pearce et al., 2018). Active transport 
comprises of primary active transport and secondary active transport. Primary active 
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transport involves utilisation of energy provided by ATP hydrolysis to the 
transmembrane proteins to act like pump to transfer the molecules across the cell 
membrane such as in the Na+/K+-ATPase pump and H+/K+-ATPase (Snoeck, 
Goddeeries & Cox, 2005). The Na+/K+-ATPase pump regulates the resting potential 
voltage of the enterocytes while H+/K+-ATPase usually lines the stomach and 
regulates its acidic milieu. Secondary active transport works by the principle of 
electrochemical gradient of the channel proteins that acts like the co-transporters and 
it consists of symporters and antiporters (Lodish et al., 2000). In symporters, the ions 
and solute are transported in the same direction while in antiporters they are 
transported in opposite directions. The sodium glucose transporter (SGLT) is a 
symporter that actively mediates the transportation of glucose along with sodium into 
the apical domain of enterocytes while the sodium calcium exchanger (NCX1) mainly 
coordinates the exit of Ca2+ from enterocytes via an antiporter mechanism  (Diaz de 
Barboza et al., 2015; Ferraris & Diamond, 1997). Calcitriol is the key regulatory 
hormone of intestinal Ca2+ transport. Basolaterally, glucose transporter 2 (GLUT2) 
mediates the transportation of glucose from the cytoplasm to the intercellular space, 
for it to move into the blood stream (Efrat et al., 1994; Navale & Paranjape, 2016). In 
diseases such as sepsis, cholera, and inflammatory bowel disease (IBD), the integrity 
of enterocytes is compromised, and invasion of the toxic agents might translocate 
into the blood circulation. The compromised barrier integrity resultant from excessive 
apoptosis and increased epithelial cell shedding in a disease state may disrupt these 
absorptive processes. 
1.7.3 Paneth cells 
Paneth cells are granulated secretory cells that constitute 5% of small intestinal 
epithelial cells, are usually located at the base of intestinal crypts and are the only 
cells that migrate downwards from the stem cell zone (Chen et al., 2018; Elphick & 
Mahida, 2005; Pearce et al., 2018). The secretory granules of Paneth cells are 
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comprised of lysozymes, antimicrobial enzymes, alpha-defensins, phospholipase A2, 
TNF, and others (Ayabe et al., 2000; Erlandsen, Parsons & Taylor, 1974; Wilson et 
al., 1999). Through the activation of myeloid differentiation primary response 88 
(MYD88)-dependent Toll-like receptor (TLR), Paneth cells can detect bacterial 
invasion and thus trigger an antimicrobial activity against it (Vaishnava et al., 2008). 
Paneth cells play major roles in innate intestinal defense mechanisms by regulating 
microbial density and actions and by protecting and defending the viability of adjacent 
stem cells against any microbial invasion (Elphick & Mahida, 2005). They are very 
important in mediating host-microbe interactions and ensuring immune homeostasis 
between gut microbes and the innate immune system (Clevers & Bevins, 2013). In 
each small intestinal epithelial crypt, there are about 5 - 12 Paneth cells with a life 
span of 20 days (Bry et al., 1994; Cheng, 1974). In disease, translocation of gut 
microbes, invasion by gut microbes, deficiency in innate immune system protection, 
or dysfunction of Paneth cell immunomodulation might result in sepsis, chronic 
inflammatory diseases, and other immune conditions. 
1.7.4 Goblet cells 
Goblet cells are specialised, simple columnar epithelial cells that have a goblet-like 
shape with length to width ratio of about 4:1 (Knoop & Newberry, 2018). About 5-10% 
of small intestinal mucosal epithelial cells are goblet cells which secrete mucus, 
especially mucins which serve as barrier maintenance that protects and lubricates 
the epithelial surface (Chen et al., 2018; Pearce et al., 2018). Goblet cells have a 
polarised arrangement of organelles; while the nucleus and other structures are 
differentially located at the base, the secretory organelles especially mucins are 
apically concentrated (Birchenough et al., 2015). In intestinal epithelial cells, MUC2 
mucin, and other carbohydrate-rich polymers are majorly secreted. Goblet cells are 
distributed in both intestinal villi and intestinal crypts, however while those in villi are 
continuously secreting mucous to ensure barrier maintenance, those residing in the 
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crypts only secrete mucous secondary to stimulation by either acetyl choline or after 
endocytosis (Birchenough et al., 2015). Goblet cells are also involved in the secretion 
of cytokines, anti-microbial peptides and proteins, and chemokines (Knoop & 
Newberry, 2018). Two postulates are thought to be responsible for the secretion of 
mucins, these are regulated vesicle secretion and compound exocytosis (Adler, 
Tuvim, & Dickey, 2013). The first process is mediated by syntaxins and other vesicle 
exocytosis proteins that cause adherence of single vesicles to the plasma membrane 
thus resulting in mucus secretion. The second process is thought to be as a result of 
fusion of many vesicles that constitute the goblet cell theca that later empty their 
mucous contents (Specian & Neutra, 1980). 
1.7.5 Enteroendocrine cells 
Enteroendocrine cells are usually located towards the top of the intestinal epithelial 
crypts of Lieberkuhn and along the villus (figure 1.4). In response to stimuli, 
enteroendocrine cells secrete hormones. The main types of endocrine cells are D 
cells, I cells, K cells, N cells, and S cells which respectively secrete somatostatin, 
cholecystokinin (CCK), gastric inhibitory peptide (incretin), neurotensin, and secretin 
hormones into the circulation. Others are enterochromaffin cells (chromaffin, 
serotonin), enterochromaffin-like cell (histamine), L cells (glucagon-like peptide-1), 
motilin, vasoactive intestinal peptide, and enteroglucagon. Release of somatostatin 
is mediated by low pH and inhibited by the vagus nerve. Somatostatin inhibits the 
releases of CCK, insulin, and glucagon, delays gastric emptying, decreases smooth 
muscle contractions, lowers the release of pancreatic enzymes, and reduces blood 
flow within the intestine (Holst et al., 1992; van der Meulen et al., 2015). In response 
to the presence of fatty acids and/or of amino acids in the small intestine, CCK is 
secreted and stimulated. The release of CCK is also mediated by acetylcholine of 
parasympathetic fibres of the vagus nerve. CCK elicits contraction of the gallbladder 
to release bile acids, increases the release of pancreatic juice -containing enzymes, 
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promotes relaxation of sphincter of Oddi, and inhibits of gastric emptying. Other 
actions of CCK are the induction of satiety and inducing an increase in anxiogenic 
and panicogenic activities (Zwanzger et al., 2012). 
1.7.6 Tuft cells 
Like enterocytes, Paneth cells, enteroendocrine cells, and goblet cells, tuft cells 
develop from Lgr5-expressing CBC stem cells (Gerbe et al., 2011). Tuft cells were 
previously thought to represent a quiescent stem cell pool and appeared at the +4 
position of the intestinal crypt. However, they have been shown to be marked by 
expression of doublecortin-like kinase 1 (DCLK1) and are now considered to be 
distinct and unique (Gerbe et al., 2009). Tuft cells (which are also known as brush-
like microvilli or caveolated cells) constitute about 0.5% of intestinal epithelial cells 
(McKinley et al., 2017). Tuft cell specification requires Atonal BHLH Transcription 
Factor 1 or Atonal homolog 1 (ATOH1), however ATOH1 is not necessary for the 
sustenance of mature differentiated tuft cells. Knockdown of Notch has been reported 
to lead to increased numbers of tuft cells (Gerbe, Legraverend, & Jay, 2012). Tuft 
cells function as chemosensory receptors. Other potentially implicated functions of 
tuft cells are their involvement in tumorigenesis, regulation of type 2 immune 
responses in the gut, and regulation of small intestinal lineage-specific transcription 
(Banerjee et al., 2018; McKinley et al., 2017). 
1.7.7 Microfold cells (M cells)  
Microfold cells (M cells) are unique, specialised intestinal epithelial cells that reside 
in Peyer’s patches, gut-associated lymphoid tissue (GALT) and other gastrointestinal 
tract mucosa-associated lymphoid tissue (MALT) (Neutra, Mantis & Kraehenbuhl, 
2001; Owen & Jones, 1974). Other GI MALT include nasopharyngeal-associated 
lymphoid tissues (NALT), colonic patches (CP) and isolated lymphoid follicles (ILF). 
Unlike enterocytes, M cells have no microvilli however similarly to enterocytes, they 
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have reliable junctional cellular complexes that provide a protective physical barrier. 
M cells have cell surface receptors such as glycoprotein-2 (GP2) and cellular prion 
protein (PrP) which detect, identify and bind bacteria or other antigens (Chieppa et 
al., 2006; Miller et al., 2007). Thus, M cells initiate responses of the mucosal immunity 
system (MIS) on its apical membrane and facilitate the transportation of bacteria and 
other injurious substances from the gut lumen via endocytosis, transcytosis or 
phagocytosis to the epithelial lamina propria where immune cells can bind to them 
and neutralise their toxic effects (Neutra et al., 2001; Owen & Jones, 1974). The M 
cells contain protease cathepsin and they recruit antigen-presenting cells (APC) 
including dendritic cell and B lymphocytes which play a major role in the immunity 
responses against microbes (Rescigno et al., 2001). Compromised protective M cell 
barriers and M cell-mediated MIS during sepsis and IBD may result in bacterial 
translocation from lumen to the vascular system thus further worsening patient 
condition.   
 
1.8 Organoids 
1.8.1 Organoid definition 
Organoids are defined as three-dimensional (3D) in vitro tissue models or cellular 
clusters that are generated from embryonic stem cells (ESCs), primary tissue, or 
induced pluripotent stem cells (iPSCs) and which have the ability to self-propagate, 
auto-renew, and auto-organise and to physiologically function in a similar way to the 
parent tissue or tissue of origin (Fatehullah, Tan & Barker, 2016).  
1.8.2 Small intestinal epithelial organoids 
The first mouse model of intestinal organoids was introduced in 2009 (Sato et al., 
2011). The International Stem Cell Consortium has now defined this type of small 
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intestinal organoid as an ‘enteroid’ (Stelzner et al., 2012) which is the term that will 
be used for the remainder of this thesis. Various growth factors are essential for 
survival of the enteroids. rmR-spondin activates WNT signalling which regulates cell 
migration, cell proliferation, cell fate specification, cell survival, and cell polarity (body 
axis patterning) during tissue homeostasis and embryogenesis (Jin & Yoon, 2012). 
Noggin protein plays a prominent role in cell signalling, in the skeletal and nervous 
systems, and somite patterning (Marcelino et al., 2001). Mouse epidermal growth 
factor (mEGF) mediates cell differentiation, cell proliferation, cell survival, and 
signalling pathways (Zhang et al., 2016). The structural crypt-villus axis is clearly 
recapitulated in small intestinal enteroids. 
1.8.3 Advantages of 3D enteroid models 
The 3D model of organoids provides a near-physiological system for studies that 
have not previously been achievable in two dimensions with cancer-derived cell lines 
(Boehnke et al., 2016; Fatehullah et al., 2016). The 3D structure enables dynamics 
to occur within enteroid systems that similarly recapitulate those observed in vivo. 
Other advantages include the ability of organoids to expand from a limited source 
and with reduced probability of genomic alterations with propagation (Fatehullah et 
al., 2016; Middendorp et al., 2014). Three-dimensional organoids have to generate 
and orientate to apical-basal polarity at their own accord while 2D cell cultures have 
automatic and instinct apical-basal polarisation and orientation. Because of the 
tendency to auto-organise in 3D, cell-to-cell interactions predominate structurally, 
while in 2D cell-substrate interactions structurally predominate. In 3D, motility is 
hindered by the extracellular matrix, whereas the continuously flat surface of 2D cell 
cultures enhances migration and adhesion. Many 3D studies have demonstrated that 
enhancing the dimensional property of extracellular matrix (ECM) around cells can 
profoundly impact cell viability, cell proliferation, cell functionality, cell differentiation, 
55 
 
mechano-responses, morphology, and cell survival (Baker & Chen, 2012; Bonnier et 
al., 2015; Gauvin et al., 2012). 
1.8.4 Disadvantages of 3D enteroid models 
Absence of the native microenvironment in enteroid cultures might hinder any study 
that involves investigating the interaction between organoids and other cell types 
such as immune cells.  However, reconstituted organoids can be produced by co-
culture of enteroids with immune cells for example. Unfortunately, the heterogeneity 
of organoids in the same culture may impede any homogenous phenotypic screening 
studies resulting in the need for single cell or cellular population studies (Fatehullah 
et al., 2016; Hynds & Giangreco, 2013). Three-dimensional cultures that are thick 
can also potentially be challenging to microscopic analyses. Enteroid culturing is very 
expensive and time consuming, whereas 2D cell models are generally more simple, 
inexpensive, and time conserving. 
1.8.5 Applications of 3D enteroids in research and medicine 
Three-dimensional enteroid models afford the opportunity for phenotypic studies, 
especially of angiogenesis, neoplastic metastasis, amyloid accumulation, 
morphogenesis, organogenesis, and chondrogenesis (Sato et al., 2009). The cell-
matrix interaction of 3D enteroid models provide the environment needed for 
phenotypic studies that resemble the dynamics of cells observed in vivo. In 
personalised genomic medicine, the role of 3D enteroid models are indispensable to 
tailoring therapeutics to individual genetic constitution (Dekkers et al., 2013). 
Enteroids provide possibilities to create and study cellular and molecular models of 
diseases, cell-cell interactions in tissues and organs, cellular interaction with the 
environment and their therapeutic modulations. Jones and colleagues demonstrated 
that TNF treatment of wild-type mouse derived enteroids induced marked rounding 
while there was attenuated rounding effect on Nfκb2-/- mice enteroids (Jones et al., 
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2019). Enteroids derived from patients with IBD demonstrated dysregulated 
endoplasmic reticulum (ER) stress that enhanced flagellin-induced IL-8 release and 
promoted TLR5 responses in IECs, thus resulting in increased activation of dendritic 
cell maturation and inflammatory responses (Rees et al., 2019). 
 
1.9 Prominent signalling pathways involved in gut 
homeostasis 
1.9.1 Wnt signalling 
Wnt signalling is responsible for the maintenance of the stem cell niche in the 
intestine and modulates the rate of epithelial cell renewal. Wnt signalling consists of 
signal transduction pathways that are of high evolutionary conservation in animals 
and are known to mediate via autocrine and paracrine interaction by downstream 
activation of Frizzled receptors and co-receptors to regulate cell proliferation, cell fate 
determination, cell polarity, cell migration, embryonic development, and tissue 
regeneration (Wodarz & Nusse, 1998). Wnt 3A and Wnt 5a are important in the gut 
and regulate proliferation at the crypt base. Wnt is a coined name derived from 
wingless (Wg) (Drosophila melanogaster fruit fly) and integration 1 (Int1) (mouse 
mammary tumour virus) genes. Wnt contains about 350 to 400 amino acids and is a 
superfamily of 19 protein members in the human (Cadigan & Nusse, 1997). Wnt is 
secreted and composed of modified lipid (palmitoleoylation), glycoproteins, and 
serine residue (Hannoush, 2015). In humans, there are 10 members of the Frizzled 
(Fz) receptor family of G-protein coupled receptors that have an ability to span cell 
membranes seven times (Schulte & Bryja, 2007). The facilitating co-receptors are 
lipoprotein receptor-related protein (LRP)-5/6, receptor tyrosine kinase-like orphan 
receptor-2 (ROR-2), and receptor tyrosine kinase (RTK) (He et al., 2004; Komiya & 
Habas, 2008). Wnt signalling consists of canonical and non-canonical (planar cell 
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polarity (PCP) and Wnt/calcium) pathways. While the former is β-catenin protein-
dependent, the latter is β-catenin protein-independent. Recently, it has been reported 
that both canonical and non-canonical Wnt signalling pathways have common, 
convergent, or integrated components especially when activated by the Wnt ligand 
(Wnt5A) (van Amerongen et al., 2012). Wnt signalling is triggered when Wnt protein 
binds extracellularly to the Frizzled receptor at its N-terminal cysteine-rich domain 
and the facilitating co-receptors stimulate the cytoplasmic phosphoprotein 
Dishevelled (Dsh/Dvl).  
Activation of the canonical Wnt signalling pathway initiates signal transduction from 
cell surface receptors to the cytoplasm that results in phosphorylation of β-catenin 
and subsequent accumulation of phosphorylated β-catenin. In the absence of Wnt 
ligands, the destruction complex of axin, glycogen synthase kinase 3 (GSK3), 
adenomatosis polyposis coli (APC), protein phosphatase 2A (PP2A), and casein 
kinase 1α (CK1α) will make β-catenin become a target for proteasomal degradation 
and prevent accumulation of β-catenin in the cytoplasm (Gordon & Nusse, 2006). 
The interaction between Wnt and FZD and LRP co-receptors induces CK1-alpha and 
GSK3β to phosphorylate LRP receptors and recruit DVL and axin (Janda et al., 
2012). This leads to polymerisation and activation of DVL that results in inactivation 
of the destruction complex and prevents biodegradation of β-catenin. This allows β-
catenin to stabilise and accumulate in the cytoplasm before subsequent translocation 
to the nucleus where it combines with lymphoid enhancer factor (LEF) and T-cell 
factor (TCF) proteins to initiate target gene transcription (Flanagan et al., 2018). 
In the non-canonical PCP pathway, a dishevelled-associated activator of 
morphogenesis 1 (DAAM1) complex is formed, which modulates Rho-associated 
kinase (ROCK) via the activation of the guanine (G)-protein Rho which regulates the 
cytoskeleton and cellular shape (Gordon & Nusse, 2006; Park et al., 2006). The non-
canonical Wnt/Ca2+ pathway involves G-protein-dependent stimulation and 
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regulation of intracellular Calcium release from endoplasmic reticulum (ER) (Kohn & 
Moon, 2005). Slusarski and colleagues reported that the frequency of Ca2+ signalling 
in the noncanonical Wnt pathway can be increased by over-expression of Wnt5a 
(Slusarski et al., 1997). Dysregulation of Wnt signalling has been implicated in many 
pathologies such as cancers, skeletal defects, spina bifida, type 2 diabetes, 
disruption of Wnt gradient, and intestinal damage during sepsis (Logan & Nusse, 
2004). 
In mammals, there are three Hedgehog (HH) homologues which include desert 
hedgehog (DHH), Indian hedgehog (IHH), and sonic hedgehog (SHH), however, a 
lot of studies have been done on sonic hedgehog. Embryologically, hedgehog (HH) 
signalling proteins play essential roles in foetal development including in the intestine. 
In adult life they are critically important in regulating tissue homeostasis, renewal, 
regeneration, and tumorigenesis (Yang et al., 2015). Depletion of HH signalling 
proteins has been implicated in defective formation of crypts and villi and lack of 
correct crypt polarity (Madison et al., 2004). Wnt signalling plays critical roles in 
intestinal homeostasis and ensures retention of stemness of the stem cells by aiding 
their ability to remain in an undifferentiated form and proliferate. Stem cells that are 
not exposed to Wnt signals differentiate into other types of intestinal epithelial cells, 
including mucus-secreting goblet cells, absorptive enterocytes, and chemosensory 
tuft cells (Pinto et al., 2003). In enteroid culture media, R-spondin is added to the 
media in order to activate, regulate, and amplify Wnt signalling of Wnt3A, Wnt1, and 
Wnt7A (Kim et al., 2008). 
1.9.2 Bone morphogenic protein (BMP) signalling 
Another protein that also plays a regulatory role in the crypt-villus axis is bone 
morphogenic protein (BMP) (figure 1.5). In the healthy gut, there are Wnt antagonists 
higher up the crypt, but Wnt agonists at the base, whereas BMP agonists are 
expressed in greater abundance higher in the villus tip with greater concentrations of 
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the BMP antagonists such as noggin being found at the crypt base (Qi & Chen, 2015). 
The Wnt gradient and BMP gradient along the crypt-villus axis are therefore in 
reverse directions. BMP signalling has been reported to induce terminal 
differentiation of cells and inhibit the auto-renewal property of intestinal stem cells. 
Noggin, an important additive of enteroid media, binds to BMP-2, -4, -5, -6, and -7 
thus preventing the BMPs from interacting with type I and type II BMP receptors 
(Groppe et al., 2002).  
1.9.3 Epidermal growth factor (EGF) signalling 
The epithelial growth factor (EGF) signalling pathway is important in controlling 
intestinal stem cell proliferation and survival and coordinating the crypt transit 
amplifying cells. Intestinal stem cell fate specification and crypt-villus axis migration 
are modulated by the Wnt, Notch, BMP, and EGF that are present in the stem cell 
niche (Qi & Chen, 2015). Preparation of enteroid media requires the presence of EGF 
to facilitate budding efficiency of the developing enteroids (Wong et al., 2012). 
1.9.4 Notch signalling 
Notch signalling is a highly evolutionarily conserved signal transduction pathway in 
which receptor proteins span the cell membrane to modulate cell proliferation, cell 
fate specification, differentiation, cell survival, neurogenesis, embryogenic 
development, and cell death (Bray, 2016; Kopan, 2012). In humans, there are four 
notch receptor homologues, NOTCH 1-4, that consist of single-pass transmembrane 
proteins with longer extracellular, transmembrane, and shorter intracellular regions 
and five canonical ligands of Delta-Serrate-Lag (DSL) (D'Souza et al., 2010). Notch 
is a surface receptor protein which presents the extracellular domain for ligand 
binding. Ligand binding triggers the initiation of endocytosis of ligand–receptor 
complexes resulting in the untwisting of the Notch proteins’ unique negative control 
region to cleave the intracellular domain (figure 1.5). The cleaved intracellular domain 
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then translocates into the nucleus where it attaches to the recombination signal 
binding protein for immunoglobulin kappa J (RBP-J) region of the DNA binding 
protein to activate Notch cascades of nuclear transcription target genes (Artavanis-
Tsakonas et al., 1999). The transcriptional target genes include hairy and enhancer 
of split-related (HESR) genes, cyclin D1, c-Myc, p21, platelet-derived growth factor 
receptor beta (PDGFRβ), and cyclin-dependent kinase 5 (CDK5) (Jin et al., 2008; 
Palomero et al., 2006; Rao & Kadesch, 2003). Notch receptor activation is regulated 
by many proteins such as endocytic adaptor protein Numb, E3 ubiquitin ligases 
(Nedd4, Neur, Deltex, and MIB), and α-adaptin (Furriols & Bray, 2001; Kopan 2012). 
Notch signalling inhibition via RBP-J deletion upregulates Math1 (proneural 
transcription factor) and promotes substitution of the proliferating transit amplifying 
region. Deficiency of Hes1 in mouse intestinal epithelial cells has been reported to 
be associated with a decline in the production of enterocytes whilst causing a rise in 
secretory cell populations including Paneth cells, goblet cells, and enteroendocrine 
cells) (van Es & Clevers, 2005). Dysregulation of Notch signalling has been 
implicated in embryonic maldevelopment (tetralogy of Fallot), cancers (T-cell acute 
lymphoblastic leukaemia), degenerative disease (multiple sclerosis), genetic disease 
(Alagille syndrome), skin disease (atopy), and Cerebral Autosomal-Dominant 
Arteriopathy with Sub-cortical Infarcts and Leukoencephalopathy (CADASIL) (Aster, 
Blacklow & Pear, 2011; de la Pompa & Epstein, 2012; Ranganathan, Weaver & 
Capobianco, 2011; Sharma et al., 2007). Tamoxifen was used to induce deletion of 
intestinal Math1 in young and adult Math1 inducible knockout mice (Durand et al., 
2012). Secretory cell lineage marker genes were significantly down-regulated by 
1,360-fold in Math1-deficient mice compared with those in the wild-type group 
(Durand et al., 2012). This strongly supports previous reports that Math1 is important 




Figure 1.5 The gradients of Wnt and BMP are very important in intestinal 
homeostasis of which WNT signal transduction ensures the sustenance of the 
intestinal stem cell population in the crypts while BMP signalling maintains cell 
location in the crypts and prevents cell proliferation. Notch signalling enhances stem 
cell proliferation and aids Wnt signalling while Hedgehog promotes villus formation. 
Modified from Jeon et al., 2013; Spit, Koo, & Maurice, 2018. 
 
1.10 NFκB signalling  
1.10.1 Structure of the NFκB family 
NFκB signalling was first reported in 1986 and was described as the κ-light chain 
enhancer that was discovered in B-cell tumour extracts (Sen & Baltimore, 1986). 
Many studies of NFκB signalling report that it is found in almost all animal cell types. 
The NFκB family has two classes of which class I includes NFκB1 and NFκB2 while 
class II contains RelA, RelB, and c-Rel. There are five NFκB subunits which are 
NFκB1 (p105/p50), NFκB2 (p100/p52), RelA (p65), RelB, and c-Rel. The p100 and 
p105 are precursors of p52 and p50 respectively. Broadly speaking, the NFκB 
signalling pathway comprises of classical and alternative pathways. 
1.10.2 Classical NFκB signalling pathway 
Activating stimuli bind to cell surface receptors and these transmembrane protein 
receptors trigger the recruitment of intracellular adaptor proteins, including TRAF. 
Basolateral and apical cell membranes of intestinal epithelial cells (IECs) express 
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pattern recognition receptors (PRRs) including toll-like receptors (TLRs) which 
become stimulated upon encountering microbial ligands (Abreu 2010; Wullaert et al., 
2011). Adaptor proteins then recruit and activate the catalytic subsets of IκB kinase 
(IKK) (IKKα and/or IKKβ) and NFκB essential modulator (NEMO) (non-enzymatic 
scaffold protein regulator) (Artis, 2008; Hayden & Ghosh, 2008). This leads to the 
phosphorylation of IκB proteins and thus release of NFκB proteins from IκB 
sequestration and enables translocation of the NFκB proteins to the nucleus for 
transcription of target genes. The phosphorylated IκB proteins become a target for 
ubiquitination- and proteasomal biodegradation. The classical pathway is involved in 
inflammatory, survival, and pathogen-derived conditions. In summary, classical NFκB 
pathway is NEMO-dependent, protein synthesis independent, rapid but diffuse and 
is activated by multiple stimuli (Chen et al., 2018; Sun, 2011). 
1.10.3 Alternative NFκB pathway 
Cell surface receptors are activated by ligand binding (B cell-activating factor (BAFF), 
CD40L, and lymphotoxin-β (LTβ)) that in turn stimulates NFκB inducing kinase (NIK) 
recruitment to the intracellular domain resulting in phosphorylation and activation of 
the IKKα complex. Thus, BAFF binds to BAFFR, CD40L interacts with CD40, LTβ 
binds to LTβR, RANK (receptor activator of nuclear factor κB) combines with RANKL, 
and LPS interacts with TLR4 (Dejardin, 2006; Merga et al., 2016). This results in 
cascades of reaction that subsequently result in phosphorylation of p100 protein (p52 
precursor) by IKKα, which results in processing and release of activated p52/RelB 
heterodimers. Thus, the liberated RelB:p52 heterodimer translocates to the nucleus 
to regulate the transcription of target genes (Amir et al., 2004). The alternative 
pathway has been implicated in developmental, organogenesis, immune cell 
maturation, and the immune response to sepsis (Chen et al., 2018; Cildir, Low, & 
Tergaonkar, 2016; Fukuyama et al., 2002; Newton & Dixit, 2012). Several mouse 
studies have reported that the alternative NFκB signalling pathway plays prominent 
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roles in modulating susceptibility to IBD and colitis-associated cancer and mediating 
intestinal epithelial barrier dysfunction, apoptosis, and cell shedding (Burkitt et al., 
2015; Jones et al., 2019; Watson et al., 2009; Williams et al., 2015). The alternative 
pathway is NEMO-independent, protein synthesis-dependent, slow but specific and 
only involves a subset of stimuli. More about the alternative NFκB signalling pathway 
will be discussed in chapter 4 of this thesis. 
1.10.4 Hybrid pathway 
The hybrid pathway has some elements of both classical and alternative activation 
pathways. In the hybrid pathway, the alternative pathway initiates the NFκB complex 
activities whilst classical pathway components stimulate the NFκB complex (Sanz et 
al., 2010). The degradation process can be triggered by acetylation, sumoylation, s-
nitrosylation or phosphorylation of IκBα and other IκB proteins (Wan & Lenardo, 
2009).  
1.10.5 IκB regulation of NFκB 
NFκB is sequestered in the cytosol and thus inactivated by the inhibitor of κB (IκB) 
proteins which combine and form complex with it. The combination of IκB proteins 
with NFκB prevents IκB from ubiquitination and proteasomal biodegradation and 
makes NFκB dimers inaccessible and unavailable for nuclear translocation and 
transcriptional reactions (Pahl, 1999). Thus, IκB tightly regulates activities of the 
NFκB signalling pathways. Presence of microorganisms or their component parts 
(such as LPS) binding to the cell surface receptor such as TLR4 rapidly leads to 
activation of NFκB signalling. TLRs have been reported to play prominent roles in 
innate and adaptive responses to sepsis and other conditions. Other inducers of 
activities of NFκB signalling pathways are reactive oxygen species (ROS), ionising 
radiation, tumour necrosis factor, ultraviolet radiations, interleukin 1-beta (IL-1β), 
burns, cocaine, and isoproterenol (Chandel et al., 2000). Activation of NFκB results 
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in phosphorylation of IκB, which causes phosphorylated IκB to be exposed to 
proteasomal biodegradation. 
In a resting state, IκB inhibits the activities of NFκB in the cytoplasm and the nuclear 
translocation of NFκB dimers. The IκB proteins contain ankyrin repeat domains which 
consist of 33 amino acid residues. The interaction of IκB proteins via their ankyrin 
repeat domains with the NFκB dimers result in the covering of the nuclear localisation 
signals (NLS) of NFκB proteins thus rendering the NFκB dimers hindered and 
isolated and they therefore remain in a continuously inactive state in the cytosol 
(Jacobs & Harrison, 1998). IκB proteins are related by having an N-terminal 
regulatory domain. The IκB proteins comprises of prototypical (IκBα, IκBβ, and IκBε) 
and atypical (Bcl-3 and IκBζ) groupings (Inoue et al., 1992). The prototypical IκB 
proteins exert their inhibitory actions in the cytosol, while the atypical IκB proteins are 
inhibitory in the nucleus. Because of the presence of ankyrin repeats at the halves of 
the C-terminal portions of p100 (IκBγ) and p105 (IκBδ), these also exhibit the same 
inhibitory properties as IκB proteins (Basak et al., 2007; Hayden & Ghosh, 2004; 
Perkins, 2007). 
  
Figure 1.6 Schematic diagram summarising the NFᴋB signalling pathways involving 
classical, alternative, and hybrid signalling pathways. In sepsis, all NFᴋB signalling 
pathways play a major role in promoting inflammation and other cascades of 
reactions that result in intestinal and other organ failures. Modified from Sanz et al., 
2010; Sun, 2011. 
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1.10.6 NFκB signalling and small intestinal homeostasis 
The intestinal epithelium, mucosal immune cells, and luminal microbiota are in a state 
of equilibrium and any disruption of this delicate and complex homeostatic status can 
result in a debilitating condition. The intestinal epithelium not only provides a physical 
barrier to luminal microorganisms, but along with the underlying intestinal mucosa, it 
also protects and promotes appropriate immune responses against any bacterial 
mucosal translocation and pathogenic gut colonisation (Sanz et al., 2010). NFκB 
signalling pathways play a prominent role in the intestinal immune homeostasis of 
the gastrointestinal tract. The development and manifestation of inflammation and 
diseases resulting from dysregulated NFκB responses to stimuli cannot be over-
emphasised. Increased and unregulated activation of NFκB signalling has been 
reported in both immune- and non-immune-related chronic inflammatory diseases 
(Sun, 2011). However, studies have also shown that inhibition of NFκB is associated 
with disruption of immune homeostasis, development of inflammation and diseases. 
In both chemical-induced colitis models and the colitis susceptible IL-10 knock out 
mouse, IKK activation was inhibited by administering antisense oligonucleotides to 
p65 or a peptide to bind NEMO and it was reported that the severity of colonic 
inflammation was ameliorated (Neurath et al., 1996). These studies demonstrated 
that excessive stimulation of NFκB signalling is implicated in the intestinal 
inflammatory responses and inhibition of NFκB signalling could have 
immunomodulatory therapeutic advantages in chronic inflammatory diseases 
including IBD (Wullaert, Bonnet, & Pasparakis, 2011). Eckmann and colleagues 
reported that conditional ablation of IKK in IECs inhibited NFκB but had no effect on 
colitis incidence or severity in the colitis-induced IL-10 knock out mouse (Eckmann 
et al., 2008). However, IKK ablation in myeloid cells demonstrated a reduction in 
colitis occurrence in colitis-induced IL-10 knock out mice (Eckmann et al., 2008; 
Greten et al., 2004).  
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Proinflammatory cytokines, cell surface receptors and PRRs play significant roles in 
mediating stimulation and activation of the classical NFκB pathway. TLRs detect 
PAMPs and subsequently activate the NFκB pathways. Rakoff-Nahoum and 
colleagues investigated the role of toll-like signalling adaptor receptors in 
commensal-dependent colitis and reported that development of colitis in interleukin-
10-deficient mice was MyD88-dependent signalling pathway while in IL2-deficient 
mice it was MyD88-independent (Rakoff-Nahoum et al., 2006). Sellon and colleagues 
experimented with IL-10-deficient mice and kept them in germ-free, specific pathogen 
free (SPF) conditions, or populated them with colitis-inducing bacteria (Sellon et al., 
1998). They reported that the IL-10-deficient mice that were maintained in germ-free 
environment did not show any evidence of colitis or an activated immune system 
(Sellon et al., 1998). By contrast, both the IL-10-deficient mice maintained in SPF 
and populated environments developed colitis and manifested activated immune 
system characteristics (Sellon et al., 1998). 
1.10.7 NFκB signalling in sepsis   
Microbes and microbial products with host cell surface PRRs such as TLR-2 and 
TLR-4 trigger NFκB signalling pathways leading to the activation of downstream gene 
transcription factors (Beutler et al., 2003). This results in the release and expression 
of mediators such as inflammatory cytokines (TNF and IL-6), chemokines, and 
superoxide. The released mediators induce local upregulation of adhesion 
molecules, enhanced vasodilation, and generation of chemotactic gradients (Faure 
et al., 2000). These cumulate in activation and mobilisation of neutrophils and 
lymphocytes and promotion of extravascular recruitment of host defence 
mechanisms essential for early microbial clearance. When local defences are 
overwhelmed, the invading microbes and microbial products including toxins are 
translocated to the vascular system where they induce systemic inflammatory 
responses such as shock, hypotension, multiple organ dysfunction and failure 
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(Perkins, 2007). There is a high concentration of p50/p65 heterodimer, an indication 
of an inflammatory process in sepsis (Li et al., 2009).  
Silva and colleagues conducted bacterial challenges on mice with Klebsiella 
pneumoniae and measured TNF concentrations before and at several intervals for 
up to 5 hours following bacterial infusion (Silva et al., 1990). They reported that serum 
TNF levels rapidly increased to 153-232 ng/ml between 50 and 90 min following 
bacterial challenge and dropped to 10-12 ng/ml within 5 hours, probably due to 
effective clearance (Silva et al., 1990). They also observed that serum peak levels of 
TNF were LPS concentration- and animal species-dependent (Silva et al., 1990). 
Michie and colleagues injected 4mg/kg of Escherichia coli endotoxin into 21 healthy 
men and reported that serum levels of TNF were increased from 50 to 90 min 
following endotoxin administration (Michie et al., 1988). The increased TNF levels in 
the subjects were associated with symptoms such as headaches, chills, nausea, and 
myalgias and symptoms were most severe at maximal circulating circulation of TNF 
(Michie et al., 1988). Even when TNF concentrations were no longer detectable, the 
symptoms persisted for 2 hours before subsiding. Fong and colleagues and Tracey 
and colleagues reported that TNF was associated with induction of production of 
secondary mediators including IL-1 and IL-6 (Fong et al., 1989; Tracey et al., 1987). 
They documented that 1- and 2-hours pre-treatment with anti-TNF prior to bacterial 
challenge in experimental models resulted in reduction of IL-1 and IL-6 thus adding 
further weight of evidence that TNF is a key mediator of sepsis (Fong et al., 1989; 
Tracey et al., 1987). Alternative pathway NFκB signalling in the gut has been 
demonstrated to be involved in sepsis, disruption of intestinal epithelial homeostasis, 
and inflammatory responses, so we will focus on the cytokines that have been 
reported to play some of these roles (Li et al., 2009). Different roles played by 
TWEAK, LIGHT and other alternative pathway activators in sepsis are discussed in 
more details in chapter 4 of this thesis. 
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1.11 Actions of cytokines in the small intestine  
Cytokines are small proteins that are released by macrophages, lymphocytes (B and 
T), endothelial cells, and mast cells to effect action on these or other cells (Dinarello 
et al., 2000; Zhang & An, 2007). The term cytokine is a generic name that 
encompasses chemokine (chemotactic cytokine), lymphokine (lymphocyte-derived 
cytokine), interleukin (leukocyte-derived cytokine) and monokine (monocyte-
generated cytokine). Cytokines have either pro-inflammatory or anti-inflammatory 
mechanisms of action. Tumour necrosis factor (TNF) is one of the most prominent 
pro-inflammatory cytokines and it has been implicated in many systemic pathological 
diseases including sepsis (Beutler et al., 1985). Some studies have reported that IL-
6 is also often upregulated when TNF is upregulated in IBD, rheumatoid arthritis and 
sepsis, so this cytokine may also be worth investigating as well. Cytokines such as 
IL-1, IL-18, IL-33, and IL-36 play key roles in regulating small intestinal mucosal 
immunity and homeostasis (Bamias & Cominelli, 2016). Some cytokines including 
TNF, TNF-like cytokine 1A (TL1A), and IL-6 exhibit dichotomous properties, that is, 
they demonstrate intestinal mucosa-protective activity in acute injury, while acting as 
proinflammatory agents during chronic inflammation (Bamias & Cominelli, 2016). 
1.11.1 Tumour necrosis factor superfamily 
1.11.1.1 TNF 
A trimeric form of tumour necrosis factor (TNF) protein was identified in mice in 1975 
as an endotoxin-induced glycoprotein and it was later cloned in humans in 1985 
(Bradley et al., 2008). It consists of membrane-associated and soluble forms with 
molecular weights of 26 kDa and 17 kDa respectively (Arakawa & Yphantis, 1987; 
Bradley et al., 2008). TNF exists in soluble and membrane bond forms and it induces 
signalling via NFκB pathway activation. Sources of TNF are activated macrophages, 
lymphocytes, osteoclasts, fibroblasts, endothelial cells, adipose tissue, and mast 
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cells, and its production is upregulated by LPS stimulation (Bradley et al., 2008). In 
healthy humans, TNF is not usually detectable in the serum, but in diseases involving 
inflammation, infection, and malignancy, its circulating concentration can be elevated 
(Damas et al., 1989; Debets et al., 1989; Girardin et al., 1988; Spooner et al., 1992; 
Waage, Halstensen, & Espevik, 1987). TNF, a pro-inflammatory cytokine, has been 
shown to modulates intestinal tight junction permeability (Al-Sadi et al., 2016; 
Dinarello et al., 2000) (tables 1.1 and 1.2). It modulates signalling pathways in both 
physiological and pathological conditions such as cell differentiation, proliferation, 
migration, inflammation, immune responses, and apoptosis. TNF mediates its 
stimulatory actions through TNF receptor 1 (TNFR1) which is universally expressed 
in humans and is the key receptor for TNF, and TNF receptor 2 (TNFR2) which is 
commonly expressed in immune cells and has more limited biological activities 
(Bradley, 2008; Piguet et al., 1998; Xu & Shi, 2007). Both TNF receptors (1 and 2) 
are expressed in intestinal epithelial cells in both apical and basolateral 
compartments. However, anti-inflammatory cytokines such as IL-10 promotes 
intestinal barrier function by counteracting the effects of TNF (Mazzon et al., 2002). 
In sepsis, microbes activate the cell surface receptors including TLR and TNFR1/2, 
which in turn switch on the adaptor receptors such as MyD88/TRIF. This eventually 
leads to activation of NFκB, ERK, JNK, and P38 signalling pathways and results in 
activation of macrophages to produce cytokines such as TNF, IL-6, and others 
(Takada et al., 2007). Conte and colleagues observed that TNF was associated with 
the pathological effects of LPS-TLR4 in sepsis, septic shock, and prolonged survival 
of macrophages (Conte et al., 2006). Waage, Halstensen and Espevik reported that 
all five patients diagnosed with sepsis who had circulating TNF concentrations 
greater than 440 units/ml (corresponding to 0·1 ng/ml recombinant TNF) did not 
survive (Waage et al., 1987). There are various measurements of TNF in health and 
diseases in serum, stool, and tissues (table 1.1). Its concentration is usually negligible 
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in health (0.20 ± 0.10 pg/mL in serum) (Martins et al., 2011), but can be very high in 
some inflammatory states (18.64 - 63.60 ng/g in stool) (Nicholls et al., 1993).  
 
Table 1.1 TNF concentrations in health and diseases from the sera, stools, and 
tissues of patients. 
 
 
Table 1.2 Alternative pathway activators of TNF superfamily with their gene, 
molecular weights (M. wt), amino acid (Aa) lengths, chromosomal (Chr.) locations, 
and functions (Alexaki et al., 2009; Armitage et al., 1992; Browning et al., 1993; 
Granger & Rickert, 2003; Moss et al., 1997; Wiley et al., 2001). These alternative 
pathway activators were selected for investigation. 
 
1.11.1.2 TWEAK 
TNF-related weak inducer of apoptosis (TWEAK) is a cytokine protein of the TNF 
superfamily that can exist in membrane-bound and soluble isoforms. TWEAK is 
produced as both type I and II transmembrane proteins and is the only TNF 
superfamily member that binds to fibroblast growth factor-inducible 14 (Fn14) 
(Bossen et al., 2006; Brown et al., 2010; Meighan-Mantha et al., 1999). TWEAK binds 
to a surface receptor protein, which when activated induces the binding of TNFR 
associated factor (TRAF) to the Fn14 cytoplasmic tail that modulates downstream 
activation of cascades of signalling pathways including NFκB, PI3K/Akt, and MAPK 
to promote cell proliferation, migration, differentiation, survival, and apoptosis (Burkly, 
Condition Serum Stool (Faeces) Tissue  References
Healthy 0.020 ng/L Komatsu et al., 2001
Active Crohn’s disease (CD) 14.0 ng/L Komatsu et al., 2001
Active ulcerative colitis (UC) 9.46 ng/L Komatsu et al., 2001
Active CD 994 [420-4,322] pg/g Braegger et al., 1992
Active UC 276-5,982 pg/g Braegger et al., 1992
Healthy children 58 pg/g Braegger et al., 1992
Shigella flexneri infection 18,640-63,600 pg/g Nicholls et al., 1993
Healthy children 12-130 pg/g Nicholls et al., 1993
Sepsis 0-587.3 pg/ml Schaumann et al., 1997
Severe sepsis and septic shock 19 (0–72) pg/ml Gordon et al., 2004
Irritable bowel syndrom 276.23 ± 266.40 pg/ml Vazquez-Frias et al., 2015
Liver metastasis 2 pg/mg Kuppen et al., 1997
Chronic wound skin tissue 6 ± 2 ng/ml Han et al., 2002
Name Gene M. wt (kDa) Aa length Chr. location Functions
TNF TNF 17 (s) & 26 (m) 233 6 (MHC) Regulates immune cells, inflammation, apoptosis
TWEAK TNFSF12 17 249 17 Induces apoptosis, proliferation, migration
LIGHT TNFSF14 26 240 19 Stimulates T cell proliferation, regulates apoptosis
CD40-L TNFSF5 33 261 Xq26-27 Regulates adaptive immune response
LTαβ LTA, LTB 25 & 33 205 & 244 6 (MHC) Induces inflammation
BAFF TNFSF13B 31 285 13 Activates B cell, proliferation
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Michaelson & Zheng, 2011; Winkles, 2008). TWEAK is an alternative NFκB pathway 
activator that binds TNF receptor-2 that in turn stimulates NIK, resulting in the 
translocation of p52 to the nucleus to effect the transcription of target genes. TWEAK 
over-expression has been reported in different types of pathological conditions 
including chronic inflammation, angiogenesis, and fibrosis, while under-expression 
has been observed in glioblastomas (Campbell et al., 2006; Jakubowski et al., 2005; 
Tran et al., 2003). Immunohistochemical studies of synovial tissue biopsies 
demonstrated over-expression of TWEAK in patients with rheumatoid arthritis in 
comparison with patients who had osteoarthritis or psoriatic arthritis (Park et al., 
2013; van Kuijk et al., 2010). It has been observed that inhibition of TWEAK-Fn14 
signalling minimises intestinal epithelial cell apoptosis and disease development 
(MacEwan, 2015). In γ-irradiation–induced, 2,4,6-trinitrobenzene sulfonic acid-
induced, and interleukin (IL)-10 deficiency-induced colitis mouse models, inhibition 
of TWEAK-Fn14 signalling resulted in protection of the intestinal epithelial mucosa 
(Dohi et al., 2009; Kawashima et al., 2011; Son et al., 2013). Chopra and colleagues 
reported that inhibition of the TWEAK-Fn14 signalling pathway reduced intestinal 
damage in graft-versus-host disease (GVHD) and prolonged survival after allogeneic 
hematopoietic cell transplantation allo-(HCT) (Chopra et al., 2015). MacEwan also 
suggested that TWEAK inhibition could be protective in other chronic inflammatory 
diseases (MacEwan, 2015).  
1.11.1.3 LIGHT  
Light is one of the members of the TNF superfamily and derives its name from 
lymphotoxin-like inducible protein that competes with glycoprotein D for herpes virus 
entry on T cells. Light is a type II transmembrane protein and it is present in dendritic 
cells, activated T and B lymphocytes, macrophages, natural killer cells, and 
granulocytes (Mauri et al., 1998). Light has been documented to activate both 
classical and alternative NFκB pathways. Many studies have reported that Light can 
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bind to herpes virus entry mediator (HVEM) (TNFRSF14, TR2, or LIGHTR) and 
lymphotoxin β receptor (LTβR) to stimulate cytokine production, whilst it can also 
interact with decoy receptors (DcR3) that are considered to be competitive Light 
inhibitors (Harrop et al., 1998; Mauri et al., 1998; Tamada et al., 2000; Lee et al., 
2019; Yu et al., 1999). Activation of HVEM leads to stimulation of activator protein-1 
(AP-1) and NFκB signalling, while LTβR activation modulates lymphogenesis, 
cancer-related inflammation, and dendritic cell homeostasis (De Togni et al., 1994; 
Haybaeck et al., 2009).  Light stimulates LTβR which then activates TNF receptor-
associated factor 2/5 (TRAF2/5) to signal classical NFκB pathway activation while 
through TRAF3 it mediates alternative NFκB pathway activation involving P52/RelB 
dimers (Dejardin et al., 2002; Force et al., 2000; Ganeff et al., 2011; Jang et al., 
2015). It has been reported that via mitogen-activated protein kinase (MAPK), 
extracellular signal–regulated kinase (ERK), and phosphoinositide 3-kinase (PI3K) 
activation, Light induces nuclear translocation and transcription of NFκB signalling to 
generate inflammatory responses (Lim, Suk, & Lee, 2013). NFκB is activated by Light 
via upregulation of CD86 expression but not through p44/42 MAPK or JNK/AP-1 
signalling pathways (Schwarz et al., 2007; Zou & Hu, 2005). Clayburgh and 
colleagues reported that administration of 5 μg of Light by intraperitoneal injection to 
Na+/H+ exchanger (NHE3)–/– mice caused intestinal epithelial barrier dysfunction via 
Myosin light-chain kinase (MLCK) activity (Clayburgh et al., 2006).  
1.11.1.4 CD40-L  
CD40-L (CD154, TRAP, gp39, or TBAM) is found as a surface receptor protein on 
both immune cells (activated CD4+ T cells, B cells, macrophages, monocytes, and 
dendritic cells) and non-immune cells (endothelial cells, epithelial cells, platelets, and 
mesenchymal cells such as fibroblasts, myofibroblasts, and stellate cells) and it plays 
a prominent role in the adaptive immune system (Michel, Zirlik & Wolf, 2017). CD40-
L consists of trimeric forms that can bind to CD40, platelet integrin αIIbβ3, α5β1, or 
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αMβ2 (Mac-1) receptors, however, the classical receptor is CD40. In most of the 
interactions of CD40-L with its receptors, it elicits downstream signalling patterns 
except in the case of Mac-1 where CD40L acted as an agonist on its own without 
receiving outside-in signalling (Michel et al., 2017). The interaction of CD40-L with 
α5β1 activates MAPK - PI3K - NFκB signalling pathways that promote translocation 
to the nucleus and the generation of pro-inflammatory gene expression (Michel et al., 
2017). CD40L binds with CD40 receptor on B lymphocytes to activate B cell 
stimulation, cell proliferation, cell survival, and immunoglobulin G (IgG)-class 
switching to synthesise other Ig groups (Danese, Sans & Fiocchi, 2004; Lesley et al., 
2006; Schönbeck & Libby, 2001). Mutational deletion of the CD40-L gene has been 
attributed to the malfunctioning of immunoglobulin that leads to production of the 
human X-linked immunodeficiency hyper IgM syndrome (XHIM) typified by deficient 
IgG antibody specificity and T cell humoral functionality (Notarangelo, Duse & 
Ugazio, 1992). CD40-L activation of endothelial cells via platelet adhesion and 
aggregation has been documented as one of the major factors in reactive oxygen 
species synthesis and inflammatory processes in the initiation, progression, and 
sequelae of atherosclerosis (Mach et al., 1997). Many studies have postulated that 
CD40-L may be a potential biomarker to determine atherosclerotic instability in the 
vascular system (Cipollone et al., 2002; Heeschen et al., 2003; Wang et al., 2013). 
Stuber and colleagues reported that CD40-CD40L signalling plays a vital role in the 
pathogenesis of colitis and that inhibition of the CD40-CD40L system using anti-
CD40L antibodies was associated with amelioration of 2,4,6-trinitrobenzene sulfonic 
acid (TNBS)-induced colitis (Stuber et al., 1996). CD40 is expressed in intestinal 
epithelial villi, colonic surface epithelial cells, and crypts and, within these structures 
it is mainly located on the basolateral membrane.  It was found to be highly expressed 
in active IBD (Borcherding et al., 2010). Gold and colleagues induced sepsis in CD40 
knockout (KO) mice by caecal ligation and puncture (CLP) and observed improved 
survival compared with wild-type mice administered the same treatment (Gold et al., 
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2003). They also reported that activation of NFκB and signal transducer and activator 
of transcription 3 (STAT3) signalling pathways were attenuated in both the liver and 
lungs of septic CD40 KO mice (Gold et al., 2003). Ischaemia-reperfusion injury was 
reported to cause local intestinal and distant lung tissue damage in control wild-type 
mice while there was significantly attenuated intestinal tissue damage and no distant 
lung injury in CD40 and CD154 deficient mice administered the same treatment 
(Lapchak et al., 2012). 
1.11.1.5 Lymphotoxin alpha and beta (LTα/β)  
Lymphotoxin (LT) α/β is a hematopoietic protein formed from lymphotoxin alpha 
combined with lymphotoxin beta on the cell surface to form heterotrimers (Nedwin et 
al., 1985; Ngo et al., 1999). LTα exerts its biological activities via interactions with 
TNF receptor 1 (TNFR1), TNF receptor 2 (TNFR2), LTβ receptor (LTβR), and HVEM 
(Crowe et al., 1994; Medvedev et al., 1996). The membrane LT-α1-β2 complex 
formation enables it to bind to and activate LT-β receptors with subsequent 
production of IKK-α, β, and γ, biodegradation of I-κB, and nuclear translocation of 
NFκB1 p50 and ReIA which modulate gene expression via classical pathway NFκB 
signalling (Muller & Siebenlist, 2003). Lymphotoxin alpha regulates cell proliferation, 
cell survival, cell differentiation, innate immune responses, apoptosis, and 
inflammation. It also plays a prominent role in cancer prevention, cancerous cell line 
destruction, and secondary lymphogenesis. Over-expression of lymphotoxin alpha 
has been implicated in carcinogenesis and unregulated cellular growth (Bauer et al., 
2012). By contrast, deletion of lymphotoxin alpha has been reported to be responsible 
for Peyer's patch maldevelopment, gastrointestinal developmental disruption, 
Staphylococcus aureus infections, Mycobacterium-induced granuloma formation, 
and splenic disorganisation (Gubernatorova & Tumanov, 2016; Roach et al., 2001). 
LTα and TNFα have 30% structural, similarity, while LTα from human and mouse are 
72% similar in primary protein sequence (Pennica et al., 1984). Wang and colleagues 
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demonstrated that LTβR on intestinal epithelial cells and hematopoietic-derived cells 
immunomodulate the host’s protective response (Wang et al., 2010). In sepsis, 
activation of LTβR signalling recruits neutrophils via the synthesis of cytokines, 
especially chemokines (CXCL1, and CXCL2) (Wang et al., 2010). In C. rodentium 
infection, the LTβR signalling pathway regulates the early innate immune cell 
response against the infection (Wang et al., 2010). 
1.11.1.6 BAFF 
B-cell activating factor (BAFF) (tumour necrosis factor ligand superfamily member 
13B, B Lymphocyte Stimulator (BLyS), TNF- and APOL-related leukocyte expressed 
ligand (TALL-1)) is a membrane-bound type II transmembrane protein (Schneider et 
al., 1999). It has a long peptide glycoprotein that can undergo glycosylation of its 
amino acid at residue 124. BAFF, which is mostly expressed on the surface of B cells, 
is also found in other cells such as dendritic cells, monocytes, and bone marrow-
derived stromal cells. BAFF is primarily involved in the activation, proliferation, 
differentiation, survival, and homeostasis of B lymphocytes (Bolkun et al., 2012; Croft, 
2009). BAFF interacts with BAFF receptor (BAFF-R) (BR3), transmembrane activator 
and calcium modulator and cyclophilin ligand interactor (TACI), and B-cell maturation 
antigen (BCMA) to activate classical and/or alternative NFκB signalling pathways 
(Kreuzaler et al., 2012). Deficiency or dysregulation of BAFF has been implicated in 
immunodeficiency secondary to insufficiency of immunoglobulin, while excessive 
production or regulation of BAFF induces over-production of abnormal antibodies that 
result in autoimmune diseases including rheumatoid arthritis and systemic lupus 
erythematosus (Steri et al., 2017). Overexpression of BAFF has been attributed to 
renal transplant acute rejection, anti-malarial humoral immunity, multiple myeloma, 
gluten-mediated coeliac disease, non-IgE-mediated reactions, inflammation, breast 
cancer, and insulin resistance (Aziz, Hadjivassiliou, & Sanders, 2012; Bolkun et al., 
2012; Banham et al., 2013; Fabris et al., 2007; Hamada et al., 2011; Pelekanou et 
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al., 2008). The luminal surface of intestinal epithelial cells expressed TLRs which 
become sensitised by the presence of microorganisms, especially bacteria in the gut 
lumen. Activation of the TLR signalling pathway stimulates intestinal epithelial cells 
to synthesise and secrete BAFF to promote cellular proliferation and the survival of 
B cell lymphocytes (Macpherson & McCoy, 2007). 
1.11.2 IL-6 
Interleukin-6 (IL-6) is a cytokine and myokine protein with both pro- and anti-
inflammatory properties. IL-6 is expressed by smooth muscle of the tunica media, 
macrophages, adipocytes, and intestinal epithelial cells (Jones et al., 1993). It 
interacts with transmembrane protein cell-surface type I cytokine receptor complex 
including IL-6 receptor (IL-6R) and glycoprotein (gp130) (Kallen, zum Buschenfelde 
& Rose-John, 1997). In response to pathogen-associated molecular patterns 
(PAMPs) or microbial molecules that usually bind to pattern recognition receptors 
(PRRs) such as Toll-like receptors (TLRs), macrophages secrete IL-6 which interacts 
with surface cell receptor proteins to activate the classical NFκB signalling pathway 
resulting in the transcription of pro-inflammatory cytokines (Tanaka, Narazaki, & 
Kishimoto, 2014; Zhang et al., 2010). IL-6 induces fever, acute phase response, bone 
marrow synthesis of neutrophils, and B lymphocyte growth (Akira, Taga, & Kishimoto 
1993). In contrast, through its inhibitory action on TNF and excitatory activities on IL-
1 receptor antagonist (IL-1ra) and IL-10 via calcium/nuclear factor of activated T-cells 
(NFAT) and glycogen/p38 MAPK pathways, IL-6 mediates anti-inflammatory myokine 
effects (Brandt & Pedersen, 2010; Heinrich et al., 1998). IL-6 plays prominent roles 
in chronic inflammatory and auto-immune pathological conditions including 
rheumatoid arthritis, systemic lupus erythematosus, Behcet’s disease, neoplasms 
(prostate cancer and multiple myeloma), diabetes, atherosclerosis, and mental health 
(depression and Alzheimer's Disease) (Nishimoto, 2006). Clinically, a lot of interest 
has been generated by studies of IL-6’s mechanisms of action and by anti-IL-6 
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agents. Tocilizumab is an anti-IL-6 agent that is used to treat chronic inflammatory 
diseases such as rheumatoid arthritis, systemic juvenile idiopathic arthritis, and 
Castleman's disease (Ogata & Tanaka, 2012). Transgenic mice that were dominant 
negative for Tgfbr2 expressed in T cells and IL10rb gene knock out mice models 
were used to determine the timing of IL-6-induced intestinal inflammation. Then 
researchers co-housed three-week-antibiotic pre-treated dnKO mice with non-
antibiotic treated IL10rb+/− littermates and serum samples were taken every three 
days. They observed that on the sixth day following co-housing, IL-6 was significantly 
increased in dnKO mice in comparison with the similarly treated IL10rb+/− littermate 
controls (Kang et al., 2008). The dnKO mice were injected with anti-IL-6 mAb and the 
control dnKO mice were treated with IgG mAb at the beginning of co-housing. A 
statistically significant weight loss was also seen in the experimental group when 
compared to the control. On the ninth day following injection, the anti-IL-6-mAb 
treated dnKO mice demonstrated significant intestinal epithelial mucosal damage 
especially severe crypt loss and defective crypt regeneration in comparison with the 
control group (Kang et al., 2008). TNF and IL-6 are therefore acute phase protein 
cytokines that are found in increased amounts in the serum during sepsis, 
inflammatory states such as, IBD, and other infective conditions. 
 
1.12 Intestinal cell death mechanisms 
1.12.1 Apoptosis in the intestinal epithelium 
Intestinal epithelial homeostasis requires a precise balance between the process of 
apoptosis that removes unwanted/damaged cells and the inherent ability of intestinal 
epithelial stem cells to regenerate and proliferate to replace the loss. Without this 
equilibrium, excessive activities of apoptosis will result in intestinal epithelial atrophy, 
while uncontrolled proliferation of intestinal epithelial stem cells may potentially lead 
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to neoplasia or hyperplasia that occludes the intestinal lumen. Rapid intestinal 
epithelial cell division that continuously replaces the apoptotic mediated cell loss 
usually takes place at the crypt base of the intestinal epithelium (Hall et al., 1994). By 
contrast the majority of the apoptotic process resulting in intestinal cell loss occurs at 
the villus tip of the epithelium during steady state conditions.  
1.12.1.1 Crypt apoptosis 
Mitotically dividing stem cells are located at the base of intestinal epithelial crypts and 
daughter cells differentiate and migrate from the crypt domain along the crypt-villus 
axis. Under normal, healthy intestinal conditions, only very few apoptotic cells can be 
detected in the crypt domain (Hall et al., 1994). In the crypt region, apoptosis can 
result from either DNA-damaged cells or excessive mitotic synthesis of intestinal 
epithelial cells (Potten, Wilson & Booth, 1997). The apoptosis that takes place in an 
intestinal epithelial cells crypt of a healthy individual is called spontaneous apoptosis. 
This spontaneous apoptosis assists in maintaining the homeostatic mechanism of 
the intestinal epithelial cell. About 1.6 cells per crypt undergo programmed cell death 
at any point in time (Potten & Grant, 1998). Exposure of intestinal epithelial cells to 
ionising radiation can induce a dramatic increase in apoptosis within 3 - 6 hours post-
exposure. It has been reported that spontaneous and radiation-induced apoptosis 
peak at four cell positions from the intestinal crypt base (Potten, 1997). The dose-
response relationship between amount of radiation exposure and the apoptotic 
responses of intestinal epithelial cells in the crypt has been well studied. The 
exposure of mouse small intestinal epithelial cells to 1 Gy and 8 Gy radiation induced 
maximal apoptotic activities after 3 - 6 hours (Potten & Grant, 1998). There is no 
cogent explanation for the variability observed in the values of some of groups of 
mice and among different mouse strains that are exposed to the same dose of 
irradiation. However, some other studies have shown that DNA damaging effects 
from other stimuli including chemotherapeutic drugs tend not to follow the +4-zone 
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positional apoptotic postulate and any cell within the transit amplifying region 
irrespective of position from the base of the crypt can undergo apoptosis (Ijiri & 
Gerbe, 1983; Ijiri & Potten, 1987). Pritchard and colleagues reported that 5-FU -
induced crypt apoptosis predominantly in the transit amplifying region at cell positions 
6 - 8 (Pritchard et al., 1997). The bcl-2 family of proteins plays a regulatory role in 
controlling spontaneous and DNA-damaging associated apoptosis in the intestinal 
epithelial crypt.  
1.12.1.2 Villus tip apoptosis 
Intestinal epithelial cell shedding is a controlled process whereby cells migrate up the 
crypt-villus axis and are expelled from the tip of the intestinal villus or colonic crypt 
table (Bullen et al., 2006). Upon expulsion of the cell from the epithelial villus tip, the 
structural epithelial integrity is sustained by the rapid remodelling process of cell 
adhesion mechanisms. This shedding and effective cell adhesion mechanism 
ensures that the intestinal epithelial villus integrity is efficiently coordinated and 
maintained (Madara, 1990). In the intestinal epithelial monolayer, major cell loss via 
shedding occurs at the villus tip, while cell replacement through proliferation takes 
place within the crypt region. In a normal physiological intestinal epithelial system, 
the rate of cell shedding at the villus tip equals the rate of cell proliferation in the crypt 
domain, thus ensuring intestinal epithelial homeostasis (Barker et al., 2007; Potten 
et al., 2009). However, in pathological states, this steady state equilibrium can tilt in 
either direction depending on the aetiological nature of the condition. Excessive 
pathological cell shedding at the villus tip can result in villus atrophy, villus loss, and 
compromised villus function. In pathological cell shedding, the rate of expulsion of 
the intestinal epithelial cell at the villus tip is more than the rate of proliferation of the 
cells in the intestinal crypt (Williams et al., 2015). In this state, the rate of replacement 
is lower than the rate of loss of cells. Lack of production or excessive production of 
cells in the crypt will alter intestinal epithelial homoeostasis. All epithelial cells have 
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cell-to-cell and cell-matrix connections that are very important for cell growth, 
survival, and support; detachment of these connections particularly from the 
basement membrane can lead to apoptosis (Guan et al., 2011). This process of 
detachment-induced apoptosis is often described as anoikis, meaning “without a 
home” (Frisch & Francis, 1994). Williams and colleagues reported that prior to 
intestinal epithelial cell shedding, cells at the villus tip expressed active caspase-3 
(Williams et al., 2013). This finding suggests that the initiation of apoptotic processes 
may precede anoikis of the expelled cells at the villus tip. Intestinal epithelial tight 
junction protein (especially ZO-1) remodelling ensures that intestinal integrity is 
maintained after cells are expelled from the villus tip (Guan et al., 2011). 
1.12.2 Apoptotic mechanisms 
Apoptosis is a reversible, energy-dependent biochemical process of programmed cell 
death that is strictly regulated by genetic mechanisms (Yuan & Horvitz, 2004). 
Apoptosis-mediated cell death is initiated when there is a need to remove aged, 
injured, malformed, or unwanted cells without causing any adverse effect on adjacent 
cells (Martin et al., 2012). Excessive activation of apoptosis can result in atrophy, 
while inadequate activation might lead to poorly regulated cell proliferation and 
differentiation, potentially predisposing to the development of cancer (table 1.2). The 
apoptosis process includes blebbing, cell shrinkage, rounding because of 
lamellipodia retraction and caspase-mediated cytoskeletal destruction (Bohm, 2003). 
This is followed by cytoplasmic changes including dense and closely arranged 
organelles. Nuclear changes consist of chromatin condensation, the formation of 
discrete chromatin bodies, chromosomal DNA fragmentation, nuclear membrane 
discontinuity and generalised mRNA decay (Nagata, 2000; Susin et al., 2000). About 
50 - 70 billion cells undergo apoptotic forms of cell death in the adult human daily 
(Cole & Kramer, 2016; Reed, 1999).  The unilateral migratory crypt-villus tip axis has 
been reported to be actively modulated by caspase-3, -6, -7, -8, and -9 (Brentnall et 
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al., 2013). Apoptosis is mediated by intrinsic and extrinsic caspase-dependent 
pathways and caspase-independent pathways. Both caspase-dependent and 
caspase-independent apoptosis is induced in the cell. Caspase-dependent signalling 
is mediated via initiator caspases such as caspases 2, 8, 9, 10, 11, and 12 and 
effector caspases, including caspases 3, 6, and 7 to induce proteolytic cleavage and 
biodegradation (Li et al., 1997). The N-terminal region of several caspases including 
caspase-8 contains death effector domains (DED), while in other caspases, the N-
terminus contains a caspase activation and recruitment domain (CARD) such as in 
caspase-9 (Degterev et al., 2003; Muzio et al., 1996). The CARD region often 
interacts with the inflammasome. Localisations of caspase-2 in the endoplasmic 
reticulum and caspase-12 in the nucleus have been reported in the mediation of 
stress-induced apoptosis and DNA-damage-induced apoptosis respectively (Lassus 
et al., 2002; Nakagawa et al., 2000). In the mouse, caspase-11 has been implicated 
in having a regulatory role in caspase-1 induced inflammation and caspase-3 
activated apoptosis (Kang et al., 2000). Pro-apoptotic proteins include Bak, Bax, Bok, 
Bad, Bid, Bik, Bcl-Xs, Fas receptors and caspases while anti-apoptotic proteins 
include Bcl-2, Bcl-xl, Bcl-w, Mcl-1, and Diva/Boo (Elmore, 2007). Over-expression of 
Bax/Bak has been observed to mediate mitochondrial dysfunction-programmed 
death in cells that do not contain apoptosome-inducing caspase signalling because 
of lack of caspase-3, caspase-9, or Apaf-1. In the study of Bax/Bak double knockouts, 
activation of the mitochondrial signalling pathway could not be induced, emphasising 
the importance of Bax/Bak role in mitochondrial-mediated apoptosis (Cheng et al., 
2001).   
1.12.2.1 Intrinsic apoptosis 
Intrinsic apoptosis is a caspase-dependent process. The intrinsic pathway involves 
the activation of mitochondria-dependent intracellular signals that respond to stress 
within the cells, resulting in the release of proteins (second mitochondria-derived 
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activator of caspases) and cytochrome c from the mitochondrial membrane 
(Carmona-Gutierrez et al., 2010; Goldstein et al., 2000). Other factors that can also 
initiate the release of apoptogenic factors are Omi/high temperature requirement 
protein A2 (HtrA2), apoptosis-inducing factor (AIF), second mitochondria-derived 
activator of caspase/direct inhibitor of apoptosis protein (IAP)-binding protein with a 
low isoelectric point (pI) (Smac/DIABLO), or endonuclease G from the mitochondrial 
intermembrane space (Cande et al., 2002; Saelens et al., 2004). Cytochrome c that 
is released from mitochondria into the cytosol attaches to apoptotic protease 
activating factor 1 (apaf-1) to form the apoptosome (Zou et al., 1999). It also leads to 
triggering of caspase-3 activation through formation of the cytochrome c/Apaf-
1/caspase-9-containing apoptosome complex that eventually provokes DNA 
fragmentation in the nucleus (Fulda & Debatin, 2006). This can also involve the 
activation of c-Jun N-terminal kinase (JNK), mitogen-activated protein kinase 
(MAPK)/extracellular signal-regulated protein kinase (ERK), and NFκB signalling to 
effect apoptosis (Davis, 2000; Karin et al., 2002). The Smac/DIABLO system and 
Omi/HtrA2 complex promote activation of caspases by neutralising the inhibitory 
effects on the IAPs (Saelens et al., 2004). Intrinsic pathway can be induced by 
oxidative stress to mediate programmed cell death in intestinal epithelial cells (Buttke 
& Sandstrom, 1994).  
1.12.2.2 Extrinsic apoptosis 
The extrinsic apoptosis pathway of caspase-dependent apoptosis comprises type I 
and type II mechanisms. The type I extrinsic apoptosis pathway mediates direct 
caspase-8 activation through death receptors resulting in cleavage of caspases 3, 6 
and 7 to effect biochemical and morphologic characteristics of apoptosis (Gunther et 
al., 2014; Kucuk et al., 2006). By contrast the type II pathway requires BH3 
interacting-domain death (Bid), a proapoptotic agonist that facilitates cross-
communication between extrinsic and intrinsic apoptotic pathways (Yang et al., 
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2009). Activation of the type I pathway is sufficient to drive the apoptotic process 
while the type II pathway cannot induce apoptosis without amplification from Bid. The 
extrinsic pathway is mediated via the binding of ligands (Fas, TNF, TNF-related 
apoptosis-induced ligands (TRAIL)) to cell surface receptors extracellularly to form a 
death-inducing signalling complex (DISC) (Irmler et al., 1997; Srinivasula et al., 
1996). Other death receptors are DR3, DR4, DR5, and DR6. The attachment of FasL 
to Fas receptors (death receptor) on target cells can cause multiple receptors to 
accumulate on and around the surface of the target cell. This leads to recruitment of 
an adaptor protein such as Fas-associated death domain protein (FADD) on the 
cytoplasmic aspect of the cell surface receptors. Following this, Caspase-8, an 
initiator protein is recruited by FADD to form the DISC. Thus, via the recruitment of 
caspase-8 to DISC, caspase-8 becomes activated, resulting in subsequent direct 
activation of caspase-3, an effector protein which initiates biodegradation of the cell 
(Adrain et al., 2002). The major executioner protease is caspase-3 and minor ones 
are caspases-6 and 7 (Slee, Adrian & Martin, 2001). In a study of bacterial 
translocation and apoptosis in the small intestine during sepsis, caspases 3, 8 and 9 
were observed to be activated (Mete et al., 2016).  
1.12.2.3 Caspase-independent apoptosis 
Caspase-independent signalling is modulated by apoptosis-inducing factor (AIF). 
The vital role played by Bcl-2 family proteins and mitochondria in caspase-
independent apoptosis was investigated in yeast (Schizosaccharomyces pombe) 
since its genome has no caspase genes (Jurgensmeier et al., 1997). Jurgensmeier 
and colleagues reported that upregulation of proapoptotic Bcl-2 family members Bax 
and Bak was associated with programmed cell death in S. pompe (Jurgensmeier et 
al., 1997). These pro-apoptotic Bcl-2 family members are responsible for 
vacuolisation of the cytosol and condensation of nuclear chromatin in yeast. 
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Activation of the pro-apoptotic Bcl-2 family has been reported to be inhibited by anti-
apoptotic Bcl-XL (Yarmolinsky, 1995).  
Caspase-independent apoptosis occurs when a signal that usually induces apoptosis 
via caspases fails to activate it. In the absence of caspase-dependent apoptotic 
activity, activation of a death receptor that binds to TNF and FasL results in a series 
of events that induces mitochondrial outer membrane permeabilisation (MOMP) 
(Holler et al., 2000). This leads to the release of different types of mitochondrial 
intermembrane space toxic proteins such as endonuclease G, cytochrome C, AIF, 
Smac/Diablo, ROS, and Htr2A/Omi, thereby creating severe loss of mitochondrial 
structure and function (Du et al., 2000; Li et al., 2001; Suzuki et al., 2001; Verhagen 
et al., 2000). This mitochondrial dysregulation activates mitochondrial fission and 
inactivates mitochondrial fusion thus disrupting mitochondrial morphology further 
(Tait & Green, 2008). Collectively, cascades of mitochondrial actions and reactions 
contribute to caspase-independent apoptosis.  
1.12.3 Necrosis 
Necrosis is an uncontrolled, non-programmed, non-specific, energy-independent, 
irreversible cell death process resulting from microbial invasion, trauma, hypoxia, 
toxins or extreme environmentally induced injury (D'Arcy, 2019; Kroemer et al., 
2009). Pathologically and morphologically, necrosis can be classified into coagulative 
necrosis, liquefactive necrosis, fibrinoid necrosis, fat necrosis, gangrenous necrosis, 
and caseous necrosis (table 1.2). Structurally, cells undergoing necrosis might be 
characterised by changes including cytoplasmic swelling, mitochondrial swelling, 
lysosomal rupture, nuclear membrane discontinuity, and plasma membrane blebbing 
and rupture (Rock, 2008). Necrosis causes inflammatory responses and severe 
adverse events on adjacent cells due to dissolution of cytoplasmic and organelle 
contents and disruption of the cell membrane (Raffray, Cohen & Cohen, 1997; 
Yagami, Yamamoto & Koma, 2019). The disequilibrium of ion homeostasis that 
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occurs in necrosis has been postulated to be mediated by calpains and lysosomal 
proteases such as cathepsins B and D (Yagami, Yamamoto & Koma, 2019). The 
necrosis process is mediated by caspase-independent proteases and has been 
reported to occur in ischemia-reperfusion injury.  
1.12.4 Autophagy 
Autophagy is the natural, regulated, self-degradative process of cell death that 
involves endocytosis-mediated lysosomal biodegradation (Mizushima, 2007). 
Autophagic mechanisms can be micro-autophagy, macro-autophagy, and 
chaperone-mediated autophagy (CMA) via proteases of calpain and autophagy-
related genes (Yagami, Yamamoto, & Koma, 2019). Lipophagy, mitophagy, 
chlorophagy, pexophagy, and ribophagy are various types of selective 
macroautophagy. Autophagy promotes cell survival and restricts tumorigenesis by 
adaptively responding to stress-induced injury and starvation, while in some 
situations it has been reported to mediate cell death and morbidity (Cuervo, 2004; 
Degenhardt et al., 2006). Autophagy is involved in both selective and non-selective 
cell death mechanisms without any inflammatory responses (Mizushima, 2007). 
Internal and external stimuli secondary to injury, aged cells, or stress can induce 
autophagic mechanisms resulting in dephosphorylation and activation of Unc-51-like 
kinases (ULK) 1 and 2, with subsequent phosphorylation and activation of Beclin-1 
and protein p62 (Chan, 2012). Autophagocytosed microbes, organelles and 
cytoplasmic contents were engulfed in autophagosomes which contain biodegrading 
lysosomes (table 1.3). There are about 30 autophagy genes that are involved in 
various types of mediation, most especially atg 1-5, 6, 8, 9, 10, 11, 13, 14, 17, and 
18, (Russell et al., 2013). Yang and colleagues reported that there was alteration of 
autophagic flux in intestinal epithelial cells that resulted in disruption of gut 
microorganism composition in a gut specific Atg5 knockout mouse model (Yang et 
al., 2018). Other studies have shown that the Atg5-knockout mice and disruption of 
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Atg5, Atg7, and Atg16L1 in intestinal epithelial cells were associated with 
morphological abnormalities in Paneth cells, enhanced intestinal permeability, and 
bacterial translocation (Cadwell et al., 2009; Yang et al., 2018). Dysregulated Atg5 
and Atg16L1 have been implicated in increased susceptibility to IBD and sepsis 
(Shao et al., 2017).  
  
Table 1.3 Comparison of the features of apoptosis, necrosis, and autophagy. 
Activation of autophagy is aimed at saving and preserving the function of cells and 
cellular organelles, especially the mitochondria. Autophagy promotes recycling of the 
unaffected organelles. When ATP is highly consumed, apoptosis is initiated which 
results in programmed cell death and intestinal epithelial cell shedding. Both 
autophagy and apoptosis processes are reversible. However, necrosis is irreversible 
and involves membrane and nuclear damage. 
 
1.13 Analysis of the intestinal proteome 
Proteomics is a systematic identification, analytic quantification, and large-scale 
study of structure, nature, and function of a comprehensive complement of proteins 
of a biological system at a specific time (Anderson & Anderson, 1996; Chandramouli 
& Qian, 2009; Graves & Haystead, 2002; Wilkins et al., 1996). The term proteomics 
was coined in 1994 by Marc Wilkins (Wasinger et al, 1995) as an amalgamation of 
the terms protein and genomics. Proteomics essentially assists in understanding, 
studying, and characterising an overall protein in an organism, organ, or cell in the 
resting, stimulated, diseased, healthy, spatial, or dynamic state (Lindon, Tranter & 
Features Apoptosis Necrosis Autophagy
Energy Dependent Independent Yes
Programming Yes No Yes
Predictability Yes No Yes
Genetic control Yes No Yes
Coordination Yes No Yes
Predetermined pathwaysYes No Selective and non-selective
Physiological Yes No Yes
Pathological Yes Yes Yes
Inflammatory responses No Yes No
Proteases Caspases Calpain and cathepsinCalpain
Adjacent cell injury No Yes No
Membrane rupture No Yes No
Cell size Decrease (shrinkage) Increase (swelling) Increase (swelling)
Biodegradation Apoptotic bodies Dissolved cytoplasm Autophagosomes
Nucleus Nuclear fragmentation Pyknosis, karyorrhexis, karyolysisNucleation
Activities Atrophy Liquefactive etc Micro, macro, and chaperone-mediated
Reversibility Yes No Yes
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Koppenaal, 2016). Proteomics is a new field of research that combines computational 
algorithms and modern mass spectrometry for interrogating both dynamic and static 
functionality of proteins (Graves & Haystead, 2002). Translational status and post-
translational modification of proteins can also be studied through proteomic analysis.  
 
Figure 1.7 Flow chart of proteomic analysis showing harvest of enteroids from 
mouse through protein extraction and protein digestion to protein identification by 
mass spectrometry method and bioinformatic analysis. Adapted from Warwick 
University Proteomic Centre. 
 
1.13.1 Proteomic technologies 
Mass spectroscopy (MS) (bottom-up type) applies analytical techniques to break 
molecules into charged fragments or ions and determines their molecular weights 
and mass-to-charge ratio based on how long it takes the ions to migrate through the 
MS flight tube (Chandramouli & Qian, 2009; Urban, 2016). The MS is a very sensitive 
and specific high-throughput tool for identification, characterisation, qualification, and 
quantification of proteins. It can also provide information on post-translational 
modifications of protein (Chandramouli & Qian, 2009). However, MS limitations 
include an inability to identify isomers having the same mass-to-charge ratio and 
failure of matrix assisted laser desorption/ionisation (MALDI) and electrospray 
ionisation (ESI) to adequately identify basic and hydrophobic peptides (Arlinghaus, 
88 
 
2008). Other common proteomic technologies include bioinformatics (usually useful 
in all proteomic analysis), protein array, two-dimensional electrophoresis (2DE), 
isotope-coded affinity tag (ICAT) labelling, and fluorescence 2D difference gel 
electrophoresis (2D-DIGE) (Chandramouli & Qian, 2009; Graves & Haystead, 2002). 
Isobaric labelling including tandem mass tags (TMT) which enables multiplexed 
proteomic analysis is used for peptide quantification. Peptide quantification involves 
a fragmentation process in a tandem MS to generate reporter ions. The higher the 
degrees of multiplexing, the smaller the mass differences between the reporter ions, 
the greater the mass resolving power and the more accurate and precise the 
proteomic analysis (Bekker-Jensen et al., 2017; Kelstrup et al., 2018). The TMT10-
plex quantification that was used in this thesis is based on sound resolution and 
accurate measurements of small mass differences of the reporter ions such as 
0.0036 Da (Werner et al., 2014). More details about TMT10-plex are provided in 
chapter 2 of this thesis. 
1.13.2 Proteomic analysis in the small intestine and enteroids 
Based on transcriptomic and proteomic analysis, about 75% of all human protein-
coding genes have been found to be expressed in the intestine (Gremel et al., 2015). 
The proteomic analysis of porcine small intestinal mucosa resulted in identification of 
5275 quantitative proteins (Qin et al., 2016). Proteomic analysis in the small intestine 
and in enteroids in resting and stimulated conditions can result inreveal significantly 
up-and down-regulated proteins and some proteins that are statistically insignificantly 
regulated as a result of treatment. Proteomic analysis can be conducted on native 
enteroids or treated enteroids. A recent study analysed the proteome of enteroids 
that were skewed to specific epithelial cell lineages induced by small molecule drug 
treatments (Luu et al., 2018). 
Through proteomic analysis, potential novel biomarker candidates such as IL-4, IL-6 
precursor, desmin, fibrinogen alpha chain (FGA), and Annexin A1 have been 
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discovered for sepsis and local infections (Cao & Robinson, 2014; Hinkelbein et al., 
2009; Sharma & Salomao, 2017; Tang et al., 2011; Zhou et al., 2011).  Future studies 
of their molecular mechanisms of actions and signalling could therefore potentially 
lead to discoveries of novel therapeutics and prevention strategies against sepsis 
and local infection (Cao & Robinson, 2014; Malmstrom et al., 2016). Biomarkers of 
sepsis will be more comprehensively discussed in chapter 5 of this thesis. 
 
1.14 Hypothesis, aims, and objectives 
1.14.1 Hypothesis 
Enteroids can be used to model intestinal damage observed during active IBD and 
sepsis to determine novel mechanisms that may be targeted therapeutically to 
ameliorate both diseases. 
1.14.2 Aims 
1.14.2.1 To determine the effects of TNF and alternative NFκB signalling pathway 
activators on mouse enteroid morphology and dynamics. 
1.14.2.2 To assess the impact of Nfκb2 deletion on the susceptibility of mouse 
enteroids to TNF-induced injury. 
1.14.2.3 To investigate the consequences of deleting NFκB family members on the 
mouse small intestinal epithelial proteome and its response to TNF. 
1.14.2.4 To develop a novel enteroid model to test potential therapeutics for IBD and 
sepsis. 
1.14.3 Objectives 
1.14.3.1 To investigate the pathological effects of TNF and a panel of alternative 
pathway NFκB signalling pathway activators on murine intestinal epithelia. 
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1.14.3.2 To use live imaging technology to capture the phenotypic responses of TNF 
treated wild-type and Nfκb2-/- mouse enteroids. 
1.14.3.3 To determine whether the responses of TNF-treated enteroids are different 
from those of forskolin-treated enteroids. 
1.14.3.4 To understand the mechanisms involved in regulating morphological 
changes in TNF-treated mouse enteroids. 
1.14.3.5 To examine the time course of events following TNF treatment of mouse 
enteroids. 
1.14.3.6 To analyse the possible mechanism of TNF induced enteroid injury using 
proteomics. 
1.14.3.7 To interrogate the inhibitory properties of various potential therapeutic 
agents against TNF-induced mouse enteroid rounding. 
1.14.3.8 To understand the similarities and differences in the intestinal epithelial 
















2. Material and methods 
2.1 Animals 
All mice were housed in groups of 3 per cage with recommended pelleted food 
(standard chow diet made from ground wheat, oats, soybean, corn, alfalfa, vegetable 
oil, minerals, vitamins and fish) supplied by Charles River (D12450B) and water and 
kept under 12-hour light: dark cycle in standard specific pathogen free (SPF) 
conditions until they were utilized for tissues or in experiments. Animals were 
maintained at a temperature of 22±2°C, 55±10% humidity, less than 50 dB noise, 
and individually ventilated cages (IVC) system with 15-20 air changes per hour and 
500 square centimetres cage floor area. Environmental enrichment included wooden 
chew sticks, cardboard houses, plastic tubes and shredded paper. Home Office 
legislation was strictly followed for all procedures. The in vivo study was conducted 
under authority of project licence number 231167 held by Professor Mark Pritchard. 
2.1.1 Wild type mice  
C57BL/6J in-bred wild type (WT) mice were purchased from Charles River 
Laboratories (Margate, UK) and, were acclimatized for at least 1 week before being 
used in experiments.  
2.1.2 Transgenic mice (Nfκb1-/-, Nfκb2-/-, c-Rel-/-)  
Nfκb1-/-, Nfκb2-/-, and c-Rel-/- transgenic mice were bred in the Biomedical Services 
Unit (BSU) of the University of Liverpool. The Nfkb2-/- colony was established from 
mice by Dr Jorge Caamaño at the University of Birmingham. 
2.1.2.1 Generation of Nfκb1-/- mice  
Nfκb1-/- mice were generated by insertion of a phosphoglycerate kinase (PGK) neo 
cassette of p50 into exon 6 of Nfκb1-/- which encodes the Rel homology domain 
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resulting in disruption of functioning Nfκb1-/- (Sha et al., 1995). The targeted 
disruption resulted in a shortened polypeptide with an inability to bind DNA, 
synthesize p50 from p105 precursor, combine with itself, or dimerize with other 
members of the NFκB/Rel family. However, this linearized targeted disruption has no 
effect on IκB-γ production from internal mRNA promotion since it is located at the C-
terminus of p105 (Inoue et al., 1992) and the targeted disruption took place within the 
N-terminus (Ghosh et al., 1990). Although Nfκb1-/- mice did not show any 
developmental deficiency, defects and non-specificity was shown in their immune 
responses, susceptibility to infection, and inability of B cells to proliferate in response 
to stimulation by LPS (Sha et al., 1995).  
2.1.2.2 Generation of Nfκb2-/- mice 
Nfκb2-/- mice were produced in embryonic stem (ES) cells with the WT genetic 
background. A PGK neo cassette was inserted into exon 4 of the Nfκb2 locus to 
achieve targeted disruption of the synthesis of p100 and p52 (Caamano et al., 1998). 
Nfκb2-/- mice show no demonstrable developmental abnormality and upon 
stimulation, the thymic cells of Nfκb2-/- mice do not express p100 or p52. This colony 
shows abnormalities in lymphoid organs with defective T- cell responses and low 
proliferative responses of B cells to LPS, CD40 and anti-IgD-dextran (Caamano et 
al., 1998).  
2.1.2.3 Generation of c-Rel-/- mice  
c-Rel-/- mice were produced on the WT genetic background. Targeted disruption of c-
Rel was achieved by inserting a PGK-neo cassette to replace exons 4-9 encoding 
amino acid residue 145-588 of c-Rel (Kontgen et al., 1995). This disruptive technique 
led to truncation of c-Rel proteins that did not have the capability of promoting 




 2.2 The 3D small intestinal enteroids  
2.2.1 Organoid generation from crypt isolation 
Using modifications of culturing methods first established in the Clevers laboratory 
(Sato & Clevers, 2013), we grew small intestinal organoids from murine small 
intestinal crypts. Mice used for the generation of small intestinal organoids were 
culled using a schedule 1 method (cervical dislocation and death confirmed by 
checking for heartbeat cessation, dilated pupils and lack of corneal reflex) at the BSU. 
The proximal 3cm of the small intestine was dissected and flushed with cold 1X PBS 
without Ca2+ and Mg2+. It was longitudinally dissected and transversely cut into about 
1 cm pieces and meticulously washed with cold 1X PBS to ensure cleanliness and 
avoid tissue disruption. The cut parts were transferred to a 30 ml 1X PBS-containing 
universal and transported in an ice box to the department. The dissected intestine 
was further washed several times before being transferred into 20 ml of 2 mmol 
ethylenediamine tetra-acetic acid (EDTA) in 1X PBS, chelation buffer, in a 50 ml 
falcon tube in a covered ice box on a shaker for 30 minutes to isolate and release villi 
into the solution. Then, the chelation buffer was discarded and 20 ml of shaking buffer 
(43.3 mmol sucrose and 59.4 mmol D-sorbitol) was added, and vigorously shaken 
for 2 minutes to enhance the release of stem cell-containing crypts from the intestinal 
basal membrane into the solution. To verify whether crypts had been released, the 
Falcon tube was viewed microscopically. A 70 µm cell strainer was used to filter the 
solution-containing crypts into a 50 ml Falcon tube kept on ice. The contents were 
transferred into a 15 ml Falcon tube and centrifuged at 200 g for 10 minutes at 4°C. 
Under a hood, the supernatant was discarded while the pellet was resuspended in 
Matrigel and 50 µl (about 500 crypts) seeded per well on a 24-well plate and placed 
in an incubator to polymerize. After polymerization, the 24-well plate-containing 
organoids was brought under the hood and 500 µl of minigut culture media was 
added per well. On the fourth day, minigut media was discarded and replaced with 
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fresh media. Enteroids were usually maintained in complete Intesticult media but 
switched to home-made individual growth factor media for experimental purposes as 
we could then be sure of all growth factor additives. 
2.2.2 Organoid media 
2.2.2.1 Intesticult media 
Intesticult mouse basal medium is a serum-free cell organoid growth medium (OGM) 
made by Stem Cell Technologies. Complete Intesticult medium was made from 
addition of 5 ml of Intesticult mouse supplement 1, 5 ml of Intesticult mouse 
supplement 2, and 200 µl of 100 µg/ml primocin to the basal Intesticult. Intesticult 
was stored at 4oC and warmed to 37oC for enteroid colony maintenance. 
2.2.2.2 Home-made individual growth factor media 
Basal minigut medium consisted of 500 ml Dulbecco’s Modified Eagle’s Medium 
(DMEM)/Nutrient mixture F-12 ham, 1% L-Glutamine, 100 µg/ml primocin, 10 ml B-
27 supplement, 5 ml N-2 supplement, and 10mM HEPES. A complete home-made 
individual growth factor culture medium was made by adding 500 ng/ml R-spondin, 
100 ng/ml noggin, 50 ng/ml mEGF to the basal medium. We used the home-made 
individual growth factor media for experimentation as Intesticult medium composition 
has not been released and may contain additional growth factors and inhibitors. 
2.2.3 Organoid passaging 
Frozen Matrigel was defrosted on ice as Matrigel solidifies at >10°C. A new 24-well 
plate was placed in the incubator for warming to 37°C. The 24-well plate-containing 
organoids was brought out of the incubator, minigut culture media was discarded and 
organoids were washed with ice cold 1X PBS. Then 500 µl of 1X PBS was added per 
well and gently pipetted up and down to break the dome shaped Matrigel that 
contained the organoids and the mixture was pipetted into a 5 ml Bijou. An insulin 
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syringe with a 27G needle was used to withdraw the mixture of organoids and 
Matrigel which were then transferred into a 15 ml Falcon tube. 1X PBS was added to 
a volume of 14 ml to the tube before being centrifuged at 200 g for 10 minutes at 4°C. 
Supernatant was then discarded, and the pellet was resuspended in Matrigel. The 50 
µl of Matrigel-containing organoids was seeded per well on a warmed 24-well plate 
and placed in an incubator for the Matrigel to polymerize. After 15 minutes of 
polymerization, 500 µl of minigut culture media was added per well (figure 2.1). The 
organoid passaging procedure was conducted under sterile conditions. 
 
 
Figure 2.1 Monitoring of the growth of enteroid from embedding in Matrigel and 
seeding in 24-well plates with the addition of noggin, mEGF, and R-spondin 
containing minigut media to provide nutrition and growth factors. 
 
2.2.4 Enteroid circularity  
Increased circularity is a good indicator of altered enteroid morphology. Several 
enteroid treatments including cytokines and chemotherapeutic agents have 
previously been shown to cause increased circularity of enteroids and this positively 
correlated with active caspase-3 activity (Jones et al., 2019). We have therefore 
treated enteroids with several stimuli (treatments discussed in section 2.5 of this 
thesis) and assessed their changes in circularity with time and dose. Enteroid 
circularities were measured at 0, 24, 48, and 72 hours and bright field images of six 
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individual enteroids per well were captured. We used two dimensional images to 
quantify circularity. The freehand selection tool available in NIH ImageJ was used to 
measure circularity. Enteroid circularity ([4π (area)]/perimeter2) was calculated to 
indicate death response/health status. Values of 0 represented an infinitely elongated 
polygon and values of 1 indicated a perfect circle (figure 2.4). Untreated WT enteroids 
have circularity values of ≤0.4 while 50 ng/ml or 100 ng/ml TNF-treated WT enteroids 
were observed to have circularity values of ≥0.7 from 24 hours post-treatment. 
2.2.5 Validation of NIH ImageJ circularity measuring technique 
Determination of the reproducibility and accuracy of circularity scoring was examined 
first by the author by randomly scoring 10 selected enteroids on two separate days 
to identify any intra-scorer variability and intra-scorer reproducibility (figure 2.2). Little 
variation was found between two temporally spaced scoring events suggesting there 
was little variability within a single scorer in determining enteroid circularity. Two 
previously trained circularity scoring researchers (a male and a female) tested inter-
scorer variability by scoring randomly the same 10 selected enteroids (figure 2.3). 
Little variation was observed when circularity scoring was conducted between three 
independent scorers, indicating that reproducibility between assessors was good, 




Figure 2.2 Circularity of enteroids was investigated for intra-scorer variability within 
the researcher. The researcher first scored 10 randomly selected enteroids from a 
range of enteroids given different treatments and rescored the same images on a 
different day. 
  
Figure 2.3 Determination of inter-scorer variability of 10 enteroids randomly selected 
from different treatment groups and quantified by three independent scorers. Scorer 
1 was the researcher, scorer 2 was a female and scorer 3 was a male. All scorers 















































Figure 2.4 Enteroids that were generated from the mouse were cultured with growth 
factors and a brightfield microscope was used to capture images. Stimulation with 
reagents could result in a circular enteroid while resting untreated enteroids had a 
non-circular, morphology. 
 
2.3 CytoSmart live cell imaging 
The CytoSMART imaging system can be used for low power bright field time-lapse 
imaging. Enteroids were placed on the cytoSMART system (figure 2.5) and put in an 
incubator with 5% CO2 and set at 37°C. The cytoSMART was focused on a field of 
enteroids and adjusted to obtain brightfield images. The field of view was imaged 
every 15 minutes for up to 4 days. Progress was also monitored remotely so that the 
incubator was not disturbed. Image analysis was conducted from time-lapse 
sequences by either tracking the motility, tracing the expansion and contraction 
pattern, or depicting the morphology of the enteroids. This image analysis technique 
was developed during this thesis project and more depth information and captured 




Figure 2.5 CytoSMART live cell imaging system with the 24-well plate containing 
enteroids placed on it to monitor behavioral patterns and morphological changes. 
Both images and videos could be accessed and assessed. 
 
2.4 Alternative NFκB signalling pathway activators 
2.4.1 TNF superfamily 
2.4.1.1 TNF 
TNF (Pepro Tech, 315-01A-20UG) was reconstituted in sterile 0.1% bovine serum 
albumin (BSA) to a stock concentration of 50 μg/ml which was immediately frozen at 
-80°C in aliquots. Enteroids were treated with 0, 1, 10, 50, 100 ng/ml TNF and 
brightfield microscopic images were captured at 0, 24, and 48 hours, n=6 (n 
represents individual enteroids), N=3 (N represents independent experiments 
conducted at different times). For CytoSMART studies, several different 
concentrations of TNF were selected, and imaging was conducted every 15 minutes 
for up to 4 days. TNF was also used as a positive control inducer of enteroid circularity 
in several experiments as discussed within results chapters 3-6. Enteroid samples 






TWEAK (R and D systems, 1237-TW) was reconstituted in sterile 0.1% bovine serum 
albumin (BSA) to 50 μg/ml and frozen in aliquots at -80°C. Enteroids were treated 
with 0, 1, 10, 50, 100 ng/ml TWEAK and brightfield microscopic images were 
captured at 0, 24, and 48 hours, n=6, N=3.  
2.4.1.3 LIGHT 
LIGHT (R and D systems, 1794-LT) was reconstituted in sterile 0.1% bovine serum 
albumin (BSA) to a stock concentration of 50 μg/ml and frozen in aliquots at -80°C. 
Enteroids were treated with 0, 1, 10, 50, 100 ng/ml LIGHT and brightfield microscopic 
images were captured at 0, 24, and 48 hours, n=6, N=3. 
2.4.1.4 CD40-L 
CD40-L (R and D systems, 8230-CL-050) was reconstituted in sterile 0.1% bovine 
serum albumin (BSA) to a stock concentration of 50 μg/ml, aliquoted and stored at -
80°C. Enteroids were treated with 0, 1, 10, 50, 100 ng/ml CD40-L and brightfield 
microscopic images captured at 0, 24, and 48 hours, n=6, N=3. 
2.4.1.5 LTα1/β2 
LTα1/β2 (R and D systems, 8884-LY/CF) was reconstituted in sterile 0.1% bovine 
serum albumin (BSA) to a stock concentration of 50 μg/ml, aliquoted and frozen at -
80°C. Enteroids were treated with 0, 1, 10, 50, 100 ng/ml LTα1/β2 and brightfield 
microscopic images captured at 0, 24, and 48 hours, n=6, N=3. 
2.4.1.6 BAFF 
BAFF (R and D systems, 2106-BF) was reconstituted in sterile 0.1% bovine serum 
albumin (BSA) to a stock concentration of 50 μg/ml and frozen in aliquots at -80°C. 
Enteroids were treated with 0, 1, 10, 50, 100 ng/ml BAFF and brightfield microscopic 




IL-6 (Invitrogen, PA5-47209) is not an alternative NFκB signalling pathway activator 
but was selected for investigation in this study as it was produced in high quantities 
following LPS stimulation of bone-marrow-derived-dendritic cells in co-culture with 
enteroids that resulted in increased enteroid circularity which was blunted in enteroids 
derived from Nfκb2-/- mice (Jones et al., 2019). IL-6 was reconstituted in sterile 0.1% 
bovine serum albumin (BSA) to a stock concentration of 50 μg/ml. Enteroids were 
treated with 0, 1, 10, 50, 100 ng/ml IL-6 and brightfield microscopic images captured 
at 0, 24, and 48 hours, n=6, N=3. 
 
2.6 Organoid preparation for proteomic analysis 
Four mice from each strain (WT, Nfκb1-/-, Nfκb2-/-, and c-Rel-/-) were used to generate 
enteroids for the proteomic study. Enteroids derived from each mouse were treated 
for 24 hours with or without 50 ng/ml TNF (32 samples in total). Minigut culture media 
containing TNF was aspirated off and enteroids were washed with 500 µl of cold 1X 
phosphate buffer saline (PBS) (Gibco, 14190136). Then, 400 µl of gentle cell 
dissociation reagent was added to enteroids on ice for 45 minutes to dissolve the 
Matrigel (Corning, 356237) to recover the organoids. It was important to remove all 
residual Matrigel from the samples as Matrigel is mouse protein-rich and could have 
interfered with downstream processes/analyses. The dissolved Matrigel-containing 
enteroid solution was centrifuged at 300 g for 5 minutes at 4°C and the supernatant 
was discarded. About 125 µl of 0.1M Triethylammonium bicarbonate (TEAB) (Sigma-
Aldrich, T7408-100ML) in 0.1 % sodium dodecyl sulphate (SDS) (Sigma-Aldrich, 
L3771-1KG) was added to the organoid pellet and pipetted up and down to facilitate 
mechanical disruption, chemical lysis, and protein solubilization. The mixture was 
then placed on ice on a shaker for 30 minutes. The lysed cells were centrifuged at 
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13,226 g for 20 minutes at 4°C and the supernatant was carefully transferred into a 
new 1.5 ml Eppendorf tube with murine organoid strain, number, date, and treatment 
or control. The Pierce bicinchoninic acid (BCA) (Thermo Fisher Scientific, 23227) 
protein assay reagents were used on the extracted supernatant of the organoid 
sample for protein quantification and the values were determined using a Tecan 
Sunrise absorbance microplate reader. A range of 130 - 390 µg of protein in 100 - 
110 µl buffer (about 400 µg) were obtained and kept in properly labelled self-lock 
Eppendorf tubes at -80°C. Samples were posted in dry ice to the Proteomics 
Research Technology Platform at University of the Warwick for proteomic analysis 
for proteins identification, quantification, and comparative analyses of the effects of 
the TNF treatment. 
Warwick Proteomic Centre used tandem mass tag (TMT) of the isobaric mass tags 
family, chemical labels for mass spectrometry (MS) to identify and quantify our 
extracted enteroid peptides solubilised by Triethylammonium bicarbonate (TEAB) 
digested by trypsin. Mass reporter region, mass normalization region, a cleavable 
linker region, and protein reactive group are the four regions of the TMT (Plubell et 
al., 2017). At Warwick Proteomic Centre, our peptides were diluted in 100 mM TEAB 
by using BCA to redetermine protein quantification following a published protocol 
(Plubell et al., 2017). Each sample was labelled with a different tag and then samples 
were pooled. The 10-plex TMT was used indicating that 10 samples could be run at 
the same time after being pooled together. The TMT machine detected which sample 
each signal came from by looking at the peptide sequence and the label.  
Normalisation of the pooled sample was achieved by adding 6.25 μg of peptide from 
each individual sample. A pooled sample was generated to run alongside 25 μg of 
each individual sample on the 10-plex assay.  We conducted 4 x 10-plex assays with 
additional pools – so 32 individual samples plus 2 pools per each 10-plex (2 x 4 = 8; 
so in total 40 samples from 32 individual samples plus 8 pooled samples) with 
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overlapping pools so that each 10-plex assay could be compared against each other 
as one experiment. Then 0.8 mg TMT 10-plex labelling reagent were dissolved in 52 
μl anhydrous acetonitrile (ACN) of which 12 μl was added to each sample of 25 μg 
of peptide in 25 μl volume of TEAB buffer and incubated for I hour at room 
temperature. 2 μl of 5% hydroxylamine was added to the 2 μl of each reaction mixture 
and incubation for 15 minutes. The combined mixture was dried before being 
dissolved in 5% formic acid. An Orbitrap Fusion protocol was used in analysing 2 μg 
of peptide by a single 2-hour LC-MS/MS method. The Orbitrap Fusion protocol 
utilised quantification accuracy and precision of number of peptide spectrum matches 
(PSMs) with short transient (faster time with ion influx). The run was conducted to 
normalise total reporter ion intensity of each multiplexed sample and ensured label-
checking and efficiency. Based on total reporter ion intensities during normalisation 
run, 2 μl 5% hydroxylamine were added to the remaining samples and then combined 
in a 1:1:1:1:1:1:1:1:1:1 ratio and then dried down in preparation for 2D-LC-MS/MS 
analysis (Plubell et al., 2017). 
 
2.7 Organoid histology 
2.7.1 Organoid preparation for histology 
Culture media was aspirated from organoid cultures and each well was washed with 
1X PBS. 400 µl gentle cell dissociation reagent (Stem Cell Technologies, 07190) was 
added to each well of a 24-well plate and the mixture was transferred to a 1.5 ml 
Eppendorf tube and incubated on ice for about 30 to 45 min to dissolve the Matrigel. 
Once Matrigel had solubilized in the gentle cell dissociation reagent, 400 µl of 4% 
paraformaldehyde (PFA) (Sigma Aldrich, P6148) (4% paraformaldehyde was made 
from 2ml of 16% stock (1:4) plus 6ml PBS or 1: 10 of 40% (37% w/v) PFA) was added 
to each mixture to make a final concentration of 2% paraformaldehyde and left for 
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30-60 min at room temperature to fix. Contents from the Eppendorf tubes were 
transferred to one 15 ml Falcon tube and centrifuged at 300 g for 3 minutes at room 
temperature. Supernatant was discarded and the pellet was re-suspended in a 
slightly warm 200 µl Histogel (Thermo-Fisher, HG-4000-012) and placed on top of 
folded 3M Micropore tape on an inverted metal lid on top of ice to rapidly polymerize 
the Histogel into a ‘button’. The button was transferred into an embedding cassette, 
labelled with pencil and stored in 70% ethanol for processing. 
2.7.2 Manual organoid processing  
Manual processing of the 70% ethanol-stored organoids involved steps 1 to 11 (table 
2.1). The cassettes-containing organoids were immersed in containers starting at 
step 1 in 70% ethanol and progressing to step 11 where they were immersed in wax. 
Forceps were used to move the cassettes-containing organoids from one container 
to another at the completion of each immersion time. At the completion of step 11, 
the fully processed cassettes-containing organoids were ready for paraffin 
embedding.  
Step Reagent Temperature Immersion time 
1 70% Ethanol Room 120 min 
2 90% Ethanol Room 120 min 
3 100% Ethanol Room 30 min 
4 100% Ethanol Room 30 min 
5 100% Ethanol Room 90 min 
6 Xylene Room 15 min 
7 Xylene Room 15 min 
8 Xylene Room 20 min 
9 Xylene Room overnight 
10 Wax 60oC 120 min 
11 Wax 60oC 180 min 
Table 2.1 Manual organoid processing steps, temperatures and times are shown 
from step 1 to step 11.  
 
2.7.3 Organoid embedding  
Processed organoids were embedded using a Histocentre 3 embedding machine. 
The machine was switched on for several hours to melt the wax ready for embedding. 
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Histogel-embedded organoids were transferred to a mould and embedded with 56°C 
liquid paraffin wax. Then the mould-containing-embedded organoids was transferred 
to the cooling plate of the Histocentre machine for about 30 minutes.  
2.7.4 APES slide coating for immunohistochemistry 
3-Aminopropyltriethoxysilane (APES) (Thermo Fisher Scientific, 80370) coating 
ensured suitably adhesive and charged slides for immunohistochemistry. Superfrost 
glass slides were successively dipped in glass jars respectively containing 100% 
acetone I, 100% acetone II, 2% APES in acetone, and 3x distilled water for 2 minutes 
each. Then APES-coated slides were placed in an incubator at 37°C overnight to dry 
before use. 
2.7.5 Microtomy 
Paraffin embedded organoids were mounted on the microtome for histological 
sectioning. The 4 μm thick sections were made and transferred to a water bath at 
45°C before being mounted on APES-coated slides. The slides were incubated at 
37°C overnight to allow sections to strongly adhere. 
2.7.6 Immunohistochemistry 
Standard dewaxing was conducted to rehydrate tissue and involved putting slides in 
xylene (Sigma-Aldrich, 1330-20-7) followed by a second container of xylene for 5 
minutes each to remove paraffin wax. Slides were transferred to 100% ethanol 1 for 
1 minute and then into 1% H2O2 in methanol to block endogenous peroxidase activity 
for 5 minutes. Thereafter, slides were placed in a second 100% ethanol bath for 1 
minute, 90% ethanol for 1 minute, 70% ethanol baths for 1 minute, and distilled water 
for 1 minute. Slides were then placed in antigen retrieval of citrate buffer at pH6 in a 
microwave at 800W for 20 minutes. Slides were then cooled for 20 minutes before 
being washed in Tris Buffered Saline (Fisher Scientific, 77-86-1) with Tween 20 
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(TBST) (Thermo Fisher Scientific, 28321) on a shaker for 5 minutes. A Pap pen was 
used to mark around the sections to prevent loss of reagents and a block using 
primary antibody diluent was used for 20 minutes. Primary antibody (table 2.2) was 
diluted to the concentration indicated in table 2.2 and was added to the slides and 
placed in a dark moist chamber for 2 hours at room temperature. After washing slides 
with TBST on a shaker for 2 x 5 minutes each, Dako Envision polymer (secondary 
antibody with amplification signal) (Dako, K4003) was added and incubated for 30 
minutes at room temperature. Secondary antibody was washed off with 2 x 5 minutes 
TBST and then a diaminobenzidine (DAB) chromogen (Sigma-Aldrich, D7304) was 
applied for 6 minutes at room temperature. Slides were washed in for 2 x 5 minutes 
in tap water.  Nuclei counterstaining was conducted by putting slides in haematoxylin 
stain (Sigma-Aldrich, H3136) for 2 minutes. Sections were washed and blued in 
running tap water and then placed through standard dehydration, were mounted with 
DPX (Sigma-Aldrich, 06522) containing mounting media, and allowed to air dry under 






































2.5 µg/ml 1:300 Citric acid 
buffer 
IHC 
Claudin-15 (Invitrogen,  
38-9200); polyclonal 
2.5 µg/ml 1:300 Citric acid 
buffer 
IHC 
Ki-67 (Abcam, ab15580); 
polyclonal 

























2.5 µg/ml 1:300 Citric acid 
buffer 
IHC 
Table 2.2 Different antibody concentrations utilized in probing for the proteins in the 
treated enteroids. Antigen retrieval used were citric acid and 
ethylenediaminetetraacetic acid (EDTA) buffers. IHC: Immunohistochemistry. 
 
2.7.7 Alkaline phosphatase co-staining  
Slides were subjected to standard dewaxing and, hydration processes as outlined 
above in section 2.7.6. A pap pen was used to mark the sections. Two drops of each 
alkaline phosphatase A, B, and C reagents (Vector Laboratories, SK-5100) was 
added to 5 ml of 100-200 mM Tris-HCl at pH 8.2-8.5 and incubated at room 
temperature for 20-30 minutes according to the Vector Laboratories manufacturer’s 
instruction. Slides were then washed in 100-200 mM Tris-HCl buffer on a shaker for 
5 minutes before being rinsed in water. Slides were bathed in 1% H2O2 in distilled 
water for 5 minutes which was followed by rinsing in distilled water for 1 minute. 
Antigen retrieval and subsequent IHC was conducted as detailed under 




2.8 Therapeutic experimentation 
2.8.1 Curcumin 
Curcumin (Aldi, L9108B) was reconstituted in sterile 100% DMSO to a stock 
concentration of 10 mM. Enteroids were treated with 0, 0.1, 1, 10 μM curcumin. Pre-
treatment with curcumin was for 1 hour. Then 50ng/ml TNF was added to the solution 
of the pre-treated enteroids. Brightfield microscopic images were captured at 0, 24, 
48, and 72 hours, n=6, N=3. 
2.8.2 Prednisolone 
Prednisolone (Sigma-Aldrich, P6004-1G) was reconstituted in sterile 100% DMSO to 
a stock concentration of 10 mM. The same steps as in curcumin were followed. 
2.8.3. Hydrocortisone 
Hydrocortisone (Sigma-Aldrich, H0888-5G) was reconstituted in sterile 100% DMSO 
to freezing stock concentration of 10 mM. The same steps as in the above curcumin 
were followed.  
2.8.4 Flunixin meglumine 
Flunixin meglumine (Sigma-Aldrich, F0429-100MG) was reconstituted in sterile 
100% DMSO to a stock concentration of 10 mM. Then same procedural steps as in 
the above curcumin were followed. 
 
2.9 Reagents and solutions 
Agents Catalogue 
number 
Vendor name Location 
3,3-Diaminobenzidine (DAB) D7304 Sigma-Aldrich MO, USA 
3-Aminopropyltriethoxysilane 
(APES) 
80370 Thermo Fisher 
Scientific 
IL, USA 
Alkaline Phosphatase (red AP) 
Substrate kit  
SK-5100 Vector 








BAFF or TNFSF13B 
(recombinant mouse) (NSO-
derived) 
2106-BF R&D systems MN, USA 
Basal minigut media (Dulbecco’s 
Modified Eagle’s 
Medium/Nutrient mixture F-12 
ham 
D8437 Sigma-Aldrich MO, USA. 
CD40 Ligand/TNFSF5 (HA-tag) 
(recombinant Mouse) Protein, 
CF 
8230-CL-050 R&D systems MN, USA 
Claudin-2, mouse monoclonal 
antibody 
32-5600 Invitrogen IL, USA. 
Claudin-7 rabbit polyclonal 
antibody   
34-9100 Invitrogen IL, USA. 
Claudin-15 antibody 38-9200 Invitrogen IL, USA 
Complete culture medium (Basal 
minigut media, R-spondin, 
noggin, mEGF, HEPES, 











Curcumin (turmeric) L9108B Aldi UK 
Cystic fibrosis transmembrane 
regulator (CFTR) inhibitor-172  
219670-5MG Merck UK 
DPX 06522 Sigma-Aldrich MO, USA 
EGF (Recombinant mouse) 
protein CF 





Sigma-Aldrich MO, USA 
Flunixin meglumine F0429-
100MG 
Sigma-Aldrich MO, USA 
Forskolin  F3917 Sigma-Aldrich MO, USA 
Gentle cell dissociation reagent 07190 Stem Cell 
Technologies 
UK 
Haematoxylin H3136 Sigma-Aldrich MO, USA 
HEPES 54457 Sigma-Aldrich MO, USA 
Histogel  HG-4000-012 Thermo-Fisher UK 
Hydrocortisone H0888-5G Sigma-Aldrich MO, USA 
IL-6 Receptor polyclonal 
antibody 
PA5-47209 Invitrogen IL, USA 
Intesticult mouse basal medium, 
catalogue number 
06000 Stem Cell 
Technologies 
UK 
Intesticult mouse supplement 1 06002 Stem Cell 
Technologies  
UK 
Intesticult mouse supplement 2 06003 Stem Cell 
Technologies 
UK 
JAM-A (mouse antibody) AF1077 R&D systems MN, USA 
Ki67, rabbit, polyclonal antibody ab15580  Abcam UK 






8884-LY/CF R&D systems MN, USA 
Matrigel matrix basement 
membrane phenol red-free 
356237 Corning,  NY, USA 




Noggin (Recombinant mouse) Bulk 1967-NG R&D Systems MN, USA 
Occludin, rabbit monoclonal 
antibody 
ab167161 Abcam UK 
Paraformaldehyde P6148 Sigma-Aldrich MO, USA 
Phosphate Buffered Saline 
(PBS) (1X), without Ca2+ and 
Mg2+  
Gibco Gibco Life 
technologies Ltd 
UK 
Pierce bicinchoninic acid (BCA) 
protein assay with a BSA 
standard  
23227 Thermo Fisher 
Scientific 
IL, USA 
Prednisolone P6004-1G  Sigma-Aldrich MO, USA 
Primocin NC9392943 Invivogen, Fisher 
Scientific 
USA 
R-spondin 1 (Recombinant 
mouse) 
3474-RS-250 R&D Systems MN, USA 
Secondary antibody (Dako 
Envision polymer, secondary 
antibody with amplification 
signal) 
K4003 Dako CA, USA 
Sorbitol S-1876 Sigma-Aldrich MO, USA 
Sucrose S9378-1KG Sigma-Aldrich MO, USA 
Sodium dodecyl sulphate (SDS) L3771-1KG Sigma-Aldrich MO, USA 
Sodium citrate dihydrate 
(sodium citrate tribasic 
dihydrate) 
S4641-1KG Sigma-Aldrich MO, USA 
TNFα (murine) 315-01A-
20UG 
PeproTech EC, UK 
TNFAIP3 receptor, rabbit 
polyclonal antibody 
ab217706 Abcam UK 
TNF receptor 1, Rabbit 
polyclonal antibody 
ab19139 Abcam UK 
TNF receptor 2, Rabbit 
monoclonal antibody 
ab109322 Abcam UK 
Triethylammonium bicarbonate T7408-100ML Sigma-Aldrich MO, USA 
Tris base 77-86-1 Fisher Scientific NJ, USA 
TWEAK (Recombinant mouse) 1237-TW R&D systems MN, USA 
Tween 20  28321 Thermo Fisher 
Scientific 
IL, USA 
Xylene 1330-20-7 Sigma-Aldrich MO, USA 
ZO-1 antibody 61-7300 Invitrogen IL, USA 
Table 2.3 Reagents, antibodies and other materials utilised for the methods of the 




2.10 Data and Statistics 
Data were analysed with analysis of variance (ANOVA) where normality ensued and 
Kruskal Wallis was conducted when data were not normally distributed. Multiple 
comparisons were performed using Dunnett's test. Statistical software used was 
GraphPad prism version 6. Student t-test and fold change analyses were used for 
proteomics. Descriptive data were presented as mean± standard deviation. p-values 
of less than 0.05 were considered statistically significant. Where applicable 95% 

























3. Characterising the actions of tumour necrosis 
factor (TNF) on enteroids  
3.1 Introduction  
Tumour necrosis factor (TNF) is a pro-inflammatory cytokine that is mainly produced 
by macrophages, but can also be manufactured by neutrophils, CD4+ lymphocytes, 
neurons, mast cells, natural killer cells and eosinophils (Wang & Lin, 2008). TNF is a 
cell signalling protein that is known to be involved in activation of the acute phase 
reaction, immune cell regulation, endogenous pyrogen generation, cell survival, 
proliferation, apoptosis and migration (Beutler et al., 1985; Calpado et al., 2014; 
Swardfager et al., 2010). TNF is a key pro-inflammatory cytokine known to be 
dysregulated in a wide variety of diseases including inflammatory bowel disease 
(IBD) and sepsis where this cytokine is massively over produced (Brynskov et al., 
2002; Dowlati et al., 2010; Ferrajoli et al., 2002; Locksley, Killeen & Lenardo, 2001; 
Plevy et al., 1997; Victor & Gottlieb, 2002). Anti-TNF therapy with drugs such as 
infliximab is effective in IBD (Monaco et al., 2015; Targan et al., 1997). In sepsis, anti-
TNF treatment including polyclonal anti‐TNF (AZD9773), Lenercept, chimeric 
antibody anti-TNF and afelimomab have also been used (Aikawa et al., 2013; Butty 
et al., 2013; Clark et al., 1998; Gallagher et al., 2001). Some anti-TNF therapies have 
ameliorated sepsis and reduced 28‐day mortality in patients while in other trials anti-
TNF therapeutics showed no reduction in 28‐day mortality in patients due to low drug 
potency and efficacy (Aikawa et al., 2013; Clark et al., 1998; Lv et al., 2014). 
Elevated TNF concentrations in the intestine cause apoptosis and cell shedding and 
tight junction redistribution in vivo (Williams et al., 2013). TNF-induced intestinal cell 
shedding disturbs epithelial cell equilibrium, particularly at the villus tip and makes it 
difficult for the normal, tight junctional protein redistribution and zipper-like 
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mechanistic process between neighbouring cells to replace the shed cells effectively 
and promptly without breeching intestinal barrier function (Kiesslich et al., 2007; 
Leppkes et al., 2014). TNF-induced epithelial cell shedding can therefore promote 
micro-erosions or epithelial gaps that cannot be easily replaced by rearrangement of 
adjacent intestinal cell tight junctional proteins (Kiesslich et al., 2007; Watson & 
Hughes, 2012). Disruptive activities of TNF also include transepithelial impedance 
loss via upregulation of MLCK, downstream NF-κB signalling pathway activation, and 
activation of AP-1 transcription factors (Wang et al., 2005). TNFR1 and TNFR2 are 
the receptors for TNF. TNFR1 which is usually stimulated by the two forms of TNF 
trimers is ubiquitously expressed in most cells, while TNFR2 which is activated by 
the membrane-bound form of the TNF homotrimer typically expressed in immune 
cells and intestinal epithelial cells (Leppkes et al., 2014; Theiss et al., 2005). TNFR1 
is the primary effector of TNF via recruitment of TNF receptor type 1-associated 
DEATH domain (TRADD), TNF receptor associated factor (TRAP) and receptor 
interacting protein (RIP) domains and activation of NF-κB and MAPK signalling 
pathways which result in apoptosis and cell shedding (Berghe et al., 2014; Hayden, 
West & Ghosh, 2006) (figure 1.6). However, TNFR2 via NIK stimulates 
phosphorylation of p100 to result in nuclear translocation of NF-κB to induce 
inflammation has also been implicated in promoting cell proliferation and survival 
(Faustman & Davis, 2010). TNFR1, but not TNFR2 activation was shown to be 
important in regulating apoptosis and intestinal cell shedding in intestinal epithelia 
following LPS injection into mice (Williams et al., 2013).   
In healthy individuals, intestinal epithelial homeostasis ensures a balance between 
programmed cell death and cell proliferation (Williams et al., 2013; Wullaert et al., 
2011). However, in diseases such as IBD and sepsis, TNF-induced apoptosis and 
cell shedding may exceed the capacity of crypts to proliferate and cell-cell tight 
junctions are modulated; these phenomena may result in epithelia becoming more 
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leaky to intestinal contents and enhancing further bacterial invasion and inflammation 
(Salim & Soderholm, 2011; Uhlig, 2013; Williams et al., 2013). Bacterial infiltration 
can disrupt immune homeostasis, cause local immune responses and potentially 
lead to systemic immune responses in severe cases (Artis, 2008). 
TNF plays significant roles in cellular and molecular mechanisms of IEC 
homeostasis. The protective and disruptive pathways of TNF on IECs are dose-, time 
point-, and context-signalling-dependent (that is, receptors and secondary signals) 
(Corredor et al., 2003; Guma et al., 2011; Leppkes et al., 2014). Protective activities 
of TNF include regulatory reconstitution of intestinal mucus by stimulating 
expressions of polymeric immunoglobulin receptor (pIgR) and mucin-2 (Muc2) to 
promote structural barrier integrity as the first line of defence of IECs (Johansson et 
al., 2008; Leppkes et al., 2014). Another important benefit of the protective 
mechanism of TNF is intestinal epithelial wound healing. Intestinal epithelial injury 
that is one of the pathognomonic features of IBD and sepsis results in influx of luminal 
content including invasive microbes into the tissue. TNF regulation of intestinal 
epithelial repair involves restitution and regeneration mechanisms via activation of 
the ErbB family of EGF receptors, lipid mediators (COX-2-derived prostaglandin E2), 
PI3K/Akt and STAT3-dependent pathways (Frey et al., 2009; Hilliard et al., 2011; 
Leppkes et al., 2014; Pickert et al., 2009). Restitution mechanisms consist of cellular 
spreading, cell invasion, cell migration, transient cell dedifferentiation, and 
cytoskeletal reorganization whilst the regeneration mechanism involves cellular 
redifferentiation, proliferation, and survival (Neufert et al., 2013; Taupin & Podolsky, 
2003). TNF activates a TNFR2 dependent pathway via focal adhesion kinase (FAK) 
to promote cell migration and survival (Corredor et al., 2003; Mizoguchi et al., 2002). 
TNF also stimulates TNFR2 signalling via regulation of the Wnt pathway to mediate 
intestinal epithelial cell proliferation (Mizoguchi et al., 2002). TNF via regulation of 
synthesis of cytokines and chemokines (e.g. CXCL-1, CXCL-5, and IL-8) actively 
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controls chemoattraction, cytokine and chemokine crosstalk and immune effector 
mechanisms (Lee et al., 2008). However, disruptive activities of TNF include 
modulation of tight-junction epithelial barrier loss, transepithelial impedance loss via 
upregulation of MLCK, downstream NFκB signalling pathway activation and AP-1 
transcription factors (Wang et al., 2005). Therefore, TNF concentrations need to be 
properly regulated to ensure the beneficial actions of TNF outweigh the negative 
consequences of having elevated TNF concentrations in the gut. 
The physiological and pathophysiological concentrations of TNF in different body 
compartments are variable. However, in disease stool concentrations have been 
shown to be much higher, reaching around 63.6 ng/g, particularly following infection 
such as by Shigella flexneri whilst serum concentrations of active CD and active UC 
were respectively 14.0 ng/l and 9.46 ng/l (Komatsu et al.,2001; Nicholls et al., 1993). 
In sepsis, the serum concentration of TNF is also high at about 440 units/ml 
(corresponding to 0.1 ng/ml recombinant TNF) (Waage et al., 1987). The 
concentration of TNF has pathophysiological relevance to the disease course and 
the severity of IBD and sepsis, with increasing concentrations correlating with more 
severe disease. 
Recent scientific advances in organoid culture have enabled enteroid studies that 
allow the direct study of the intestinal epithelium without the complexities of other 
cellular compartments found in vivo (Dekkers et al., 2013; Sato et al., 2009; 2011). 
Our lab has recently established enteroid cultures from mice and observed dose-
dependent and time-dependent effects of TNF on enteroid morphology and apoptosis 
that aligned well with observations from intestinal tissues from TNF treated mice in 
vivo (Jones et al., 2019). Enteroids were shown to become more spherical containing 
an increased abundance of shed cells with increased doses of TNF and time post-
treatment, suggesting that enteroids are a good model for investigating the actions 
of TNF on intestinal epithelia (Jones et al., 2019). The time course of these studies 
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was arbitrary, and the dynamic processes involved in enteroid rounding were not 
investigated (Jones et al., 2019). Understanding the balance between beneficial and 
disease-causing concentrations of TNF in IBD and sepsis and the direct actions of 
TNF on intestinal epithelia will guide future therapeutic approaches in IBD and sepsis. 
We have therefore further characterised the effects of TNF on enteroids and have 
investigated the consequences of elevated TNF concentrations at higher resolution 
using time-lapse microscopy.  
In the early parts of the twenty first century, live cell imaging system with an in-built 
time lapse microscopy device to monitor the dynamics of cells started to come into 
the limelight (Baker, 2010). The CytoSMART Lux is a live cell imaging system built 
with a phase contrast microscope innovative development and works within a tissue 
culturing incubator. It is user friendly and can monitor and capture cell culture, growth, 
treatment, and migration using time-lapse microscopy. Morphological changes that 
take place in enteroids after being treated with TNF could therefore be monitored at 
short time intervals over several days. Remotely, images and videos of cell culture 
can be viewed and warning messages in the case of something going wrong with the 
system can also be received. We therefore used CytoSMART Lux to monitor the 




3.2.1 TNF induces rounding in WT enteroids  
Jones and colleagues previously investigated the effects of TNF on WT enteroids 
using TNF doses of 0, 1, 10, 100, and 1000 ng/ml. TNF induced enteroid rounding 
reliably and reproducibly following 100 ng/ml by 24 hours post-treatment (Jones et 
al., 2019). However, maximal stool concentrations of TNF in humans infected by 
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Shigella flexneri were approximately 63.6 ng/g (Nicholls et al., 1993) and so we 
wanted to investigate whether doses of TNF applied to enteroids between 10 and 
100 ng/ml caused altered enteroid morphology to align with previously recorded 
pathologically relevant doses in humans.   
Different concentrations of TNF (0, 1, 10, 50, and 100 ng/ml) were used to treat 
enteroids and images were recorded at time intervals of 0, 24, and 48 hours post-
treatment (figure 3.1). We observed that 50 and 100 ng/ml TNF induced statistically 
significantly increased the rounding of enteroids while 1 ng/ml, and 10 ng/ml did not 
(figure 3.2). 
   
Figure 3.1 Bright field images of TNF-treated WT enteroids. A dose-dependent and 
time-dependent increase in TNF-treated WT enteroid circularity was observed. 
Images were taken with x10 original magnification and scale bars = 100 μm. 
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Figure 3.2 TNF caused a dose-dependent increase in WT-derived enteroid 
circularity. TNF was applied to enteroids at concentrations of 0 (purple), 1 (orange), 
10 (grey), 50 (yellow) and 100 (purple) ng/ml and circularity was assessed at 0, 24 
and 48 hrs; (P = *≤0.05, ***≤0.001 by one-way ANOVA), error bars represent SEM, 
n=6, N=3. 
 
3.2.2 TNF-treated WT-derived enteroids show reduced epithelial 
thickness 
As intestinal epithelial cells in enteroids have been shown to undergo TNF-induced 
apoptosis and cell shedding similarly to that observed in TNF treated small intestinal 
epithelia in vivo (Jones et al., 2019), we wanted to determine whether any other 
histological features present in the small intestine in vivo in response to TNF were 
also present in organoids in vitro in the absence of lamina propria. Enteroids were 
treated with 50 ng/ml TNF and collected for histology at time intervals of 0, 6, and 24 
hours.  Alkaline phosphatase stained enteroids counterstained with haematoxylin 
demonstrated there was a gradual loss of epithelial thickness from 0-24 hours 
following TNF addition (figure 3.3 and appendix B). Epithelial thickness was 
quantified and untreated enteroids had a relative thickness of 153.62±27 units that 



























24 hours thus demonstrating a reduction in epithelial thickness of around 56.74% 
over a 24-hour period in response to 50 ng/ml TNF (figure 3.4).  
 
    
Figure 3.3 Alkaline phosphatase counterstained with haematoxylin micrographs of 
50 ng/ml TNF-treated enteroids at 0, 6, and 24 hours. Epithelial thinning over time 
from 0 to 24 hours is indicated. Original magnification, x63 and scale bar = 100 μm. 
 
     
Figure 3.4 Relative epithelial thickness of untreated and 50 ng/ml TNF-treated WT 
enteroids were compared over a time course of 0 (blue), untreated 6 hours (brown), 
TNF-6 hours (grey), untreated 24 hours (orange) and TNF-24 hours (grey) hours, (P 
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3.2.3 TNF treatment induces claudin-7 remodelling in WT enteroids 
The claudin family are major proteins forming the tight junctional complexes of 
intestinal epithelial cells. Regulation of intestinal barrier function is managed by the 
integrity of junctional complexes. TNF has been shown previously to modulate the 
porosity of these junctional complexes (Marchiando et al., 2011) and redistribution of 
claudin family members may potentially contribute to IBD and sepsis pathogenesis.  
We therefore selected a panel of claudin family members and JAM-A known to be 
expressed in intestinal epithelia to determine whether they were remodelled in the 
enteroid system over the time-course of TNF treatment. 
Claudins that were selected for analysis included claudins -2, -7, 15, and JAM-A. 
Several of these proteins did not show redistribution or selected antibodies were not 
convincingly reliable (appendix B). However, TNF treatment of WT enteroids resulted 
in prominent claudin-7 redistribution. Immunohistochemistry demonstrated claudin-7 
expression along the epithelial junctions between neighbouring cells of untreated 
enteroids and this progressively decreased in intensity from untreated to 24 hours 
post-treatment with TNF. Claudin-7 staining gradually became more punctate and 
redistributed away from cell-cell junctions, suggesting that TNF treated enteroids may 
start to show differences in the regulation of the paracellular space between 










    
Figure 3.5 Immunohistochemical images of untreated and 6-hour and 24-hour post-
treatment of 50 ng/ml TNF-induced enteroids stained for claudin-7. Untreated 
enteroids displayed intact tight junction structural architecture (black arrows) whilst 
TNF-treated enteroids depicted remodelled junctions and punctate characterisations 
(red arrows), N=3. Original image (A) and enlarged (B) section. Original 
magnification, x63 and scale bars, A (100 μm) and B (20 μm). 
 
3.2.4 TNF-treated WT enteroids show asynchronous expansions and 
contractions 
TNF-induced behavioural patterns and morphological changes have not been 
monitored under dynamic conditions in enteroids.  Additionally, current studies have 
not investigated the process of TNF-induced enteroid rounding and how this may 
relate to in vivo activity. TNF concentrations of 0 ng/ml, 50 ng/ml, 100 ng/ml, and 200 
ng/ml were used to treat WT murine proximal enteroids and were imaged every 15 





time course. There were no overt expansions and contractions in the untreated 
enteroids (figure 3.6). However, TNF treatment caused expansions and contractions 
of enteroids that were asynchronous between different enteroids.  Each enteroid had 
different times of onset and duration of expansions and contractions (figure 3.7). In 
general, the expansion phase was longer than the contraction phase in TNF-treated 
enteroids.  
The earliest phenotypic behaviours of asynchronous expansions and contractions 
following 50, 100, and 200 ng/ml TNF started at 6 hours and 15 minutes, 6 hours and 
30 minutes, and 6 hours and 15 minutes for each dose respectively suggesting that 
expansions and contraction initiation in enteroids is not TNF dose-dependent. The 
last expansions and contractions following 50, 100, and 200 ng/ml TNF were 
observed at 61, 69, and 67 hours for each dose respectively, suggesting that it is only 
necessary for TNF to reach a threshold concentration to initiate these effects (figures 
3.7B-D). The mean duration of expansions and contractions of 50, 100, and 200 
ng/ml TNF-treated WT enteroids were respectively 34±0.49 hours, 47±3.64 hours, 
and 44 hours±7.39 hours. We observed that the majority of TNF-treated enteroids 
became auto-punctured before 50 hours, however this required timelapse 
visualisation to confirm so we could not determine whether enteroids that were not 
subjected to time lapse imaging got punctured. There was inconsistency of expansion 
and contraction among the TNF-treated enteroids which could be due to differences 
in the sizes and extent of responses of enteroids to TNF treatment. 
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Figure 3.6 The 50 ng/ml TNF treatment induced periodic, asynchronous expansions 
and contractions of WT murine enteroids. Untreated WT mouse enteroids did not 
demonstrate this behavioural pattern. Under the dynamic monitoring by CytoSMART, 
live cell imaging, the asynchronous expansions and contractions of TNF-treated 
enteroids were captured. During the expansion phase, the enteroids continued to 
expand until at a certain point they abruptly contracted and resumed the expansion 
phase and the expanding surface area seemed to be larger than the previous phase 
and suddenly contracted again. These interrupting cycles of expansions and 
contractions continued until the enteroid finally ruptured or leaked. Even though 
alternating expansion and contraction phases were not observed in untreated 
enteroids, these continued to grow and increase in surface area. Brightfield images 
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Figure 3.7 WT enteroids were treated with 0 (A), 50 (B), 100 (C), and 200 (D) ng/ml 
TNF and the CytoSMART imager collected images of nine individual enteroids per 
treatment every 15 minutes to monitor behavioural and morphological patterns over 
72 hours. The TNF-treated enteroids demonstrated periodic, asynchronous 
expansions and contractions while untreated enteroids did not. Enteroids showed 
differential onsets of expansion and contraction. In the graphs, experiments 1 (blue), 
2 (yellow) and green (3), n=3, N=3 
 
3.2.5 TNF treatment is associated with increased motility of enteroids 
Enteroids were observed to move within the Matrigel (a source of extracellular matrix 
ECM). We used the CytoSMART live cell imaging system to capture and monitor the 
migration of both untreated and treated WT-derived enteroids for 72 hours. WT-
derived enteroids migrated in unpredictable patterns within the ECM (figure 3.8). TNF 
treatment induced increased migratory distance and erratic patterns of motility in WT-
derived enteroids (figures 3.8B-D). The distance covered by untreated enteroids 
ranged from 200 to 300 µm with a mean distance of 260±18.56 µm (figure 3.8A). 
Enteroids treated with 50 ng/ml TNF covered distances ranging from 240 to 580 µm 
with a mean distance of 415.56±50.48 µm. Similarly, enteroids treated with 100ng/ml 
TNF covered distances ranging from 270 to 680 µm with a mean distance of 
453.33±60.00 µm and enteroids treated with 200 ng/ml TNF covered distances 
ranging from 290 to 660 µm with a mean distance of 398.89±50.48 µm. Within the 
first 12 hours post-treatment with TNF, the cumulative distance covered by TNF 
treated enteroids was not statistically significantly different compared with untreated 
enteroids.  However, by 24 hours post-TNF treatment, enteroids treated with 200 
ng/ml TNF were statistically significantly more motile than untreated enteroids 
(P=0.0075; 95% confidence interval (CI) = +12.36 to +43.20) and at 36 hours post-
TNF treatment, only enteroids treated with 100 ng/ml TNF had statistically 
significantly increased motility (P=0.0295; 95%CI +18.74 to +212.4). By 48 hours, all 
concentrations of TNF-treated enteroids exhibited migrations that were statistically 
significantly increased compared to untreated enteroids (figure 3.9).  
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TNF-treated WT-derived enteroids also demonstrated increased velocity in 
comparison to untreated enteroids (figure 3.10). All the different concentrations of 
TNF caused increased enteroid velocity between 36- and 60-hours post-treatment. 
100 ng/ml TNF resulted in the highest enteroid velocity (10.00±5.30 µm/hr) at 36 
hours post-treatment. This was almost triple the velocity (3.52±0.58 µm/hr) of 







Figure 3.8 Each enteroid migrated independently and without a defined direction. 
The motility of enteroids was captured by CytoSMART live cell imaging and motility 
patterns are presented. Untreated WT enteroids migrated through the ECM in multi-
directional patterns and covered distances of 200-300 µm (A). TNF-treated WT 
enteroids covered distances of 240-580 µm following 50 ng/ml (B), 270-680 µm 
following 100 ng/ml (C), and 270-660 µm following 200 ng/ml(D). Both untreated and 
TNF-treated WT enteroids covered different distances at different paces. Motility 








   
Figure 3.9 Cumulative distances covered by untreated WT control enteroids (blue) 
in 72 hours was 260±18.56 µm while that of 50 (orange), 100 (grey) and 200 (yellow) 
ng/ml, TNF were respectively 415.56±50.48 µm, 453.33±60.00 µm, and 
398.89±50.48 µm. *P≤0.05, **≤0.01, ***≤0.001, n=3, N=3, error bars = SEM. 
   
Figure 3.10 The velocity pattern of untreated WT enteroids (blue) was steady without 
any sudden increases. 50 (orange), 100 (grey), and 200 (yellow) ng/ml TNF-treated 
WT enteroids showed marked accelerations and decelerations at different times. 
*P≤0.05, **≤0.01, n=3, N=3, error bars = SEM. 
 
3.2.6 TNF-treated enteroids showed early increases in surface area 
Normally, growing enteroids continue to increase in surface area as stem cell division 
is supported by their culture media. However, TNF-treated enteroids responded to 



































































imaging system was used to capture the growth patterns of both resting and TNF-
stimulated enteroids. At 24 hours post-treatment, TNF-treated enteroids were about 
three times larger in relative net surface area (TNF 50 ng/ml [3183.78±1123.61 
units2], TNF 100 ng/ml [2748±722.62 units2], and TNF 200 ng/ml [2849.65±1051.10 
units2]) than control enteroids (1085.44±76.05 units2) (figure 3.11). Untreated 
enteroids did not demonstrate interrupted growth patterns as seen in the TNF-treated 
enteroids. The growth patterns of TNF-treated enteroids were perturbed by an abrupt 
increase in relative net surface area followed by a sudden decrease in their relative 
net surface area. All TNF doses resulted in increased surface area from 24 - 36 hrs. 
This then plateaued or enteroids even showed decreased surface area to lower 
values than that of the control.     
     
Figure 3.11 TNF induced early and sudden increases in the relative net surface area 
of enteroids while untreated enteroids (blue) progressively increased in the net 
surface area. Control (blue), TNF 50 ng/ml (orange), TNF 100 ng/ml (grey), and TNF 
200 ng/ml (yellow), *P≤0.05, n=3, N=3, error bars = SEM. 
 
3.2.7 Rescued TNF-treated enteroids demonstrated no rhythmic 
contractions and expansions 
TNF caused extensive damage to enteroids over 72 hours of treatment.  We have 










































enteroid stem cell niche may be negatively affected by TNF (Jones et al., 2019).  Due 
to extensive apoptosis caused by TNF in this system, we wanted to address whether 
enteroid stem cells were capable of surviving and replicating upon TNF stimulation 
and subsequent removal. TNF was added to cultures for 72 hours and then the 
culture media was discarded, enteroids were washed to remove residual TNF, fresh, 
culture media was added to the 24-well plates, and cultures were monitored for an 
additional 72 hours via CytoSMART live cell imaging. There were no periodic, 
asynchronous expansion and contraction patterns observed in the rescued enteroids 
following previous TNF treatment. The growth dynamics were similar to control 
enteroids and no sudden increases in enteroid area or abrupt decreases in area as 
a result of contractions were observed. The growth rate of rescued enteroids was 
however faster than that observed in untreated enteroids (although there was 
enteroid-enteroid variation), suggesting that stem cells remained active post-TNF 
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Figure 3.12 Rescued enteroids from the previously 50, 100, and 200 ng/ml TNF 
treated enteroids did not show the spikes of asynchronous expansions and 
contractions that they showed while in the presence of the stimulant (B-D). In 
comparison with untreated enteroids (A) their growth patterns were similar. The 
rescued enteroids showed progressive, uninterrupted growth patterns as captured by 
CytoSMART live cell imaging. Over 72 hours continuous monitoring, the rescued 
enteroids progressively increased in surface area. In the graphs, experiments 1 
(blue), 2 (yellow) and green (3), n=3, N=3. 
 
3.2.8 Rescued TNF-treated enteroids show reduced motility 
TNF treatment was applied to WT-derived enteroids for 72 hours, after which the 
treated culture media were discarded, enteroids were washed and the media was 
replaced. CytoSMART live cell imaging was used to capture the movement of 
rescued enteroids. The motility patterns of rescued WT enteroids were similar to 
those of untreated WT enteroids. There was no greatly accelerated motility in the 
rescued enteroids unlike during the previous 72 hours when TNF was applied. The 
cumulative distance covered within 72 hours by untreated WT enteroids was 
260±18.56 µm (figures 3.13 and 14). The cumulative distance covered within 72 
hours following the removal of 50 ng/ml TNF was 246.67± 14.53 µm, following the 
removal of 100 ng/ml TNF was 181.11± 44.39 µm and following removal of 200 ng/ml 





Figure 3.13 Micrographs of rescued enteroids that were previously treated with 50 
ng/ml, 100 ng/ml and 200 ng/ml TNF against untreated control. Rescued enteroids 
did not exhibit asynchronous expansions and contractions or increased motility. 
Magnification, x10 and scale bars, 100 μm. 
 
 
Figure 3.14 Cumulative distance (μm) travelled by control (blue), 50 (orange), 100 
(grey), and 200 (yellow) ng/ml TNF rescued enteroids over a 72-hour period following 
TNF washout. No statistically significant difference was observed between untreated 
and TNF rescued enteroids, n=3, N=3, error bars = SEM. 
 
3.2.9 Forskolin-treated enteroids are associated with asynchronous 
expansions and contractions 
Forskolin is an adenylyl cyclase activator and as such can be used to stimulate 
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Niisato & Marunaka, 2001). Boj and colleagues developed organoids from rectal 
biopsies containing either wild type or mutant cystic fibrosis transmembrane 
conductance regulator (CFTR) and showed that wild-type colonoids swelled in 
response to forskolin whereas CFTR mutant colonoids did not respond, showing the 
specificity of forskolin for CFTR-induced chloride secretion (Boj et al., 2017).  
We used forskolin in this study as a positive control for enteroid expansion to 
determine whether increased enteroid expansion was responsible for our observed 
increased enteroid motility in response to TNF. CytoSMART live cell imaging was 
used to capture the behavioural patterns and morphological changes of forskolin-
treated enteroids. The earliest observations of asynchronous expansions and 
contractions of forskolin-treated enteroids started at 2 hours and 15 minutes post-
treatment and lasted for 70 hours (figure 3.14). The mean duration of expansions and 
contractions of forskolin treated WT enteroids was 52±0.27 hours. The expansion 
phase ranged from 15 minutes to 8 hours while the contraction phase was shorter, 
usually up to 15 minutes. The expansion and contraction phases of forskolin-treated 
enteroids started earlier than those observed post-TNF treatment. During live cell 
imaging, the mean frequency of expansions and contractions of forskolin-treated 
enteroids was almost double that of TNF-treated enteroid (figure 3.15). However, the 
lengths of the contraction phases of forskolin-treated and TNF-treated enteroids were 




Figure 3.15 The 5 µM Forskolin was added to WT-derived enteroids for 72 hours. 
CytoSMART images were captured every 15 minutes to monitor the behavioural and 
morphological patterns of forskolin-treated enteroids. In the graphs, experiments 1 
(blue), 2 (yellow) and green (3), n=3, N=3. 
 
3.2.10 Forskolin-treated enteroids demonstrated reduced mobility 
As previously stated, we used forskolin in this study as a positive control for enteroid 
expansion. We treated enteroids with 5 µM forskolin and monitored them using time-
lapse imaging to capture behavioural and morphological changes. Forskolin-treated 
WT enteroids showed reduced motility compared with untreated and TNF -treated 
enteroids, but exhibited multi-directional patterns similarly to untreated and TNF 
treated enteroids (figures 3.8 & 3.16). The cumulative distance covered by forskolin-
treated WT enteroids in 72 hours ranged from 130 to 320 µm with a mean distance 
of 196.67±31.80 µm (figure 3.17). Patterns of velocity are shown in figure 3.18. We 
statistically compared the motility of forskolin treated enteroids to untreated control 
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Figure 3.16 Forskolin (5 µM)-treated WT enteroids migrated through the ECM in 
multi-directional patterns slowly and covered different distances. The shortest 
distance covered was 130 µm while the longest was 320 µm in 72 hours. Each 
enteroid migrated independently without a common direction. The motility of 
forskolin-treated enteroids was captured by CytoSMART live cell imaging (n=3, N=3). 
 
   
Figure 3.17 Cumulative distances covered by untreated WT enteroids (blue) in 72 
hours was 260±18.56 µm while that of forskolin-treated enteroids (orange) was 
196.67±31.80 µm. There was no statistically significant difference between the 
distance covered by untreated WT and forskolin-treated enteroids by one-way 
ANOVA, n=3, N=3, error bars = SEM. 
    
Figure 3.18 The velocity of both untreated (blue) and forskolin (5 µM)-treated 
(orange) WT enteroids were constant without any sudden increases or decreases in 
the first 48 hours of observation. Whilst the velocity of untreated enteroids continued 
to be constant throughout, that of forskolin-treated enteroids reduced at 48-72 hours 
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3.2.11 Forskolin stimulates increased enteroid surface area 
Forskolin-treated enteroids did not grow and show a steady increase in area like 
untreated enteroids (figure 3.19), but followed a similar trajectory to those treated 
with TNF. At 24 hours following forskolin treatment, the relative net surface area was 
doubled from 4052.11±1679.14 units2 to 8014.78±3221.73 units2. The maximal 
relative net surface areas of forskolin-induced swelling were observed at 36 hours 
(10427.89±6961.87) units2 and 48 hours (10517. 89±11386.20) units2 following 
forskolin treatment (figure 3.20). The growth patterns of forskolin-treated enteroids 
were perturbed by abrupt increases in the net surface areas followed by sudden 
decreases in the net surface areas.  
    
Figure 3.19 Bright field images of forskolin and TNF-treated WT enteroids. Dose-
dependent and time-dependent increases were observed in the circularity of 
forskolin-treated WT enteroids. Forskolin and TNF induced the highest degree of 
circularity on the treated WT enteroids at 48 hours while untreated WT enteroids had 





    
Figure 3.20 Forskolin (5 µM) induced an early and sudden increase in the net surface 
area of enteroids (orange) while untreated enteroids progressively increased in the 
net surface area at a slower rate (blue). Forskolin (5 µM) stimulated the largest net 
surface area (10517.89±11386.20) units2 at 48 hours post-treatment while the largest 
net surface area in untreated enteroids (6208.89±1468.32) units2 was at 72 hours. (P 
= **≤0.01, ***≤0.001), ANOVA, n=3, N=3, error bars = SEM. 
 
3.2.12 CFTR inhibition does not prevent TNF-induced rounding, 
expansion, and contraction in enteroids 
We observed that both TNF- and forskolin-treated enteroids demonstrated increased 
circularity. Previous studies have reported that forskolin-induced swelling was cystic 
fibrosis transmembrane conductance regulator (CFTR)-dependent (Boj et al., 2017; 
De Wolf et al., 1989). We therefore wanted to determine the mechanism responsible 
for TNF-induced enteroid expansions and contractions so utilised a specific CFTR 
inhibitor to determine whether chloride secretion was responsible for the altered 
enteroid morphology observed following TNF treatment.   
We treated WT enteroids with 0, 5, 20, and 50 µM CFTRinh-172 (CFTR inhibitor) and 
assessed enteroids for circularity at 0, 24 and 48 hours. The CFTRinh-172 did not 
induce any increase in circularity or cause pronounced cell apoptosis when 










































then proceeded to first pre-treat WT enteroids with different concentrations of 
CFTRinh-172 for one hour, after which we exposed them to 50 ng/ml TNF and 
obtained brightfield images at 0, 24, and 48 hours. We noticed that the actions of 
TNF on WT enteroids were not CFTR-dependent, since pre-treatment with the CFTR-
inhibitor failed to block TNF-induced increases in circularity (figures 3.22 and 3.23B). 
However, pre-treatment with 50 µM CFTRinh-172 has been shown the ability to 
inhibit forskolin-induced swelling and completely suppress an α-gliadin derived 
peptide-induced swelling in our laboratory under the same treatment conditions 
(Thompson and Duckworth unpublished observations, data not shown).  
 
    
Figure 3.21 Bright field images of CFTRinh-172-treated WT enteroids. There was no 
observed increase in circularity at 0, 24, and 48 hours following treatment with CFTR 






Figure 3.22 Bright field images of TNF treated enteroids following one-hour pre-
treatment with CFTRinh-172 at indicated concentrations. Circularity increased in 
response to TNF following CFTR inhibition. However, there was no increase in 
circularity of untreated enteroids. Micrograph x10 magnification and scale bar = 100 
μm. 
        
Figure 3.23 TNF causes increased enteroid circularity following CFTR inhibition 
Circularity analysis at 0, 24 and 48 hrs following 0, 5, 20 and 50 μM CFTRinh-172 
pre-treatment (A). Circularity analysis following 1hr CFTRinh-172 pre-treatment 
followed by 50 ng/ml TNF at 0, 24 and 48 hrs (B). (P = ***≤0.001), one-way ANOVA, 


















































































CFTRinh-172 5 μM+TNF 50 ng/ml
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3.2.13 Summary table of the characteristics of actions of TNF on WT 
enteroids 
Several parameters were investigated following treatment of WT-derived enteroids 
with TNF. Our observations are summarised in the table below.  
Differences between untreated and treated WT enteroids 
Features Untreated TNF-treated 





Growth predictability Almost steadily 
progressive 
Unpredictable with spikes 
Relative surface areas Progressively increasing Larger with expansions; 
smaller with contractions 
Motility Normal Increased 
Morphological shape Increasing irregularity Increasing rounding 
Epithelial thinning Normal Present 
Claudin-7 redistribution Normal Present 
Permeability Normal Increased 
CFTR inhibitor No rounding Does not prevent 
rounding 
Table 3.1 Phenotypic differences between untreated and TNF-treated enteroids. The 
growth patterns of untreated enteroids were not interrupted with asynchronous 
expansions and contractions as seen in TNF treated enteroids. Untreated enteroids 
showed a steady increase in relative surface areas, while TNF treated enteroids 
demonstrated frequent increases and decreases in relative surface areas. Untreated 




In this study, we characterised several novel actions of the pro-inflammatory cytokine 
TNF on enteroid cultures to further understand how TNF interacts with the intestinal 
epithelium to cause local and systemic disease. Previous studies have investigated 
the actions of TNF on cell populations along the crypt-villus axis in vivo and several 
of these studies have characterised the dynamic nature of villus tip epithelial cells 
using time-lapse microscopy over 1-4 hours (Kiesslich et al., 2007; Marchiando et al., 
2011; Duckworth & Watson, 2011). However, to date, to the best of our knowledge, 
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whilst cellular dynamics in response to TNF have been explored, tissue level 
dynamics have not. Therefore, we investigated whether we could dynamically via 
CytoSMART live cell imaging monitor the pathological responses of enteroids derived 
from the proximal small intestinal epithelia of WT mice to different concentrations (0, 
50, 100 and 200 ng/ml) of TNF treatment. 
The intraperitoneal injection of TNF into mice in vivo results in a rapid onset of small 
intestinal apoptosis and cell shedding that peaks around 90 minutes following 
administration (Duckworth & Watson, 2011; Watson et al., 2009). The administration 
of lipopolysaccharide (LPS) intraperitoneally to WT mice also resulted in intestinal 
mucosal cell shedding and apoptosis that was likely mediated by the actions of LPS 
on monocytes and macrophages to produce TNF (Williams et al., 2013). It has been 
widely reported in the literature that LPS treatment stimulates abundant cytokine 
production, most notably TNF as a major mediator of sepsis (Amiot et al., 1997; 
Amura et al., 1998; Hesse et al., 1988; Werner, Barken & Hoffmann, 2005). The 
intestinal epithelium is one of the first tissues to be damaged during the first 1-2 hours 
of sepsis and mechanistically there are many similarities with hyper-inflammation and 
mucosal damage observed during active inflammatory bowel disease where anti-
TNF therapy shows efficacy (Doig et al., 1998; Julian et al., 2011; Monaco et al., 
2015). Until recently, in vitro studies of tissue level dynamics have not been possible, 
as the majority of studies relied on standard two-dimensional tissue culture of cancer-
derived cell lines. It is now possible to reproduce the epithelial structure of the 
intestinal epithelium in enteroid cultures that display similar crypt-villus orientation 
and dynamics to that observed in vivo (Middendorp et al., 2014; Wallach & Bayrer, 
2017). The current study firstly corroborated our previous work (Jones et al., 2019) 
and demonstrated that TNF treatment caused dose-dependent and time-dependent 
enteroid rounding consistent with an increase in epithelial cell shedding and 
apoptosis. Building on these studies, we observed histologically that TNF treated 
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enteroids showed a time-dependent reduction in epithelial thickness – a 
phenomenon observed following TNF administration in experimental in vivo models 
and in recovery from active intestinal disease in humans (Dotti et al., 2017; Yoo & 
Donowitz, 2019). This suggests that intestinal enteroids are a good in vitro model that 
accurately replicates in vivo intestinal epithelial dynamics.   
We have previously investigated the actions of TNF in static conditions by bright field 
microscopy and by histology which have only allowed the analysis of a snapshot in 
time. In this chapter we dynamically monitored behavioural patterns and 
morphological changes in TNF-treated enteroids using CytoSMART time-lapse 
imaging and observed several surprising and unexpected phenomena. Though 
previous studies have reported the secretion of MMP from TNF-treatment (Yan et al., 
2001), we are not sure whether digestive effect of MMP might contribute to the 
increased motility of TNF-treated enteroids within the Matrigel. However, our 
proteomic results (chapter 5) shows that MMP7 proteins were upregulated in all the 
four strains. More investigations are warranted to understand the plausible 
mechanisms that might be responsible for the TNF-induced motility. 
Our results showed that different concentrations (50, 100, and 200 ng/ml) of TNF 
administered to WT enteroids were associated with periodic, expansions and 
contractions of whole enteroids that were asynchronous between enteroids within the 
same Matrigel support matrix. Previous studies have investigated TNF-induced 
oscillations of NFκB subunits (especially p65) between the cytosol and the nucleus 
in individual cells in two-dimensional tissue culture and observed a frequency of 
around 0.5 oscillations per hour (Dorrington & Fraser, 2019; Lane et al., 2017; Lee et 
al., 2014; Pekalski et al., 2013; Zambrano et al., 2016). It warrants more 
investigations to elicit what might be the driving mechanisms behind asynchronous 
expansions and contractions of TNF-treated enteroids. Further work is needed to 
determine whether this is related to NFκB signalling activation.   
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The CytoSMART live cell imaging system that we used to monitor the behavioural 
patterns of TNF-treated enteroids captured increased motility and multi-directional 
migration of enteroids. Different concentrations of TNF were associated with changes 
in velocities, acceleration, deceleration, and overall distance migrated. TNF has been 
widely reported in many studies to play a key role in promoting cell motility. Wolczyk 
and colleagues reported that the cell migration induced by TNF treatment of MCF7 
and MDA-MB-231 cell lines was due to an increase in matrix metalloprotease 9 
(MMP9) (Wolczyk et al., 2016). Boecke and colleagues in a B16 mouse melanoma 
cell line study reported that TNF induced motility and invasion occurred via TNF-
receptor-1 adaptor protein FAN (factor associated with neutral sphingomyelinase 
activation) (Boecke et al., 2013). TNF and transforming growth factor-β (TGF-β) 
synergistically stimulated epithelial-mesenchymal transition (EMT) to promote cell 
motility, cell-cell adhesion dissociation, and spindle-cell shape reorganization (Saito 
et al., 2013; Zhang et al., 2015). Pathologically, TNF-mediated motility contributes in 
no small measure to cancer migration, invasion, and metastasis and physiologically 
it is very relevant in wound healing and repair (Bingle, Brown & Lewis, 2002; Waters, 
Pober & Bradley, 2013; Yu et al., 2010). The biological significance of the expansions 
and contractions and enhanced motility observed in TNF treated enteroids is 
currently unclear. However, migration of stem cell containing crypts at the tissue level 
within intestinal epithelia could help to distribute stem cells around the mucosa 
efficiently to stimulate and enhance the production of new crypts, thus aiding greatly 
in tissue restitution following injury. We hypothesise that intestinal stem cells had the 
capacity to resist cell death and apoptosis by demonstrating the capacity of enteroids 
to continue to grow following TNF removal. This ability to regenerate persisted at all 
TNF concentrations tested including 200 ng/ml, which is a supra-pathophysiological 
concentration. To date, tissue-level dynamics in the intestinal mucosa have not been 
extensively investigated in real-time and in 3 dimensions, and so the enteroid 
platform may provide a novel approach to study this area.  
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We demonstrated that TNF treatment caused rapid swelling of WT murine enteroids 
by using NIH ImageJ to quantity the net surface areas and wanted to understand the 
responsible mechanism, as fluid infiltrate is also observed within the intestinal luminal 
compartment following TNF or LPS injection into mice (Williams et al., 2013) and 
diarrhoea is associated with human IBD and sepsis (Anbazhagan et al., 2018; 
Larmonier et al., 2011; Laubitz et al., 2016). It is possible that TNF mediates these 
biological activities of fluid effusion into the lumen via ion channels opening and 
dysfunction of cell-cell junctions leading to increased epithelial barrier porosity (Ma 
et al., 2005; Schmitz et al., 1996; Ye et al., 2006). We observed an accumulation of 
fluid in the enteroid lumen following TNF administration and reported a decrease in 
epithelial thickness which may have caused a similar phenotypic response as to that 
shown in in vivo intestinal epithelia following TNF or LPS administration and also in 
humans with resultant fluid accumulation in the gut prior to diarrhoea. We therefore 
sought to investigate potential mechanisms. Several protein components make up 
intestinal tight junctions which modulate the paracellular space and are the 
components that modulate the leakiness of the epithelial barrier. We identified 
several claudins and junctional adhesion molecules that are known to be important 
in maintaining gut barrier function and investigated their expression in enteroids over 
the time-course of TNF treatment. Claudin-7 knockout and intestinal-specific claudin-
7 knockout mice die soon after birth due to a lack of intestinal crypt and villus 
formation, connective tissue hyperplasia and excessive inflammatory infiltrate (Xu et 
al., 2019). Claudin-7 showed significant remodelling following the application of TNF 
to enteroids suggesting that this claudin is important in regulating the epithelial cell 
response to TNF and may be at least partially responsible for enhanced permeability 
leading to fluid accumulation. Tanaka and colleagues investigated the role claudin-7 
played in initiating inflammation via paracellular-barrier change by conducting an 
experiment on intestine-specific conditional knockout mice of claudin-7 (Tanaka et 
al., 2015). Claudin-7 deficiency increased paracellular permeability across the 
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colonic epithelium (paracellular flux (pFlux). They observed passage of the small 
organic solute Lucifer Yellow (457 Da) across the intestinal epithelium due to 
enhanced paracellular permeability whilst larger organic solute such as FITC-Dextran 
(4400 Da) could not pass through (Tanaka et al., 2015).  
To address further potential mechanisms responsible for fluid accumulation in TNF 
treated enteroids and to determine whether the act of expansion was responsible for 
enhanced enteroid motility, we explored whether forskolin (Sigma-Aldrich, F3917) 
treatment had similar phenotypic consequences when applied to enteroids. Forskolin 
is an adenylate cyclase activator that has previously been used to stimulate chloride 
ion secretion in enteroids resulting in enteroid expansion. Forskolin-mediated 
chloride secretion was shown to be mainly mediated by CFTR as cystic fibrosis 
patient-derived or CFTR mutant mouse enteroids were resistant to forskolin-induced 
swelling (Dekkers et al., 2013). Forskolin-treated enteroids demonstrated early rapid 
swelling and reduced motility compared with untreated enteroids as previously 
reported in other studies (Dekkers et al., 2013). The observation that forskolin treated 
enteroids did not migrate to the magnitude observed in TNF-treated enteroids 
suggests that the act of expansion itself is not responsible for stimulating this 
enhanced motility and that other as yet unknown mechanisms are therefore likely to 
be responsible. Enteroids migrated in seemingly random directions and no obvious 
chemotactic gradient in the surrounding matrix was observed. We cannot rule out the 
production of TNF-induced secretions from neighbouring enteroids that would have 
influenced the direction of migration depending on each individual enteroid’s local 
environment.     
We further explored whether the swelling observed in TNF treated enteroids was 
CFTR-dependent. We first treated enteroids with CFTR inhibitor-172 (Merck, 
219670-5MG) to observe whether it would have any lethal effect and/or 
morphological changes on the enteroids. We did not observe any CFTR inhibitor-
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172-lethal effects or induced morphological changes. We blocked CFTR in TNF-
treated enteroids using a CFTR-specific inhibitor at concentrations previously shown 
in our lab to block forskolin-induced enteroid swelling. CFTR inhibition did not 
however prevent the expansion, contraction or motility changes observed in TNF 
treated enteroids, so we can conclude that the mechanisms of TNF and forskolin-
induced expansions are likely to be different. CFTR inhibitor-172 was applied prior to 
forskolin in a separate study at the same concentration and was shown to block 
forskolin-induced enteroid expansion.  Unfortunately, this combination of treatments 
was not conducted at the same time as other treatments in the current study. 
We have therefore demonstrated under static and dynamic conditions that TNF 
treatment of enteroids induces various types of pathological actions which might have 
significant importance in the dysregulation of intestinal barrier function that is present 
during active IBD and sepsis. The enteroid model shows features of intestinal 
damage that are consistent with damage in inflammatory disease conditions of the 
gut and in isolation will be important in the exploration of tissue level dynamics within 
the intestinal epithelium that are difficult to conduct in vivo. Future studies of pro-
inflammatory cytokines and their mechanisms of action both at the cellular and tissue 
levels will enable far greater understanding of the processes of IBD and sepsis 
pathogenesis, but will also shed light into future novel therapeutic approaches to 








4. The effect of alternative pathway NFκB activation on 
enteroids 
4.1 Introduction  
Intestinal epithelial cells provide physical (mucus layer, glycocalyx and cell junctional 
complexes) and chemical barriers (antimicrobial peptides, lysozyme and immune 
cell-derived cytokines) to protect the gut against any invading microorganisms and 
maintain intestinal homeostasis between the luminal commensal microbiota and the 
body (Liang et al., 2006; Okumura &Takeda, 2017). Any disruption of this delicate 
equilibrium can result in compromised intestinal epithelial barrier function. Kiesslich 
and colleagues reported that the defective intestinal barrier integrity that resulted from 
cell shedding in the terminal ileum played a major role in the prediction of relapse of 
IBD in humans (Kiesslich et al., 2012). Additionally, Cani and colleagues and Piton 
and colleagues postulated that a dysfunctional intestinal barrier is a critical 
component of the pathogenesis of acute intestinal failure due to sepsis and metabolic 
endotoxemia-induced inflammation (Cani et al., 2008; Piton et al., 2011).  
Activation of NFκB signalling pathways is involved in the regulation of various cellular 
processes. The alternative NFκB signalling pathway has been implicated in 
modulating disease susceptibility in sepsis and IBD and has also been demonstrated 
to regulate intestinal epithelial cell-specific apoptosis and cell shedding in mice and 
in enteroid cultures (Williams et al., 2013, Jones et al., 2019).  In particular, NFκB2 
was shown to be an important NFκB family member in regulating the epithelial 
damage response to TNF and IFNγ (Jones et al., 2019, chapter 4 of this thesis).  
However, these previous studies did not investigate how extensive the protective 
response conferred by alternative NFκB pathway inhibition (by deletion of NFκB2) 
was to other stimuli and whether the response was fully mediated via alternative 
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NFκB signalling pathway activation or whether complex links with classical pathway 
NFκB signalling were also implicated. Alternative pathway NFκB signalling can be 
activated by the interaction of a ligand (LPS, virus, BAFF, CD40L and others) with 
intestinal cell surface receptors such as TLR4 and LTβR (Dejardin, 2006; Luftig et 
al., 2004). The ligand triggers recruitment of TRAFs especially TRAF3, which only 
regulates the alternative NFκB signalling pathway (Greten et al., 2004). This results 
in activation of NIK and IKKα that stimulate the processing of p100 into p52, which 
dimerizes with RelB. The p52/RelB heterodimers translocates from the cytoplasm to 
the nucleus resulting in the transcription of inflammatory target genes (Merga et al., 
2016; Nishikori et al., 2005). Several members of the TNF superfamily are thought to 
exclusively regulate alternative pathway NFκB signalling. 
The TNF superfamily is a group of cytokines with common features and currently 
consists of 19 TNF superfamily (TNFSF) ligands and 29 TNF receptor superfamily 
(TNFRSF) receptors in humans (Lang et al., 2016) (table 1). The majority of TNFSF 
ligands are type II transmembrane proteins (single pass molecules that anchored 
with a signal-anchor sequence with its C-terminal (not N-terminal) directed toward 
the endoplasmic reticulum) with polytopic proteins that readily aggregate and easily 
precipitate in water (Qu, Zhao, & Li, 2017). By contrast, the TNFRSF receptors are 
derived from oligomeric, type I, or type III transmembrane proteins (Smulski et al., 
2017; Ward-Kavanagh et al., 2016). Ligands of TNFSF interact with TNFRSF to 
generate intracellular signals on target cells such as the intestinal epithelium.   
The TNFSF ligands and TNFRSF receptors play regulatory and signalling roles in 
inflammation, proliferation, apoptosis, immune cells, cell functions, embryogenesis 
cell differentiation and tissue homeostasis (Bodmer et al., 2002; Locksley, Killeen, & 
Lenardo, 2001). From 19 TNFSF ligands, we selected 6 for evaluation based on their 
ability to strongly activate alternative pathway NFκB signalling (table 4.1). The 
selected family members were TNF, TNF-related weak inducer of apoptosis 
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(TWEAK), lymphotoxin-like, exhibits inducible expression and competes with HSV 
glycoprotein D for herpesvirus entry mediator [HVEM] receptor, expressed by T 
lymphocytes (LIGHT), cluster of differentiation 40-L (CD 40-L), lymphotoxin α/β 
(LTα/β), and B-cell activating factor (BAFF). Expression of these TNFSF members 
has previously been detected in humans and is upregulated in inflammatory 
conditions, however, most studies report serum concentrations and not local tissue 
or stool concentrations which may be further elevated beyond those found in serum 
similarly to TNF (Komatsu et al., 2001; Nicholls et al., 1993, table 4.2).  
TWEAK is associated with cell apoptosis, proliferation and survival via activation of 
TNF receptor-2 followed by stimulation of NIK to effect transcriptional inflammatory 
genes (Burkly et al., 2011). Activation of TWEAK signalling via Fn14 induces a 
dysfunctional intestinal epithelial cell barrier and promotes recruitment of 
inflammatory cells and enhanced synthesis of inflammatory mediators, especially in 
IBD and sepsis (Chicheportiche et al., 1997; Dohi & Burkly, 2012; Winkles, 2008). 
Upregulation of the TWEAK signalling pathway disrupts intestinal epithelial 
homeostasis and encourages translocation of commensal and invading microbes. 
Chopra and colleagues reported that inhibition of TWEAK-Fn14 signalling resulted in 
reduction of intestinal cell apoptosis and development of disease (Chopra et al., 
2015). As previous studies have been performed to evaluate whole organ 
pathophysiology, we wanted to determine whether the actions of TWEAK were 
important specifically by direct interaction with intestinal epithelial cells. 
LIGHT, through activation of HVEM, TNFRSF14 (TR2 or LIGHTR), and lymphotoxin 
β receptor (LTβR) modulates T cell proliferation, cell survival and apoptotic regulation 
(Clayburgh et al., 2006; Granger & Rickert, 2003). Krause and colleagues 
administered dextran sulphate sodium (DSS) to TNFSF14 (LIGHT) KO mice and 
reported that they had lower survival rates, higher loss of body weight, and developed 
more severe colitis in comparison with WT mice (Krause et al., 2014). Activation of 
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LIGHT via MLCK causes compromised intestinal epithelial integrity (Clayburgh et al., 
2006). We therefore assessed the direct effects of LIGHT on the intestinal epithelium 
in the context of Nfκb2 deletion.   
CD40-L interacts with CD40 cell-surface glycoprotein to modulate adaptive immune 
responses by upregulating MHC and co-stimulatory mediators including CD80 or 
CD86. CD40 can be found in various cells including intestinal epithelial cells, antigen 
presenting cells (APCs), B cells, endothelial cells, and epithelial cells of other organs 
(Gelbmann et al., 2003). Activation of CD40-L and its interaction with the CD40 cell 
surface of intestinal epithelial cells (IECs) stimulates effector T cells and inflammatory 
processes in IBD (van Kooten & Banchereau, 2000). Borcherding and colleagues 
obtained biopsies from 112 patients with Crohn’s disease and 67 patients with 
ulcerative colitis and reported that patients with active IBD showed 
immunofluorescence staining for CD40 in IECs within inflamed mucosae 
(Borcherding et al., 2010). However, biopsies from 38 healthy controls, patients with 
IBD in remission, and the non-involved mucosa of patients with active IBD 
consistently showed lack of CD40 immunofluorescence staining in IECs (Borcherding 
et al., 2010).  We therefore wanted to assess the epithelial cell-specific effects of 
CD40 binding to CD40-L.  
Lymphotoxin plays an important role in the regulation of intestinal mucosal immune 
responses (Wang et al., 2010). Activation of LTβ receptor (LTβR) signalling has been 
reported to mediate both protective and pathogenic responses during intestinal 
inflammation (Upadhyay & Fu, 2013). Several studies using sepsis-induced models 
have demonstrated that lymphotoxin had protective properties against intestinal 
injury (Jungbeck et al., 2008; Tumanov et al., 2011) while inhibition of the LTβR 
signalling pathway has been observed to decrease intestinal damage in a T-cell-
mediated colitis model (Mackay et al., 1998). 
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BAFF through high affinity receptors such as BAFFR and transmembrane activator‐
calcium modulator and cyclophilin ligand interactor (TACI) mediates cell proliferation, 
differentiation and survival of B cells, while through low affinity receptors such as B 
cell maturation antigen (BCMA) it coordinates immunoglobulin class‐switch 
recombination (Mackay & Leung, 2006; Ng, Mackay, & Mackay, 2005). BAFF 
promotes intestinal epithelial cell proliferation by activating the TLR signalling 
pathway (Macpherson & McCoy, 2007). Zhang and colleagues conducted a study on 
44 healthy controls, 78 patients with UC, and 37 patients with CD and reported that 
serum BAFF concentrations (pg/ml) were 977 (482-1345) in healthy, 1430 (1105-
1624) in CD and 1472 (1018-1772) in CD subjects (Zhang et al., 2016). The 
sensitivity and specificity of serum BAFF concentration in identifying active IBD from 
healthy controls was 64% and 93% respectively (Zhang et al., 2016). Previous 
studies in our laboratory have demonstrated that Nfκb2-/- enteroids were protected 
against damage caused by IFNγ, which is not known to directly stimulate alternative 
pathway NFκB signalling (Jones et al., 2019). Several studies in lung epithelia have 
suggested that IFNγ can upregulate BAFF which is known to activate the alternative 
NFκB signalling cascade hence we sought to address whether BAFF can cause 
direct epithelial cell damage in an enteroid model.  
One of the aims of this study was to understand how activation of alternative pathway 
NFκB signalling by members of the TNFSF superfamily regulates epithelial cell 
survival and contributes to the disease processes of IBD and sepsis. Many previous 
studies that have been conducted in our laboratory have demonstrated rounding 
effects of TNF in WT enteroids and a blunted effect of TNF on rounding in Nfκb2-/- 
enteroids. Therefore, we were interested in investigating the actions of other 
members of the TNF superfamily and to find out how this family of cytokines 
modulates the development of intestinal and systemic diseases. 
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TNF TNF 17 (s) & 
26 (m) 
233 6 (MHC) Regulates immune cells, 
induces fever, cachexia, 
inflammation, apoptosis; 
inhibits tumorigenesis, viral 
replication, response to 
sepsis  
TWEAK TNFSF12 17 249 17 Induces apoptosis, 
proliferation, migration, 
regulates angiogenesis 
LIGHT TNFSF14 26 240 19 Stimulates T cell proliferation, 
regulates apoptosis 
CD40-L TNFSF5 33 261 Xq26-27 Regulates adaptive immune 
response, activates antigen-
presenting cell 
LTαβ LTA, LTB 25 & 33 205 & 
244 





BAFF TNFSF13B 31 285 13 Activates B cell, proliferation 
and differentiation of B cells 
Table 4.1 Alternative pathway activators with their gene, molecular weights, amino 
acid lengths, chromosomal locations, and functions (Alexaki et al., 2009; Armitage et 
al., 1992; Browning et al., 1993; Granger & Rickert, 2003; Moss et al., 1997; Wiley et 

















TNF superfamily Health Disease 
TNF Serum: 0.020 ng/ml;  
Faecal: undetectable  




TWEAK Plasma: 307 (63-3492) pg/ml
  
Plasma: 352 (101–







fatty liver disease) 
CD40-L Plasma: 1.10±0.07 ng/ml Plasma: 3.55±0.67 
ng/ml (CD); 
2.71±0.37 ng/ml (UC) 





BAFF Serum: 977 (482-1345) 
pg/ml; 
Faecal: 295 (284-309) pg/ml 
Serum: 1472 (1018-




493) pg/ml (CD), 542 
(358-1758) pg/ml 
(UC) 
Table 4.2 The TNF superfamily, alternative pathway activators with their 
concentrations in health and disease (Arican et al., 2005; Damas et al., 1992; 
Grimstad et al., 2017; Komatsu et al., 2001; Ludwiczek et al., 2003; Nicholls et al., 
1993; Otterdal et al., 2015; Schwartz et al., 2009; Waage et al., 1987; Young et al., 
2010; Zhang et al., 2016). 
 
4.2 Results 
4.2.1 TNF-induced phenotypic changes in enteroids is blunted following 
Nfκb2 deletion 
WT mouse intestinal epithelial enteroids were treated with different TNF 
concentrations (0, 1, 10, 50, and 100 ng/ml) for 48 hours. Under static conditions, 
bright field images were taken at 0, 24, and 48 hours from six individual enteroids for 
each of 3 independent experiments (n=6, N=3). TNF caused a dose-dependent 
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increase in enteroid rounding (figures 4.1 and 4.3a) which has previously been 
linearly correlated with enteroid cell death (Jones et al., 2019). Baseline circularity in 
untreated WT enteroids was 0.36±0.01 and 24 hours post-TNF, circularity values 
increased to 0.41±0.05 following 1 ng/ml TNF up to 0.73±0.02 following 100 ng/ml 
TNF and reaching statistical significance versus control by 10 ng/ml. Similar 
significantly increased TNF-induced circularity values were obtained up to 48 hours 
post treatment (figure 4.3a). Nfκb2-/- enteroids proliferated at similar rates to WT 
enteroids and displayed morphologically identical features at baseline. Baseline 
circularity of Nfκb2-/- enteroids was 0.35±0.02 and was not statistically significantly 
different from baseline WT enteroid circularity. However, TNF-treated Nfκb2-/- 
enteroids did not respond with the same degree of rounding observed in TNF-treated 
WT enteroids at the same TNF doses and time points (figures 4.2 and 4.3b). Nfκb2-/- 
enteroids achieved maximal circularity across all doses and time-points of only 
0.58±0.03 at 48 hours post 100 ng/ml TNF suggesting that they were more resistant 
than WT enteroids to the effects of TNF (figure 4.3b). Comparison of TNF-treated WT 
with TNF-treated Nfκb2-/- enteroids demonstrated that there were statistically 
significant differences between them at 24- and 48-hours following treatment. 





   
Figure 4.1 Bright field images of TNF-treated WT enteroids. Enteroids were treated 
with 0, 1, 10, 50 and 100 ng/ml TNF and images were collected at 0, 24, and 48 
hours post treatment as indicated. Marked dose-dependent and time-dependent 
increases in enteroid circularity were observed. Images were taken at 10x original 
magnification; scale bars, 100 μm. 
 
  
Figure 4.2 Bright field images of TNF-treated Nfκb2-/- enteroids. Enteroids were 
treated with 0, 1, 10, 50 and 100 ng/ml TNF and images were collected at 0, 24, 
and 48 hours post treatment as indicated. Subtle dose-dependent and time-
dependent increases in TNF-treated Nfκb2-/- enteroid circularity can be discerned. 






Figure 4.3 WT and Nfκb2-/- enteroids treated with TNF (A). TNF causes a dose-
dependent and time-dependent increase in WT-derived enteroid circularity (A) but a 
blunted increase in circularity in Nfκb2-/- enteroids (B). Statistical differences were 
identified by ANOVA vs control at same time point, P = (*≤0.05, **≤0.01, ***≤0.001), 
and statistically significant differences between WT + TNF vs Nfκb2-/- + TNF at the 
same concentration and time point are shown by (###p≤0.001), n=6 organoids per 
treatment group, N=3 independent experiments, error bars with SEM.   
 
4.2.2 TWEAK requires Nfκb2 signalling to cause morphological changes 
of enteroids   
Differential doses of TWEAK ranging from 0,1, 10, 50, and 100 ng/ml were used to 
treat WT mouse intestinal epithelial enteroids for 48 hours. At 0, 24, and 48 hours, 
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independent experiments (n=6, N=3). TWEAK induced a dose-dependent increase 
in enteroid rounding (figures 4.4 and 4.6a). Untreated WT enteroid circularity at the 
outset was 0.37±0.03 and at 24 hours post-treatment with TWEAK, circularity 
increased from 0.44±0.03 following 1 ng/ml TWEAK to 0.66±0.07 following 100 ng/ml 
TWEAK. TWEAK treatment versus control became statistically significant at doses 
at and greater than 10 ng/ml TWEAK. At 48 hours post-TWEAK treatment, similar 
significantly increased TWEAK-associated circularity was observed. Baseline 
morphological characteristics of WT and Nfκb2-/- enteroids were similar. There was 
no statistically significant difference between baseline WT enteroid circularity and 
baseline Nfκb2-/- enteroid circularity (0.39±0.01) (figures 4.4 and 4.5). However, there 
was a stark difference in the degree of rounding in TWEAK-treated WT enteroids in 
contrast with TWEAK treated Nfκb2-/- enteroids. TWEAK-treated WT enteroids 
demonstrated higher circularity values than Nfκb2-/- enteroids at the same doses and 
time points (figure 4.6). At 48 hours following TWEAK administration, Nfκb2-/- 
enteroids attained maximal circularity of 0.49±0.01 following 100 ng/ml TWEAK 
suggesting that they exhibited more attenuated effects than WT enteroid responses 
to actions of TWEAK (figure 4.6b). At 24- and 48- hours following treatment, we 
compared TWEAK-treated WT with TWEAK-treated Nfκb2-/- enteroids and observed 





Figure 4.4 Bright field micrographs of TWEAK-treated WT enteroids. Enteroids 
were treated with different concentrations of TWEAK from 0, 1, 10, 50 to 100 ng/ml. 
Their images were collected at 0, 24 and 48 hours post-treatment. Apparent dose-
dependent and time-dependent increases in enteroid circularity were noticed. 
Images were taken at 10x original magnification; scale bars, 100 μm. 
 
  
Figure 4.5 Bright field images of TWEAK-treated Nfκb2-/- enteroids. Enteroids were 
treated with 0, 1, 10, 50 and 100 ng/ml TWEAKF and images were captured at 0, 
24 and 48 hours following TWEAK treatment. Blunted dose-dependent and time-
dependent increases in TWEAK-treated Nfκb2-/- enteroid circularity were observed. 




Figure 4.6 TWEAK induced a dose-dependent and time-dependent increase in WT-
derived enteroid circularity (A) but attenuated increase in circularity in Nfκb2-/- 
enteroids [Control (blue), 1 ng/ml TWEAK (orange), 10 ng/ml TWEAK (grey), 50 
ng/ml TWEAK (yellow), 100 ng/ml TWEAK (purple) and 100 ng/ml TNF (green)]. 
Statistical differences were identified by ANOVA vs control at same time point, P = 
(*≤0.05, **≤0.01, ***≤0.001), and statistically significant differences between WT + 
TWEAK vs Nfκb2-/- + TWEAK at the same concentration and time point are shown 
by (#≤0.05, ##≤0.01, ###p≤0.001), n=6 organoids per treatment group, N=3 
independent experiments, error bars with SEM. 
 
4.2.3 LIGHT causes increased WT enteroid circularity which is blunted 
following Nfκb2 deletion  
We treated WT mouse enteroids with different LIGHT concentrations (0,1, 10, 50, 
and 100 ng/ml) for 48 hours. Bright field images were captured at 0, 24, and 48 hours 
from six individual enteroids for each of 3 independent experiments (n=6, N=3). 
LIGHT stimulated a dose-dependent increase in enteroid rounding (figures 4.7 and 
4.9a). Untreated WT enteroid circularity at baseline was 0.36±0.01, but at 24 hours 
following treatment with LIGHT, circularity values increased dose-dependently from 
0.41±0.02 following 1 ng/ml LIGHT to 0.55±0.03 following 100 ng/ml LIGHT. LIGHT-
induced circularity showed a significant increase following 50 ng/ml. Similarly, LIGHT-
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values at 48 hours following treatment (4.9a). LIGHT-treated Nfκb2-/- enteroids 
demonstrated a blunted rounding response compared to LIGHT-treated WT 
enteroids at similar LIGHT concentrations and time points (4.8 and 4.9b). Across all 
doses and time courses, the maximal LIGHT-induced circularity obtained in Nfκb2-/- 
enteroids was only 0.41±0.04 at 48 hours following 100 ng/ml LIGHT. This suggests 
that Nfκb2-/- enteroids are more resistant to LIGHT treatment than WT enteroids 
exposed to the same treatment (figure 4.9b). Comparison of LIGHT-treated WT with 
LIGHT-treated Nfκb2-/- enteroids demonstrated that there were statistically significant 
differences at 24- and 48-hours following treatment.  
  
Figure 4.7 LIGHT-treated WT enteroid bright field micrographs. Enteroids were 
treated with 0, 1, 10, 50 and 100 ng/ml LIGHT. At 0, 24 and 48 hours post-
treatment images were recorded. Relative dose-dependent and time-dependent 
increases in enteroid circularity were noticed. Images were taken at 10x original 






Figure 4.8 Bright field images of LIGHT-treated Nfκb2-/- enteroids. LIGHT 
concentrations of 0, 1, 10, 50 and 100 ng/ml were used to treat Nfκb2-/- enteroids 
and images were captured at 0, 24 and 48 hours following treatment. Diminished 
dose-dependent and time-dependent increases in LIGHT-treated Nfκb2-/- enteroid 
circularity can be observed. Images were taken at 10x original magnification; scale 
bars, 100 μm. 
 
 
Figure 4.9 LIGHT induced a dose-dependent and time-dependent increase in WT-
derived enteroid circularity (A) but diminished responses in circularity in Nfκb2-/- 
enteroids (B) [Control (blue), 1 ng/ml LIGHT (orange), 10 ng/ml LIGHT (grey), 50 
ng/ml LIGHT (yellow), 100 ng/ml LIGHT (purple) and 100 ng/ml TNF (green)]. 
Statistical differences were identified by ANOVA vs control at same time point, P = 
(*≤0.05, **≤0.01, ***≤0.001), and statistically significant differences between WT + 
LIGHT vs Nfκb2-/- + LIGHT at the same concentration and time point are shown by 
(#≤0.05, ##≤0.01, ###p≤0.001), n=6 organoids per treatment group, N=3 
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4.2.4 CD40-L induces moderate morphological changes in WT enteroids 
but less in Nfκb2-/- enteroids 
A range of CD40-L concentrations (0,1, 10, 50, and 100 ng/ml) were similarly used 
to treat WT mouse intestinal epithelial enteroids for 48 hours. Under static conditions, 
bright field images were taken at 0, 24, and 48 hours of six individual enteroids in 
each of 3 independent experiments (n=6, N=3). Dose-dependent and time-
dependent increases in rounding in the CD40-L-treated WT enteroid were observed 
(figures 4.10 and 4.12a). Baseline circularity in untreated WT enteroids was 
0.36±0.01, while at 24 hours following CD40-L treatment, the circularity increased 
from 0.40±0.03 following 1 ng/ml to 0.55±0.02 following 100 ng/ml CD40-L. There 
was a similar trend of increased CD40-L-induced circularity values observed 48 hours 
following CD40-L treatment (4.12a). The degree of rounding caused by CD40-L-
treatment of Nfκb2-/- enteroids differed from the response observed in CD40-L-treated 
WT enteroids at the same CD40-L doses and time points (figures 4.11 and 4.12b). 
Nfκb2-/- enteroids reached maximal circularity values across all concentrations and 
time course of 0.45±0.03 at 48 hours post 100 ng/ml indicating that they were less 
susceptible than WT enteroids to the effects of CD40-L (figure 4.12b). At 24- and 48- 
hours following treatment, comparison of CD40-L-treated WT with CD40-L-treated 





Figure 4.10 Bright field micrographs of CD40L-treated WT enteroids. CD40-L 
concentrations (0, 1, 10, 50 and 100 ng/ml) were utilised to treat WT enteroids and 
images were taken at 0, 24 and 48 hours post-treatment. Subtle dose-dependent 
and time-dependent increases in enteroid circularity were demonstrated. Images 
were taken at 10x original magnification; scale bars, 100 μm. 
 
  
Figure 4.11 Bright field images of CD40-L-treated Nfκb2-/- enteroids. Enteroids 
were treated with 0, 1, 10, 50 and 100 ng/ml CD40-L. At 0, 24 and 48 hours 
following treatment with CD40-L images were captured. No significant dose-
dependent and time-dependent increases in CD40-L-treated Nfκb2-/- enteroid 
circularity can be discerned. Images were taken at 10x original magnification; scale 





Figure 4.12 CD40-L triggered a dose-dependent and time-dependent increase in WT 
enteroid circularity (A) more reduced responses in circularity in Nfκb2-/- enteroids (B) 
[Control (blue), 1 ng/ml CD40-L (orange), 10 ng/ml CD40-L (grey), 50 ng/ml CD40-L 
(yellow), 100 ng/ml CD40-L (purple) and 100 ng/ml TNF (green)]. Statistical 
differences were identified by ANOVA vs control at same time point, P = (*≤0.05, 
**≤0.01, ***≤0.001), and statistically significant differences between WT + CD40-L vs 
Nfκb2-/- + CD40-L at the same concentration and time point are shown by (##≤0.01, 
###p≤0.001), n=6 organoids per treatment group, N=3 independent experiments, 
error bars with SEM.  
 
4.2.5 LTα/β slightly regulates WT and Nfκb2-/- enteroid phenotype  
WT mouse intestinal epithelial enteroids were treated with different LTα/β 
concentrations (0,1, 10, 50, and 100 ng/ml) for 48 hours. Using a microscope, bright 
field images were captured at 0, 24, and 48 hours from six individual enteroids for 
each of 3 independent experiments (n=6, N=3). LTα/β slightly caused a dose-
dependent increase in enteroid rounding (figures 4.13 and 4.15a). Baseline circularity 
in untreated WT enteroids was (0.40±0.03) and 24 hours following treatment with 
LTα/β, circularity values gradually increased from 0.43±0.04 following 1 ng/ml LTα/β 
to 0.48±0.04 following 100 ng/ml LTα/β. In comparison with the control, LTα/β 
treatment did not induce any statistically significant circularity at 24 hours post-
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increased circularity only at the highest concentrations of 50 and 100 ng/ml LTα/β 
(figure 4.15a). Although LTα/β-treated Nfκb2-/- enteroids slightly responded with 
minimal rounding at 24 hours following treatment, there was no statistically significant 
difference between the LTα/β-induced responses at 48 hours compared to controls 
(figures 4.14 and 4.15b). Maximal LTα/β-induced Nfκb2-/- enteroid circularity 
achieved across all doses and time-points was only 0.40±0.02 at 48 hours post 100 
ng/ml LTα/β (figure 4.15) suggesting that this stimulus has little direct impact on 
damage to the intestinal epithelium. Comparison of LTα/β-treated WT with LTα/β-
treated Nfκb2-/- enteroids demonstrated that there was significant difference at 48 
hours.  
  
Figure 4.13 Bright field micrographs of LTα/β-treated WT enteroids. Enteroids were 
treated with 0, 1, 10, 50 and 100 ng/ml LTα/β. At 0, 24, and 48 hours post-treatment 
various images of the enteroids were recorded. No major dose-dependent and 
time-dependent increases in enteroid circularity were observed. Images were taken 





Figure 4.14 Bright field images of LTα/β-treated Nfκb2-/- enteroids. Enteroids were 
treated with 0, 1, 10, 50 and 100 ng/ml LTα/β. At 0, 24, and 48 hours following 
treatment with LTα/β images were captured. No major significant dose-dependent 
and time-dependent increases in LTα/β-treated Nfκb2-/- enteroid circularity can be 
discerned. Images were taken at 10x original magnification; scale bars, 100 μm.   
 
        
Figure 4.15 LTα/β induces a minor dose-dependent and time-dependent increase in 
WT-derived enteroids circularity (A) and slightly appreciable responses in circularity 
in Nfκb2-/- enteroids (B) [Control (blue), 1 ng/ml LTα/β (orange), 10 ng/ml LTα/β 
(grey), 50 ng/ml LTα/β (yellow), 100 ng/ml LTα/β (purple) and 100 ng/ml TNF 
(green)]. Statistical differences were identified by ANOVA vs control at same time 
point, P = (*≤0.05, **≤0.01, ***≤0.001), and statistically significant differences 
between WT + LTα/β vs Nfκb2-/- + LTα/β at the same concentration and time point 
are shown by (ns = not significant, #≤0.05, ##p≤0.01), n=6 organoids per treatment 
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4.2.6 BAFF does not modulate a major WT or Nfκb2-/- enteroid 
morphology   
In our previous study (Jones et al 2019), IFNγ stimulated enteroid rounding that was 
blunted in Nfκb2-/- enteroids but the mechanism responsible for this remains intriguing 
and elusive. As IFNγ is known to stimulate BAFF production (Lundell et al., 2017) 
and BAFF is a known NFκB alternative pathway activator, we wanted to determine 
whether BAFF had a direct effect on enteroids that may partially explain the 
protection of Nfκb2-/- enteroids from INFγ.  BAFFR is normally expressed on immune 
cell populations and less is known about its expression/potential to be expressed 
following stimulation on intestinal enterocytes. Our broad-spectrum proteomic 
analysis (Chapter 5) did not enrich for cell surface receptors and BAFFR was not 
detected, however, this may have been due to assay sensitivity. We therefore treated 
WT mouse intestinal epithelial enteroids with different BAFF concentrations (0, 1, 10, 
50, to 100 ng/ml) for 48 hours to determine wither BAFF caused any morphological 
effects on WT enteroids. Bright field micrographs were obtained at 0, 24, and 48 
hours from six individual enteroids for each of 3 independent experiments (n=6, N=3). 
BAFF induced a minor dose-dependent increase in enteroid rounding (figures 4.16 
and 4.18a). The baseline circularity value in untreated WT enteroids was 0.36±0.00 
and 24 hours following BAFF treatment when compared with control, there was no 
remarkable increase in circularity values from the lowest concentration of 1 ng/ml 
BAFF (0.41±0.02) to the highest concentration of 100 ng/ml BAFF (0.49±0.05). 
Similarly, there was no significant increase in BAFF-induced circularity values at 48 
hours post-treatment (Figure 4.18a). There were minor significant differences in 
circularity between WT and BAFF-treated Nfκb2-/- enteroids. BAFF doses and time 
points tested (figure 4.17 and 4.18b). Nfκb2-/- enteroids achieved maximal circularity 
across all doses and time-points of only 0.45±0.01 at 48 hours following 100 ng/ml 
BAFF suggesting that BAFF has a minimal effect on the rounding of WT or Nfκb2-/- 
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enteroids at the doses and time-points tested (figure 4.18b). At 24- and 48- hours 
following treatment, comparison of BAFF-treated WT with BAFF-treated Nfκb2-/- 
enteroids did not demonstrate any statistical significance.  
  
Figure 4.16 Bright field images of BAFF-treated WT enteroids. Enteroids were 
treated with 0, 1, 10, 50 and 100 ng/ml BAFF. At 0, 24, and 48 hours following 
treatment several images of the enteroids were captured. BAFF induced minor dose-
dependent and time-dependent increases in enteroid circularity. Images were taken 
at 10x original magnification; scale bars, 100 μm.  
 
 
Figure 4.17 Bright field micrographs of BAFF-treated Nfκb2-/- enteroids. Enteroids 
were treated with 0, 1, 10, 50 and 100 ng/ml BAFF. At 0, 24, and 48 hours following 
treatment with BAFF images were taken. No major significant dose-dependent and 
time-dependent increases in BAFF-treated Nfκb2-/- enteroid circularity were 





Figure 4.18 BAFF caused a minimal dose-dependent increase in WT-derived (A) 
and Nfκb2-/- (B) enteroid circularity [Control (blue), 1 ng/ml BAFF (orange), 10 ng/ml 
BAFF (grey), 50 ng/ml BAFF (yellow), 100 ng/ml BAFF (purple) and 100 ng/ml TNF 
(green)]. Statistical differences were identified by ANOVA vs control at same time 
point, P = (*≤0.05, **≤0.01, ***≤0.001), and statistically significant differences 
between WT + LTα/β vs Nfκb2-/- + LTα/β at the same concentration and time point 
are not significant, n=6 organoids per treatment group, N=3 independent 
experiments, error bars with SEM. 
 
4.2.7 TNF and TWEAK have additive effects on WT enteroid morphology 
As TNF and TWEAK both independently stimulated increased enteroid circularity, but 
mostly at concentrations at the higher end of the pathological concentrations 
observed in humans, we wanted to determine whether reduced amounts of these 
cytokines in combination would have an additive effect on inducing enteroid 
circularity. WT mouse enteroids were therefore treated with various concentrations 
of both TNF and TWEAK in combination (0, 1, 10, 50, and 100 ng/ml) for 48 hours. 
Under static conditions, bright field images were taken at 0, 24 and 48 hours of six 
individual enteroids from each of 3 independent experiments (n = 6, N = 3). WT 
enteroids showed dose- and time-dependent increases in circularity with various 
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those observed in experiments where the cytokines were added alone (figures 4.19 
and 4.20). Untreated WT enteroids had a baseline circularity of 0.37±0.00 which was 
similar to all previous studies above. Following 24 hours of treatment with each 
cytokine in equal quantities measured in ng/ml, circularity values were 0.39±0.02 (1 
ng/ml), 0.54±0.00 (10 ng/ml), 0.72±0.01 (50 ng/ml) and 0.77±0.02 (100 ng/ml). A 
similar trend was observed at 48 hours post treatment (figure 4.2). Enteroids treated 
with 10 ng/ml TNF and 10 ng/ml TWEAK had statistically significantly increased 
circularity compared to enteroids treated with 10 ng/ml of each cytokine alone. The 
mean difference in circularity between 10 ng/ml each of TWEAK and TNF compared 
to 10 ng/ml TWEAK was 0.05±0.04 (p = 0.05) at 24 hours post treatment and 
0.12±0.05 (p = 4.9 x 10-3) at 48 hours post-treatment. Similarly, the mean difference 
in circularity between 10 ng/ml each of TWEAK and TNF and 10 ng/ml TNF alone 
were 0.08±0.08 (p = 0.11) at 24 hours and 0.17±0.06 (p = 0.02) at 48 hours post-
treatment.  
  
Figure 4.19 Bright field images of TWEAK-TNF-treated WT enteroids. Enteroids 
were treated with 0, 1, 10, 50 and 100 ng/ml each of TWEAK and TNF. At 0, 24, 
and 48 hours following treatment several images of the enteroids were obtained. 
TWEAK-TNF induces marked increase in dose-dependent and time-dependent 
increases in enteroid circularity values. Images were taken at 10x original 
magnification; scale bars, 100 μm.  
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Figure 4.20 TWEAK-TNF causes a dose-dependent increase in WT enteroids 
circularity. The dose of combined 10 ng/ml each of TWEAK and TNF (C) induced a 
significant increase in circularity compared to individual TNF (A) or TWEAK (B) doses 
of the same concentration at 48 hours post-treatment. Statistical differences were 
identified by ANOVA vs control at same time point, P = (*≤0.05, **≤0.01, ***≤0.001), 
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4.2.8 Other cytokines: IL-6 induced major increase in circularity of WT 
but reduced in Nfκb2-/- enteroids 
When WT enteroids were reconstituted with LPS-activated bone-marrow-derived-
dendritic cells, enteroids underwent circularity changes similarly to enteroids treated 
with 100 ng/ml (Jones et al., 2019). However, when a panel of cytokines were 
assayed from the enteroid media, the concentration of TNF was lower than that 
necessary to induce the observed circularity changes suggesting that another 
cytokine may contribute to enteroid damage.  IL-6 was the most abundant cytokine 
detected (Jones et al., 2019). We therefore assessed the effects of IL-6 on enteroid 
circularity in addition to the panel of alternative pathway NFκB activators, as 
increased concentrations of this cytokine are often found in conditions that cause 
elevated circulating TNF concentrations. WT enteroids were therefore treated with 
different IL-6 concentrations (0, 1, 10, 50 and 100 ng/ml) for 48 hours. Under static 
conditions, bright field images were taken at 0, 24, and 48 hours of six individual 
enteroids each of from 3 independent experiments (n=6, N=3). A dose-dependent 
and time-dependent increase in circularity was quantified in IL-6-treated WT 
enteroids (figures 4.21 and 4.23a). Untreated WT enteroids displayed a baseline 
circularity of 0.39±0.03. Enteroids treated with IL-6 showed dose-dependent 
increases in circularity by 24 hours post-treatment which were 0.42±0.03 (1 ng/ml), 
0.43±0.05 (10 ng/ml), 0.57±0.05 (50 ng/ml), and 0.63±0.04 (100 ng/ml). TNF (100 
ng/ml) was used as a positive rounding control and showed a circularity of 0.72±0.01 
at 24 hours which was greater than the degree of circularity generated by IL-6 at the 
same dose and time-point. Similar trends continued to be observed in enteroids at 
the 48-hour time point. IL-6-treated Nfκb2-/- enteroids did not respond with the same 
degree of rounding that was observed in IL-6-treated WT enteroids (figure 4.22). 
They exhibited a blunted response to IL-6 treatment (figure 4.23b). Untreated Nfκb2-
/- enteroids had a baseline circularity of 0.40±0.01 and at 24 hours post-treatment 
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showed a maximum circularity of 0.49±0.01 following 100 ng/ml which was 
significantly lower than the circularity observed in WT enteroids given the same dose 
of IL-6 (0.63±0.04) and time. The blunted circularity response of Nfκb2-/- enteroids to 
IL-6 continued at 48 hours post-treatment. Comparison between IL-6-treated WT with 
IL-6-treated Nfκb2-/- enteroids demonstrated that there were statistically significant 
differences at 24- and 48-hours following treatment.  
 
Figure 4.21 Bright field images of IL-6-treated WT enteroids. Enteroids were 
treated with 0, 1, 10, 50 and 100 ng/ml IL-6. Images were taken at 0, 24, and 48 
hours post-IL-6 treatment. Marked dose-dependent and time-dependent increases 
in enteroid circularity were demonstrated. Images were taken at 10x original 
magnification; scale bars, 100 μm. 
 
  
Figure 4.22 Bright field micrographs of IL-6-treated Nfκb2-/- enteroids. Enteroids 
were treated with 0, 1, 10, 50 and 100 ng/ml TNF and images were collected at 0, 
24, and 48 hours following treatment as indicated. Blunted dose-dependent and 
time-dependent increases in TNF-treated Nfκb2-/- enteroid circularity can be 
discerned. Images were taken at 10x original magnification; scale bars, 100 μm. 
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Figure 4.23 IL-6 caused a dose-dependent and time-dependent increase in WT-
derived enteroid circularity (A) which was suppressed in Nfκb2-/- enteroids (B) 
[Control (blue), 1 ng/ml IL-6 (orange), 10 ng/ml IL-6 (grey), 50 ng/ml IL-6 (yellow), IL-
6 (purple), and 100 ng/ml TNF (green)]. Statistical differences were identified by 
ANOVA vs control at same time point, P = (*≤0.05, **≤0.01, ***≤0.001), and 
statistically significant differences between WT + IL-6 vs Nfκb2-/- + IL-6 at the same 
concentration and time point are shown by (#≤0.05, ##≤0.01, ###≤0.001), n=6 
organoids per treatment group, N=3 independent experiments, error bars with SEM.  
 
4.2.9 Summary of action of alternative pathway activators 
Different actions of the alternative pathway activators on WT and Nfκb2-/- enteroids 
are tabulated below (table 4.3). 
Cytokines WT enteroids Nfκb2-/- enteroids 
TNF ↑↑↑↑ ↑ 
TWEAK ↑↑ ↑ 
LIGHT ↑↑ ↑ 
CD40-L ↑ ↑ 
LTαβ ↑ - 
BAFF ↑ - 
IL-6 ↑↑↑ ↑ 
Table 4.3 A summarise table of different rounding responses of WT and Nfκb2-/- 
enteroids to treatment of various cytokines. TNF induces the highest rounding while 
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TNF, TWEAK, LIGHT, CD40-L, LTαβ, and BAFF are TNF superfamily members with 
alternative pathway NFκB activation properties. Members of the TNF superfamily and 
IL-6 are proinflammatory cytokines. Most of the alternative pathway activators in our 
study induced rounding in WT intestinal epithelial enteroids derived from the proximal 
small intestine of mice, while none of them exerted the same degree of rounding in 
Nfκb2-/- enteroids. We showed a hierarchical effect of the TNF superfamily on 
circularity of WT enteroids with TNF having the greatest and BAFF the least effect. 
The extent of TNF superfamily-induced circularity of WT enteroids decreased in the 
order TNF, TWEAK, LIGHT, CD40-L, LTαβ and BAFF. By contrast, in the Nfκb2-/- 
enteroids the hierarchical effects of TNF superfamily-induced circularity were not 
applicable as a blunted response to enteroid rounding in Nfκb2-/- enteroids compared 
to WT enteroids administered the same treatment was observed. This finding of 
relative resistance to morphological changes caused by Nfκb2 deletion was 
previously reported in enteroids treated with TNF and IFNγ (Jones et al., 2019 and in 
chapter 3 of this thesis) and in dextran sulphate sodium (DSS) treated Nfκb2-/- mice 
in our lab (Burkitt et al., 2015).  
Enteroid rounding is associated with apoptosis, cell shedding, cell death, loss of villus 
domains and loss of epithelial thickness (Jones et al., 2019 and Duckworth et al. 
unpublished). Enteroid rounding results from the accumulation of fluid in the enteroid 
lumen; this may correspond to a clinical feature often seen prior to diarrhoea or 
increased intestinal motility. Increased fluid accumulation in the small intestine has 
also been observed following systemic LPS injection into mice (Williams et al., 2013) 
suggesting that similar mechanisms are observed in vivo and in enteroids in vitro. 
TWEAK was previously thought to exclusively activate the alternative NFκB signalling 
pathway (Armstrong et al., 2016) however in renal epithelial junctional protein 
expression perturbance, TWEAK has been implicated in the activation of canonical 
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NFκB pathway (Berzal et al., 2015). Previous studies reported that TWEAK was up-
regulated in Crohn’s disease and played a major role in mediating Crohn’s-like ileitis 
and intestinal inflammation via multiple innate and adaptive cellular pathways in 
experimental animals (Di Martino et al., 2019). The elevated concentration of TWEAK 
detected in serum during traumatic brain injury has also been associated with the 
severity of inflammatory response, morbidity, mortality, and clinical outcome index 
(Tang et al., 2019). It is not clear from previous whole organism studies however 
whether TWEAK has a direct effect on the intestinal epithelium to modulate cellular 
dynamics. We were able to isolate the epithelium from other cellular compartments 
using enteroids to address the direct impact of TWEAK on epithelial cells alone. 
Similarly, to the increased circularity induced by TNF, TWEAK induced rounding of 
WT murine enteroids, but with a lesser degree of potency than that caused by TNF, 
suggesting that TWEAK has a direct effect on the intestinal epithelium. The 
combination of TWEAK and TNF treatment in WT enteroids induced more rounding 
following 10 ng/ml each of TNF and TWEAK and was greater than the circularity 
induced by either TNF or TWEAK alone. This finding demonstrates that in vivo there 
may be a complex milieu of cytokines that regulate the damage response of the 
intestinal epithelium and the tissue concentration of individual cytokines may exert 
damaging effects at significantly lower concentrations than single cytokines or 
combinations of a small number of cytokines in vitro. 
LIGHT signals lymphotoxin beta receptor (LTβR) to mediate many proinflammatory 
responses, progression of DSS-induced colitis, autoimmune encephalomyelitis, 
systemic sclerosis, multiple myeloma, and severity of inflammation-related diseases 
(Brunetti et al., 2018; Gindzienska-Sieskiewicz et al., 2019; Mana et al., 2103). 
However, LIGHT signalling through the receptor of herpes virus entry mediator 
(HVEM) had a protective effect against DSS-induced colitis in mouse models (Giles 
et al., 2018). LIGHT signalling is therefore context and tissue dependent.  Our results 
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showed that LIGHT induced rounding of WT enteroids, though this was greatly 
blunted in Nfκb2-/- enteroids suggesting that LIGHT damages the intestinal epithelium 
and that alternative pathway NF-κB signalling is important for LIGHT-induced 
pathology in this tissue. CD40 is present on the surfaces of non-immune (epithelial, 
platelets, endothelial and mesenchymal) and immune (B cells, monocytes, 
macrophages and dendritic cells) cells (Schonbeck & Libby, 2001). CD40 combines 
with CD40L to trigger a complex signalling pathway that involve activation of TNF 
receptors and stimulation of ERK-1/2, p38 and JNK resulting in activation and 
translocation of transcription factors (NFκB, activator protein 1 (AP-1) and nuclear 
factor of activated T-cells (NFAT)) to induce inflammatory conditions including IBD 
(Danese, Sans & Fiocchi, 2004; Grammer & Lipsky, 2001). Many studies have 
reported that CD40-L is expressed by activated T-cells and via CD40 acts on B cells 
to mediate cell proliferation, survival, inflammation, thrombosis, oxidative stress, and 
differentiation (Jabati et al., 2018; Lai et al., 2019; Rizvi et al., 2008). Sathawane and 
colleagues in their mouse tumour model reported that CD40 had a dual functionality 
because they observed that lower expression levels of CD40/CD40-L promoted 
tumour growth while higher expression levels of CD40/CD40-L were associated with 
tumour regression (2013). In our study, CD40-L induced a moderate rounding 
response in treated WT mouse enteroids and this may suggest that interaction of 
CD40 with CD40-L plays an important role in the epithelial cell-specific 
immunomodulation. Portillo and colleagues reported the functional importance of 
how simultaneous stimulation of mouse macrophages via CD40 and TNF activation 
resulted in up-regulation of inducible nitric oxide synthase (NOS2) and nitric oxide 
production which play prominent roles in proinflammatory production and 
hyperinflammatory response (Portillo et al., 2012). 
LTαβ did not induce any rounding effect on the WT enteroids at 24 hours post-
treatment, the minimal rounding response it induced on WT enteroids was only 
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observed at 48 hours post-treatment. Previous studies have shown that LTαβ 
signalling through LTβ receptor mediated regulatory control of inflammation, cell 
proliferation, survival, immune response, apoptosis, and differentiation (Bauer et al., 
2012; Shen et al., 2017). LTαβ therefore has little direct impact on the intestinal 
epithelium, but its effects could be exerted indirectly by modulating intestinal immune 
responses. Clinically, BAFF plays a significant role in immunostimulatory modulation 
and deficiency or impairment of BAFF function has been associated with reduced 
immunoglobulin production and development of immunodeficiencies (Sakai & 
Akkoyunlu, 2017; Vincent et al., 2013). Damage to lung epithelia has been 
demonstrated by the IFNγ induction of BAFF (Kato et al., 2006) and we therefore 
wanted to address whether this alternative pathway NFκB activator was important in 
directly regulating intestinal epithelial damage. BAFF induced minimal rounding of 
WT or Nfκb2-/- enteroids during the experimental time course at all doses investigate 
suggesting that BAFF is not an important direct regulator of the intestinal epithelial 
damage response. In a previous study using a co-culture of bone marrow-derived 
dendritic cells with enteroids, we determined that secreted factors from LPS activated 
dendritic cells induced increased enteroid circularity. Interestingly, the concentration 
of TNF produced from activated dendritic cells was not high enough to generate the 
observed circularity increases alone, but we identified that IL-6 in the supernatant of 
LPS activated dendritic cells was in great abundance (43967.35 ± 4220.72 pg/ml) 
(Jones et al., 2019). We therefore conducted IL-6 dose-response and time-course 
studies on enteroids. IL-6 induced enteroid circularity, but to a lesser extent than that 
observed following TNF treatment and this effect was blunted following Nfκb2 
deletion. This suggests that the combination of TNF and IL-6 may have caused 
increased enteroid circularity when LPS activated bone marrow-derived dendritic 
cells were previously co-cultured with enteroids. These two cytokines are also major 
players in the pathogenesis of IBD, rheumatoid arthritis, sepsis and other 
inflammatory diseases (Koss et al., 2000; Matsumoto et al., 2018). Various studies 
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have reported that patients with active IBD presented with highly increased serum 
concentrations of IL-6 and inflamed intestinal mucosa exhibited several IL-6-positive 
mesenchymal cells on tissue biopsies (Mudter & Neurath, 2007; Reinisch et al., 
1999). The combined inhibition of TNF, IL-6 and NFκB2 signalling may therefore 
show added efficacy in IBD and sepsis therapy and warrants further investigation.  
The results presented in this chapter indicate the important role alternative NFκB 
pathway activators play in health and disease especially during sepsis and IBD (Tak 
& Firestein, 2001). Further interrogation of the mechanisms involved in the 
susceptibility of WT enteroids to the effects of alternative pathway activators and 
resistance of Nfκb2-/- enteroids to the alternative NFκB pathway activators maybe a 
gateway to understanding the pathogenesis, progression, and prognosis of sepsis 
and the development of directed therapeutics against it. Various receptors (BAFFR, 
LTβr and others) play prominent roles in binding with the alternative NFκB pathway 
activators (Vincent et al., 2013; Shen et al., 2017) but the degree of accessibility and 














5 Mechanisms by which TNF may modulate enteroid 
morphology and dynamics 
5.1 Introduction 
In studies presented in chapters 3 and 4 under both dynamic and static conditions, 
we reported morphological changes and behavioural patterns of enteroids induced 
by NFκB signalling pathway activators. We also previously reported in chapter 3 that 
TNF treated WT and TNF treated Nfκb2-/- enteroids demonstrated different 
morphological responses. WT enteroids rounded in the presence of TNF whereas 
this response was blunted in Nfκb2-/- enteroids, suggesting that the deletion of Nfκb2 
in mice confers protectivity against TNF-induced injury in the small intestinal 
epithelium. Several additional TNF superfamily members were also shown to alter 
enteroid morphology, indicating that this phenotype is not unique to TNF and 
suggesting that some of the downstream signalling that occurs following receptor 
ligation and NFκB activation may be similar.   
TNF is widely recognised to activate both classical and alternative NFκB signalling 
pathways to perpetuate or inhibit inflammation. Several publications have utilised 
animal models to demonstrate that perturbation of the classical NFκB signalling 
pathway specifically in the intestinal epithelium modulates the response to 
inflammatory stimuli (Gebert et al., 2020; Han et al., 2018; Mikuda et al., 2020). We 
have also demonstrated that signalling via alternative NFκB pathway activation is 
important in regulating the intestinal epithelial response to injury (chapters 3 and 4 
and Jones et al., 2019). TNF stimulation of Nfκb1-/- enteroids resulted in a similar 
degree of rounding compared to enteroids derived from WT jejunum (Jones et al., 
2019), suggesting that Nfκb1 itself either confers protectivity that could not be 
demonstrated at the time points and doses of TNF selected or that there is functional 
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redundancy with other classical NFκB signalling pathway members within intestinal 
epithelial cells (Jones et al., 2019). However, global knockout of Nfκb1 increased the 
susceptibility of Nfκb1-/- mice to experimental colitis (Burkitt et al., 2015; Williams et 
al., 2013) and radiation-induced intestinal mucositis (Burkitt et al., 2017; Wang et al., 
2004), suggesting that there is a complex interplay between different tissue 
compartments such as intestinal immune cells and the intestinal epithelium.  
We therefore wanted to interrogate the possible mechanisms responsible for the 
blunted effects of TNF on Nfκb2-/- enteroids and the potential alterations in the 
intestinal epithelial-specific proteome that occur when various different NFκB family 
members have been deleted. This will allow an increased understanding of how the 
NFκB family of transcription factors modulates the intestinal epithelium under 
homeostatic conditions and under inflammatory stress present during IBD and 
sepsis.  
Proteomics is a vast field and it combines computational algorithms and modern 
mass spectrometry to study the dynamics of functional and static proteins (Graves & 
Haystead, 2002). It enables a thorough study of proteins in a system at the 
translational level. To date, no studies have been conducted to determine how TNF 
impacts the enteroid proteome, however, several broad-spectrum proteomic 
analyses of the intestinal mucosa under inflammatory conditions have been 
described (Han et al., 2013). These studies have used either human intestinal 
mucosa from pinch biopsies, resected intestinal tissue (M'Koma et al., 2011; Starr et 
al., 2017) or mucosal scrapes from the murine intestine (Jensen et al., 2017; Sotillo 
et al., 2017) which all contain multiple cell types in addition to epithelial cells. Mixed 
cell populations can make proteomic analysis difficult to interpret, as it is unclear as 
to whether inflammatory mediators modulate the proteome of immune, mesenchymal 
stromal cells or epithelial cells and whether changes in the proteome of specific cell 
types are direct or indirect consequences of interaction with these mediators. The 
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intestinal enteroid system is a culture system that contains purely epithelial cells and 
has been shown to have consistent cellular dynamics and degrees of differentiation 
with the intestine in vivo. We have therefore determined the direct impact of a defined 
cytokine specifically on the epithelium using enteroids and a broad-spectrum 
proteome analysis approach.   
 
5. 2 Results 
5.2.1 There are differences in the intestinal epithelial proteome following 
Nfκb modulation 
Intestinal epithelial enteroids were cultured from Nfκb1-/-, Nfκb2-/- and c-Rel-/- 
transgenic and wild type mice. Due to anticipated baseline differences in epithelial 
protein expression between different transgenic enteroid lines, comparative analyses 
of protein profiles for the resting murine transgenic enteroids against the proteome of 
resting WT enteroids was first conducted (Figures 5.1). We identified around 5000-
6000 different proteins from each enteroid sample. From comparison of the untreated 
WT enteroids against untreated Nfκb1-/- enteroids, there were only 3 (43%) proteins 
that were significantly up-regulated and 4 (57%) that were significantly down-
regulated. We are not sure what could be responsible for the small difference we 
observed between untreated WT and Nfκb1-/- enteroids, probably due to redundancy, 
variability in sample preparation for proteomic analysis or limitation of the lysing buffer 
we used. The comparison of untreated Nfκb2-/- with untreated WT-derived enteroids 
yielded 52 significantly differentially regulated proteins of which 27 (52%) were 
upregulated and 25 (48%) were down-regulated. When untreated c-Rel-/- enteroids 
were compared against WT enteroids, 36 significantly differentially regulated proteins 
were detected, of which 14 (39%) were up-regulated and 22 (61%) were down-
regulated (figure 5.1). These data indicate that whilst enteroids derived from Nfκb1-/-
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, Nfκb2-/- and c-Rel-/- proximal small intestine look morphologically alike at baseline 
(chapter 4 and Duckworth unpublished), subtle changes in their proteome can be 
identified using our broad-spectrum proteomic approach.  
Several of these differentially regulated proteins may contribute to the background 
susceptibility of the intestinal epithelium to cytokine induced damage and therefore 
contribute to IBD and sepsis severity. For example, Regenerating islet-derived 
protein 4 (Reg4) was up-regulated in Nfκb1-/-, Nfκb2-/- and c-Rel-/- enteroids. Reg4 is 
known to be epithelial cell-derived and is upregulated in the human intestinal mucosa 
during active ulcerative colitis and following remission (Planell et al., 2013). ATP-
binding cassette sub-family G member 5 (Abcg5) and H2-m2 were both down-
regulated in Nfκb1-/-, Nfκb2-/- and c-Rel-/- enteroids. Abcg5 is an intestinal transporter 
implicated in the regulation of fat digestion and absorption and may therefore 
modulate the intestinal luminal environment resulting in different susceptibilities of 
the intestinal epithelium to damage. A protein that was exclusively up-regulated in 
Nfκb1-/- enteroids was alcohol dehydrogenase 4 (Aldh4) which is implicated in the 
formation of retinoic acid from retinol and contributes to maintaining normal 
morphology. Down-regulated proteins found exclusively in Nfκb1-/- enteroids were 
cytochrome b-245 light chain, which is required for efficient microbicidal activity and 
alcohol dehydrogenase 6 (Adh6a). H-2 class II histocompatibility antigen and 
transcription factor RelB, and ubiquitin-like protein Isg15 proteins were commonly up-
regulated in Nfκb2-/- and c-Rel-/- enteroids, suggesting that these enteroids have 
altered immune regulation and show potential compensatory increases in other major 
NFκB family members. Regenerating islet-derived protein 3-gamma (Reg3) protein 
was over-expressed in Nfκb2-/- but under-expressed in c-Rel-/- enteroids, which could 
potentially account for some of the protectivity against epithelial injury observed in 
Nfkb2-/- enteroids, but not in other transgenic enteroid lines. Reg3 is a protective 
factor in experimental colitis and is induced by propionate (shown to confer 
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protectivity in inflammatory GI experimental models) in intestinal organoids (Bajic et 
al., 2020; Shin et al., 2019). Therefore, at baseline there are several proteins that are 
known to be expressed in intestinal epithelia that may regulate the response of the 
epithelium to damage-inducing stimuli via direct or indirect mechanisms.  
 
Figure 5.1 Pie charts representing the total number of quantified proteins that were 
up- (blue) and down- (orange) regulated in untreated Nfκb1-/-, Nfκb2-/- and c-Rel-/- 
enteroids when compared with untreated WT enteroids. The comparison of multiple 
means was tested by student t-test, N = 4. 
 
5.2.2 There are changes in the enteroid proteome following TNF 
treatment 
Resting murine WT enteroids had total number of 5770 quantified proteins and 
following treatment with TNF 50 ng/ml for 24 hours, we demonstrated that 173 of 
these proteins were significantly up-regulated and 117 were significantly down-
regulated (figure 5.2A). We detected 5646 proteins in untreated murine Nfκb1-/- 
enteroids. Twenty-four hours post-treatment with 50 ng/ml TNF, we detected 55 
proteins that were significantly upregulated and 73 that were significantly down 
regulated (figure 5.2B). Untreated Nfκb2-/- proximal small intestinal-derived enteroids 
showed a total number of 5951 detected proteins. Following 24 hours treatment with 
50 ng/ml TNF, 266 proteins were significantly up-regulated and 91 were significantly 
down-regulated (figure 5.2C). The total number of proteins detected in unstimulated 
c-Rel-/- enteroids was 5411. Following 24 hours of treatment with 50 ng/ml TNF, 28 
A B C 
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proteins were significantly up-regulated and 26 were significantly down-regulated 
(figure 5.2D). Ubiquitin-like protein (interferon-stimulated gene 15 ubiquitin-like 
modifier, (ISG15)) protein was the most significantly upregulated protein in TNF 
treated WT vs untreated WT enteroids (3.23-fold change and p-value 5.89 x 10-4), 
Nfκb1-/- (1.24 and 1.99 x 10-3) Nfκb2-/- (1.97 and 0.03) and c-Rel-/- (1.61 and 0.02). 
Isg15 has been implicated in IBD and colon cancer and it is also responsible for 
chemotaxis of neutrophils (Zuo et al., 2016). Isg15 up-regulation by TNF could 
therefore potentially contribute to the enhanced motility we observed in TNF-treated 
enteroids (chapter 3) and is worth further exploration. Our findings of upregulated 
Isg15 were supported by the previously reported by Isg15 signature and upregulation 
in the proteome-wide mass spectrometry of mouse experiment (Ballegeer et al., 
2018).  
 
Figure 5.2 Pie charts showing that the total significantly up-regulated and down-
regulated proteins in murine WT, Nfҡb1-/-, Nfҡb2-/- and c-Rel-/- enteroids following 24 
hours treatment with TNF 50 ng/ml in comparison respectively with untreated WT, 
Nfҡb1-/-, Nfҡb2-/- and c-Rel-/- enteroids of the same strains were 290, 128, 357 and 54 
respectively. The comparison of multiple means was tested by student t-test, N = 4. 
 
5.2.3 TNF alters the abundance of NF-κB signalling pathway components 
in enteroids 
Alternative NFκB signalling pathway protein markers were identified in WT enteroids 





derived from the other transgenic mouse strains (figure 5.3). Transcription factor RelB 
expression was significantly increased in all the four strains of enteroids following 
TNF treatment, suggesting that this alternative NFκB pathway regulator is important 
in regulating the intestinal epithelial response to TNF. Reassuringly, NF-κB2 p100 
and p52 subunits were significantly up-regulated in WT, Nfκb1-/- and c-Rel-/- enteroids 
following TNF treatment, but were not detected in Nfκb2-/- enteroids. There was no 
detection of inhibitor of nuclear factor kappa-B kinase subunit epsilon (Iκbke) in c-
Rel-/- or Nfκb1-/- enteroids, however, it was significantly up-regulated in Nfκb2-/- and 
WT enteroids. Iκbke regulates inflammatory processes, immune system, cell 
proliferation, growth and cancer progression and invasion (Boehm et al., 2007; Lu et 
al., 2017). Therefore, we hypothesise that Iκbke regulation could play a major role in 
the restrictive activity of TNF-treated Nfκb2-/- enteroids. 
 
Figure 5.3 Heat map of alternative pathway protein markers of untreated versus 
24-hour 50 ng/ml TNF-treated Nfκb1-/-, Nfκb2-/- and c-Rel-/- intestinal epithelial 
enteroids. Fold change (FC) and p-value (PV) of various detected proteins were 
analysed; green colour highest and red indicated lowest value, t-test, upregulated 
protein values ranged from p ≤1.0 x 10-7 - ≤1.0 x 10-5, (N = 4). 
 
5.2.4 TNF modulates the crypt and villus proteome 
TNF treatment in vivo causes a biphasic apoptotic response with structural changes 
and increased apoptosis occurring at the small intestinal villus tip within hours and 
later onset apoptosis being observed in the crypt at around 24 hours. We therefore 
wanted to assess whether there were any differences in the profile of proteins 
normally associated with the crypt and villus domains in enteroids following TNF 
treatment. Crypt domain protein markers were identified in TNF treated WT enteroids 





Genes RelB RelB Nfҡb2 Nfҡb2 Ikbke Ikbke
187 
 
and their fold change was determined compared to untreated enteroids (table 5.1 
and appendix C). We also determined whether there were any expression changes 
within these crypt domain proteins in Nfҡb1-/-, Nfҡb2-/- and c-Rel-/- enteroids treated 
with TNF versus untreated enteroids of the same genotype. Telomerase protein 
component 1 (Tep1), integrin beta-1, group XIIB secretory phospholipase A2-like 
protein, and cytosolic phospholipase A2 proteins were all significantly up-regulated 
by TNF in the four (WT, Nfҡb1-/-, Nfҡb2-/-, and c-Rel-/-) enteroid genotypes, suggesting 
that TNF is important for their up-regulation, but deletion of components of the NF-
κB signalling pathways did not modulate their expression. Bone morphogenetic 
protein 3 (Bmp3), calcium-independent phospholipase A2-gamma, RNA-binding 
protein Musashi homolog 2, and olfactomedin-4 were upregulated in WT, Nfҡb1-/-, 
and Nfҡb2-/- but down-regulated in c-Rel-/- enteroids following TNF treatment. These 
differences in protein regulation suggests that there may be an altered stem cell niche 
within the c-Rel-/- intestinal epithelium, as these proteins are all differentially 
expressed in crypt stem cells.  BMP3 down-regulation is observed in 89% of human 
colon cancers (Loh et al., 2008) and c-Rel-/- mice are more susceptible to the 
experimental induction of colon tumours (Burkitt et al., 2015). Group XIIA secretory 
phospholipase A2 (Pla2g12a) was not expressed in WT but was over-expressed in 
Nfҡb1-/- and c-Rel-/- and down-regulated in Nfҡb2-/- enteroids following TNF treatment. 
Phospholipase is involved in the breakdown of arachidonic acid into fatty acid and 
the mediation of inflammation (Rouault et al., 2003). The downregulation of Pla2g12a 
in Nfҡb2-/- enteroids may therefore partly explain why the response to TNF treatment 






WT (treated v untreated) Expressions in genotypes 
(treated vs untreated) 








Tep1 1.18 2.27 x 10-4 ↑   
























Pla2g4a 1.04 0.43  ↑ ↑ 
Olfactomedin-4 Olfm4 1.04 0.88  ↑ ↓ 
Ephrin type-B 
receptor 2 











- -  ↓ ↑ 
Table 5.1 Crypt domain protein markers from untreated versus 24-hour 50 ng/ml 
TNF-treated WT, Nfҡb1-/-, Nfҡb2-/- and c-Rel-/- enteroids. Proteins detected are 
indicated by none (-), upregulated (↑), downregulated (↓) and statistically significantly 
upregulated ( ) or down-regulated ( ) t-test, p ≤1.0 x 10-4 - 0.05, (N = 4). 
 
In addition to crypt domain-associated proteins, villus domain protein markers were 
also identified in WT enteroids at baseline and following TNF treatment. We also 
wanted to determine whether there were any differences in expression between WT 
and Nfҡb1-/-, Nfҡb2-/- and c-Rel-/- enteroids (table 5.3). Guanylate cyclase activator 
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2B (Guca2b) was upregulated in all four enteroid genotypes and is known to regulate 
proliferation, metabolism, barrier function and intestinal tumourigenesis via its 
interaction with Gucy2c. This interaction now warrants further exploration in 
inflammation-driven colon cancers (Pattison et al., 2016; 2020). The most abundant 
protein expressed in intestinal villi is villin-1 (Vil1) and we determined that Vil1 was 
significantly down-regulated following TNF treatment in enteroids derived from WT, 
Nfҡb1-/- and c-Rel-/- jejunum, but reassuringly, Vil1 was up-regulated although not 
significantly in Nfҡb2-/- enteroids, which corroborates our previous findings that 
Nfҡb2-/- enteroids are less susceptible to the effects of TNF than other enteroid lines 
(table 5.2).  
WT (treated v untreated) Expressions in genotypes 
(treated v untreated) 












Alppl2 1.26 0.04 ↑ ↓ - 
Alpha-actinin-1 Actn1 1.03 0.47  ↑ ↑ ↓ 
Alpha-actinin-4 Actn4 1.04 0.52 ↓ ↑ ↓ 
Acid trehalase-
like protein 1 
Athl1 1.05 0.58 - ↑ - 
Supervillin Svil 1.02 0.64    
Alkaline 
phosphatase 
Alpi 1.05 0.72 ↓ ↓ ↑ 
Alkaline 
phosphatase 
Akp3 1.06 0.76 ↑ ↓ ↑ 
Villin-1  Vil1 -1.10 1.70 x 10-5  ↑  
Trehalase Treh -1.12 0.03  ↑ ↓ 
Advillin-1 Avil - - ↑ ↓ - 
Table 5.2 Villi domain protein markers from untreated versus 24-hour 50 ng/ml TNF-
treated WT, Nfҡb1-/-, Nfҡb2-/- and c-Rel-/- enteroids. Proteins detected are indicated 
by none (-), upregulated (↑), downregulated (↓) and statistically significantly up-
regulated ( ) or down-regulated ( ) t-test, p ≤1.0 x 10-8 - 0.05, (N = 4).  
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5.2.5 TNF treatment of enteroids modulates autophagy and apoptosis 
Autophagy protein markers were identified in WT intestinal enteroids and we wanted 
to understand whether they were also expressed by other enteroids that were 
deficient in NFκB signalling components (table 5.3). Lysosome-associated 
membrane glycoprotein 2 (Lamp2) and microtubule-associated proteins 1A/1B light 
chain 3B (Map1lc3b) were upregulated in all four enteroid lines in response to TNF, 
suggesting that the degree of autophagy is increased in enteroids following TNF 
treatment. Map1lc3b (Lc3b-II) has also been shown to be increased in cell line culture 
and the resultant increase in epithelial monolayer permeability was attributed to the 
inhibition of autophagic degradation (Zhang et al., 2017). LC3B and LAMP2 are also 
upregulated in human colonic tumours (Furuta et al., 2001; Niklaus et al., 2017) again 
suggesting that TNF may induce an intestinal tumour-like phenotype. Bcl-2-like 
protein 15 (Bcl2l15) is an intestinal-specific pro-apoptotic protein (Coultas et al., 
2003; Ozoren et al., 2009) that was down-regulated by TNF in all enteroid strains. 
This protein also shows reduced expression during malignant transformation in the 
human gastrointestinal tract (Dempsey et al., 2005). However, small intestinal 
tumours are rare and constitute only 5% of the GI tumours and about 0.6% of all 
cancers whilst colonic tumours make up about 95% of GI tumours and about 11% of 
all cancers (Bray et al., 2018; Neugut et al., 1998). Enteroids are therefore not the 
best model to investigate intestinal tumourigenesis, nonetheless, several 
mechanisms that drive epithelial regeneration in homeostasis and in pathogenic 
conditions are similar in the colon and small intestine and several findings from our 






WT (treated v untreated) Expressions in genotypes 
(treated v untreated) 








glycoprotein 2  




light chain 3B 
Map1lc3b 1.21 0.05 ↑ ↑ ↑ 
Autophagy-
related protein 
16-1   
Atg16l1 1.03 0.06 ↑  ↓ 
Beclin-1  Becn1 1.15 0.05 ↑  ↓ 
Bcl-2-like protein 
15  





protein 2  






Atg14 - - ↓ - - 
Autophagy 
protein 5  
Atg5 -1.03 0.07 ↓ ↑ ↓ 
Autophagy-
related protein 2 
homolog B  




Atg9a - - ↓ ↓ ↓ 
Table 5.3 Autophagy protein markers of untreated versus 24-hour 50 ng/ml TNF-
treated WT, Nfҡb1-/-, Nfҡb1-/- and c-Rel-/- enteroids. Proteins detected are indicated 
by none (-), up-regulated (↑), down-regulated (↓) and statistically significantly 
upregulated ( ) or down-regulated ( ) t-test, p ≤1.0 x 10-3 - 0.05, (N = 4).  
 
Apoptosis-related proteins were identified in WT enteroids and we wanted to 
understand whether they were also expressed by enteroids derived from other 
transgenic mouse strains (table 5.4). Interleukin-1 receptor antagonist protein (Il1rn) 
was significantly up-regulated in c-Rel-/- enteroids and non-significantly up-regulated 
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in all other enteroid strains treated with TNF. The deletion of Il1rn in mice has 
previously been shown to result in a reduction of villus height and width and the 
development of spontaneous IBD (Dosh et al., 2019). Bcl-2-like protein 15 was 
significantly downregulated in WT, Nfκb1-/- and Nfκb2-/- enteroids. E3 ubiquitin-protein 
ligase (XIAP) was downregulated in Nfκb1-/- enteroids. Bcl-2-like protein 1 was 
significantly upregulated in WT and Nfκb2-/- enteroids. Bcl-2-associated transcription 
factor 1 was under-expressed in all the enteroids tested except in WT, where it was 
overexpressed. Tumour necrosis factor alpha-induced protein 3 (Tnfaip3), fas-
associated death domain protein (Fadd), tumour necrosis factor receptor superfamily 
member 6 (Fas) and caspase-8 (Casp8) were significantly upregulated only in Nfκb2-
/- enteroids. Tnfaip3 is a regulator of immune cell homeostasis, apoptosis and NFκB 
activation (Jung et al., 2019; Serramito et al., 2019). Its upregulation in TNF-treated 
Nfκb2-/- enteroids may play a key role in dampening TNF-induced injury observed in 
this enteroid and murine strain. Fas plays a prominent function in regulating cell 
apoptosis, survival, proliferation and immune response (Siegel et al., 2000). 
Increased Fas expression has been shown previously in murine embryonic 
fibroblasts (MEFs) deficient in p52 and increased Fas expression is thought to protect 
against spontaneous colon carcinoma development (Liu et al., 2012). These findings 
could partially explain why Nfκb2-/- mice are less susceptible to the induction of 








WT (treated v untreated) Expressions in genotypes 
(treated v untreated) 




p-value Nfκb1-/- Nfҡb2-/- c-Rel-/- 
Bcl-2-like protein 1 Bcl2l1 1.16 5.16 x 10-3 ↓  ↑ 




Irak4 -1.04 0.10 ↓ ↑ ↑ 
Bcl-2-like protein 15 Bcl2l15 -1.27 0.02   ↓ 
Apoptosis facilitator 
Bcl-2-like protein 14 








Bak1 -1.08 0.30 ↓ ↓ ↓ 
E3 ubiquitin-protein 
ligase XIAP 
Xiap -1.09 0.18  ↓ ↓ 








Fadd -1.09 0.12 ↓  ↓ 
Caspase-3 Casp3 -1.07 5.16 x 10-3  ↑  
Caspase-9 Casp9 -1.06 0.07 ↓ ↑ ↓ 
Bax inhibitor 1 Tmbim
6 
1.21 0.01 ↑ ↑ ↑ 
Tumor necrosis 
factor alpha-
induced protein 3 





Fas - - -  - 
Table 5.4 Apoptosis-related protein markers of untreated versus 24-hour 50 ng/ml 
TNF-treated WT, Nfҡb1-/-, Nfҡb2-/- and c-Rel-/- enteroids. Proteins detected are 
indicated by none (-), upregulated (↑), downregulated (↓) and statistically significantly 




5.2.6 TNF treatment causes perturbations in small intestinal secretory 
cell populations  
Goblet cell protein markers were identified in in all enteroid strains and we were 
interested in knowing if there were any alterations in goblet cell-associated protein 
abundance with TNF treatment and also as a result of NFκB perturbation. (table 5.5). 
Endoplasmic reticulum lectin 1 (Erlec1) was significantly up-regulated in Nfκb1-/- 
enteroids with insignificant up-regulations also being observed in Nfκb2-/- and c-Re-l- 
enteroids. Trefoil factor 3 (Tff3) was upregulated in all groups of enteroid following 
TNF treatment and Mucin-2 (Muc2) was insignificantly upregulated in WT, Nfκb1-/- 
and C-rel-/-, but down-regulated in Nfκb2-/- enteroids, although these changes did not 
reach statistical significance. These data suggest that TNF may stimulate goblet cell 
differentiation in general and the mucous composition in Nfκb2-/- enteroids.  
WT (treated v untreated) Expressions in genotypes 
(treated v untreated) 




p-value Nfҡb1-/- Nfҡb2-/- c-Rel-/- 
Endoplasmic 
reticulum lectin 1 
Erlec1 1.02 0.53  ↑ ↑ 
Homeobox protein 
CDX-2   
Cdx2 -1.05 0.39 ↑ ↑ ↑ 
Trefoil factor 3  Tff3 1.27 0.21 ↑ ↑ ↑ 
Muc5ac Muc5ac -1.31 0.12 ↓ ↓ ↓ 
Mucin-2 Muc2 1.16 0.30 ↑ ↓ ↑ 
Table 5.5 Goblet cell protein markers of untreated versus 24-hour 50 ng/ml TNF-
treated WT, Nfҡb1-/-, Nfҡb2-/- and c-Rel-/- enteroids. Proteins detected are indicated 
by none (-), upregulated (↑), downregulated (↓) t-test and statistically significantly 
upregulated ( ), p ≤0.05, (N = 4). 
 
Paneth cell protein markers were identified in the profiled enteroid proteome and we 
were interested in determining whether they were modulated by TNF or NFκB 
perturbation (table 5.6). Matrilysin (Mmp7) was significantly upregulated in the WT, 
Nfκb1-/-, Nfκb2-/- and c-Rel-/- enteroids suggesting that Paneth cell composition may 
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be altered following TNF stimulation. Mmp7 has several biological roles, however, it 
has been implicated in defensin regulation and defensins are abundantly produced 
by Paneth cells. Tumour necrosis factor receptor type 1-associated DEATH domain 
protein (Tradd) and alpha-defensin 20 (Defa20) were down-regulated in all the four 
enteroid genotypes whilst tuftelin-interacting protein 11 (Tfip11) was upregulated in 
Nfκb2-/- but down-regulated in the others; although these changes did not reach 
statistical significance.  
WT (treated v untreated) Expressions in genotypes 
(treated v untreated) 









-1.20 0.51 ↓ ↓ ↓ 
Alpha-defensin 
23 






Litaf -1.02 0.70 - ↑ - 
Matrilysin  Mmp7 1.33 0.17    
Angiogenin-4  Ang4 1.56 1.22 x 10-3 ↑ ↓  
Lysozyme C-1  Lyz1 -1.18 0.09 ↑ ↓ ↓ 
Serine/threonine-
protein kinase  










Tfip11 -1.01 0.78 ↓ ↑ ↓ 
Table 5.6 Paneth cell protein markers of untreated versus 24-hour 50 ng/ml TNF-
treated WT, Nfҡb1-/-, Nfҡb2-/- and c-Rel-/- enteroids. Proteins detected are indicated 
by none (-), upregulated (↑), downregulated (↓) and statistically significantly 





5.2.7 Mechanisms by which TNF may modulate intestinal barrier function 
Barrier function and tight junction protein markers were identified in WT intestinal 
enteroids and we wanted to understand whether they were also expressed by other 
transgenic enteroid lines (table 5.7). Integrin alpha-2 (Itga2), junctional adhesion 
molecule A (F11r), claudin-4 (Cldn4), integrin beta-6 (Itgb6), integrin alpha-V (Itgbv), 
claudin-3 (Cldn3), and neural cell adhesion molecule L1 (L1cam) were upregulated 
in all the four enteroid genotypes, suggesting that these components are regulated 
by TNF, but may not require the NfκB signalling components that were deleted in our 
enteroids for transcription/translation. Interestingly, some of these components not 
only regulate intestinal tight junctions, but can contribute to the regulation of the 
intestinal barrier in other ways, such as by modulating the immune function of 
intestinal epithelial cells (Holmes et al., 2006; Lee & Juliano, 2000). Intercellular 
adhesion molecule 1 was significantly overexpressed in all enteroid lines except in 
Nfκb1-/- where it was not detected, suggesting that NF-κB1 is required for its 
transcription/translation. Nfκb1-/- enteroids showed reduced expression of cadherin-
related family member 5 (Cdhr5) while it was upregulated in all other enteroid lines. 
Cdhr5 (also known as μ-protocadherin) has a role in regulating osmotic diarrhoea 
due to microvillus modulation and is down-regulated in human colon cancers 









WT (treated v untreated) Expressions in genotypes 
(treated v untreated) 








Icam1 3.47 1.07 x 10-5 -   
Claudin-7 Cldn7 1.04 0.26 ↓ ↓ ↑ 
Integrin alpha-2 Itga2 1.30 1.03 x 10-4 ↑   
Junctional 
adhesion 
molecule A  
F11r 1.43 4.80 x 10-4    
Claudin-4 Cldn4 1.76 7.67 x 10-4    
Integrin beta-6  Itgb6 1.14 0.03  ↑  
Integrin alpha-V Itgav 1.21 8.55 x 10-4   ↑ 
Claudin-3 Cldn3 1.29 9.83 x 10-5   ↑ 
Cadherin-related 
family member 5 
Cdhr5 1.28 1.78 x 10-3 ↓  ↑ 
Claudin-2 Cldn2 1.02 0.85  ↓ ↑ 
Claudin-23 Cldn23 1.16 0.04  ↑ ↓ - 
Table 5.7 Barrier function and tight junction protein markers of untreated versus 24-
hour 50 ng/ml TNF-treated c-Rel-/- intestinal epithelial enteroids. Proteins detected 
are indicated by none (-), upregulated (↑), downregulated (↓) and statistically 
significantly upregulated ( ) t-test, p ≤1.0 x 10-5 - 0.05, (N = 4).  
  
5.2.8 Determining the effects of NFκB modulation on the intestinal 
epithelial response to TNF-induced injury  
The proteomes of TNF treated murine WT enteroids were compared with TNF treated 
Nfκb1-/-, Nfκb2-/- and c-Rel-/- enteroids following the elimination of proteins which 
showed altered expressions between all enteroid lines at baseline to determine how 
downstream signalling following TNF is affected by the deletion of individual NF-κB 
family members. A total of 1239 proteins were significantly differentially regulated 
across TNF treated Nfκb2-/-, Nfκb1-/- and c-Rel-/- enteroids of which 791 were 
identified in Nfκb2-/-, 464 in Nfκb1-/- and 56 in c-Rel-/- enteroids (figure 5.4). There 
were only 8 significantly up-regulated proteins and 4 significantly down-regulated 
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proteins that were common to all three transgenic enteroid lines. Regenerating islet-
derived family member 4 (Reg4) is known to be upregulated in epithelial cells during 
intestinal inflammation, its deletion confers protectivity against mucosal injury, 
however, Reg4 also drives the growth of colonic organoids via STAT3 signalling in 
vitro and is thought to regulate the Lgr5+ stem cell niche (Sasaki et al., 2016; Xiao et 
al., 2019). Different expression levels of Reg4 across different NFκB deficient 
enteroid lines in response to TNF may potentially regulate their susceptibility to TNF-
induced injury. Little is known about B box and SPRY domain-containing protein 
(Bspry), myoferlin (Myof), Mitochondrial tRNA-specific 2-thiouridylase 1 (Trmu) and 
Cytoskeleton-associated protein 4 (Ckap4) in the intestinal epithelium, although 
nuclear expression of Ckap4 is found in most rectal squamous cell carcinomas (Long 
et al., 2009) and this protein may therefore be implicated in tumourigenesis. Nfκb2-/-, 
Nfκb1-/- and c-Rel-/- enteroids all demonstrated reduced expression of lithostathine-1 
(Reg1) (table 5.8). Reg1 is protective against nonsteroidal anti-inflammatory drug-
induced gastrointestinal toxicity and is thought to protect the intestinal epithelial 













 Nfκb1-/- Nfκb2-/- c-Rel-/- 















Reg4 2.40 5.30  
x 10-8 
1.87 1.19  
x 10-3 
2.02 5.63  
x 10-4 




Bspry 1.31 3.82  
x 10-6 
1.28 1.19  
x 10-4 





Ckap4 1.71 9.68  
x 10-5 
1.32 5.93  
x 10-3 
1.45 5.82  
x 10-3 
Myoferlin Myof 2.58 2.82  
x 10-3 






Trmu 1.40 8.76  
x 10-3 
1.30 8.70  
x 10-3 





Nat2 1.38 8.93  
x 10-3 
1.38 7.04  
x 10-4 






-1.70 6.01  
x 10-5 
-1.50 1.73  
x 10-3 




Relb -1.91 2.08  
x 10-4 
-2.08 7.35  
x 10-6 
-1.70 2.41  
x 10-3 
Lithostathine-1 Reg1 -3.02 1.36  
x 10-3 
-1.43 3.91  
x 10-2 





Naa30 -1.38 1.22  
x 10-2 
-1.60 5.35  
x 10-5 
-1.38 3.98  
x 10-4 
Table 5.8 Commonly under-and over-expressed proteins in Nfκb2-/-, Nfκb1-/-, and c-
Rel-/- all the three transgenics compared to WT after 24 hours of 50 ng/ml TNF 
treatment and were individually compared with the 24 hours TNF-treated WT; up-






Figure 5.4 Venn diagrams depicting comparisons of significant proteomic changes 
(up-regulated proteins [A] and down-regulated proteins [B]) between WT and Nfκb1-
/-, WT and Nfκb2-/-, and WT and c-Rel-/- enteroids 24 hours following 50 ng/ml TNF 
treatment. Exclusive indicates proteins only found in that strain while mixed indicates 
that the same proteins are upregulated in one strain but are downregulated in another 
strain. B1, B2, and Cr indicate Nfκb1-/-, Nfκb2-/-, and c-Rel-/- respectively. Of the up-
regulated proteins, 8 were common among the three transgenic lines while 4 were 
commonly downregulated among the three transgenic lines, N=4.  
 
5.2.9 Similarities and differences between proteomes of TNF treated 
enteroids and LPS-treated intestinal mucosa 
WT, Nfκb2-/-, Nfκb1-/- and c-Rel-/- murine strains were treated with 0.125 mg/kg LPS 
for 1.5 hours to induce small intestinal epithelial apoptosis and shedding before being 
culled (with help from PhD student Ahmed Elramli). The small intestine was opened 
longitudinally, and the mucosa was isolated from the proximal small intestine for 
protein extraction and proteomic analysis. This was performed using the same 





region from the same murine strain and were these were either untreated or TNF 
treated (methods described in chapter 2.6). The proteomes generated from both LPS 
treated murine small intestinal crypts and villi and TNF-treated murine organoids 
were comparatively analysed to determine their similarities and differences. The total 
number of proteins detected in untreated WT mice was 5770 in enteroids and 5845 
in small intestinal mucosal scrapes, for Nfκb1- /- the number of proteins was 5646 in 
enteroids and 5678 in small intestinal mucosa, for Nfκb2-/-, 5951 in enteroids and 
5686 in small intestinal mucosa, and for c-Rel-/-, 5411 in enteroids and 5750 in 
intestinal mucosa suggesting that protein extractions, processing and detection were 
similar across the in vitro and in vivo model systems (table 5.9). 
We first wanted to determine whether different transgenic and treatment conditions 
resulted in similar numbers of up-regulated and down-regulated proteins across the 
enteroids and small intestinal crypts/villi (table 5.10). For the majority of comparisons, 
there were more up- and down- regulated proteins detected within the small intestinal 
isolates compared to the enteroid cultures. Of note, there were few up- and down-
regulated proteins detected in the small intestinal mucosa of Nfκb2-/- mice following 
treatment compared to untreated mice of the same genotype (14 changes) and many 
more changes were detected in enteroids following TNF treatment (357 changes). 
This may be a result of direct tissue crypt/villus isolates containing several different 
cell populations in addition to epithelial cells which could potentially dilute epithelial 
cell-specific proteins, whereas enteroids are purely epithelial cells and may be more 
sensitive for the detection of lower abundant proteins. These data may also 
demonstrate the importance of NFκB2 signalling within the epithelial cell 
compartment.   
We also wanted to explore the percentages of similarities and differences across all 
proteins with significant up- or down-regulations between murine enteroids and small 
intestinal mucosa at baseline and following treatment (table 5.11). The percentage 
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similarity between murine enteroids and small intestinal crypt/villus isolates for 
significantly down-regulated proteins ranged from 0% in untreated WT versus 
untreated Nfκb1-/- to 37% in untreated WT v untreated Nfκb2-/- suggesting that 
interpretation of specific protein regulations at the epithelial level in enteroids may 
untangle part of the epithelial cell-specific mechanisms responsible for Nfκb2-/--
induced protectivity against epithelial damage. However additional information may 
be yielded from the interaction of complex cellular systems by further assessment in 
vivo.   
Many significantly regulated proteins were expressed in enteroids (appendices D – 
J) and small intestinal mucosae. Additionally, several proteins were detected in 
enteroids that fell below the limit of detection in small intestinal crypt/villus isolates 
and vice versa (table 5.12). Guanylate cyclase activator 2B (Guca2b) was 
upregulated in both WT enteroids and small intestinal crypt/villus isolates following 
treatment, suggesting that this protein demonstrates similarity between in vitro and 
in vivo model systems. Isocitrate dehydrogenase [NADP] cytoplasmic (Idh1) was 
downregulated in enteroids, but upregulated in mucosae. Acyl-CoA dehydrogenase 
family member 11 (Acad11) was down-regulated in TNF treated c-Rel-/- enteroids, 
but was not detected in c-Rel-/- small intestinal crypt/villus isolates. By contrast, 
splicing regulatory glutamine/lysine-rich protein 1 (Srek1) was downregulated 
following LPS treatment in c-Rel-/- small intestinal crypt/villus isolates but was not 
detected in c-Rel-/- enteroids.  
Strains Enteroids Mucosae 
WT 5570 5845 
Nfκb1-/- 5646 5678 
Nfκb2-/- 5951 5686 
c-Rel-/- 5411 5750 
Table 5.9 Total number of different proteins identified in untreated mouse enteroids 
and small intestinal mucosae with about 9 – 37% similarity. 
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Features Enteroids Mucosae 
Samples  Up Down Up Down 
Untreated WT v treated WT 173 117 255 579 
Untreated WT v untreated Nfκb1-/- 3 4 250 251 
Untreated Nfκb1-/- v treated Nfκb1-/- 55 73 59 43 
Treated WT v treated Nfκb1-/- 247 217 144 154 
Untreated WT v untreated Nfκb2-/- 27 25 1036 1237 
Untreated Nfκb2-/- v treated Nfκb2-/- 266 91 7 7 
Treated WT v treated Nfκb2-/- 329 390 419 496 
Untreated WT v untreated c-Rel-/- 14 22 220 143 
Untreated c-Rel-/- v treated c-Rel-/- 28 26 87 114 
Treated WT v treated c-Rel-/- 21 35 83 93 
Table 5.10 Significantly over- and under-expressed proteins in enteroids and small 





















Enteroids Differences Similarities 
Samples Up Down Up Down 















































































3 (14.3%) 7 (20.0%) 
Table 5.11 Similarities and differences between murine intestinal epithelial organoids 
and murine intestinal mucosa. Bold black fonts represent commonly expressed 
proteins between enteroids and mucosa while bold brown fonts represent proteins 














Enteroids  Mucosae 
 
Strains 
























Idh1 -1.19 3.69 x 10-4  
Thymidine kinase, 
cytosolic 











Kctd5 1.45 8.59 x 10-4  
Sodium/nucleoside 
cotransporter 
Slc28a1 1.48 3.38 x 10-3  
BCL2/adenovirus E1B 
19 kDa protein-
interacting protein 3 
Bnip3 -1.86 1.84 x 10-4 - 














Ptprf -1.47 5.06 x 10-8 - 
Pre-B-cell leukemia 
transcription factor 1 
Pbx1;Pbx2 - -  














Srek1 - -  
Nuclear prelamin A 
recognition factor 
Narf - -  
Table 5.12 Significantly up-and down-regulated proteins in TNF-treated enteroids 
and their corresponding proteins in murine small intestinal mucosa treated with LPS.  
Changes in regulation are shown as, none (-), upregulation (↑), downregulation (↓) 
and statistically significant (  or ), in the small intestinal mucosae, t-test, p ≤1.0 x 10-





5.2.10 Integration of proteomic analyses with known sepsis biomarkers 
We further analysed the proteomic data from TNF treated WT, Nfκb1-/-, Nfκb2-/- and 
c-Rel-/-enteroids and identified protein biomarkers that have previously been 
implicated in contributing to sepsis (table 5.14). Serum amyloid A-3 protein (Saa3) is 
an acute phase protein biomarker that was significantly upregulated in Nfκb2-/- 
without any detection in the enteroids from the other mouse strains. Fan and 
colleagues reported that serum Amyloid A3 protected against acute lung injury in 
Pseudomonas aeruginosa-infected mice (Fan et al., 2020). Saa3 also plays a 
prominent role in protecting epithelial cells against sepsis (Ather et al, 2018). This 
suggests that protectivity against TNF-induced enteroid death following Nfκb2 
deletion may be partially a result of TNF-induced Saa3 production. We identified 
peptidoglycan recognition protein 1 (Pglyrp1), which is implicated in host defence and 
it showed the highest significant upregulation following TNF treatment compared to 
all the other enteroid strains. Pglyrp1 has been reported to demonstrate protective 
effects against sepsis during experimental colitis in mice (Saha et al., 2010). Pglyrp1 
may also therefore contribute to Nfκb2-/- enteroid resistance to TNF-induced 
morphological changes. Protein S100a11 (S100a11) is an organ dysfunction 
biomarker and was observed to be insignificantly upregulated in Nfκb2-/-, but 
significantly upregulated in the WT and all other transgenic enteroid lines. S100a11 
has been reported to play a major role in cell proliferation, apoptosis, migration and 
chemotaxis (Donato et al., 2013). In critically ill patients, serum S100a11 has been 
reported to be increased in Staphylococcal infection (Thuny et al., 2012). The 
attenuated effect of TNF on Nfκb2-/- enteroids could therefore partly be due to 
reduced expression of S100a11. Laminin subunit gamma-1 (Lamc1) is a vascular 
endothelial damage biomarker and was observed to be downregulated in Nfκb2-/- 
enteroids, but was upregulated in all other enteroid lines. In critically ill patients, 
serum laminin has been reported to be increased in Candida-induced sepsis (Presterl 
et al., 2012). One of the receptor biomarkers identified from our proteomic analysis 
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was TNF receptor-associated factor 4 (Traf4). Traf4 is an adapter and signal-
transducing protein and has been implicated in regulation of cell apoptosis and 
survival and modulation of Traf6 and NFκB inflammatory responses (Ayala et al., 
1996; Shiels et al., 2000). Traf4 was downregulated in Nfκb2-/-, but up-regulated in 
Nfκb1-/- and c-Rel-/- enteroids, but was not detected in WT enteroids. Traf4 was not 
significantly expressed, however, its downregulation in only Nfκb2-/- enteroids could 
have a protective effect and could potentially contribute to why Nfκb2-/- enteroids 



























WT Serum amyloid A-3 
protein 






Nfκb1-/- Serum amyloid A-3 
protein 
Saa3 - - 






c-Rel-/- Serum amyloid A-3 
protein 
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Nfb1-/- Protein S100-A11 S100a11 2.41 4.17 x 
10-3 
Nfb2-/- Protein S100-A11 S100a11 1.62 0.15 










WT Laminin subunit 
gamma-1 







Nfκb1-/- Laminin subunit 
gamma-1 
Lamc1 1.13 0.33 
Nfκb2-/- Laminin subunit 
gamma-1 
Lamc1 -1.02 0.93 
c-Rel-/- Laminin subunit 
gamma-1 









associated factor 4  









associated factor 4 
Traf4 1.14 0.14 
Nfκb2-/- TNF receptor-
associated factor 4 
Traf4 -1.07 0.28 
c-Rel-/- TNF receptor-
associated factor 4 
Traf4 1.03 0.75 
Table 5.13 Protein biomarkers of sepsis detected in WT, Nfκb1-/-, Nfκb2-/- and c-Rel-






5.2.11 Hallmark analysis of TNF-treated enteroid proteomes 
The total number of significant proteomic changes with log2 fold ≥-0.5 and ≤+0.5 in 
WT and Nfκb2-/- intestinal epithelial enteroids that were treated with 50 ng/ml TNF 
were 141 and 276 respectively. Gene ontology (GO) analysis, functional annotation 
and pathway analysis of these significant changes was performed with the NIH 
Database for Annotation, Visualization and Integrated Discovery (DAVID) software 
to determine gene count, percentage of categorised gene count (GC), fold 
enrichment (FE) and false discovery rate (FDR) (table 5.14). The higher the 
enrichment the more significant the annotation group and the lower the p-values of 
the hits. The lower the false discovery rate (<0.05) the more positive the annotation 
group. The functional annotation clustering describes various components including 
protein domains, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and 
GO. In order to determine whether there was any TNF-mediated effect on the strains, 
the baseline characteristics were first observed (table 5.14A). The enrichment score 
(ES) of immune response in WT enteroids treated with TNF (5.3) was observed to be 
higher than in Nfκb2-/- enteroids treated with TNF (4.7). In the functional annotation 
clustering analysis, serpin signalling was observed in the annotation cluster of TNF-
treated Nfκb2-/- enteroids which was not present in WT enteroids. Previous studies 
have reported the protective property of Nfκb2-/- against chemical carcinogenesis in 
AOM/DSS-induced colon cancer model (Burkitts et al., 2015). ISG15-protein 
conjugation was not detected under the GO process category at baseline, however, 
when enteroids were treated with TNF, fold enrichment was 55.2 in WT and 42.5 in 
Nfκb2-/-. ISG15 has been previously reported to demonstrate both innate and 





A.           GO process category Untreated WT v untreated Nfκb2-/- 
Features GC % FE FDR 
NIK/NF-kappa B signalling - - - - 
Protection from natural killer cell mediated 
cytotoxicity 
- - - - 
Antigen processing and presentation  4 2.9 11 0.5300 
ISG15-protein conjugation - - - - 
Negative regulation of mature B cell apoptotic 
process 
- - - - 
KEGG Pathway GC % FE FDR 
Complement and coagulation cascades - - - - 
TNF signalling pathway - - - - 
Chemical carcinogenesis 5 3.6 5.6 0.2300 
PPAR signalling pathway - - - - 
Cell adhesion molecules (CAMs) - - - - 
Functional annotation cluster GC FC ES FDR 
Immune system process  7 2.7 1.11 1.0000 
Innate immunity - - - - 
Innate immune response 4 1.5 1.11 1.0000 
Serpin  3 5.8 1.5 0.8100 
Acute-phase response - - - - 
 
B.      GO process category Treated WT Treated Nfκb2-/- 
Features GC % FE FDR GC % FE FDR 
NIK/NF-kappa B signalling 2 1.4 55.2 0.7800 - - - - 
Antigen processing and 
presentation 
2 1.4 55.2 0.0190 4 1.4 56.7 0.0190 
ISG15-protein conjugation 2 1.4 55.2 0.7800 3 1.1 42.5 0.1800 
Negative regulation of mature B 
cell apoptotic process 
2 1.4 55.2 0.7800 3 1.1 42.5 0.1800 
Protection from natural killer 
cell mediated cytotoxicity 
- - - - 3 1.1 35.5 0.2000 
KEGG Pathway GC % FE FDR GC % FE FDR 
Complement and coagulation 
cascades 
- - - - 8 2.9 5.3 0.0270 
TNF signalling pathway - - - - 9 3.3 4.2 0.0380 
Chemical carcinogenesis 12 8.5 12.1 3.3x10-7 7 2.5 3.8 0.1800 
PPAR signalling pathway 8 5.7 9.3 4.9x10-4 5 1.8 3.1 0.5600 
Cell adhesion molecules 
(CAMs) 
8 5.7 4.6 0.0220 8 2.9 2.5 0.4600 
Functional annotation 
cluster 
GC FC ES FDR GC FC ES FDR 
Immune system process 15 5.4 5.3 0.0006 22 4.1 4.7 0.0002 
Innate immunity 14 4.8 5.3 0.0019 10 3.4 4.7 0.0300 
Innate immune response 8 5.3 5.3 0.0130 14 2.5 4.7 0.2400 
Serpin - - - - 9 8.2 3.6 0.0005 
Acute-phase response - - - - 6 12.0 3.6 0.0250 
Table 5.14 Summary of the hallmark analysis showing the name process category, 
pathway description, gene count (GC, percentage (%), fold enrichment (FE), fold 
change (FC), enrichment score (ES) and false discovery rate (FDR) of some 
significant functional annotation cluster, gene ontology and Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathway of baseline (A) and 50 ng/ml TNF-treated WT 
vs untreated WT and 50 ng/ml TNF-treated Nfκb2-/- vs untreated Nfκb2-/- (B). Yellow 





We investigated the proximal small intestinal epithelial cell-specific proteome of WT 
mice and changes in the proteome secondary to germline deletion of Nfκb1-/-, Nfκb2-
/- and c-Rel-/- in enteroids (appendices D – J). This study also determined the impacts 
of TNF treatment on the proximal small intestinal epithelial proteome of WT enteroids 
and in the context of NFκB signalling perturbation. From the changes anticipated in 
protein expression and abundance, we wanted to understand the mechanisms that 
could potentially be responsible for the TNF-induced enteroid rounding, expansion, 
contraction and enhanced motility that have been described in chapter 3. 
Furthermore, a deeper investigation of how the intestinal epithelial proteome changes 
in response to the disturbance of NFκB signalling could elucidate potential 
mechanisms by which Nfκb2-/- enteroids are more resistant to TNF treatment than all 
other NFκB deficient enteroids.  
We initially showed that a range of epithelial cell specific proteins were expressed by 
enteroids, thus validating their epithelial nature in culture and reliability to represent 
the intestinal epithelium in subsequent proteomic analyses. At baseline, Nfκb2-/- 
enteroids exhibited more Reg3 than WT-derived, Nfκb1-/- and c-Rel-/- enteroids which 
may have conferred protectivity from TNF-induced damage prior to the application of 
TNF (Dessein et al., 2009). Villin (Vil1) is the most abundant protein produced in 
small intestinal villi and as such is often the gene promoter of choice to generate 
intestinal-specific and conditional knockout animals.  Reassuringly, Vil1 was detected 
by our proteomic analyses in all enteroid genotypes and was shown to be depleted 
following TNF treatment in all enteroids except Nfκb2-/- in which its abundance was 
insignificantly elevated following TNF treatment. This finding demonstrates at the 
molecular level that Nfκb2-/- enteroids maintain a consistent proportion of villus 
domains after TNF administration (Vlantis et al., 2016), whereas the other strains are 
depleted similarly to histological observations of villus blunting following excessive 
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apoptosis and cell shedding in vivo and increased circularity in enteroids in vitro. 
Nfκb2-/- enteroids also demonstrated increased expression of RelB compared to WT 
enteroids, suggesting that enteroids were attempting to activate alternative NFκB 
pathway signalling and there was no feedback inhibition for this pathway. RelB was 
up-regulated in all enteroid lines following TNF stimulation, demonstrating activation 
of the alternative NFκB signalling pathway by this stimulus. Reassuringly, no Nfκb2 
was detected in Nfκb2-/- enteroids, whereas it was detected in all the other enteroid 
lines, validating that these enteroids were devoid of Nfκb2. RelB-/- mice have been 
shown to exhibit similar pathologic and histological changes to WT mice following 
stimulating with LPS (unpublished observations by Ahmed Elramli in our laboratory) 
and RelB-/- enteroids (unpublished observations by Steph James in our laboratory) 
also responded similarly to WT enteroids, suggesting that its binding partner NFκB2 
p52 is more important in regulating this response. 
Several proteins were upregulated in all enteroid lines following TNF treatment. 
Whilst this does not demonstrate the importance of the specific contributions of 
Nfκb1-/-, Nfκb2-/- and c-Rel-/- in regulating the epithelial damage response, the 
contribution of these elucidated proteins to the induction of TNF-induced pathology 
should be further explored. Whilst small intestinal pathology is ameliorated following 
TNF treatment of Nfκb2-/- enteroids and in mice in vivo, pathology is not completely 
inhibited and there is likely a complex set of proteins and signalling cascades involved 
in generating the morphological and histological response that is observed. Guca2b 
was identified as being upregulated in all enteroid strains in response to TNF and is 
known to regulate proliferation, metabolism, barrier function and intestinal 
tumourigenesis via its interaction with Gucy2c (Lorenz et al., 2003; Yoshikawa et al., 
2007). This was one of the most up-regulated proteins detected. Interestingly, a SNP 
was recently detected in Gucy2c in colonic tumouroids versus normal colonoids 
generated from azoxymethane/dextran sulphate colitis treated WT mice by another 
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PhD student (Harvey Fowler-Williams) in our laboratory (unpublished observations). 
This interaction now warrants further exploration in inflammation-driven colon 
cancers and also in its potential contribution to IBD and sepsis pathogenesis.  
We observed an increase in Tnfaip3 (also well known as A20) following TNF 
treatment of Nfκb2-/- enteroids, but we did not observe any such increase in all other 
enteroid lines. Tnfaip3 is a well characterised inhibitor of NFκB activity; it regulates 
the response to TNF-induced apoptosis (Jung et al., 2019; Lerebours et al., 2008; 
Serramito et al., 2019) and may contribute to the resistance of Nfκb2-/- enteroids to 
TNF-induced pathology. Alternative pathway NF-κB signalling is predominantly 
activated by the processing of inactive p100 to transcriptionally active p52. This 
process occurs by the kinase activity of NIK and IKKα which are directly inhibited by 
Tnfaip3 (A20), resulting in reduced p100 processing and therefore reduced 
alternative pathway NF-κB signalling activation (Jung et al., 2019; Serramito et al., 
2019; Verhelst et al., 2015). Nfκb2-/- mice have been shown to be resistant to the 
induction of experimental colitis and colitis-associated colon cancer (Burkitt et al, 
2015), however, the mechanisms responsible for this have not been extensively 
explored.  From our studies, Tnfaip3 is an attractive candidate that could be an 
important regulator of colonic tumour development as its expression has been shown 
to be reduced in human colonic adenomas and carcinomas (Perrot-Applanat et al., 
2011; Shao et al., 2013; Wang et al., 2016). We conducted a preliminary test to 
confirm our proteomics data using a Tnfaip3 antibody via IHC on enteroids, but did 
not observe any obvious differences in Tnfaip3 expression between NFκB genotypes 
with or without TNF treatment (data not shown). Further work is now warranted to 
conduct an antibody titration and explore different antigen retrieval methods and 
antibodies to validate this finding. Kattah and colleagues reported that Tnfaip3 (A20) 
and A20 Binding and Inhibitor of NFκB (ABIN-1) were protective against autoimmune 
and inflammatory diseases including IBD (Kattah et al., 2018). They showed that the 
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mechanism was via Tnfaip3 and ABIN-1 mediated restriction of NFκB signalling and 
cell death via caspase-8 and RIPK1 activation (Kattah et al., 2018). However, they 
also reported that IEC-specific deletion of either A20 or ABIN-1 did not induce rapid 
and severe death of intestinal epithelial enteroids and that down regulation of both 
A20 and ABIN-1 was required (Kattah et al., 2018). We interrogated the epithelial 
proteome for Abin-1 with and without TNF treatment and in WT and NFκB-deficient 
lines and this protein was not detected. Tnfaip3 tends to regulate intestinal 
homeostasis, autophagic response and NFκB activation (Jung et al., 2019; Serramito 
et al., 2019).  
One of the acute phase protein biomarkers we identified in enteroids was Saa3 which 
was significantly upregulated in Nfκb2-/- enteroids only. It was not detected in the 
enteroids derived from the other transgenic mouse lines. It has been reported that 
Saa3 has a protective property against Pseudomonas aeruginosa-induced acute 
lung injury mice (Fan et al., 2020). Pglyrp1 is a host defence protein marker and was 
observed to be most significantly upregulated in Nfκb2-/- compared to the other 
enteroids tested. Pglyrp1 protected the intestine against experimental colitis in mice 
(Saha et al., 2010).  
There are several advantages and limitations to studies using enteroids in order to 
investigate the intestinal epithelial proteome. A clear advantage of these in vitro 
studies compared to in vivo investigations is the absence of other cellular 
compartments that could complicate the interpretation of direct epithelial cell-specific 
effects in response to treatment with cytokines such as TNF (and others presented 
in chapter 4 of this thesis). However, whilst enteroids have been demonstrated to 
consistently recapitulate the cellular dynamics and constitution of intestinal epithelia, 
we cannot ignore the impact of culture conditions and indirect effects of other cellular 
compartments on the intestinal proteome. We therefore injected LPS into WT, Nfκb1-
/-, Nfκb2-/- and c-Rel-/- mice from the same sex and inbred mouse colony from which 
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the enteroids were derived to elicit a TNF response that caused cell shedding and 
apoptosis (Beutler & Grau, 1993; van der Bruggen, 1999; Williams et al., 2013; Yao 
et al., 1997). We harvested proximal small intestinal crypts and villi from the same 
location from which the enteroids were derived and conducted comparative 
proteomic analyses to determine similarities and differences between enteroid 
cultures and in vivo tissues. We observed several similarities between the protein 
profiles of enteroids and crypt/villus isolates at baseline and following treatment, but 
these only reached a maximal percentage of 37% similarity. Small intestinal 
crypt/villus isolates contained several different cell populations including epithelial 
cells, immune cells, mesenchymal stromal cells and supporting extracellular matrices 
that are likely responsible for the majority of these differences and from in vivo 
studies, it is difficult to interpret which compartment specific proteins are derived from. 
Care was taken to remove the Matrigel matrix very thoroughly prior to protein 
extraction from enteroids as Matrigel is derived from a mouse sarcoma and is heavily 
enriched for murine laminin and fibronectin extracellular matrix components that 
could have interfered with downstream proteomic analyses. Growth factors used to 
maintain enteroids in culture could also impact on protein expression within enteroids 
(for instance, high concentrations of Wnt activators would enhance the detection of 
proteins that are associated with proliferation). Culture conditions were however kept 
constant between different enteroid strains and treatments. Though we did not 
perform proteomic analysis on rescued enteroids following TNF treatment, their 
proteome would be interesting to analyse in the future to determine any potential 
longterm differences induced by prior TNF treatment. The proteomic analyses 
conducted were undertaken at 24 hours post treatment.  The time selection was 
arbitrary and based on the start of morphological changes being observed via bright 
field microscopy at this time point.  Time course studies of the proteome at earlier 
time points from at 0, 3, 6, 9, 12 and 24 hour time points may yield further information 
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about the time course of protein activation but also may have identified different 
proteins whose production and utility is short lived.   
Broad-spectrum proteomic analyses were selected for this study, but future studies 
could focus on specific protein populations such as membrane-enriched or nuclear 
protein extracts to further define intestinal epithelial proteome differences induced by 
TNF or NFκB modulation that may elucidate further potential targets for IBD and 
sepsis. However, several proteins have been elucidated in this study that may 
contribute towards the observed protectivity from TNF-induced small intestinal 
epithelial cell damage that is conferred by Nfκb2 deletion. Several additional proteins 
have also been identified that may be modulate TNF-induced damage independent 
of NFκB2 signalling. Further work is now warranted to understand the importance of 
the contributions of these proteins and the pathways they regulate to the 
development of epithelial cell damage in the intestine and how this relates to damage 
responses in the local mucosal and systemic immune system responses to modulate 
the susceptibility to sepsis and IBD.  
In summary, we postulated that Tnfaip3 which has been previously reported in many 
studies (Jung et al., 2019; Katta et al., 2018; Lerebours et al., 2008; Serramito et al., 
2019) as having inhibitory actions on inflammation, apoptosis and autoimmune 
responses might play a significant role in blunting the Nfκb2-/- enteroid response to 
TNF treatment. TNF treated WT, Nfκb1-/- and c-Rel-/- enteroids demonstrated reduced 
vil1, however TNF treatment of Nfκb2-/- enteroids led to reduced Vil1 depletion 
suggesting that there was a better retention of absorptive villus enterocytes and less 
intestinal cell shedding from the villus domains). The upregulation of Saa3 and 
Pglyrp1 in Nfκb2-/- enteroids could also contribute to the blunted response of these 
enteroids to TNF treatment.  
We utilised the NIH Database for Annotation, Visualization and Integrated Discovery 
(DAVID) software to determine the hallmark analysis of the significant proteins of the 
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proteomic results. Uchiyama and colleagues reported the protective property of 
serpin B1 in colonic epithelial cells to inflammation-induced damage via blockage of 
neutrophil elastase activity (Uchiyama et al., 2012). Serpin has also been shown to 
play a regulatory role in cellular proliferation and cell death via modulation of 
apoptosis and perturbance of proteasome activity (Gatto et al., 2013; Van Gent et al., 
2003). We hypothesise that the protective actions of serpin signalling against pro-
inflammatory responses contribute to the blunted response of Nfκb2-/- enteroids 
against to TNF treatment. This now warrants further interrogation. We also observed 
in hallmark analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway 
that chemical carcinogenesis, PPAR signalling pathway and cell adhesion molecules 
(CAMs) were notably higher in WT than the corresponding expressions in Nfκb2-/- 
enteroids. ISG15 is a posttranslational modifier and protein ISGylation via activation 
of IFN-α/β signalling at the interferon receptor can attenuate IFN responses and 
through stimulation of natural killer cells promote type 2 interferon (IFN-γ) secretion 
(Ballegeer et al., 2018). An ISG proteome signature has been implicated in the 
regulation of intestinal STAT1 and TNF-induced intestinal inflammation in mice in 
vivo (Ballegeer et al., 2018), we determined that Isg15 was upregulated following 
TNF treatment of enteroids suggested that ISG might be very important in 
characterising actions of TNF and that this may be driven by the intestinal epithelium 
in terms of helping the recruitment of immune cells and in the motility of epithelial 
cells within the mucosa. The differential regulation of these proteins may modulate 
IBD and sepsis clinically and are worth interrogating to determine the potential role 
they play in modulating the response to TNF-induced sepsis. The possibly 






6 Development of an enteroid model to test potential 
sepsis and inflammatory bowel disease therapeutics 
6.1 Introduction 
Currently, the only form of treatment for critically ill patients with sepsis is supportive 
or symptomatic relief. There is no cellular or molecularly directed specific therapeutic 
intervention. Highly specific and sensitive diagnostics for sepsis are also yet to be 
optimally developed. Clinically, goal-oriented approaches for ameliorating sepsis 
include early recognition and commencement of supportive treatment within 6 hours 
of onset in order to improve a patient’s condition, prevent deterioration and prevent 
the development of multiple organ dysfunction syndrome (MODS) or organ failure. 
The four major elements of this goal-targeted approach are supportive care, 
monitoring, anti-inflammatory therapy and antibiotic administration. 
Key players driving sepsis pathogenesis systemically are similar to those that drive 
inflammatory bowel disease (IBD) pathogenesis at a local level in the intestinal 
mucosa and are characterised by a hyperactive immune response containing high 
concentrations of TNF and IL-6 (Murch et al., 1993; Remick et al., 2005). Similar 
pathologies resulting from excessive cytokine stimulation in the lungs and intestine 
are observed in patients with sepsis prior to the onset of MODS and also early in 
sepsis pathogenesis. Therefore, if molecular mechanisms can be targeted at the 
earlier stages of onset of sepsis, early onset pathologies such as in the intestine and 
lung may be ameliorated, thus preventing the perpetual positive feedback systemic 
inflammatory response syndrome that results partially from the cytokine storm, but 
also from increased bacterial invasion across these mucosal surfaces due to the 
breakdown of barrier function. Such an approach could greatly enhance the 
opportunity for life saving antibiotic therapy to be efficacious.      
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Over recent years, enteroids and colonoids have been generated from patients with 
inflammatory diseases of the gut. A recent study has identified differences in the 
expression of antigen presentation genes within enteroids and colonoids from IBD 
patients, suggesting that there are epithelial cell-intrinsic differences that contribute 
to IBD susceptibility and that these are retained in culture (Kelsen et al., 2020). 
Enteroids derived from an inflammatory environment in either SAMP1/YitFc or 
TNFΔARE/+ murine intestine (murine models of Crohn’s disease-like ileitis) have also 
been demonstrated to have an impaired intestinal stem cell niche and have a reduced 
capacity to grow. However, treatment with the corticosteroid dexamethasone partially 
rescued this altered enteroid phenotype (Butto et al., 2020). Dexamethasone is also 
known to downregulate pro-inflammatory NF-κB signals and has been shown to 
reduce Nfκb1, Jak1 and Mmp9 expression in SAMP-derived enteroids (Butto et al., 
2020). We have identified different susceptibilities of Nfκb-deficient murine-derived 
enteroids to the damaging effects of TNF (chapter 3 and in Jones et al., 2019), also 
demonstrating the epithelial cell-intrinsic differences that can contribute to different 
phenotypic responses in different environments known to modulate NF-κB signalling. 
We therefore wanted to investigate whether the phenotypic responses that we have 
previously robustly observed in enteroids in response to TNF (and recently 
corroborated by Butto et al., 2020) could be ameliorated by the direct application of 
potential therapeutic agents that modulate the epithelial cell intrinsic environment 
prior to the addition of TNF. This would enable the generation of an in vitro assay to 
test novel therapeutics for both sepsis and IBD without the initial need for co-culture 
of enteroids with immune cells. 
TNF is a cytokine that robustly causes dose- and time-dependent damage to enteroid 
cultures (Buto et al., 2020; Jones et al., 2019). Anti-TNF therapy has shown efficacy 
in inflammatory conditions such as IBD and rheumatoid arthritis (Monaco et al., 2015) 
and there are also limited studies of its use to treat sepsis. This cytokine is therefore 
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highly relevant to the pathogenesis of sepsis and IBD and we wanted to determine 
whether there were any pharmacological ways of blocking its effects other than direct 
receptor or cytokine blockade, as these approaches are known to cause potentially 
severe side effects (Abraham et al., 1998; Murch et al., 1993; Remick et al., 2005). 
Corticosteroids are known to mediate immune dampening effects by modulating 
NFκB signalling. There has been more focus on the actions of classical NFκB 
pathway components than alternative pathway NFκB components in response to 
corticosteroids, however it is also possible that corticosteroids could modulate 
alternative NFκB pathway signalling to exert their protective effects (Inoue et al., 
1992).  
We therefore investigated the potential therapeutic properties of several different 
classes of agent including corticosteroids (prednisolone and hydrocortisone), a non-
steroidal anti-inflammatory drug (flunixin meglumine), and a natural agent (curcumin) 
that have shown efficacy in murine IBD models to determine whether the damage 
caused by TNF could be ameliorated in vitro. Several of these agents have shown 
efficacy in humans and/or murine and rat IBD models and have proven anti-
inflammatory properties (Berg et al., 2002; Clarke et al., 2019; Herfarth et al., 1998).  
Prednisolone and hydrocortisone are corticosteroids that are administered to IBD 
patients who have a moderate to severe disease flare up to suppress intestinal 
inflammation and allow their intestinal mucosa to heal. These corticosteroids are 
known to suppress NFκB signalling and thus dampen the production of, and 
signalling mediated by, TNF (Ardite et al., 1998; Schreiber, Nikolaus & Hampe, 1998; 
Quaglio et al., 2015). Both of these corticosteroids have also shown efficacy in the 
DSS and TNBS experimental models of colitis (Zhang et al., 2019), but it is currently 
not clear whether they will also show efficacy in an enteroid model. We wanted to 
determine whether the intestinal epithelium is an important regulator of the anti-
inflammatory effects of prednisolone and hydrocortisone in the absence of the 
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intestinal immune system. The demonstration that epithelial cells themselves could 
respond to corticosteroids and prevent the break down in intestinal barrier function 
caused by TNF would pave the way for novel therapeutics that target the epithelial 
cellular compartment to prevent the breakdown of barrier function by pro-
inflammatory cytokines rather than causing overt immune suppression to the patient. 
Flunixin meglumine is a potent, analgesic, anti-pyretic, non-narcotic, and 
nonsteroidal anti-inflammatory drug (NSAID) that is currently licensed for use in 
horses, pigs, and cattle (Anderson, Hunt, & Davis, 1991). Flunixin meglumine inhibits 
cyclooxygenase (COX) to prevent arachidonic acid from synthesizing prostaglandins 
(Vane & Botting, 1996). Flunixin meglumine is a nonselective COX inhibitor that is 
known to inhibit the activation of NFκB (Bryant et al., 2003). A dose of 2.2 mg/kg has 
been administered in horses with 0.1 to 0.3 L/kg volume of distribution and plasma 
elimination half-life of 1 to 2 hours (Konigsson et al., 2003). A low dose of 0.25 mg/kg 
Flunixin meglumine was given as an adjunctive treatment for sepsis in horses 
(Papich, 2016). However, this low dose had no anti-endotoxin effect, but was 
efficacious enough to inhibit the prostaglandin that mediates sepsis-induced 
haemodynamic derangement in horses (Papich, 2016). The inhibition of LPS-
induction of iNOS by flunixin meglumine has been demonstrated, suggesting that this 
drug may modulate mechanisms other than COX metabolism (Bryant et al., 2003) 
and is worth investigating to determine whether it has any direct protective effects on 
the intestinal epithelium. We therefore wanted to determine whether another class of 
drug (non-steroidal anti-inflammatory drug) known to show efficacy in sepsis would 
also demonstrate protectivity against TNF in an enteroid culture model.   
Curcumin (also known as diferuloylmethane), is a non-steroidal anti-inflammatory 
agent found in the diet (Srimal & Dhawan, 1973). The anti-inflammatory effect of 
curcumin has been reported to be mediated by several mechanisms including via 
upregulation of peroxisome proliferator-activated receptor gamma (PPAR-γ) 
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activation, and by inhibition of NFκB signalling (Jacob et al., 2007; Siddiqui et al., 
2006; Song et al., 2010). In a caecal ligation and puncture (CLP) model of sepsis, 
curcumin was shown to be protective against pulmonary oedema and chronic lung 
injury (Liu et al., 2017). Pre- or post-treatment with curcumin in the CLP model also 
decreased tissue injury, reduced mortality, and lowered TNF expression in septic 
animals (Siddiqui et al., 2006). Curcumin has also shown efficacy in dextran sulphate-
sodium (DSS) and trinitrobenzene sulphonic acid (TNBS)-induced colitis models and 
suppresses the LPS-induced NFκB p65 nuclear translocation that is associated with 
immune cell activation and small intestinal epithelial cell shedding (Burge et al., 2013; 
Toden et al., 2017; Zhang et al., 2016). Curcumin is thought to block TNF production 
and TNF-induced signalling pathways to exert its protective effects. We therefore 
wanted to determine whether curcumin had protective effects against the damaging 
effects of TNF on the epithelium in an enteroid model in the absence of the intestinal 
immune system. Curcumin was chosen because of reports from previous studies in 
cell lines that it has anti-inflammatory properties (Edwards et al., 2017) and we 




6.2.1 Prednisolone delays TNF-induced enteroid rounding  
WT enteroids were treated with prednisolone alone to determine whether this drug 
caused any adverse morphological effects.  Prednisolone treatment did not induce 
any significant changes in enteroid circularity vs untreated enteroids for 0-72 hours 
post-treatment, with all enteroids consistently showing circularity values of around 
0.4 throughout the time course (figures 6.1 and 6.3A). This demonstrated that 
enteroid treatment with prednisolone did not show any obvious deviation from the 
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growth patterns of untreated enteroids. We therefore wanted to determine whether 
prednisolone protected enteroids from the damaging effects of TNF. Enteroids were 
pre-treated with 0.1, 1 or 10 μmol/l prednisolone for 1 hour prior to the addition of 50 
ng/ml TNF. Enteroid circularity was measured at 0, 24, 48, and 72 hours post-TNF 
treatment. At 24 hours post-treatment, 10 μmol/l prednisolone exhibited statistically 
significant inhibitory effects against TNF-induced rounding in WT enteroids. 
Prednisolone at this dose almost completely suppressed the morphological changes 
associated with TNF treatment.  There was no statistically significant difference in the 
measurement of enteroid circularity between untreated and 10 μmol/l prednisolone-
treated enteroids at 24 hours following TNF treatment. However, at 48 hours and 72 
hours post-treatment the protective effects of prednisolone were abrogated, and 
circularity values were not statistically different from TNF alone treated enteroids, 
suggesting that the effects of a single treatment of prednisolone may be shorter lived 
than a single treatment of TNF (figures 6.2 and 6.3B). Alternatively, it could mean 
that prednisolone delays the onset of TNF-induced effects. 
  
Figure 6.1 Bright field micrographs of untreated, 0.1, 1 and, 10 μmol/l prednisolone 
treated WT enteroids at 0, 24, 48, and 72 hours post-treatment. Both untreated 
(DMSO control) and prednisolone treated enteroids have phenotypically irregular 
shapes. Prednisolone treatment did not induce any injury or death of the enteroids. 




Figure 6.2 Bright field images of untreated, 0.1, 1, 10 μmol/l prednisolone 1-hour 
pre-treated WT enteroids stimulated by 50 ng/ml TNF for 0, 24, 48, and 72 hours. 
Untreated enteroids (DMSO control) showed phenotypically normal structures while 
all TNF treated enteroids displayed rounding morphology. Original magnification 
x10, scale bars, 100 μm. 
 
   
Figure 6.3 WT enteroids were treated with 0, 0.1, 1, and 10 μmol/l prednisolone alone 
for 0, 24, 48, and 72 hours (A). Pre-treatment of WT enteroids with 0.1, 1, and 10 
μmol/l prednisolone for 1 hour before 50 ng/ml TNF was added (B). Statistically 
significant differences vs untreated (DMSO control) at the same time point are 
indicated ***p≤0.001, and statistically significant differences between prednisolone + 
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6.2.2 Hydrocortisone delays TNF-induced enteroid injury  
In order to determine whether hydrocortisone caused any adverse morphological 
effects, we treated WT enteroids with hydrocortisone alone. Hydrocortisone 
treatment was not associated with any significant changes in enteroid circularity vs 
untreated enteroids for 0-72 hours and all enteroids consistently showed circularity 
values of around 0.4 throughout the time course (figures 6.4 and 6.6A). This 
demonstrated that enteroid treatment with hydrocortisone followed similar growth 
patterns to untreated enteroids. We then wanted to determine whether 
hydrocortisone pre-treatment protected enteroids from the TNF-induced damaging 
effects. Enteroids were first pre-treated with 0.1, 1 or 10 μmol/l hydrocortisone for 1 
hour before the addition of 50 ng/ml TNF. Enteroid circularity was measured at 0, 24, 
48, and 72 hours following treatment with TNF. At 24 hours post-treatment, 10 μmol/l 
hydrocortisone caused statistically significant inhibitory effects against TNF-induced 
rounding in WT enteroids. At this dose (10 μmol/l), hydrocortisone almost completely 
suppressed the rounding changes that were induced by TNF. At 24 hours following 
treatment with 10 μmol/l hydrocortisone, there was no statistically significant 
difference in the measurement of enteroid circularity between untreated enteroids 
and enteroids treated with 10 μmol/l hydrocortisone. By 48 hours following a single 
treatment with hydrocortisone, we did not observe the protective actions of 
hydrocortisone any longer and the morphological changes and circularity values of 
hydrocortisone-treated enteroids were not statistically different from TNF treated 
enteroids suggesting that a single treatment of hydrocortisone seemed to have a 





Figure 6.4 Bright field micrographs of untreated, 0.1, 1, 10 μmol/l hydrocortisone 
treated WT enteroids at 0, 24, 48, and 72 hours. Both untreated (DMSO control) 
and hydrocortisone treated enteroids have phenotypically irregular shapes. 
Hydrocortisone treatment did not induce any morphologically demonstrated injury or 
death on the enteroids. Magnification x10, scale bar, 80 μm. 
 
  
Figure 6.5 Bright field images of untreated, 0.1, 1, 10 μmol/l hydrocortisone- and 50 
ng/ml TNF-treated WT enteroids at 0, 24, 48, and 72 hours. Untreated enteroids 
(DMSO control) had phenotypically irregular structures while TNF treated enteroids 
had a rounded appearance at 24, 48, and 72 hours post-treatment 10 μmol/l 
hydrocortisone protected against TNF-induced rounding at 24 hours post-treatment. 




   
Figure 6.6 Measurement of WT enteroid circularity was performed following 
treatment with 0, 0.1, 1, and 10 μmol/l hydrocortisone for 0, 24, 48, and 72 hours (A). 
WT-enteroids were pre-treated with 0.1, 1, and 10 μmol/l hydrocortisone for 1 hour 
prior to addition of 50 ng/ml TNF and circularity was analysed at 0, 24, 48, 72 hours 
(B). Statistically significant differences vs untreated (DMSO control) at the same time 
point are indicated ***p≤0.001, and statistically significant differences between 
hydrocortisone + TNF vs TNF alone at the same time point are shown by ##p≤0.01, 
n=6, N=3, n=6, SEM = error bars, 2-way ANOVA. 
 
6.2.3 Flunixin meglumine transiently protects enteroids against TNF-
treated induced injury  
Flunixin meglumine alone was administered to WT enteroids in order to determine 
whether flunixin meglumine induced any adverse morphological effects. When we 
compared flunixin meglumine-treated enteroids with non-flunixin meglumine-treated 
enteroids, there were no significant changes in enteroid circularity for 0-72 hours 
post-treatment and all enteroids consistently showed circularity values of around 0.4 
throughout the time course (figures 6.7 and 6.9A). This showed that flunixin 
meglumine treatment of enteroids did not cause any obvious deviation from the 
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flunixin meglumine would protect enteroids from the injurious effects of TNF. Prior to 
addition of 50 ng/ml TNF to enteroids, we first pre-treated enteroids with 0.1, 1 or 10 
μmol/l flunixin meglumine for 1 hour. Following TNF treatment, we measured enteroid 
circularity at 0, 24, 48, and 72 hours. At 24 hours post-treatment, 10 μmol/l flunixin 
meglumine demonstrated statistically significant inhibitory effects against TNF-
associated rounding in WT enteroids. Flunixin meglumine at this dose almost 
completely attenuated the morphological changes induced by TNF. There was no 
statistically significant difference in the phenotypic appearance and measurement of 
enteroid circularity between untreated and 10 μmol/l flunixin meglumine-treated 
enteroids at 24 hours post-treatment. At 48- and 72-hours following treatment, flunixin 
meglumine did not continue to exert protective effects. At 48- and 72-hours following 
treatment, circularity values were not statistically different from TNF-treated enteroids 
suggesting that a single treatment of flunixin meglumine may not provide long-lasting 
protection from TNF and repeat doses may be needed (figures 6.8 and 6.9B). 
 
  
Figure 6.7 Bright field micrographs of untreated, 0.1, 1, 10 μmol/l flunixin 
meglumine treated WT enteroids at 0, 24, 48, and 72 hours. Both untreated 
enteroids (DMSO control) and flunixin meglumine treated have phenotypically 
irregular shapes. Flunixin meglumine treatment did not induce any morphological 





Figure 6.8 Bright field images of untreated, 0.1, 1, 10 μmol/l flunixin meglumine and 
50 ng/ml TNF-treated WT enteroids at 0, 24, 48, and 72 hours. Untreated enteroids 
(DMSO (0.1%) control) have phenotypically irregular structures while TNF treated 
enteroids showed rounding at 24, 48, and 72 hours post-treatment; 10 μmol/l 
flunixin prevented TNF-induced enteroid at 24 hours post-treatment. Magnification 
x10, scale bar, 100 μm. 
 
   
Figure 6.9 WT enteroids were treated with 0, 0.1, 1 and 10 μmol/l flunixin meglumine 
alone for 0, 24, 48, and 72 hours (A). Prior to addition of 50 ng/ml TNF, WT enteroids 
were pre-treated with 0.1, 1, and 10 μmol/l flunixin meglumine for 1 hour (B). 
Statistically significant differences vs untreated (DMSO (0.1%) control) at the same 
time point are indicated ***p≤0.001, statistically significant differences between 
flunixin meglumine + TNF vs TNF alone are depicted by ##p≤0.01, n=6, N=3, SEM = 































































6.2.4 Curcumin does not protect against TNF-induced enteroid damages 
We first treated WT enteroids with curcumin alone to determine if there were any 
adverse morphological effects such as cell death caused by curcumin treatment. 
None of the curcumin doses selected caused increased cell death or enteroid 
rounding beyond that observed in untreated control enteroids. Baseline circularities 
of all treatment groups were similar to those presented in chapters 3 and 4 and were 
all less than 0.44±0.01 (Fig 6.10). Observations of curcumin-treated enteroids at 24, 
48, and 72 hours demonstrated continuous normal, polygonal growths without any 
morphological signs of rounding suggestive of apoptosis with consistent circularity 
values of less than 0.44±0.10 that were not statistically significant from baseline 
values or untreated enteroid circularity values at the same time point (figure 6.12A).  
Based on the above results, we proceeded to phase two of the study by pre-treating 
enteroids with curcumin prior to the addition of TNF to determine whether curcumin 
protected enteroids against TNF-induced enteroid cell death and consequent 
increased circularity. WT enteroids were pre-treated with 0-10 μmol/l curcumin for 1 
hour prior to the addition of 50 ng/ml TNF and circularity was measured at 0, 24, 48, 
and 72 hours post-TNF treatment. As expected, and in line with data presented in 
chapters 3 and 4, TNF induced a significant increase in enteroid circularity from 
baseline by 24 hours reaching 0.79±0.05. However, there was no statistical 
significance between curcumin pre-treated enteroids and TNF treated enteroids at 
any dose or time point tested, suggesting that curcumin is unable to protect enteroids 




Figure 6.10 Bright field micrographs of untreated, 0.1, 1 and, 10 μmol/l curcumin 
treated WT enteroids at 0, 24, 48, and 72 hours post-treatment. Both untreated 
enteroids (DMSO control) and curcumin treated have phenotypically irregular 
shapes. Curcumin treatment did not induce any morphological changes. Original 
magnification x10, scale bars, 100 μm. 
 
  
Figure 6.11 Bright field images of untreated WT enteroids and enteroids pre-treated 
with 0.1, 1, 10 μmol/l curcumin for 1 hr prior to the addition of 50 ng/ml TNF. Enteroids 
were imaged at 0, 24, 48, and 72 hours post-TNF treatment. Untreated enteroids 
(DMSO control) had phenotypically irregular structures whilst all TNF treated 





   
Figure 6.12 WT enteroid circularity values following treatment with 0, 0.1, 1, and 10 
μmol/l curcumin for 0, 24, 48, and 72 hours (A). WT enteroids were pre-treated with 
0.1, 1, and 10 μmol/l curcumin for 1 hour followed by the addition of 50 ng/ml TNF 
(B). Statistically significant differences vs untreated (DMSO control) at the same time 
point are indicated ***p≤0.001. There were no statistically significant differences 
between curcumin + TNF groups vs TNF treated enteroids, n=6, N=3, SEM = error 
bars, 2-way ANOVA. 
 
6.2.5 Summary of the actions of therapeutics on TNF-treated enteroids 
Below is a summary table of the biological actions of therapeutics on TNF-treated 
enteroids over the course of 72 hours. 
Therapeutic agents 24 hours post-
treatment inhibitory 
effect (10 μmol/l only) 
48- & 72-hours post-
treatment inhibitory 
effect 
Prednisolone ↑↑↑ - 
Hydrocortisone ↑↑↑ - 
Flunixin meglumine ↑↑↑ - 
Curcumin - - 
Table 6.1 Prednisolone, hydrocortisone, and flunixin meglumine ameliorated TNF-
induced rounding in WT enteroids at 24 hours following treatment, but curcumin did 
not exert any inhibitory effect at the same time point. However, at 48- and 72- hours 
following treatment, none of the therapeutics exhibited any inhibitory properties 
































































In this study we investigated whether prednisolone, hydrocortisone, flunixin 
meglumine and curcumin had abilities to inhibit TNF-induced enteroid rounding. Our 
data indicate that several agents known to have therapeutic actions against 
inflammation-induced injury in the gut also show some efficacy in an in vitro intestinal 
epithelial cell model in the absence of other cellular compartments such as immune 
cells. The 3D enteroid model may therefore provide great future opportunities to study 
whether repurposed and novel therapeutics are potential candidates for attenuating 
inflammatory bowel disease (IBD) and sepsis-mediated adverse effects. This needs 
to be interrogated; whether the results we observed in in vitro can be reproduced in 
in vivo and species-specificity and species-sensitivity and metabolism will also need 
to be taken into consideration. 
Corticosteroids are drugs administered to dampen inflammation in a variety of 
disease conditions including IBD (Ardite et al., 1998). Efficacy of corticosteroid use 
has also been demonstrated in the prevention of death in sepsis (Marik et al., 2017). 
A Cochrane review including 61 human trials and 12,192 patients was published in 
2019 suggesting that corticosteroids (including prednisolone and hydrocortisone) 
reduce the 28-day mortality risk in sepsis (Annane et al., 2019) and a recent meta-
analysis indicated that hydrocortisone showed greater efficacy than prednisolone in 
reversing septic shock (Gibbison et al., 2017). In vivo studies also support these 
observations and suggest that rodent tissues respond similarly to humans. For 
instance, in a CLP-induced abdominal sepsis model in rats, a methylprednisolone (2 
mg/kg) peritoneal lavage improved survival rates in abdominal sepsis (Tetikcok et al., 
2016). Corticosteroids are also known to mediate their anti-inflammatory properties 
by modulating NFκB signalling and I have shown in chapters 3, 4 and 5 of this thesis 
that perturbation of NFκB signalling specifically in the intestinal epithelium modulates 
the epithelial response to TNF and other TNFSF members, so it is not unreasonable 
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to speculate that corticosteroids could have a direct effect on the intestinal epithelium 
to desensitise this tissue to the actions of pro-inflammatory cytokines. We identified 
that at a concentration of 10 μmol/l of either prednisolone or hydrocortisone 
prevented intestinal epithelial cell-specific damage mediated by TNF over a 24-hour 
period. However, this protectivity did not persist beyond 24 hours. This is likely to be 
due to the experimental approach taken and future studies should consider the re-
administration of corticosteroid at 12- or 24-hour intervals. The plasma half-life of 
prednisolone is 2-3 hours in human adults (Bennett et al., 1994; Schijvens et al., 
2018), although the biological half-life is around 24 hours allowing for a single daily 
dose (Cronin et al., 2012). The plasma half-life of hydrocortisone is around 1.5 hours 
in human plasma (Lennernas, Skrtic & Johannsson, 2008), with a biological half-life 
of 8-12 hours (Yasir et al., 2020).  It is difficult to extrapolate half-lives into the enteroid 
culture system, however, enteroids express cytochrome P450 enzymes which are 
responsible for corticosteroid metabolism (Parween et al., 2019) and regular 
replenishment of the corticosteroids may therefore be needed to confer continued 
protectivity from TNF-induced pathology. Whilst our study was aimed at assessing 
the capacity of corticosteroids to desensitise the intestinal epithelium to TNF, they 
may also protect against further TNF-mediated production of TNF that has been 
observed in enteroid culture (Bradford et al., 2017). Barber and colleagues reported 
that administration of hydrocortisone in healthy subjects reduced the concentration 
of plasma TNF (Barber et al., 1993). Hydrocortisone has been documented to 
improve survival and haemodynamic response, lower plasma IL-6 concentrations 
and decrease the levels of phospholipase A2 and E-selectin (Briegel et al., 1994; 
Heming et al., 2018; Keh et al., 2003; White et al., 1978). The assay of TNF 
concentration in enteroid culture media should therefore be considered in future 
experiments to determine whether the observed protectivity in TNF-induced enteroid 
injury conferred by corticosteroids may in part result from inhibition of TNF production 
from intestinal epithelial cells. We observed that 1 μmol/l of hydrocortisone or 
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prednisolone did not show any statistically significant response, whereas 10 μmol/l 
was protective at 24 hours, so further investigation of doses between 1 and 10 μmol/l 
will now be required to investigate this dose response relationship in more detail. 
Our findings also demonstrated that flunixin meglumine attenuated the effects of 
TNF-induced rounding at 24 hours post-treatment with TNF in WT enteroids. Flunixin 
meglumine is a non-steroidal anti-inflammatory drug (NSAID) that has shown efficacy 
in treating sepsis in horses and dogs and is known to modulate NF-κB activity 
(Konigsson et al., 2003; Hardie et al., 1983). The plasma half-life of flunixin 
meglumine is 1.6 - 2.5 hours, but it has been reported that its effects can last up to 
30 hours as a result of the drug accumulation in an inflammatory environment (May 
& Lees, 1996). The degradation and uptake of flunixin meglumine in enteroid cultures 
has not been measured. However, in our study at 48 and 72 hours we did not observe 
any ameliorating effects of flunixin meglumine on TNF-induced rounding and re-
application of the drug may therefore be necessary every 12-24 hours to observe 
continued protectivity due to reduced potency of flunixin meglumine following drug 
metabolism.  
Unlike the previously reported therapeutics, we observed that curcumin had no 
inhibitory activity on TNF-induced enteroid rounding despite it showing efficacy in in 
vivo CLP sepsis and IBD models (Anand et al., 2007; Da Silva et al., 2017; Nelson 
et al., 2017). Curcumin significantly lowered levels of sepsis-induced proinflammatory 
cytokines (IL-1β and IL-6) in the plasma and peritoneal lavage fluid following CLP. 
However, plasma curcumin levels were shown to decrease from 2.5 ng/mL at 4 hours, 
to being undetectable by 24 hours (Da Silva et al., 2017). Curcumin is relatively 
insoluble in water with unstable, poor bioavailability and rapid metabolism (Anand et 
al., 2007; Nelson et al., 2017). The half-life of curcumin is between 6 and 7 hours 
(Jager et al., 2014). So, our lack of curcumin inhibitory findings against TNF-induced 
rounding at 24, 48, and 72 hours could be due to its shorter half-life and poor solubility 
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which might affect its absorption. The protective effects of curcumin against IBD and 
sepsis may also be a result of the inhibition of TNF (and other cytokine inhibition) 
rather than reducing the sensitivity of the intestinal epithelium to the effects of TNF 
as we have demonstrated with prednisolone, hydrocortisone and flunixin meglumine. 
All of the drugs tested above for their ability to ameliorate TNF-induced enteroid 
pathology are known to modulate NFκB signalling.  The true nature of how NFκB 
signalling is modulated specifically in intestinal epithelial cells by these agents is 
however still to be elucidated. Two broad mechanisms by which these drugs 
modulate the epithelial damage response have been proposed. The first is by means 
of reducing the sensitivity of enteroids to TNF by blunting downstream signalling 
following TNF binding to TNFR1 or TNFR2 and this is the component that the assays 
in this chapter were designed to assess. The second mechanism is likely to involve 
inhibition of cytokine production from immune cells and to a lesser extent by intestinal 
epithelial cells themselves. NFκB signalling is likely to be implicated in both of these 
proposed processes. Work has been carried out in vivo demonstrating the 
suppression of classical pathway NFκB signalling by means of dampening p50 or 
p65 by these agents (Sanz et al., 2010; Sun, 2011), but little attention has been 
directed towards their impact on alternative pathway NFκB signalling, which we have 
demonstrated as being important in regulating the epithelial-specific damage 
response (chapters 3 and 4, Jones et al., 2019). Auphan and colleagues and Haskill 
and colleagues documented that corticosteroid treatment enhances cytoplasmic IκB 
sequestering of NFκB, thus preventing it from being translocated to the nucleus to 
induce inflammatory gene transcription (Auphan et al., 1995; Haskill et al., 1991). 
They also reported that corticosteroid, through MAD-3, induces production of IκBα to 
prevent activation of the NFκB signalling pathway (Auphan et al., 1995; Haskill et al., 
1991).    
237 
 
In summary, we have developed and tested a 3D enteroid model of intestinal 
inflammation that can potentially be used in future to assess repurposed and novel 
therapeutic agents for IBD and sepsis. The model provides structures that accurately 
recapitulate the intestinal epithelium and isolates this cellular compartment from 
others in order to address epithelial cell-specific responses without the complex 
signalling between the epithelium and other mucosal compartments. Future 
adaptations of the enteroid model to include multiple cell populations (termed 
reconstituted organoids) are possible to assess specific cell-cell interactions. We 
have demonstrated the importance of therapeutic approaches to inhibit the actions 
of TNF specifically on the intestinal epithelium and how targeting this component of 
the mucosa may ameliorate local and systemic inflammation by promoting the 
maintenance of intestinal barrier function, thus preventing the perpetuation of 
inflammation. We would in future like to use this enteroid model to investigate the 
consequences of 5-aminosalicylic acid (5-ASA) treatment, an anti-inflammatory 
agent that interferes with the synthesis of prostaglandin from arachidonic acid, and 
which is widely used to treat IBD (Punchard, Greenfield & Thompson, 1992). We 
would like to investigate concentrations of tested agents between 1 μmol/l and 10 
μmol/l for possible inhibitory effects on induced circularity in enteroids. We 
demonstrated in chapter 3 (forskolin) and chapter 4 (alternative pathway activators 
such as TWEAK, LIGHT, CD40-L and another cytokine IL-6) that various other stimuli 
also induced the rounding of enteroids, so we would like to investigate whether the 
therapeutic agents that we tested in this chapter also delay, ameliorate or annul the 
circularity changes that are induced by these stimuli. We would also like to explore 
the extent to which NF-κB signalling modulates these drug responses.  Whilst 
inflammatory bowel disease can affect the small intestine, there are many more 
cases where the colon is inflamed, and the small intestine is not involved.  Enteroids 
are quicker to grow and are more abundant in culture and were chosen to represent 
both IBD and sepsis where quantification of epithelial dynamics normally yields 
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greater differences in response to drug treatment compared to the colon. We are 
currently not certain whether similar findings would have been demonstrated in 
colonoid culture but studies using colonoids are warranted. Quantification of 
circularity is less robust in colonoid culture compared with enteroid culture and other 
analysis methods will be needed to assess changes in morphology. Histological 
quantification of active caspase 3 and Ki67 would be achievable to assess the impact 















7 General discussion 
Sepsis and inflammatory bowel disease (IBD) have several common features and 
mechanisms. One of the first organs to be damaged in sepsis is the intestine whilst 
this is also the main location of IBD manifestation. Both conditions are perpetuated 
by uncontrolled inflammation. Both sepsis and IBD have local and systemic sequelae 
resulting in dysregulated inflammatory responses. They are both characterised by 
the hyperproduction of TNF, IFNγ, IL-6 and other pro-inflammatory cytokines, a 
hyper-inflammatory response to inflammation-inducing agents and intestinal 
epithelial barrier dysfunction, leading to compromised mucosal protection, microbe 
translocation, gut leakage, interstitial oedema, apoptosis and intestinal epithelial cell 
shedding (Kiesslich, 2012; Michielan & D'Inca, 2015; Salim & Soderholm, 2011). 
Poorly managed IBD can also eventually lead to sepsis. Currently, antibiotics, 
corticosteroids, biologics and immunomodulatory drugs are the main components of 
clinical treatment of both sepsis and IBD (Sartor, 2004; Song et al., 2015; Targan et 
al., 1997). Therefore, in order to effectively generate efficient and efficacious novel 
therapeutics against both diseases, the importance of in-depth understanding of 
these conditions at both the cellular and molecular levels cannot be over-emphasised 
and lessons from one condition may inform the other.  It has historically been difficult 
to develop models of these conditions in vitro due to the need for interaction of 
epithelia with the immune system, the limitation of generating exact culture media to 
mimic that of the diseased state in humans and an inability to replicate the 
environmental factors encountered by humans. As a result, new higher throughput 
reliable in vitro models to generate a more physiological environment are needed to 
complement in vivo and clinical studies.  The generation of enteroid cultures leading 
to the data presented in this thesis have addressed some of the limitations previously 
encountered in model development and have allowed novel studies of NFκB 
signalling in the intestinal epithelium.   
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As previously stated in chapter 1.9.6 and 1.9.7, both classical and alternative NFκB 
signalling pathways play key roles in gut immune homeostasis. NFκB signal 
transduction plays major regulatory roles in DNA transcription, intestinal epithelial 
homeostasis, cytokine production and cell proliferation (Brasier, 2006; Gilmore, 2006; 
Perkins, 2007). In sepsis, microbes and microbial products interact with host 
intestinal cell surface pattern recognition receptors (PRRs) such as TLR-2 and TLR-
4 to trigger activation of NFκB signalling pathways that result in a cascade of 
reactions leading to downstream gene transcription of pro-inflammatory cytokines 
(Beutler et al., 2003). In IBD, dysregulation of the immune system results in the 
production of pro-inflammatory cytokines that interact with gut epithelial cell surface 
receptors such as TLR4 to trigger activation of NFκB signalling pathways and 
subsequent inflammatory reactions (Isaacs et al., 1992; Reinecker et al., 1993). 
Previous studies have documented TNF as a major activator of the classical and 
alternative NFκB signalling pathways and have characterised the key role it plays in 
inducing intestinal damage during IBD and sepsis (Gutierrez et al., 2008; Jones et 
al., 2019; Kelliher et al., 1998). This is why it was selected as the predominant 
cytokine for investigation in this thesis. NFκB signalling is important in maintaining 
epithelial integrity, normal antimicrobial peptide expression, intestinal immune 
homeostasis, and prevention of translocation of bacteria into the intestinal mucosa 
(Nenci et al., 2007). However, extensive studies have not been conducted of the 
importance of alternative NFκB pathway signalling compared with classical NFκB 
pathway signalling in the intestine.  
RelB and NFκB2 mediate alternative NFκB pathway signalling via NEMO-
independent signalling to activate alternative activator inducing hyperinflammatory 
responses including intestinal apoptosis (Moore et al., 2007). Williams and 
colleagues reported that classical NFκB signalling via NFκB1 (p105/p50) and c-Rel 
mediated cell survival, whilst alternative pathway signalling via NFκB2 (p100/p52) 
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coordinated intestinal cell apoptosis (Williams et al., 2013). Burkitt and colleagues 
additionally demonstrated that that Nfκb2-/- mice were protected from DSS-induced 
experimental colitis, suggesting that alternative pathway NFκB signalling is important 
in regulating the intestinal damage response (Burkitt et al., 2017). Nfκb2-/- mice also 
showed reduced inflammation in their stomachs compared to WT and Nfκb1-/- mice 
when infected with Helicobacter felis (Burkitt et al., 2013). From these studies, the 
importance of intestinal epithelial cell-specific NFκB signalling was not discernible as 
global Nfκb knockout mouse strains also have defective immune systems and altered 
damage responses in Nfκb2-/- mice could have been a result of perturbed 
inflammation.  Jones and colleagues addressed the importance of epithelial-specific 
NF-κB2 signalling using enteroids (Jones et al., 2019). Nfκb2-/- enteroids were less 
susceptible to the damaging effects of TNF compared with WT enteroids and other 
Nfκb-/- enteroid lines, suggesting that alternative pathway NFκB signalling specifically 
in the intestinal epithelium regulates the epithelial damage response and 
consequently regulates the intestinal barrier (Jones et al., 2019). 
This thesis builds on previous findings that the intestinal epithelial damage response 
is regulated by alternative pathway NFκB signalling. Reports from previous enteroid 
studies were only based on static conditions and arbitrarily defined time-points. We 
wanted to extend these findings by determining the range of actions of TNF 
stimulation and NFκB modulation in enteroids at higher resolution by assessment of 
enteroids under dynamic conditions using live cell time-lapse imaging technology. 
We further wanted to determine the mechanistic nature of the resistance to TNF-
induced intestinal epithelial damage, so we conducted broad spectrum proteomic 
analyses of WT, Nfκb1-/-, Nfκb2-/- and c-Rel-/- enteroids with and without TNF to 
determine factors that may be responsible for modulating the intestinal damage 
response. Our studies also identified that other stimuli which are known to stimulate 
alternative pathway NFκB signalling also affect the enteroid damage response 
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suggesting that the epithelial damage response is not solely regulated by TNF, but 
also by other cytokines that are known to be upregulated during IBD and sepsis. We 
were also interested in developing an enteroid model to test potential therapeutics 
against sepsis and IBD and through interrogation of the enteroid proteome wanted to 
discover proteins that might be responsible for the protective effects demonstrated 
by Nfκb2 null enteroids to the to damage caused by TNF to determine potential new 
therapeutic targets for sepsis and IBD.  
 
7. 1 Main findings 
7.1.1 TNF causes altered enteroid morphology 
TNF caused enteroids to undergo a rounding morphology which we have shown 
previously to be associated with increased apoptosis (Jones et al., 2019). The actions 
of TNF were associated with shortening of the crypt and villus domains and 
immunohistochemistry demonstrated a significant reduction in proliferation (by Ki67 
quantification) (appendix C) and a dose and time-dependent decline in the epithelial 
thickness of TNF treated enteroids (chapter 3, figures 3.3, 3.4). Through co-staining 
immunohistochemical techniques developed in this thesis, we were able to identify 
enteroid villus domains using alkaline phosphatase and crypt domains using Ki67 
staining within the same enteroid which may be useful in future studies to understand 
the differences in sensitivity to different damaging stimuli between these crypt-villus 
axis regions. We demonstrated villus atrophy as a result of cell shedding in TNF 
treated enteroids (figure 3.3) and this supported previously reported studies of TNF 
induced small intestinal epithelial apoptosis and cell shedding following 
administration to WT mice (Williams et al., 2013). TNF treatment has previously been 
reported to play key roles in the dysregulation of the integrity of intestinal epithelial 
tight junction function and structure in vivo (Al-Sadi et al., 2013; Arrieta et al., 2009; 
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Hollander, 1999; Mayhew et al., 1999; Turner, 2009). We also demonstrated a 
redistribution of claudin-7 in enteroids in response to TNF treatment which suggests 
that the permeability of the intestinal barrier is altered in enteroids by the actions of 
TNF (figure 3.5). Clinically, loss of villi and epithelial integrity have been reported to 
be responsible for malabsorption, increased intestinal permeability, and diarrhoea 
(Blander, 2016; Mankertz & Schulzke, 2007; Schulzke et al., 2009; Watson & 
Hughes, 2012). 
7.1.2 TNF alters tissue dynamics of enteroids 
Live cell imaging of TNF-treated WT intestinal epithelial enteroids demonstrated 
several behavioural patterns that could not be observed by static bright field imaging. 
TNF treated enteroids underwent periodic expansions and contractions that were 
nonsynchronous between enteroids, whereas untreated enteroids did not undergo 
the same degree of expansion and contraction. TNF treated enteroids were also 
observed to migrate erratically with a greater cumulative distance of migration and 
greater speed compared to untreated enteroids. These observations suggest that 
TNF not only regulates cellular dynamics (a widely reported phenomenon) 
(Middendorp et al., 2014; Wallach & Bayrer, 2017), but also regulates tissue level 
dynamics within the intestinal epithelium (a process that is not currently well 
understood). We were able to show that WT enteroids treated with high doses of TNF 
regained proliferative capacity once TNF was removed, suggesting that intestinal 
stem cells are resistant to long-lasting TNF-induced damage compared to other 
epithelial cell populations. TNF may therefore contribute to the distribution of 
intestinal stem cells laterally within the intestinal mucosa to aid in healing. There is 
likely a fine balance between the impact of TNF on cell death and cell shedding (the 
increased rate of cell shedding induced by TNF could partially be a result of enhanced 
TNF-induced cellular migration along the crypt-villus axis) with the protective effects 
that we have potentially demonstrated at the tissue level using enteroids. 
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7.1.3 NFκB2 signalling is important in regulating the actions of TNF in 
intestinal epithelia  
Enteroids generated from Nfκb2-/- mice showed blunted responses to TNF treatment 
compared with WT enteroids (Chapters 3 and 4; Jones et al., 2019). Whilst TNF-
treated WT enteroids became more spherical in appearance and demonstrated 
increased cell death and cell shedding, Nfκb2-/- enteroids showed resistance to the 
effects of TNF displaying a significantly blunted rounding response. Furthermore, 
Nfkb2-/- enteroids did not expand and contract or migrate to the extent observed in 
WT enteroids treated with TNF. NF-κB2 signalling is therefore an important regulator 
of TNF-induced injury specifically in intestinal epithelial cells and may also contribute 
to the regulation of tissue restitution following mucosal damage.   
7.1.4 The intestinal epithelial proteome is modulated by TNF and NFκB 
perturbations 
Several proteins were identified from proteomic analyses that may contribute to the 
actions of TNF on the intestinal epithelium and the resistance to TNF-induced 
damage observed in Nfκb2-/- enteroids.  Ubiquitin-like protein (interferon-stimulated 
gene 15 ubiquitin-like modifier, (ISG15)), cytoskeleton-associated protein 4 (Ckap4), 
myoferlin (Myof), and N-alpha-acetyltransferase 30 (Naa30) proteins from our 
proteomic analysis were upregulated following TNF and have been reported in 
previous studies to play important roles in cell migration or motility. Isg15 has been 
implicated to be responsible for chemotaxis of neutrophils in IBD and colon cancer 
(Zuo et al., 2016). Cytoskeleton-associated protein 4 (Ckap4), N-alpha-
acetyltransferase 30 (Naa30) and ribonuclease pancreatic (Rnase1) were up-
regulated cytoskeletal proteins which play key role in cell dynamics. Ckap4 
modulation of actin dynamics via the Abelson interactor 1 (Abi-1) pathway and other 
intracellular trafficking and signalling coordinated cell contraction, retraction, 
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migration, focal adhesions, and other cell mechanics (Cleary et al., 2014; Gerthoffer, 
2008; Tang & Gerlach, 2017). Intestinal tight junction proteins such as integrin alpha-
2 (Itga2), junctional adhesion molecule A (F11r), claudin-4 (Cldn4), integrin beta-6 
(Itgb6), integrin alpha-V (Itgbv), claudin-3 (Cldn3), and neural cell adhesion molecule 
L1 (L1cam) were upregulated following treatment with TNF. They are also involved 
in regulation of the intestinal barrier and the immunomodulating function of intestinal 
epithelial cells (Holmes et al., 2006; Lee & Juliano, 2000). 
Serum amyloid A-3 protein (Saa3) was significantly upregulated in Nfκb2-/- enteroids 
following TNF treatment and saa3 has previously been reported to protect against 
acute lung injury in Pseudomonas aeruginosa-infected mice (Fan et al., 2020) and 
against sepsis (Ather et al., 2018). Saa3 also plays a prominent role in protecting 
epithelial cells against sepsis (Ather et al., 2018). Peptidoglycan recognition protein 
1 (Pglyrp1) was most significantly up-regulated in Nfκb2-/- enteroids and Pglyrp1 
demonstrated protection against sepsis during experimental colitis in mice (Saha et 
al., 2010). Traf4 was downregulated in Nfκb2-/- enteroids and is involved in the 
protective modulation of cell apoptosis and survival and regulation of Traf6 and NFκB 
inflammatory responses (Ayala et al., 1996; Shiels et al., 2000). Downregulation of 
traf4 in Nfκb2-/- enteroids might be one of the factors responsible for the attenuating 
effects observed in this transgenic mouse strain. Tnfaip3 was significantly 
upregulated in Nfκb2-/- enteroids and it has been well documented that Tnfaip3 
exhibits inhibitory activity on NF-κB pathway signalling and regulation of TNF-induced 
apoptosis (Jung et al., 2019; Lerebours et al., 2008; Serramito et al., 2019). Some 
interesting proteins were therefore identified that warrant further exploration as 
targets for modulating the severity of TNF-induced damage in the gut during IBD and 




7.1.5 Alternative pathway NFκB2 activators regulate intestinal epithelial 
survival 
We demonstrated in Chapter 3 that alternative pathway NFκB signalling was 
important in regulating the intestinal epithelial response to TNF.  However, we wanted 
to determine whether this protective effect of Nfκb2 deletion was unique to TNF or 
whether Nfκb2 deletion would confer a similar resistance to other TNF superfamily 
members that are known to modulate alternative pathway NFκB signalling. We found 
that there were differential responses to treatment with several TNF superfamily 
members in WT and Nfκb2-/- enteroids. Four out of six members of the TNFSF (TNF, 
TWEAK, LIGHT and CD40-L with decreasing induced-circularity hierarchy) 
investigated in this thesis demonstrated different degrees of damage to WT enteroids 
whilst Nfκb2-/- enteroids  showed reduced responses to some of these stimuli. Several 
stimuli however did not induce major rounding in both WT and Nfκb2-/- enteroids 
(CD40-l, LTα/β and BAFF) and no stimulus tested induced greater rounding effects 
in Nfκb2-/- enteroids than in WT. NFκB2 signalling specifically in intestinal epithelial 
cells is therefore important in regulating the damage response to several cytokines 
and is not restricted to TNF.   
7.1.6 Development of an in vitro enteroid model to investigate potential 
sepsis and IBD therapeutics known to modulate intestinal epithelial cell-
specific NFκB signalling 
As previous studies have consistently shown, the intestine is one of the first tissues 
to be damaged during sepsis. So, a reliable in vitro model of the GI epithelium would 
be good to model sepsis and IBD-induced intestinal epithelial effects and thus the 
potential development of novel therapeutics. TNF is a major cytokine responsible for 
sepsis and IBD severity and its effects on enteroids were extensively studied in 
chapters 3-5. We therefore used TNF as an inflammatory stimulus in the enteroid 
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model to assess various different treatment approaches. Different drug classes such 
as corticosteroids, an NSAID and a natural anti-inflammatory herb were selected and 
showed different responses in the model. Corticosteroids tested included 
prednisolone and hydrocortisone, flunixin meglumine was the NSAID and curcumin 
was the natural anti-inflammatory herb. Previous studies demonstrated the major 
roles NFκB signalling pathways play in initiation, propagation, and progression of 
both IBD and sepsis with resultant hyper-production of cytokines, dysregulation of 
hyper-inflammatory responses and disruption of intestinal barrier function and 
immune system (Beutler et al., 2003; Burkitt et al., 2015; Ghosh et al., 1998). The 
drugs that were selected to test potential in vitro therapeutic approaches in this thesis 
are already known to modulate NFκB signalling. We observed that corticosteroids 
and the NSAID were partially protective against TNF-induced enteroid damage 24-
hour following treatment (chapters 4 and 5). NFκB signalling modulation following 
treatment still remains to be explored.  Many therapeutics are well known to modulate 
classical pathway NFκB signalling, but the alternative pathway is relatively under-
explored. Future studies will determine whether some of the therapeutic effects 
observed specifically on the intestinal epithelium may be modulated by suppression 
of alternative pathway NFκB signalling.  
In this thesis, we therefore demonstrated the reliability of our enteroid model in 
providing a near-physiological microenvironment of the intestinal epithelium and how 
it was used as a good model for investigating different classes of agents for potential 
development of novel therapeutics for the amelioration of sepsis and IBD. At 24 hours 
following putative therapeutic agent treatment, only prednisolone, hydrocortisone and 
flunixin meglumine exhibited inhibitory effects against TNF-induced rounding in our 
enteroid model, whilst curcumin did not demonstrate any inhibition. Further 
investigation of these promising therapeutic candidates is now needed and 
approaches to test repurposed and novel IBD and sepsis therapeutics in human 
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enteroid models would also be useful to determine whether the results in mouse 
enteroids translate into human enteroids and ultimately humans. 
 
7.2 Implications for sepsis and IBD research and therapeutic 
intervention 
Sepsis and IBD have related pathophysiological mechanisms. Lessons about sepsis 
management including intestinal epithelial repair and restoration can be learned from 
IBD research owing to this tissue being one of the first damaged tissues in sepsis. 
Other tissues particularly epithelial-derived ones such as the lung may undergo 
similar damage responses to cytokines such as TNF and management of intestinal 
epithelial-specific signalling pathway derangement may be applicable to cytokine-
induced lung hyper-inflammatory responses. Tissue-level dynamic alterations 
observed in this thesis may also not be exclusive to TNF, as other TNFSF members 
also induce enteroid morphological changes. It is now timely to investigate whether 
other pro-inflammatory cytokines also induce expansions/contractions/enhanced 
motility and other behavioural patterns in enteroids. 
We observed that Ckap4, Naa30 and Rnase1 are altered in the intestinal epithelial 
proteome following TNF treatment, suggesting that these proteins may be 
responsible for intracellular trafficking and cell mechanics including enhanced 
motility. We reported that TNF-induced damage in Nfκb2-/- enteroids was milder than 
that observed in WT enteroids and from our proteomic analysis we found that Tnfaip3 
protein was upregulated in Nfκb2-/- enteroids. Many studies have reported the 
protective effects of TNFAIP3 protein in Nfκb2-/- mice (Kovalenko et al., 2003; Mauro 
et al., 2006; Nijman et al., 2005; Stilo et al., 2008). This might warrant further 
investigations in order to understand mechanisms and any plausible inherent 
therapeutic advantages against sepsis in Tnfaip3 protein signalling. 
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We demonstrated that some TNF-treated enteroids were rescued after we discarded 
the TNF-treated media and replaced it with fresh culture media. Results from our 
therapeutic experiments also demonstrated that pre-treatment with corticosteroids 
and NSAID attenuated the effects of TNF in the 24-hours following treatment. Thus, 
we suggest that focusing on nutritional support, cell growth-enhancers, and 
antagonising sepsis-induced hyper-production of cytokines might be important in 
treating sepsis. Translationally, this could lead to studies of samples obtained from 
patients with sepsis and IBD who have been treated with these therapeutics.   
We demonstrated that live cell imaging technology provides additional information 
about morphological changes and behavioural responses to pro-inflammatory 
cytokines that are easily missed using static bright field microscopy. The importance 
of these observations is not currently clear, but is likely to present a method of 
investigating tissue-level dynamics in vitro which may greatly enhance the field by 
providing mechanistic understanding of intestinal tissue restitution following injury 
such as that observed in IBD and sepsis. Many studies currently use time-lapse 
confocal imaging, but over short time courses of minutes to several hours. However, 
imaging multiple enteroids at low power bright-field magnification over a time course 
of several days was more effective at demonstrating the full extent of tissue-level 
dynamics. TNF is a major cytokine that contributes to the intestinal pathologies 
observed in IBD and sepsis. TNF induces apoptosis and in our enteroid model, 
promising therapeutic agents (prednisolone, hydrocortisone and flunixin meglumine) 
might have potentially inhibited inflammatory and apoptotic mediated signalling 
pathways (for an example, NFκB) in the 24-hour period following treatment during 





7.3 Strengths of the study 
Enteroids were grown in a 3D microenvironment that is widely demonstrated to be a 
near-physiological model system for the study of the intestinal epithelium. Enteroids 
self-propagate, self-organize, undergo self-renewal, and differentiate with little 
genomic variation for many passages allowing reproducible studies and many more 
doses and time points to be tested compared to in vivo analyses (Fatehullah et al., 
2016; Lancaster & Knoblich, 2014). Enteroids contain solely intestinal epithelial cells 
and therefore allow investigation of the direct impact of factors such as pro-
inflammatory cytokines on the epithelium without the complex interplay of signalling 
networks present between different cellular compartments in vivo. This has allowed 
us to demonstrate the direct impact of TNF and other TNFSF members on the 
epithelium to address the importance of this tissue compartment in regulating its 
response to pro-inflammatory cytokines. We have shown that alternative pathway 
NFκB signalling in this tissue is an important regulator of the damage response and 
that differences in NFκB2 transcription factor signalling between patients may 
therefore modulate patients’ responses to the development of IBD and sepsis. The 
live cell imaging technology system provided a real-time and time course video and 
image capturing of the behavioural responses and morphological changes of the 
organoids to various treatments. Both static and dynamic images showed cytokine-
induced circularity and TNF-induced enteroid circularity has previously been 
correlated with degree of apoptosis and cell shedding (Jones et al., 2019). The 
comparison of the proteomic data from intestinal epithelium following administration 
of LPS to mice and treatment of organoids generated from the same strains of mice 
with TNF is novel and adds to the generalisable knowledge of pathways that are 
activated by LPS and TNF and highlights similarities and differences between in vivo 
and in vitro approaches at the proteome level.  
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Crypt and villus compartments of intestinal epithelia demonstrate different functions. 
Whilst self-propagation and auto-renewal of cells take place in the crypt domain, 
apoptosis, shedding and expulsion predominantly take place in villus domain. These 
crypt/villus compartments also exhibit different resistances and responses to cytokine 
treatment. We developed a co-staining immunohistochemical technique which made 
it possible to simultaneously investigate crypt/villus domains of interest in enteroids. 
Our enteroid model has now been developed to test repurposed drugs and novel 
therapeutics. This will also aid in investigating the alternative pathway NF-kB 
signalling pathway more mechanistically and may potentially facilitate the 
development of drugs that may target this pathway. 
 
7.4 Limitations of the study 
Enteroids within a single culture have a range of different sizes, shapes and number 
of cells. The heterogeneity of organoids might cause clonal drift and slight variation 
in reproducibility and responses to stimulation and treatment (Fatehullah et al., 2016; 
Huch et al., 2017). In this study we used a Lonza cytoSMART live cell imaging system 
which only had 10x magnification to capture enteroid morphological changes and 
behavioural patterns. The resolution of video-microscopy used could not capture all 
the detailed information. Confocal imaging would be necessary in enteroids that are 
several 100 μm thick to generate high quality cellular resolution.  However, low power 
imaging did allow us to capture many enteroids per field of view that would not be 
possible by standard confocal microscopy. High throughput 96-well plate confocal 
imaging is now possible, but unfortunately the equipment is expensive and very 
specialized.  We observed during treatment with TNF that some enteroids migrated 
away from the microscopic field of view thereby making them lost to follow up. There 
were also several enteroids that migrated into the microscopic field without us having 
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prior knowledge of their motility at the beginning of the experiment. These are some 
of the limitations of the image capture system that we used.  
In our proteomic study, we opted for a broad-spectrum proteomic analysis. The 
proteomic buffer we used was not strong enough to efficiently lyse the membrane 
and nuclear proteins. According to Wallin and von Heijne, about 30% of genes in the 
majority of organisms encode membrane proteins (Wallin & von Heijne, 1998). 
Moreover, membrane proteins have amphipathic biomacromolecules which 
comprises of central hydrophobic entity and the two hydrophilic ends, thus making it 
challenging to solubilize membrane proteins for proteomic study (Vit & Petrak, 2017). 
Future investigation of membrane proteins in the enteroid system with and without 
TNF might be helpful in determining their roles in tight junction regulation, cell 
migration, and integrity of the mechanical protective function against bacterial 
invasion and translocation. Further investigation of nuclear proteins might also be 
helpful in analysing transcription factors such as NFκB and post-translational 
modification, acylation and methylation analysis would enable us to determine the 
activation states of some protein families. 
 
7.5 Future directions 
Several potential future directions have already been discussed in this thesis and 
conducting these studies could help to provide deeper insights into our understanding 
of the molecular mechanisms that are associated with sepsis and IBD pathogenesis, 
altered intestinal epithelial cell mechanics, morphological changes, perturbed 
intestinal tissue level dynamics and regulation of gut barrier function integrity. We 
have comprehensively demonstrated the prominent roles NFκB signalling pathways 
in the activation, modulation and propagation of pathological intestinal epithelial 
responses including rounding, apoptosis and tight junction redistribution subsequent 
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to various damage-inducing stimuli. From our proteomic analysis, we have also 
identified many up-and down-regulated proteins following Nfκb subunit deletion. It 
would now be interesting to discover which proteins play passenger or driver roles in 
intestinal epithelial hyper-inflammatory responses. It would be fascinating to know 
biological relevance of the TNF phenotype in WT enteroids and fully understand how 
TNF affects the intestinal epithelium and other tissues (especially the epithelia lining 
other organ systems such as the lung) during sepsis. Furthermore, we would like to 
understand whether sepsis-induced intestinal epithelial dysregulation may mimic 
similar processes in other tissues or whether it is unique to the intestine, so it would 
be interesting to analyse other tissues including lung.  
Performance of further experiments on the identified proteins for pathway analysis, 
proteomic signatures, nuclear transcriptional analysis, trans-membrane specific 
analysis and the roles they play in sepsis and IBD would be of great importance in 
further understanding the mechanism of sepsis and IBD pathogenesis. Some of 
these identified proteins could then be selected for location identification by 
immunohistochemistry and quantification by western blotting experiments.  
Various members of the TNFSF have been investigated in this thesis. It would be of 
scientific and translational importance to further investigate their roles in intestinal 
epithelial specific NFκB signalling as well as in other tissues such as lungs that are 
affected during sepsis. It would also be fascinating to understand how specific 
inhibitors of the alternative NFκB pathway signalling (eg IKKα, NIK) modulate and 
regulate the protective response in WT epithelia as the responses may be similar to 
those which we observed in Nfκb2-/- enteroids and mice with experimentally induced 
gastrointestinal damage. Therapeutics for sepsis and IBD may therefore also be 
elucidated based by modulation of this pathway.   
We would like to use our enteroid model to test 5-ASA and derivatives (therapeutics 
commonly used to treat human IBD in the clinic) to determine any possible regulating 
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and attenuating roles they might have on NFκB signalling pathway and ameliorating 
effects on sepsis and IBD in vitro. Studies of therapeutic combinations on our enteroid 
model for potential synergistic, additive or antagonistic action might also shed more 
light on the NFκB signalling pathway, sepsis and IBD.  
One of the limitations of the enteroid model is that it has an immune deficit, so we 
would like to develop enteroid co-cultures with immune cells, mesenchymal cells and 
other cell populations and then study the interactions between different cellular 
compartments and test therapeutic agents on induced sepsis and observe how they 
affect sepsis and NFκB signalling pathway activation. Based on our proteomic results 
we observed that intestinal epithelial enteroids and mucosa from the same mouse 
strain had some differences in expressed proteins so we would like to perform animal 
studies and observe their differences and similarities in term of refining doses, time 
points and pre-treatment of the investigated therapeutics.  
The ultimate aim of this study was to characterise the actions of TNF in dynamic and 
static states, understand the roles played by the NFκB signalling pathway in intestinal 
epithelia and to develop potential novel in vitro models of IBD and sepsis in which 
therapeutic approaches could be tested. Future studies of epithelial ultrastructure 
using transmission electron microscopy and 3D scanning electron microscopy would 
enable detailed mapping of tight junction and sub-cellular responses to cytokine 
treatment and NFκB signal transduction modulation. Advanced real-time and 
quantitative fluorescent live-cell imaging to spatiotemporally monitor complex cell 
biology would further elucidate cellular and sub-cellular dynamic changes. 
Development of real-time software to capture, collate, and analyse circularity data 
would not only minimize manual errors, but would also reduce the screening time for 




7.6 Overall conclusions  
 
Figure 7.1 A graphical representation of the main findings of the actions of TNF on 
WT and Nfκb2-/- intestinal epithelial (IE) enteroids and quantified proteomes.  
This thesis project has identified and described in detail the roles that some members 
of the TNF superfamily play in modulating susceptibility to developing IBD and sepsis 
and how NFκB2 contributes to regulating the susceptibility of the intestinal epithelium 
to cytokine-induced damage (figure 7.1). We have also identified through proteomic 
analysis several interesting protein targets that warrant further investigation. We have 
extensively discussed the role of the alternative NFκB signalling pathway activators 
in inducing pathological morphological changes. The dose- and time-dependent 
inhibitory roles of several corticosteroids and an NSAID in modulating TNF-induced 
rounding in enteroids have also been studied. Intestinal epithelial susceptibility to 
injury caused by TNF superfamily members is modulated by intestinal epithelial cell-
specific expression of Nfκb2. Interrogation of this signalling pathway is now warranted 









Abraham, E., Anzueto, A., Gutierrez, G., Tessler, S., San Pedro, G., Wunderink, R., 
. . . Porter, S. (1998). Double-blind randomised controlled trial of monoclonal 
antibody to human tumour necrosis factor in treatment of septic shock. 
NORASEPT II Study Group. Lancet, 351(9107), 929-933.  
Abreu, M. T. (2010). Toll-like receptor signalling in the intestinal epithelium: how 
bacterial recognition shapes intestinal function. Nat Rev Immunol, 10(2), 
131-144. doi:10.1038/nri2707 
Adler, K. B., Tuvim, M. J., & Dickey, B. F. (2013). Regulated mucin secretion from 
airway epithelial cells. Front Endocrinol (Lausanne), 4, 129. 
doi:10.3389/fendo.2013.00129 
Adrain, C., Creagh, E. M., Cullen, S. P., & Martin, S. J. (2004). Caspase-dependent 
inactivation of proteasome function during programmed cell death in 
Drosophila and man. J Biol Chem, 279(35), 36923-36930. 
doi:10.1074/jbc.M402638200 
Aikawa, N., Takahashi, T., Fujimi, S., Yokoyama, T., Yoshihara, K., Ikeda, T., . . . 
Maruyama, T. (2013). A Phase II study of polyclonal anti-TNF-alpha 
(AZD9773) in Japanese patients with severe sepsis and/or septic shock. J 
Infect Chemother, 19(5), 931-940. doi:10.1007/s10156-013-0612-y 
Akira, S., Taga, T., & Kishimoto, T. (1993). Interleukin-6 in biology and medicine. 
Adv Immunol, 54, 1-78. doi:10.1016/s0065-2776(08)60532-5 
Alexaki, V. I., Notas, G., Pelekanou, V., Kampa, M., Valkanou, M., Theodoropoulos, 
P., . . . Castanas, E. (2009). Adipocytes as immune cells: differential 
expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-
R, TACI, and BCMA) at different stages of normal and pathological adipose 
tissue development. J Immunol, 183(9), 5948-5956. 
doi:10.4049/jimmunol.0901186 
Al-Sadi, R., Guo, S., Ye, D., & Ma, T. Y. (2013). TNF-alpha modulation of intestinal 
epithelial tight junction barrier is regulated by ERK1/2 activation of Elk-1. Am 
J Pathol, 183(6), 1871-1884. doi:10.1016/j.ajpath.2013.09.001 
Al-Sadi, R., Guo, S., Ye, D., Rawat, M., & Ma, T. Y. (2016). TNF-alpha Modulation 
of Intestinal Tight Junction Permeability Is Mediated by NIK/IKK-alpha Axis 
Activation of the Canonical NF-kappaB Pathway. Am J Pathol, 186(5), 1151-
1165. doi:10.1016/j.ajpath.2015.12.016 
Amalakuhan, B., Habib, S. A., Mangat, M., Reyes, L. F., Rodriguez, A. H., Hinojosa, 
C. A., . . . Restrepo, M. I. (2016). Endothelial adhesion molecules and 
multiple organ failure in patients with severe sepsis. Cytokine, 88, 267-273. 
doi:10.1016/j.cyto.2016.08.028 
Amiot, F., Fitting, C., Tracey, K. J., Cavaillon, J. M., & Dautry, F. (1997). 
Lipopolysaccharide-induced cytokine cascade and lethality in LT alpha/TNF 
alpha-deficient mice. Mol Med, 3(12), 864-875.  
Amir, R. E., Haecker, H., Karin, M., & Ciechanover, A. (2004). Mechanism of 
processing of the NF-kappa B2 p100 precursor: identification of the specific 
polyubiquitin chain-anchoring lysine residue and analysis of the role of 
NEDD8-modification on the SCF(beta-TrCP) ubiquitin ligase. Oncogene, 
23(14), 2540-2547. doi:10.1038/sj.onc.1207366 
Amoozadeh, Y., Dan, Q., Xiao, J., Waheed, F., & Szaszi, K. (2015). Tumor necrosis 
factor-alpha induces a biphasic change in claudin-2 expression in tubular 
epithelial cells: role in barrier functions. Am J Physiol Cell Physiol, 309(1), 
C38-50. doi:10.1152/ajpcell.00388.2014 
Amura, C. R., Silverstein, R., & Morrison, D. C. (1998). Mechanisms involved in the 
pathogenesis of sepsis are not necessarily reflected by in vitro cell activation 
257 
 
studies. Infect Immun, 66(11), 5372-5378. doi:10.1128/IAI.66.11.5372-
5378.1998 
Anbazhagan, A. N., Priyamvada, S., Alrefai, W. A., & Dudeja, P. K. (2018). 
Pathophysiology of IBD associated diarrhea. Tissue Barriers, 6(2), 
e1463897. doi:10.1080/21688370.2018.1463897 
Anderson, K. L., Hunt, E., & Davis, B. J. (1991). The influence of anti-inflammatory 
therapy on bacterial clearance following intramammary Escherichia coli 
challenge in goats. Vet Res Commun, 15(2), 147-161. 
doi:10.1007/BF00405146 
Anderson, N. G., & Anderson, N. L. (1996). Twenty years of two-dimensional 
electrophoresis: past, present and future. Electrophoresis, 17(3), 443-453. 
doi:10.1002/elps.1150170303 
Ando-Akatsuka, Y., Saitou, M., Hirase, T., Kishi, M., Sakakibara, A., Itoh, M., . . . 
Tsukita, S. (1996). Interspecies diversity of the occludin sequence: cDNA 
cloning of human, mouse, dog, and rat-kangaroo homologues. J Cell Biol, 
133(1), 43-47. doi:10.1083/jcb.133.1.43 
Annane, D., Bellissant, E., Bollaert, P. E., Briegel, J., Keh, D., Kupfer, Y., . . . 
Rochwerg, B. (2019). Corticosteroids for treating sepsis in children and 
adults. Cochrane Database Syst Rev, 12, CD002243. 
doi:10.1002/14651858.CD002243.pub4 
Arakawa, T., & Yphantis, D. A. (1987). Molecular weight of recombinant human 
tumor necrosis factor-alpha. J Biol Chem, 262(16), 7484-7485.  
Ardite, E., Panes, J., Miranda, M., Salas, A., Elizalde, J. I., Sans, M., . . . Pique, J. 
M. (1998). Effects of steroid treatment on activation of nuclear factor kappaB 
in patients with inflammatory bowel disease. Br J Pharmacol, 124(3), 431-
433. doi:10.1038/sj.bjp.0701887 
Ardizzone, S., & Bianchi Porro, G. (2002). Inflammatory bowel disease: new 
insights into pathogenesis and treatment. J Intern Med, 252(6), 475-496. 
doi:10.1046/j.1365-2796.2002.01067.x 
Arens, C., Bajwa, S. A., Koch, C., Siegler, B. H., Schneck, E., Hecker, A., . . . Uhle, 
F. (2016). Sepsis-induced long-term immune paralysis--results of a 
descriptive, explorative study. Crit Care, 20, 93. doi:10.1186/s13054-016-
1233-5 
Arican, O., Aral, M., Sasmaz, S., & Ciragil, P. (2005). Serum levels of TNF-alpha, 
IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active 
psoriasis and correlation with disease severity. Mediators Inflamm, 2005(5), 
273-279. doi:10.1155/MI.2005.273 
Armitage, R. J., Fanslow, W. C., Strockbine, L., Sato, T. A., Clifford, K. N., Macduff, 
B. M., . . . et al. (1992). Molecular and biological characterization of a murine 
ligand for CD40. Nature, 357(6373), 80-82. doi:10.1038/357080a0 
Armstrong, C. L., Galisteo, R., Brown, S. A., & Winkles, J. A. (2016). TWEAK 
activation of the non-canonical NF-kappaB signaling pathway differentially 
regulates melanoma and prostate cancer cell invasion. Oncotarget, 7(49), 
81474-81492. doi:10.18632/oncotarget.13034 
Armstrong, R. (2000). The Gray's anatomy (1st ed.). London: Serpent's Tail. 
Arrieta, M. C., Madsen, K., Doyle, J., & Meddings, J. (2009). Reducing small 
intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. 
Gut, 58(1), 41-48. doi:10.1136/gut.2008.150888 
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999). Notch signaling: cell fate 
control and signal integration in development. Science, 284(5415), 770-776. 
doi:10.1126/science.284.5415.770 
Artis, D. (2008). Epithelial-cell recognition of commensal bacteria and maintenance 




Aslan, A., van Meurs, M., Moser, J., Popa, E. R., Jongman, R. M., Zwiers, P. J., . . . 
Zijlstra, J. G. (2017). Organ-Specific Differences in Endothelial Permeability-
Regulating Molecular Responses in Mouse and Human Sepsis. Shock, 
48(1), 69-77. doi:10.1097/SHK.0000000000000841 
Aster, J. C., Blacklow, S. C., & Pear, W. S. (2011). Notch signalling in T-cell 
lymphoblastic leukaemia/lymphoma and other haematological malignancies. 
J Pathol, 223(2), 262-273. doi:10.1002/path.2789 
Ather, J. L., Dienz, O., Boyson, J. E., Anathy, V., Amiel, E., & Poynter, M. E. (2018). 
Serum Amyloid A3 is required for normal lung development and survival 
following influenza infection. Sci Rep, 8(1), 16571. doi:10.1038/s41598-018-
34901-x 
Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., & Karin, M. (1995). 
Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity 
through induction of I kappa B synthesis. Science, 270(5234), 286-290. 
doi:10.1126/science.270.5234.286 
Ayabe, T., Satchell, D. P., Wilson, C. L., Parks, W. C., Selsted, M. E., & Ouellette, 
A. J. (2000). Secretion of microbicidal alpha-defensins by intestinal Paneth 
cells in response to bacteria. Nat Immunol, 1(2), 113-118. 
doi:10.1038/77783 
Ayala, A., Herdon, C. D., Lehman, D. L., Ayala, C. A., & Chaudry, I. H. (1996). 
Differential induction of apoptosis in lymphoid tissues during sepsis: 
variation in onset, frequency, and the nature of the mediators. Blood, 87(10), 
4261-4275.  
Aziz, I., Hadjivassiliou, M., & Sanders, D. S. (2012). Does gluten sensitivity in the 
absence of coeliac disease exist? BMJ, 345, e7907. doi:10.1136/bmj.e7907 
Bajic, D., Niemann, A., Hillmer, A. K., Mejias-Luque, R., Bluemel, S., Docampo, M., 
. . . Stein-Thoeringer, C. K. (2020). Gut microbiota derived propionate 
regulates the expression of Reg3 mucosal lectins and ameliorates 
experimental colitis in mice. J Crohns Colitis. doi:10.1093/ecco-jcc/jjaa065 
Baker, B. M., & Chen, C. S. (2012). Deconstructing the third dimension: how 3D 
culture microenvironments alter cellular cues. J Cell Sci, 125(Pt 13), 3015-
3024. doi:10.1242/jcs.079509 
Baker, M. (2010). Cellular imaging: Taking a long, hard look. Nature, 466(7310), 
1137-1140. doi:10.1038/4661137a 
Balda, M. S., & Matter, K. (2008). Tight junctions at a glance. J Cell Sci, 121(Pt 22), 
3677-3682. doi:10.1242/jcs.023887 
Ballegeer, M., Van Looveren, K., Timmermans, S., Eggermont, M., Vandevyver, S., 
Thery, F., . . . Libert, C. (2018). Glucocorticoid receptor dimers control 
intestinal STAT1 and TNF-induced inflammation in mice. J Clin Invest, 
128(8), 3265-3279. doi:10.1172/JCI96636 
Bamias, G., & Cominelli, F. (2016). Cytokines and intestinal inflammation. Curr 
Opin Gastroenterol, 32(6), 437-442. doi:10.1097/MOG.0000000000000315 
Banerjee, A., McKinley, E. T., von Moltke, J., Coffey, R. J., & Lau, K. S. (2018). 
Interpreting heterogeneity in intestinal tuft cell structure and function. J Clin 
Invest, 128(5), 1711-1719. doi:10.1172/JCI120330 
Banham, G., Prezzi, D., Harford, S., Taylor, C. J., Hamer, R., Higgins, R., . . . 
Clatworthy, M. R. (2013). Elevated pretransplantation soluble BAFF is 
associated with an increased risk of acute antibody-mediated rejection. 
Transplantation, 96(4), 413-420. doi:10.1097/TP.0b013e318298dd65 
Barber, A. E., Coyle, S. M., Marano, M. A., Fischer, E., Calvano, S. E., Fong, Y., . . 
. Lowry, S. F. (1993). Glucocorticoid therapy alters hormonal and cytokine 
responses to endotoxin in man. J Immunol, 150(5), 1999-2006.  
Barker, N. (2014). Adult intestinal stem cells: critical drivers of epithelial 




Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., . . 
. Clevers, H. (2007). Identification of stem cells in small intestine and colon 
by marker gene Lgr5. Nature, 449(7165), 1003-1007. 
doi:10.1038/nature06196 
Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., . . 
. Clevers, H. (2007). Identification of stem cells in small intestine and colon 
by marker gene Lgr5. Nature, 449(7165), 1003-1007. 
doi:10.1038/nature06196 
Barnes, P. J. (2006). How corticosteroids control inflammation: Quintiles Prize 
Lecture 2005. Br J Pharmacol, 148(3), 245-254. doi:10.1038/sj.bjp.0706736 
Basak, S., Kim, H., Kearns, J. D., Tergaonkar, V., O'Dea, E., Werner, S. L., . . . 
Hoffmann, A. (2007). A fourth IkappaB protein within the NF-kappaB 
signaling module. Cell, 128(2), 369-381. doi:10.1016/j.cell.2006.12.033 
Bauer, H., Zweimueller-Mayer, J., Steinbacher, P., Lametschwandtner, A., & Bauer, 
H. C. (2010). The dual role of zonula occludens (ZO) proteins. J Biomed 
Biotechnol, 2010, 402593. doi:10.1155/2010/402593 
Bauer, J., Namineni, S., Reisinger, F., Zoller, J., Yuan, D., & Heikenwalder, M. 
(2012). Lymphotoxin, NF-kB, and cancer: the dark side of cytokines. Dig 
Dis, 30(5), 453-468. doi:10.1159/000341690 
Baumgart, D. C., & Sandborn, W. J. (2012). Crohn's disease. Lancet, 380(9853), 
1590-1605. doi:10.1016/S0140-6736(12)60026-9 
Becker, C., Wirtz, S., Blessing, M., Pirhonen, J., Strand, D., Bechthold, O., . . . 
Neurath, M. F. (2003). Constitutive p40 promoter activation and IL-23 
production in the terminal ileum mediated by dendritic cells. J Clin Invest, 
112(5), 693-706. doi:10.1172/JCI17464 
Bekker-Jensen, D. B., Kelstrup, C. D., Batth, T. S., Larsen, S. C., Haldrup, C., 
Bramsen, J. B., . . . Olsen, J. V. (2017). An Optimized Shotgun Strategy for 
the Rapid Generation of Comprehensive Human Proteomes. Cell Syst, 4(6), 
587-599 e584. doi:10.1016/j.cels.2017.05.009 
Bennett, W. M., Aronoff, G. R., Morrison, G., Golper, T. A., Pulliam, J., Wolfson, M., 
& Singer, I. (1983). Drug prescribing in renal failure: dosing guidelines for 
adults. Am J Kidney Dis, 3(3), 155-193. doi:10.1016/s0272-6386(83)80060-
2 
Berg, D. J., Zhang, J., Weinstock, J. V., Ismail, H. F., Earle, K. A., Alila, H., . . . 
Lynch, R. G. (2002). Rapid development of colitis in NSAID-treated IL-10-
deficient mice. Gastroenterology, 123(5), 1527-1542. 
doi:10.1053/gast.2002.1231527 
Berzal, S., Gonzalez-Guerrero, C., Rayego-Mateos, S., Ucero, A., Ocana-Salceda, 
C., Egido, J., . . . Ramos, A. M. (2015). TNF-related weak inducer of 
apoptosis (TWEAK) regulates junctional proteins in tubular epithelial cells 
via canonical NF-kappaB pathway and ERK activation. J Cell Physiol, 
230(7), 1580-1593. doi:10.1002/jcp.24905 
Beutler, B., Greenwald, D., Hulmes, J. D., Chang, M., Pan, Y. C., Mathison, J., . . . 
Cerami, A. (1985). Identity of tumour necrosis factor and the macrophage-
secreted factor cachectin. Nature, 316(6028), 552-554. 
doi:10.1038/316552a0 
Beutler, B., Hoebe, K., Du, X., & Ulevitch, R. J. (2003). How we detect microbes 
and respond to them: the Toll-like receptors and their transducers. J Leukoc 
Biol, 74(4), 479-485. doi:10.1189/jlb.0203082 
Bingle, L., Brown, N. J., & Lewis, C. E. (2002). The role of tumour-associated 
macrophages in tumour progression: implications for new anticancer 
therapies. J Pathol, 196(3), 254-265. doi:10.1002/path.1027 
Birchenough, G. M., Johansson, M. E., Gustafsson, J. K., Bergstrom, J. H., & 
Hansson, G. C. (2015). New developments in goblet cell mucus secretion 
and function. Mucosal Immunol, 8(4), 712-719. doi:10.1038/mi.2015.32 
260 
 
Blander, J. M. (2016). Death in the intestinal epithelium-basic biology and 
implications for inflammatory bowel disease. FEBS J, 283(14), 2720-2730. 
doi:10.1111/febs.13771 
Blikslager, A. T., Moeser, A. J., Gookin, J. L., Jones, S. L., & Odle, J. (2007). 
Restoration of barrier function in injured intestinal mucosa. Physiol Rev, 
87(2), 545-564. doi:10.1152/physrev.00012.2006 
Boecke, A., Carstens, A. C., Neacsu, C. D., Baschuk, N., Haubert, D., Kashkar, H., 
. . . Kronke, M. (2013). TNF-receptor-1 adaptor protein FAN mediates TNF-
induced B16 melanoma motility and invasion. Br J Cancer, 109(2), 422-432. 
doi:10.1038/bjc.2013.242 
Boehm, J. S., Zhao, J. J., Yao, J., Kim, S. Y., Firestein, R., Dunn, I. F., . . . Hahn, 
W. C. (2007). Integrative genomic approaches identify IKBKE as a breast 
cancer oncogene. Cell, 129(6), 1065-1079. doi:10.1016/j.cell.2007.03.052 
Boehnke, K., Iversen, P. W., Schumacher, D., Lallena, M. J., Haro, R., Amat, J., . . . 
Velasco, J. A. (2016). Assay Establishment and Validation of a High-
Throughput Screening Platform for Three-Dimensional Patient-Derived 
Colon Cancer Organoid Cultures. J Biomol Screen, 21(9), 931-941. 
doi:10.1177/1087057116650965 
Bohm, I. (2003). Disruption of the cytoskeleton after apoptosis induction with 
autoantibodies. Autoimmunity, 36(3), 183-189. 
doi:10.1080/0891693031000105617 
Boj, S. F., Vonk, A. M., Statia, M., Su, J., Vries, R. R., Beekman, J. M., & Clevers, 
H. (2017). Forskolin-induced Swelling in Intestinal Organoids: An In Vitro 
Assay for Assessing Drug Response in Cystic Fibrosis Patients. J Vis 
Exp(120). doi:10.3791/55159 
Bolkun, L., Lemancewicz, D., Jablonska, E., Kulczynska, A., Bolkun-Skornicka, U., 
Kloczko, J., & Dzieciol, J. (2014). BAFF and APRIL as TNF superfamily 
molecules and angiogenesis parallel progression of human multiple 
myeloma. Ann Hematol, 93(4), 635-644. doi:10.1007/s00277-013-1924-9 
Bonnier, F., Keating, M. E., Wrobel, T. P., Majzner, K., Baranska, M., Garcia-
Munoz, A., . . . Byrne, H. J. (2015). Cell viability assessment using the 
Alamar blue assay: a comparison of 2D and 3D cell culture models. Toxicol 
In Vitro, 29(1), 124-131. doi:10.1016/j.tiv.2014.09.014 
Borcherding, F., Nitschke, M., Hundorfean, G., Rupp, J., von Smolinski, D., Bieber, 
K., . . . Buning, J. (2010). The CD40-CD40L pathway contributes to the 
proinflammatory function of intestinal epithelial cells in inflammatory bowel 
disease. Am J Pathol, 176(4), 1816-1827. doi:10.2353/ajpath.2010.090461 
Bossen, C., Ingold, K., Tardivel, A., Bodmer, J. L., Gaide, O., Hertig, S., . . . 
Schneider, P. (2006). Interactions of tumor necrosis factor (TNF) and TNF 
receptor family members in the mouse and human. J Biol Chem, 281(20), 
13964-13971. doi:10.1074/jbc.M601553200 
Bradford, E. M., Ryu, S. H., Singh, A. P., Lee, G., Goretsky, T., Sinh, P., . . . Barrett, 
T. A. (2017). Epithelial TNF Receptor Signaling Promotes Mucosal Repair in 
Inflammatory Bowel Disease. J Immunol, 199(5), 1886-1897. 
doi:10.4049/jimmunol.1601066 
Bradley, J. R. (2008). TNF-mediated inflammatory disease. J Pathol, 214(2), 149-
160. doi:10.1002/path.2287 
Braegger, C. P., Nicholls, S., Murch, S. H., Stephens, S., & MacDonald, T. T. 
(1992). Tumour necrosis factor alpha in stool as a marker of intestinal 
inflammation. Lancet, 339(8785), 89-91. doi:10.1016/0140-6736(92)90999-j 
Brandt, C., & Pedersen, B. K. (2010). The role of exercise-induced myokines in 
muscle homeostasis and the defense against chronic diseases. J Biomed 
Biotechnol, 2010, 520258. doi:10.1155/2010/520258 




Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. 
(2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence 
and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 
68(6), 394-424. doi:10.3322/caac.21492 
Bray, S. J. (2016). Notch signalling in context. Nat Rev Mol Cell Biol, 17(11), 722-
735. doi:10.1038/nrm.2016.94 
Brentnall, M., Rodriguez-Menocal, L., De Guevara, R. L., Cepero, E., & Boise, L. H. 
(2013). Caspase-9, caspase-3 and caspase-7 have distinct roles during 
intrinsic apoptosis. BMC Cell Biol, 14, 32. doi:10.1186/1471-2121-14-32 
Briegel, J., Kellermann, W., Forst, H., Haller, M., Bittl, M., Hoffmann, G. E., . . . 
Peter, K. (1994). Low-dose hydrocortisone infusion attenuates the systemic 
inflammatory response syndrome. The Phospholipase A2 Study Group. Clin 
Investig, 72(10), 782-787. doi:10.1007/BF00180547 
Brown, S. A., Ghosh, A., & Winkles, J. A. (2010). Full-length, membrane-anchored 
TWEAK can function as a juxtacrine signaling molecule and activate the NF-
kappaB pathway. J Biol Chem, 285(23), 17432-17441. 
doi:10.1074/jbc.M110.131979 
Browning, J. L., Ngam-ek, A., Lawton, P., DeMarinis, J., Tizard, R., Chow, E. P., . . . 
Ware, C. F. (1993). Lymphotoxin beta, a novel member of the TNF family 
that forms a heteromeric complex with lymphotoxin on the cell surface. Cell, 
72(6), 847-856. doi:10.1016/0092-8674(93)90574-a 
Brunetti, G., Rizzi, R., Storlino, G., Bortolotti, S., Colaianni, G., Sanesi, L., . . . 
Colucci, S. (2018). LIGHT/TNFSF14 as a New Biomarker of Bone Disease 
in Multiple Myeloma Patients Experiencing Therapeutic Regimens. Front 
Immunol, 9, 2459. doi:10.3389/fimmu.2018.02459 
Bry, L., Falk, P., Huttner, K., Ouellette, A., Midtvedt, T., & Gordon, J. I. (1994). 
Paneth cell differentiation in the developing intestine of normal and 
transgenic mice. Proc Natl Acad Sci U S A, 91(22), 10335-10339. 
doi:10.1073/pnas.91.22.10335 
Bryant, C. E., Farnfield, B. A., & Janicke, H. J. (2003). Evaluation of the ability of 
carprofen and flunixin meglumine to inhibit activation of nuclear factor kappa 
B. Am J Vet Res, 64(2), 211-215. doi:10.2460/ajvr.2003.64.211 
Brynskov, J., Foegh, P., Pedersen, G., Ellervik, C., Kirkegaard, T., Bingham, A., & 
Saermark, T. (2002). Tumour necrosis factor alpha converting enzyme 
(TACE) activity in the colonic mucosa of patients with inflammatory bowel 
disease. Gut, 51(1), 37-43. doi:10.1136/gut.51.1.37 
Buckley, A., & Turner, J. R. (2018). Cell Biology of Tight Junction Barrier Regulation 
and Mucosal Disease. Cold Spring Harb Perspect Biol, 10(1). 
doi:10.1101/cshperspect.a029314 
Bullen, T. F., Forrest, S., Campbell, F., Dodson, A. R., Hershman, M. J., Pritchard, 
D. M., . . . Watson, A. J. (2006). Characterization of epithelial cell shedding 
from human small intestine. Lab Invest, 86(10), 1052-1063. 
doi:10.1038/labinvest.3700464 
Bunte, K., Smith, D. J., Chappell, M. J., Hassan-Smith, Z. K., Tomlinson, J. W., Arlt, 
W., & Tino, P. (2018). Learning pharmacokinetic models for in vivo 
glucocorticoid activation. J Theor Biol, 455, 222-231. 
doi:10.1016/j.jtbi.2018.07.025 
Burge, K., Gunasekaran, A., Eckert, J., & Chaaban, H. (2019). Curcumin and 
Intestinal Inflammatory Diseases: Molecular Mechanisms of Protection. Int J 
Mol Sci, 20(8). doi:10.3390/ijms20081912 
Burkitt, M. D., Hanedi, A. F., Duckworth, C. A., Williams, J. M., Tang, J. M., O'Reilly, 
L. A., . . . Pritchard, D. M. (2015). NF-kappaB1, NF-kappaB2 and c-Rel 
differentially regulate susceptibility to colitis-associated adenoma 




Burkitt, M. D., Williams, J. M., Duckworth, C. A., O'Hara, A., Hanedi, A., Varro, A., . 
. . Pritchard, D. M. (2013). Signaling mediated by the NF-kappaB sub-units 
NF-kappaB1, NF-kappaB2 and c-Rel differentially regulate Helicobacter 
felis-induced gastric carcinogenesis in C57BL/6 mice. Oncogene, 32(50), 
5563-5573. doi:10.1038/onc.2013.334 
Burkitt, M. D., Williams, J. M., Townsend, T., Hough, R., Duckworth, C. A., & 
Pritchard, D. M. (2017). Mice lacking NF-kappaB1 exhibit marked DNA 
damage responses and more severe gastric pathology in response to 
intraperitoneal tamoxifen administration. Cell Death Dis, 8(7), e2939. 
doi:10.1038/cddis.2017.332 
Burkly, L., Hession, C., Ogata, L., Reilly, C., Marconi, L. A., Olson, D., . . . Lo, D. 
(1995). Expression of relB is required for the development of thymic medulla 
and dendritic cells. Nature, 373(6514), 531-536. doi:10.1038/373531a0 
Burkly, L. C., Michaelson, J. S., & Zheng, T. S. (2011). TWEAK/Fn14 pathway: an 
immunological switch for shaping tissue responses. Immunol Rev, 244(1), 
99-114. doi:10.1111/j.1600-065X.2011.01054.x 
Burns, A. J., Roberts, R. R., Bornstein, J. C., & Young, H. M. (2009). Development 
of the enteric nervous system and its role in intestinal motility during fetal 
and early postnatal stages. Semin Pediatr Surg, 18(4), 196-205. 
doi:10.1053/j.sempedsurg.2009.07.001 
Buttke, T. M., & Sandstrom, P. A. (1994). Oxidative stress as a mediator of 
apoptosis. Immunol Today, 15(1), 7-10. doi:10.1016/0167-5699(94)90018-3 
Butto, L. F., Pelletier, A., More, S. K., Zhao, N., Osme, A., Hager, C. L., . . . Dave, 
M. (2020). Intestinal Stem Cell Niche Defects Result in Impaired 3D 
Organoid Formation in Mouse Models of Crohn's Disease-like Ileitis. Stem 
Cell Reports, 15(2), 389-407. doi:10.1016/j.stemcr.2020.06.017 
Butty, V. L., Roux-Lombard, P., Garbino, J., Dayer, J. M., Ricou, B., & Geneva 
Sepsis, N. (2003). Anti-inflammatory response after infusion of p55 soluble 
tumor necrosis factor receptor fusion protein for severe sepsis. Eur Cytokine 
Netw, 14(1), 15-19.  
Caamano, J. H., Rizzo, C. A., Durham, S. K., Barton, D. S., Raventos-Suarez, C., 
Snapper, C. M., & Bravo, R. (1998). Nuclear factor (NF)-kappa B2 
(p100/p52) is required for normal splenic microarchitecture and B cell-
mediated immune responses. J Exp Med, 187(2), 185-196. 
doi:10.1084/jem.187.2.185 
Cadigan, K. M., & Nusse, R. (1997). Wnt signaling: a common theme in animal 
development. Genes Dev, 11(24), 3286-3305. doi:10.1101/gad.11.24.3286 
Cadwell, K., Patel, K. K., Komatsu, M., Virgin, H. W. t., & Stappenbeck, T. S. 
(2009). A common role for Atg16L1, Atg5 and Atg7 in small intestinal 
Paneth cells and Crohn disease. Autophagy, 5(2), 250-252. 
doi:10.4161/auto.5.2.7560 
Calabresi, P. (1996). Results of the National Cancer Advisory Board evaluation of 
the National Cancer Program. Cancer, 78(12), 2607-2608. 
doi:10.1002/(sici)1097-0142(19961215)78:12<2607::aid-cncr30>3.0.co;2-y 
Campbell, S., Burkly, L. C., Gao, H. X., Berman, J. W., Su, L., Browning, B., . . . 
Putterman, C. (2006). Proinflammatory effects of TWEAK/Fn14 interactions 
in glomerular mesangial cells. J Immunol, 176(3), 1889-1898. 
doi:10.4049/jimmunol.176.3.1889 
Cande, C., Vahsen, N., Kouranti, I., Schmitt, E., Daugas, E., Spahr, C., . . . 
Kroemer, G. (2004). AIF and cyclophilin A cooperate in apoptosis-
associated chromatinolysis. Oncogene, 23(8), 1514-1521. 
doi:10.1038/sj.onc.1207279 
Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & 
Burcelin, R. (2008). Changes in gut microbiota control metabolic 
263 
 
endotoxemia-induced inflammation in high-fat diet-induced obesity and 
diabetes in mice. Diabetes, 57(6), 1470-1481. doi:10.2337/db07-1403 
Cao, Z., & Robinson, R. A. (2014). The role of proteomics in understanding 
biological mechanisms of sepsis. Proteomics Clin Appl, 8(1-2), 35-52. 
doi:10.1002/prca.201300101 
Capaldo, C. T., Farkas, A. E., Hilgarth, R. S., Krug, S. M., Wolf, M. F., Benedik, J. 
K., . . . Nusrat, A. (2014). Proinflammatory cytokine-induced tight junction 
remodeling through dynamic self-assembly of claudins. Mol Biol Cell, 
25(18), 2710-2719. doi:10.1091/mbc.E14-02-0773 
Carmona-Gutierrez, D., Eisenberg, T., Buttner, S., Meisinger, C., Kroemer, G., & 
Madeo, F. (2010). Apoptosis in yeast: triggers, pathways, subroutines. Cell 
Death Differ, 17(5), 763-773. doi:10.1038/cdd.2009.219 
Cerovic, V., Bain, C. C., Mowat, A. M., & Milling, S. W. (2014). Intestinal 
macrophages and dendritic cells: what's the difference? Trends Immunol, 
35(6), 270-277. doi:10.1016/j.it.2014.04.003 
Chan, E. Y. (2012). Regulation and function of uncoordinated-51 like kinase 
proteins. Antioxid Redox Signal, 17(5), 775-785. doi:10.1089/ars.2011.4396 
Chandel, N. S., Trzyna, W. C., McClintock, D. S., & Schumacker, P. T. (2000). Role 
of oxidants in NF-kappa B activation and TNF-alpha gene transcription 
induced by hypoxia and endotoxin. J Immunol, 165(2), 1013-1021. 
doi:10.4049/jimmunol.165.2.1013 
Chandramouli, K., & Qian, P. Y. (2009). Proteomics: challenges, techniques and 
possibilities to overcome biological sample complexity. Hum Genomics 
Proteomics, 2009. doi:10.4061/2009/239204 
Chavarria-Velazquez, C. O., Torres-Martinez, A. C., Montano, L. F., & Rendon-
Huerta, E. P. (2018). TLR2 activation induced by H. pylori LPS promotes the 
differential expression of claudin-4, -6, -7 and -9 via either STAT3 and 
ERK1/2 in AGS cells. Immunobiology, 223(1), 38-48. 
doi:10.1016/j.imbio.2017.10.016 
Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., . . . Zhao, L. (2018). 
Inflammatory responses and inflammation-associated diseases in organs. 
Oncotarget, 9(6), 7204-7218. doi:10.18632/oncotarget.23208 
Chen, S., Xia, Y., Zhu, G., Yan, J., Tan, C., Deng, B., . . . Ren, W. (2018). 
Glutamine supplementation improves intestinal cell proliferation and stem 
cell differentiation in weanling mice. Food Nutr Res, 62. 
doi:10.29219/fnr.v62.1439 
Chen, Y., Merzdorf, C., Paul, D. L., & Goodenough, D. A. (1997). COOH terminus 
of occludin is required for tight junction barrier function in early Xenopus 
embryos. J Cell Biol, 138(4), 891-899. doi:10.1083/jcb.138.4.891 
Cheng, E. H., Wei, M. C., Weiler, S., Flavell, R. A., Mak, T. W., Lindsten, T., & 
Korsmeyer, S. J. (2001). BCL-2, BCL-X(L) sequester BH3 domain-only 
molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol 
Cell, 8(3), 705-711. doi:10.1016/s1097-2765(01)00320-3 
Cheng, H. (1974). Origin, differentiation and renewal of the four main epithelial cell 
types in the mouse small intestine. IV. Paneth cells. Am J Anat, 141(4), 521-
535. doi:10.1002/aja.1001410406 
Chicheportiche, Y., Bourdon, P. R., Xu, H., Hsu, Y. M., Scott, H., Hession, C., . . . 
Browning, J. L. (1997). TWEAK, a new secreted ligand in the tumor necrosis 
factor family that weakly induces apoptosis. J Biol Chem, 272(51), 32401-
32410. doi:10.1074/jbc.272.51.32401 
Chieppa, M., Rescigno, M., Huang, A. Y., & Germain, R. N. (2006). Dynamic 
imaging of dendritic cell extension into the small bowel lumen in response to 




Cho, J. H., & Brant, S. R. (2011). Recent insights into the genetics of inflammatory 
bowel disease. Gastroenterology, 140(6), 1704-1712. 
doi:10.1053/j.gastro.2011.02.046 
Chopra, M., Brandl, A., Siegmund, D., Mottok, A., Schafer, V., Biehl, M., . . . 
Wajant, H. (2015). Blocking TWEAK-Fn14 interaction inhibits hematopoietic 
stem cell transplantation-induced intestinal cell death and reduces GVHD. 
Blood, 126(4), 437-444. doi:10.1182/blood-2015-01-620583 
Cildir, G., Low, K. C., & Tergaonkar, V. (2016). Noncanonical NF-kappaB Signaling 
in Health and Disease. Trends Mol Med, 22(5), 414-429. 
doi:10.1016/j.molmed.2016.03.002 
Cipollone, F., Mezzetti, A., Porreca, E., Di Febbo, C., Nutini, M., Fazia, M., . . . Davi, 
G. (2002). Association between enhanced soluble CD40L and prothrombotic 
state in hypercholesterolemia: effects of statin therapy. Circulation, 106(4), 
399-402. doi:10.1161/01.cir.0000025419.95769.f0 
Clark, J. A., Clark, A. T., Hotchkiss, R. S., Buchman, T. G., & Coopersmith, C. M. 
(2008). Epidermal growth factor treatment decreases mortality and is 
associated with improved gut integrity in sepsis. Shock, 30(1), 36-42. 
doi:10.1097/shk.0b013e31815D0820 
Clark, M. A., Plank, L. D., Connolly, A. B., Streat, S. J., Hill, A. A., Gupta, R., . . . 
Hill, G. L. (1998). Effect of a chimeric antibody to tumor necrosis factor-
alpha on cytokine and physiologic responses in patients with severe sepsis--
a randomized, clinical trial. Crit Care Med, 26(10), 1650-1659. 
doi:10.1097/00003246-199810000-00016 
Clarke, K., & Chintanaboina, J. (2019). Allergic and Immunologic Perspectives of 
Inflammatory Bowel Disease. Clin Rev Allergy Immunol, 57(2), 179-193. 
doi:10.1007/s12016-018-8690-3 
Clayburgh, D. R., Musch, M. W., Leitges, M., Fu, Y. X., & Turner, J. R. (2006). 
Coordinated epithelial NHE3 inhibition and barrier dysfunction are required 
for TNF-mediated diarrhea in vivo. J Clin Invest, 116(10), 2682-2694. 
doi:10.1172/JCI29218 
Clayburgh, D. R., Musch, M. W., Leitges, M., Fu, Y. X., & Turner, J. R. (2006). 
Coordinated epithelial NHE3 inhibition and barrier dysfunction are required 
for TNF-mediated diarrhea in vivo. J Clin Invest, 116(10), 2682-2694. 
doi:10.1172/JCI29218 
Cleary, R. A., Wang, R., Waqar, O., Singer, H. A., & Tang, D. D. (2014). Role of c-
Abl tyrosine kinase in smooth muscle cell migration. Am J Physiol Cell 
Physiol, 306(8), C753-761. doi:10.1152/ajpcell.00327.2013 
Clevers, H. C., & Bevins, C. L. (2013). Paneth cells: maestros of the small intestinal 
crypts. Annu Rev Physiol, 75, 289-311. doi:10.1146/annurev-physiol-
030212-183744 
Cohen, J. (2002). The immunopathogenesis of sepsis. Nature, 420(6917), 885-891. 
doi:10.1038/nature01326 
Colbert, J. F., Schmidt, E. P., Faubel, S., & Ginde, A. A. (2017). Severe Sepsis 
Outcomes Among Hospitalizations With Inflammatory Bowel Disease. 
Shock, 47(2), 128-131. doi:10.1097/SHK.0000000000000742 
Cole, L. A., & Kramer, P. R. (2016). Human physiology, biochemistry, and basic 
medicine. Amsterdam ; Boston: Elsevier/AP, Academic Press is an imprint 
of Elsevier. 
Collins, J. F., Honda, T., Knobel, S., Bulus, N. M., Conary, J., DuBois, R., & 
Ghishan, F. K. (1993). Molecular cloning, sequencing, tissue distribution, 
and functional expression of a Na+/H+ exchanger (NHE-2). Proc Natl Acad 
Sci U S A, 90(9), 3938-3942. doi:10.1073/pnas.90.9.3938 
Conrad, U., Plagmann, I., Malchow, S., Sack, M., Floss, D. M., Kruglov, A. A., . . . 
Scheller, J. (2011). ELPylated anti-human TNF therapeutic single-domain 
265 
 
antibodies for prevention of lethal septic shock. Plant Biotechnol J, 9(1), 22-
31. doi:10.1111/j.1467-7652.2010.00523.x 
Conte, D., Holcik, M., Lefebvre, C. A., Lacasse, E., Picketts, D. J., Wright, K. E., & 
Korneluk, R. G. (2006). Inhibitor of apoptosis protein cIAP2 is essential for 
lipopolysaccharide-induced macrophage survival. Mol Cell Biol, 26(2), 699-
708. doi:10.1128/MCB.26.2.699-708.2006 
Cook, M. J. (1965). The anatomy of the laboratory mouse. London, New York,: 
Academic Press. 
Corredor, J., Yan, F., Shen, C. C., Tong, W., John, S. K., Wilson, G., . . . Polk, D. B. 
(2003). Tumor necrosis factor regulates intestinal epithelial cell migration by 
receptor-dependent mechanisms. Am J Physiol Cell Physiol, 284(4), C953-
961. doi:10.1152/ajpcell.00309.2002 
Coultas, L., Pellegrini, M., Visvader, J. E., Lindeman, G. J., Chen, L., Adams, J. M., 
. . . Strasser, A. (2003). Bfk: a novel weakly proapoptotic member of the Bcl-
2 protein family with a BH3 and a BH2 region. Cell Death Differ, 10(2), 185-
192. doi:10.1038/sj.cdd.4401204 
Crawley, S. W., Mooseker, M. S., & Tyska, M. J. (2014). Shaping the intestinal 
brush border. J Cell Biol, 207(4), 441-451. doi:10.1083/jcb.201407015 
Crawley, S. W., Shifrin, D. A., Jr., Grega-Larson, N. E., McConnell, R. E., Benesh, 
A. E., Mao, S., . . . Tyska, M. J. (2014). Intestinal brush border assembly 
driven by protocadherin-based intermicrovillar adhesion. Cell, 157(2), 433-
446. doi:10.1016/j.cell.2014.01.067 
Croft, M. (2009). The role of TNF superfamily members in T-cell function and 
diseases. Nat Rev Immunol, 9(4), 271-285. doi:10.1038/nri2526 
Cronin, J., Kennedy, U., McCoy, S., An Fhaili, S. N., Crispino-O'Connell, G., 
Hayden, J., . . . O'Sullivan, R. (2012). Single dose oral dexamethasone 
versus multi-dose prednisolone in the treatment of acute exacerbations of 
asthma in children who attend the emergency department: study protocol for 
a randomized controlled trial. Trials, 13, 141. doi:10.1186/1745-6215-13-141 
Crowe, P. D., VanArsdale, T. L., Walter, B. N., Ware, C. F., Hession, C., Ehrenfels, 
B., . . . Smith, C. A. (1994). A lymphotoxin-beta-specific receptor. Science, 
264(5159), 707-710. doi:10.1126/science.8171323 
Cuervo, A. M. (2004). Autophagy: in sickness and in health. Trends Cell Biol, 14(2), 
70-77. doi:10.1016/j.tcb.2003.12.002 
Cutuli, S. L., Artigas, A., Fumagalli, R., Monti, G., Ranieri, V. M., Ronco, C., . . . 
Group, E. C. (2016). Polymyxin-B hemoperfusion in septic patients: analysis 
of a multicenter registry. Ann Intensive Care, 6(1), 77. doi:10.1186/s13613-
016-0178-9 
Damas, P., Ledoux, D., Nys, M., Vrindts, Y., De Groote, D., Franchimont, P., & 
Lamy, M. (1992). Cytokine serum level during severe sepsis in human IL-6 
as a marker of severity. Ann Surg, 215(4), 356-362. doi:10.1097/00000658-
199204000-00009 
Damas, P., Reuter, A., Gysen, P., Demonty, J., Lamy, M., & Franchimont, P. 
(1989). Tumor necrosis factor and interleukin-1 serum levels during severe 
sepsis in humans. Crit Care Med, 17(10), 975-978. doi:10.1097/00003246-
198910000-00001 
Danese, S., Sans, M., & Fiocchi, C. (2004). The CD40/CD40L costimulatory 
pathway in inflammatory bowel disease. Gut, 53(7), 1035-1043. 
doi:10.1136/gut.2003.026278 
Danese, S., Sans, M., & Fiocchi, C. (2004). The CD40/CD40L costimulatory 
pathway in inflammatory bowel disease. Gut, 53(7), 1035-1043. 
doi:10.1136/gut.2003.026278 
D'Arcy, M. S. (2019). Cell death: a review of the major forms of apoptosis, necrosis 
and autophagy. Cell Biol Int, 43(6), 582-592. doi:10.1002/cbin.11137 
266 
 
Davis, R. J. (2000). Signal transduction by the JNK group of MAP kinases. Cell, 
103(2), 239-252. doi:10.1016/s0092-8674(00)00116-1 
De Backer, D., Creteur, J., Preiser, J. C., Dubois, M. J., & Vincent, J. L. (2002). 
Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit 
Care Med, 166(1), 98-104. doi:10.1164/rccm.200109-016oc 
de la Pompa, J. L., & Epstein, J. A. (2012). Coordinating tissue interactions: Notch 
signaling in cardiac development and disease. Dev Cell, 22(2), 244-254. 
doi:10.1016/j.devcel.2012.01.014 
De Togni, P., Goellner, J., Ruddle, N. H., Streeter, P. R., Fick, A., Mariathasan, S., . 
. . et al. (1994). Abnormal development of peripheral lymphoid organs in 
mice deficient in lymphotoxin. Science, 264(5159), 703-707. 
doi:10.1126/science.8171322 
De Wolf, I., Van Driessche, W., & Nagel, W. (1989). Forskolin activates gated Cl- 
channels in frog skin. Am J Physiol, 256(6 Pt 1), C1239-1249. 
doi:10.1152/ajpcell.1989.256.6.C1239 
Debets, J. M., Kampmeijer, R., van der Linden, M. P., Buurman, W. A., & van der 
Linden, C. J. (1989). Plasma tumor necrosis factor and mortality in critically 
ill septic patients. Crit Care Med, 17(6), 489-494. doi:10.1097/00003246-
198906000-00001 
Degenhardt, K., Mathew, R., Beaudoin, B., Bray, K., Anderson, D., Chen, G., . . . 
White, E. (2006). Autophagy promotes tumor cell survival and restricts 
necrosis, inflammation, and tumorigenesis. Cancer Cell, 10(1), 51-64. 
doi:10.1016/j.ccr.2006.06.001 
Degterev, A., Boyce, M., & Yuan, J. (2003). A decade of caspases. Oncogene, 
22(53), 8543-8567. doi:10.1038/sj.onc.1207107 
Dejardin, E. (2006). The alternative NF-kappaB pathway from biochemistry to 
biology: pitfalls and promises for future drug development. Biochem 
Pharmacol, 72(9), 1161-1179. doi:10.1016/j.bcp.2006.08.007 
Dejardin, E., Droin, N. M., Delhase, M., Haas, E., Cao, Y., Makris, C., . . . Green, D. 
R. (2002). The lymphotoxin-beta receptor induces different patterns of gene 
expression via two NF-kappaB pathways. Immunity, 17(4), 525-535. 
doi:10.1016/s1074-7613(02)00423-5 
Dekkers, J. F., Wiegerinck, C. L., de Jonge, H. R., Bronsveld, I., Janssens, H. M., 
de Winter-de Groot, K. M., . . . Beekman, J. M. (2013). A functional CFTR 
assay using primary cystic fibrosis intestinal organoids. Nat Med, 19(7), 939-
945. doi:10.1038/nm.3201 
Dellinger, R. P., Carlet, J. M., Masur, H., Gerlach, H., Calandra, T., Cohen, J., . . . 
Levy, M. M. (2004). Surviving Sepsis Campaign guidelines for management 
of severe sepsis and septic shock. Intensive Care Med, 30(4), 536-555. 
doi:10.1007/s00134-004-2210-z 
Dempsey, C. E., Dive, C., Fletcher, D. J., Barnes, F. A., Lobo, A., Bingle, C. D., . . . 
Renshaw, S. A. (2005). Expression of pro-apoptotic Bfk isoforms reduces 
during malignant transformation in the human gastrointestinal tract. FEBS 
Lett, 579(17), 3646-3650. doi:10.1016/j.febslet.2005.05.050 
Dessein, R., Gironella, M., Vignal, C., Peyrin-Biroulet, L., Sokol, H., Secher, T., . . . 
Chamaillard, M. (2009). Toll-like receptor 2 is critical for induction of Reg3 
beta expression and intestinal clearance of Yersinia pseudotuberculosis. 
Gut, 58(6), 771-776. doi:10.1136/gut.2008.168443 
Di Martino, L., Osme, A., Kossak-Gupta, S., Pizarro, T. T., & Cominelli, F. (2019). 
TWEAK/Fn14 Is Overexpressed in Crohn's Disease and Mediates 
Experimental Ileitis by Regulating Critical Innate and Adaptive Immune 




Diaz de Barboza, G., Guizzardi, S., & Tolosa de Talamoni, N. (2015). Molecular 
aspects of intestinal calcium absorption. World J Gastroenterol, 21(23), 
7142-7154. doi:10.3748/wjg.v21.i23.7142 
Dinarello, C. A. (2000). Proinflammatory cytokines. Chest, 118(2), 503-508. 
doi:10.1378/chest.118.2.503 
Ding, L., Lu, Z., Foreman, O., Tatum, R., Lu, Q., Renegar, R., . . . Chen, Y. H. 
(2012). Inflammation and disruption of the mucosal architecture in claudin-7-
deficient mice. Gastroenterology, 142(2), 305-315. 
doi:10.1053/j.gastro.2011.10.025 
Dohi, T., Borodovsky, A., Wu, P., Shearstone, J. R., Kawashima, R., Runkel, L., . . . 
Burkly, L. C. (2009). TWEAK/Fn14 pathway: a nonredundant role in 
intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. 
Gastroenterology, 136(3), 912-923. doi:10.1053/j.gastro.2008.11.017 
Dohi, T., & Burkly, L. C. (2012). The TWEAK/Fn14 pathway as an aggravating and 
perpetuating factor in inflammatory diseases: focus on inflammatory bowel 
diseases. J Leukoc Biol, 92(2), 265-279. doi:10.1189/jlb.0112042 
Doig, C. J., Sutherland, L. R., Sandham, J. D., Fick, G. H., Verhoef, M., & 
Meddings, J. B. (1998). Increased intestinal permeability is associated with 
the development of multiple organ dysfunction syndrome in critically ill ICU 
patients. Am J Respir Crit Care Med, 158(2), 444-451. 
doi:10.1164/ajrccm.158.2.9710092 
Dominguez, J. A., Samocha, A. J., Liang, Z., Burd, E. M., Farris, A. B., & 
Coopersmith, C. M. (2013). Inhibition of IKKbeta in enterocytes exacerbates 
sepsis-induced intestinal injury and worsens mortality. Crit Care Med, 
41(10), e275-285. doi:10.1097/CCM.0b013e31828a44ed 
Donato, R., Cannon, B. R., Sorci, G., Riuzzi, F., Hsu, K., Weber, D. J., & Geczy, C. 
L. (2013). Functions of S100 proteins. Curr Mol Med, 13(1), 24-57.  
Dorrington, M. G., & Fraser, I. D. C. (2019). NF-kappaB Signaling in Macrophages: 
Dynamics, Crosstalk, and Signal Integration. Front Immunol, 10, 705. 
doi:10.3389/fimmu.2019.00705 
Dotti, I., Mora-Buch, R., Ferrer-Picon, E., Planell, N., Jung, P., Masamunt, M. C., . . 
. Salas, A. (2017). Alterations in the epithelial stem cell compartment could 
contribute to permanent changes in the mucosa of patients with ulcerative 
colitis. Gut, 66(12), 2069-2079. doi:10.1136/gutjnl-2016-312609 
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & 
Lanctot, K. L. (2010). A meta-analysis of cytokines in major depression. Biol 
Psychiatry, 67(5), 446-457. doi:10.1016/j.biopsych.2009.09.033 
Drake, R. L. (2019). Gray's anatomy for students (4th edition. ed.). Philadelphia, 
MO: Elsevier. 
D'Souza, B., Meloty-Kapella, L., & Weinmaster, G. (2010). Canonical and non-
canonical Notch ligands. Curr Top Dev Biol, 92, 73-129. doi:10.1016/S0070-
2153(10)92003-6 
Du, C., Fang, M., Li, Y., Li, L., & Wang, X. (2000). Smac, a mitochondrial protein 
that promotes cytochrome c-dependent caspase activation by eliminating 
IAP inhibition. Cell, 102(1), 33-42. doi:10.1016/s0092-8674(00)00008-8 
Duckworth, C. A., & Watson, A. J. (2011). Analysis of epithelial cell shedding and 
gaps in the intestinal epithelium. Methods Mol Biol, 763, 105-114. 
doi:10.1007/978-1-61779-191-8_7 
Durand, A., Donahue, B., Peignon, G., Letourneur, F., Cagnard, N., Slomianny, C., 
. . . Romagnolo, B. (2012). Functional intestinal stem cells after Paneth cell 
ablation induced by the loss of transcription factor Math1 (Atoh1). Proc Natl 
Acad Sci U S A, 109(23), 8965-8970. doi:10.1073/pnas.1201652109 
Ebnet, K., Suzuki, A., Ohno, S., & Vestweber, D. (2004). Junctional adhesion 
molecules (JAMs): more molecules with dual functions? J Cell Sci, 117(Pt 
1), 19-29. doi:10.1242/jcs.00930 
268 
 
Eckmann, L., Nebelsiek, T., Fingerle, A. A., Dann, S. M., Mages, J., Lang, R., . . . 
Greten, F. R. (2008). Opposing functions of IKKbeta during acute and 
chronic intestinal inflammation. Proc Natl Acad Sci U S A, 105(39), 15058-
15063. doi:10.1073/pnas.0808216105 
Edwards, R. L., Luis, P. B., Varuzza, P. V., Joseph, A. I., Presley, S. H., Chaturvedi, 
R., & Schneider, C. (2017). The anti-inflammatory activity of curcumin is 
mediated by its oxidative metabolites. J Biol Chem, 292(52), 21243-21252. 
doi:10.1074/jbc.RA117.000123 
Efrat, S., Leiser, M., Wu, Y. J., Fusco-DeMane, D., Emran, O. A., Surana, M., . . . 
Fleischer, N. (1994). Ribozyme-mediated attenuation of pancreatic beta-cell 
glucokinase expression in transgenic mice results in impaired glucose-
induced insulin secretion. Proc Natl Acad Sci U S A, 91(6), 2051-2055. 
doi:10.1073/pnas.91.6.2051 
Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicol Pathol, 
35(4), 495-516. doi:10.1080/01926230701320337 
Elphick, D. A., & Mahida, Y. R. (2005). Paneth cells: their role in innate immunity 
and inflammatory disease. Gut, 54(12), 1802-1809. 
doi:10.1136/gut.2005.068601 
Erlandsen, S. L., Parsons, J. A., & Taylor, T. D. (1974). Ultrastructural 
immunocytochemical localization of lysozyme in the Paneth cells of man. J 
Histochem Cytochem, 22(6), 401-413. doi:10.1177/22.6.401 
Fabris, M., Visentini, D., De Re, V., Picierno, A., Maieron, R., Cannizzaro, R., . . . 
Tonutti, E. (2007). Elevated B cell-activating factor of the tumour necrosis 
factor family in coeliac disease. Scand J Gastroenterol, 42(12), 1434-1439. 
doi:10.1080/00365520701452225 
Fan, Y., Zhang, G., Vong, C. T., & Ye, R. D. (2020). Serum amyloid A3 confers 
protection against acute lung injury in Pseudomonas aeruginosa-infected 
mice. Am J Physiol Lung Cell Mol Physiol, 318(2), L314-L322. 
doi:10.1152/ajplung.00309.2019 
Fatehullah, A., Tan, S. H., & Barker, N. (2016). Organoids as an in vitro model of 
human development and disease. Nat Cell Biol, 18(3), 246-254. 
doi:10.1038/ncb3312 
Fatehullah, A., Tan, S. H., & Barker, N. (2016). Organoids as an in vitro model of 
human development and disease. Nat Cell Biol, 18(3), 246-254. 
doi:10.1038/ncb3312 
Faure, E., Equils, O., Sieling, P. A., Thomas, L., Zhang, F. X., Kirschning, C. J., . . . 
Arditi, M. (2000). Bacterial lipopolysaccharide activates NF-kappaB through 
toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. 
Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem, 
275(15), 11058-11063. doi:10.1074/jbc.275.15.11058 
Faustman, D., & Davis, M. (2010). TNF receptor 2 pathway: drug target for 
autoimmune diseases. Nat Rev Drug Discov, 9(6), 482-493. 
doi:10.1038/nrd3030 
Feldman, G. J., Mullin, J. M., & Ryan, M. P. (2005). Occludin: structure, function 
and regulation. Adv Drug Deliv Rev, 57(6), 883-917. 
doi:10.1016/j.addr.2005.01.009 
Ferrajoli, A., Keating, M. J., Manshouri, T., Giles, F. J., Dey, A., Estrov, Z., . . . 
Albitar, M. (2002). The clinical significance of tumor necrosis factor-alpha 
plasma level in patients having chronic lymphocytic leukemia. Blood, 100(4), 
1215-1219.  
Ferraris, R. P., & Diamond, J. (1997). Regulation of intestinal sugar transport. 
Physiol Rev, 77(1), 257-302. doi:10.1152/physrev.1997.77.1.257 
Fink, M. P., & Heard, S. O. (1990). Laboratory models of sepsis and septic shock. J 
Surg Res, 49(2), 186-196. doi:10.1016/0022-4804(90)90260-9 
269 
 
Flanagan, D. J., Austin, C. R., Vincan, E., & Phesse, T. J. (2018). Wnt Signalling in 
Gastrointestinal Epithelial Stem Cells. Genes (Basel), 9(4). 
doi:10.3390/genes9040178 
Fleischmann-Struzek, C., Goldfarb, D. M., Schlattmann, P., Schlapbach, L. J., 
Reinhart, K., & Kissoon, N. (2018). The global burden of paediatric and 
neonatal sepsis: a systematic review. Lancet Respir Med, 6(3), 223-230. 
doi:10.1016/S2213-2600(18)30063-8 
Flynn, D. C. (2001). Adaptor proteins. Oncogene, 20(44), 6270-6272. 
doi:10.1038/sj.onc.1204769 
Fong, Y., Tracey, K. J., Moldawer, L. L., Hesse, D. G., Manogue, K. B., Kenney, J. 
S., . . . et al. (1989). Antibodies to cachectin/tumor necrosis factor reduce 
interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J 
Exp Med, 170(5), 1627-1633. doi:10.1084/jem.170.5.1627 
Force, W. R., Glass, A. A., Benedict, C. A., Cheung, T. C., Lama, J., & Ware, C. F. 
(2000). Discrete signaling regions in the lymphotoxin-beta receptor for tumor 
necrosis factor receptor-associated factor binding, subcellular localization, 
and activation of cell death and NF-kappaB pathways. J Biol Chem, 
275(15), 11121-11129. doi:10.1074/jbc.275.15.11121 
Formigli, L., Papucci, L., Tani, A., Schiavone, N., Tempestini, A., Orlandini, G. E., . . 
. Orlandini, S. Z. (2000). Aponecrosis: morphological and biochemical 
exploration of a syncretic process of cell death sharing apoptosis and 
necrosis. J Cell Physiol, 182(1), 41-49. doi:10.1002/(SICI)1097-
4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7 
Frey, M. R., Edelblum, K. L., Mullane, M. T., Liang, D., & Polk, D. B. (2009). The 
ErbB4 growth factor receptor is required for colon epithelial cell survival in 
the presence of TNF. Gastroenterology, 136(1), 217-226. 
doi:10.1053/j.gastro.2008.09.023 
Frisch, S. M., & Francis, H. (1994). Disruption of epithelial cell-matrix interactions 
induces apoptosis. J Cell Biol, 124(4), 619-626. doi:10.1083/jcb.124.4.619 
Fukuyama, S., Hiroi, T., Yokota, Y., Rennert, P. D., Yanagita, M., Kinoshita, N., . . . 
Kiyono, H. (2002). Initiation of NALT organogenesis is independent of the 
IL-7R, LTbetaR, and NIK signaling pathways but requires the Id2 gene and 
CD3(-)CD4(+)CD45(+) cells. Immunity, 17(1), 31-40. doi:10.1016/s1074-
7613(02)00339-4 
Fulda, S., & Debatin, K. M. (2006). Extrinsic versus intrinsic apoptosis pathways in 
anticancer chemotherapy. Oncogene, 25(34), 4798-4811. 
doi:10.1038/sj.onc.1209608 
Furness, J. B., Kunze, W. A., & Clerc, N. (1999). Nutrient tasting and signaling 
mechanisms in the gut. II. The intestine as a sensory organ: neural, 
endocrine, and immune responses. Am J Physiol, 277(5), G922-928. 
doi:10.1152/ajpgi.1999.277.5.G922 
Furriols, M., & Bray, S. (2001). A model Notch response element detects 
Suppressor of Hairless-dependent molecular switch. Curr Biol, 11(1), 60-64. 
doi:10.1016/s0960-9822(00)00044-0 
Furuse, M., Fujita, K., Hiiragi, T., Fujimoto, K., & Tsukita, S. (1998). Claudin-1 and -
2: novel integral membrane proteins localizing at tight junctions with no 
sequence similarity to occludin. J Cell Biol, 141(7), 1539-1550. 
doi:10.1083/jcb.141.7.1539 
Furuse, M., Hirase, T., Itoh, M., Nagafuchi, A., Yonemura, S., Tsukita, S., & Tsukita, 
S. (1993). Occludin: a novel integral membrane protein localizing at tight 
junctions. J Cell Biol, 123(6 Pt 2), 1777-1788. doi:10.1083/jcb.123.6.1777 
Furuta, K., Ikeda, M., Nakayama, Y., Nakamura, K., Tanaka, M., Hamasaki, N., . . . 
August, J. T. (2001). Expression of lysosome-associated membrane 
proteins in human colorectal neoplasms and inflammatory diseases. Am J 
Pathol, 159(2), 449-455. doi:10.1016/S0002-9440(10)61716-6 
270 
 
Gallagher, J., Fisher, C., Sherman, B., Munger, M., Meyers, B., Ellison, T., . . . 
Velagapudi, R. (2001). A multicenter, open-label, prospective, randomized, 
dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody 
afelimomab in patients with sepsis syndrome. Intensive Care Med, 27(7), 
1169-1178. doi:10.1007/s001340100973 
Ganeff, C., Remouchamps, C., Boutaffala, L., Benezech, C., Galopin, G., 
Vandepaer, S., . . . Dejardin, E. (2011). Induction of the alternative NF-
kappaB pathway by lymphotoxin alphabeta (LTalphabeta) relies on 
internalization of LTbeta receptor. Mol Cell Biol, 31(21), 4319-4334. 
doi:10.1128/MCB.05033-11 
Gasbarrini, G., & Montalto, M. (1999). Structure and function of tight junctions. Role 
in intestinal barrier. Ital J Gastroenterol Hepatol, 31(6), 481-488.  
Gatto, M., Iaccarino, L., Ghirardello, A., Bassi, N., Pontisso, P., Punzi, L., . . . Doria, 
A. (2013). Serpins, immunity and autoimmunity: old molecules, new 
functions. Clin Rev Allergy Immunol, 45(2), 267-280. doi:10.1007/s12016-
013-8353-3 
Gauvin, R., Chen, Y. C., Lee, J. W., Soman, P., Zorlutuna, P., Nichol, J. W., . . . 
Khademhosseini, A. (2012). Microfabrication of complex porous tissue 
engineering scaffolds using 3D projection stereolithography. Biomaterials, 
33(15), 3824-3834. doi:10.1016/j.biomaterials.2012.01.048 
Gebert, N., Cheng, C. W., Kirkpatrick, J. M., Di Fraia, D., Yun, J., Schadel, P., . . . 
Ori, A. (2020). Region-Specific Proteome Changes of the Intestinal 
Epithelium during Aging and Dietary Restriction. Cell Rep, 31(4), 107565. 
doi:10.1016/j.celrep.2020.107565 
Gelbmann, C. M., Leeb, S. N., Vogl, D., Maendel, M., Herfarth, H., Scholmerich, J., 
. . . Rogler, G. (2003). Inducible CD40 expression mediates NFkappaB 
activation and cytokine secretion in human colonic fibroblasts. Gut, 52(10), 
1448-1456. doi:10.1136/gut.52.10.1448 
Gerbe, F., Brulin, B., Makrini, L., Legraverend, C., & Jay, P. (2009). DCAMKL-1 
expression identifies Tuft cells rather than stem cells in the adult mouse 
intestinal epithelium. Gastroenterology, 137(6), 2179-2180; author reply 
2180-2171. doi:10.1053/j.gastro.2009.06.072 
Gerbe, F., Legraverend, C., & Jay, P. (2012). The intestinal epithelium tuft cells: 
specification and function. Cell Mol Life Sci, 69(17), 2907-2917. 
doi:10.1007/s00018-012-0984-7 
Gerbe, F., van Es, J. H., Makrini, L., Brulin, B., Mellitzer, G., Robine, S., . . . Jay, P. 
(2011). Distinct ATOH1 and Neurog3 requirements define tuft cells as a new 
secretory cell type in the intestinal epithelium. J Cell Biol, 192(5), 767-780. 
doi:10.1083/jcb.201010127 
Gerthoffer, W. T. (2008). Migration of airway smooth muscle cells. Proc Am Thorac 
Soc, 5(1), 97-105. doi:10.1513/pats.200704-051VS 
Ghosh, S., Gifford, A. M., Riviere, L. R., Tempst, P., Nolan, G. P., & Baltimore, D. 
(1990). Cloning of the p50 DNA binding subunit of NF-kappa B: homology to 
rel and dorsal. Cell, 62(5), 1019-1029. doi:10.1016/0092-8674(90)90276-k 
Ghosh, S., May, M. J., & Kopp, E. B. (1998). NF-kappa B and Rel proteins: 
evolutionarily conserved mediators of immune responses. Annu Rev 
Immunol, 16, 225-260. doi:10.1146/annurev.immunol.16.1.225 
Giammanco, A., Cefalu, A. B., Noto, D., & Averna, M. R. (2015). The 
pathophysiology of intestinal lipoprotein production. Front Physiol, 6, 61. 
doi:10.3389/fphys.2015.00061 
Gibbison, B., Lopez-Lopez, J. A., Higgins, J. P., Miller, T., Angelini, G. D., 
Lightman, S. L., & Annane, D. (2017). Corticosteroids in septic shock: a 




Giles, D. A., Zahner, S., Krause, P., Van Der Gracht, E., Riffelmacher, T., Morris, 
V., . . . Kronenberg, M. (2018). The Tumor Necrosis Factor Superfamily 
Members TNFSF14 (LIGHT), Lymphotoxin beta and Lymphotoxin beta 
Receptor Interact to Regulate Intestinal Inflammation. Front Immunol, 9, 
2585. doi:10.3389/fimmu.2018.02585 
Gilmore, T. D. (2006). Introduction to NF-kappaB: players, pathways, perspectives. 
Oncogene, 25(51), 6680-6684. doi:10.1038/sj.onc.1209954 
Gindzienska-Sieskiewicz, E., Distler, O., Reszec, J., Jordan, S., Bielecki, P., 
Sieskiewicz, A., . . . Kowal-Bielecka, O. (2019). Increased expression of the 
TNF superfamily member LIGHT/TNFSF14 and its receptors (HVEM and 
LTssR) in patients with systemic sclerosis. Rheumatology (Oxford), 58(3), 
502-510. doi:10.1093/rheumatology/key348 
Girardin, E., Grau, G. E., Dayer, J. M., Roux-Lombard, P., & Lambert, P. H. (1988). 
Tumor necrosis factor and interleukin-1 in the serum of children with severe 
infectious purpura. N Engl J Med, 319(7), 397-400. 
doi:10.1056/NEJM198808183190703 
Gold, J. A., Parsey, M., Hoshino, Y., Hoshino, S., Nolan, A., Yee, H., . . . Weiden, 
M. D. (2003). CD40 contributes to lethality in acute sepsis: in vivo role for 
CD40 in innate immunity. Infect Immun, 71(6), 3521-3528. 
doi:10.1128/iai.71.6.3521-3528.2003 
Goldstein, J. C., Waterhouse, N. J., Juin, P., Evan, G. I., & Green, D. R. (2000). 
The coordinate release of cytochrome c during apoptosis is rapid, complete 
and kinetically invariant. Nat Cell Biol, 2(3), 156-162. doi:10.1038/35004029 
Gordon, A. C., Waheed, U., Hansen, T. K., Hitman, G. A., Garrard, C. S., Turner, 
M. W., . . . Hinds, C. J. (2006). Mannose-binding lectin polymorphisms in 
severe sepsis: relationship to levels, incidence, and outcome. Shock, 25(1), 
88-93. doi:10.1097/01.shk.0000186928.57109.8d 
Gordon, M. D., & Nusse, R. (2006). Wnt signaling: multiple pathways, multiple 
receptors, and multiple transcription factors. J Biol Chem, 281(32), 22429-
22433. doi:10.1074/jbc.R600015200 
Goren, I., Brom, A., Yanai, H., Dagan, A., Segal, G., & Israel, A. (2020). Risk of 
bacteremia in hospitalised patients with inflammatory bowel disease: a 9-
year cohort study. United European Gastroenterol J, 8(2), 195-203. 
doi:10.1177/2050640619874524 
Grammer, A. C., & Lipsky, P. E. (2000). CD40-mediated regulation of immune 
responses by TRAF-dependent and TRAF-independent signaling 
mechanisms. Adv Immunol, 76, 61-178. doi:10.1016/s0065-2776(01)76019-
1 
Granger, S. W., & Rickert, S. (2003). LIGHT-HVEM signaling and the regulation of 
T cell-mediated immunity. Cytokine Growth Factor Rev, 14(3-4), 289-296. 
doi:10.1016/s1359-6101(03)00031-5 
Graves, P. R., & Haystead, T. A. (2002). Molecular biologist's guide to proteomics. 
Microbiol Mol Biol Rev, 66(1), 39-63; table of contents. 
doi:10.1128/mmbr.66.1.39-63.2002 
Gremel, G., Wanders, A., Cedernaes, J., Fagerberg, L., Hallstrom, B., Edlund, K., . 
. . Ponten, F. (2015). The human gastrointestinal tract-specific transcriptome 
and proteome as defined by RNA sequencing and antibody-based profiling. 
J Gastroenterol, 50(1), 46-57. doi:10.1007/s00535-014-0958-7 
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z. W., Egan, L. J., . . . 
Karin, M. (2004). IKKbeta links inflammation and tumorigenesis in a mouse 
model of colitis-associated cancer. Cell, 118(3), 285-296. 
doi:10.1016/j.cell.2004.07.013 
Grimstad, T., Skoie, I. M., Doerner, J., Isaksen, K., Karlsen, L., Aabakken, L., . . . 
Putterman, C. (2017). TWEAK is not elevated in patients with newly 
272 
 
diagnosed inflammatory bowel disease. Scand J Gastroenterol, 52(4), 420-
424. doi:10.1080/00365521.2016.1273382 
Groppe, J., Greenwald, J., Wiater, E., Rodriguez-Leon, J., Economides, A. N., 
Kwiatkowski, W., . . . Choe, S. (2002). Structural basis of BMP signalling 
inhibition by the cystine knot protein Noggin. Nature, 420(6916), 636-642. 
doi:10.1038/nature01245 
Guan, Y., Watson, A. J., Marchiando, A. M., Bradford, E., Shen, L., Turner, J. R., & 
Montrose, M. H. (2011). Redistribution of the tight junction protein ZO-1 
during physiological shedding of mouse intestinal epithelial cells. Am J 
Physiol Cell Physiol, 300(6), C1404-1414. doi:10.1152/ajpcell.00270.2010 
Gubernatorova, E. O., & Tumanov, A. V. (2016). Tumor Necrosis Factor and 
Lymphotoxin in Regulation of Intestinal Inflammation. Biochemistry (Mosc), 
81(11), 1309-1325. doi:10.1134/S0006297916110092 
Guma, M., Stepniak, D., Shaked, H., Spehlmann, M. E., Shenouda, S., Cheroutre, 
H., . . . Karin, M. (2011). Constitutive intestinal NF-kappaB does not trigger 
destructive inflammation unless accompanied by MAPK activation. J Exp 
Med, 208(9), 1889-1900. doi:10.1084/jem.20110242 
Gunawardene, A. R., Corfe, B. M., & Staton, C. A. (2011). Classification and 
functions of enteroendocrine cells of the lower gastrointestinal tract. Int J 
Exp Pathol, 92(4), 219-231. doi:10.1111/j.1365-2613.2011.00767.x 
Gunther, C., Buchen, B., He, G. W., Hornef, M., Torow, N., Neumann, H., . . . 
Becker, C. (2015). Caspase-8 controls the gut response to microbial 
challenges by Tnf-alpha-dependent and independent pathways. Gut, 64(4), 
601-610. doi:10.1136/gutjnl-2014-307226 
Gunzel, D., & Yu, A. S. (2013). Claudins and the modulation of tight junction 
permeability. Physiol Rev, 93(2), 525-569. doi:10.1152/physrev.00019.2012 
Gutierrez, M. G., Mishra, B. B., Jordao, L., Elliott, E., Anes, E., & Griffiths, G. 
(2008). NF-kappa B activation controls phagolysosome fusion-mediated 
killing of mycobacteria by macrophages. J Immunol, 181(4), 2651-2663. 
doi:10.4049/jimmunol.181.4.2651 
Hall, P. A., Coates, P. J., Ansari, B., & Hopwood, D. (1994). Regulation of cell 
number in the mammalian gastrointestinal tract: the importance of 
apoptosis. J Cell Sci, 107 ( Pt 12), 3569-3577.  
Hamada, M., Abe, M., Miyake, T., Kawasaki, K., Tada, F., Furukawa, S., . . . Onji, 
M. (2011). B cell-activating factor controls the production of adipokines and 
induces insulin resistance. Obesity (Silver Spring), 19(10), 1915-1922. 
doi:10.1038/oby.2011.165 
Han, M. K., Baker, M., Zhang, Y., Yang, C., Zhang, M., Garg, P., . . . Merlin, D. 
(2018). Overexpression of CD98 in intestinal epithelium dysregulates 
miRNAs and their targeted proteins along the ileal villus-crypt axis. Sci Rep, 
8(1), 16220. doi:10.1038/s41598-018-34474-9 
Han, N. Y., Choi, W., Park, J. M., Kim, E. H., Lee, H., & Hahm, K. B. (2013). Label-
free quantification for discovering novel biomarkers in the diagnosis and 
assessment of disease activity in inflammatory bowel disease. J Dig Dis, 
14(4), 166-174. doi:10.1111/1751-2980.12035 
Han, Y. P., Nien, Y. D., & Garner, W. L. (2002). Tumor necrosis factor-alpha-
induced proteolytic activation of pro-matrix metalloproteinase-9 by human 
skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 
and mediated by tissue-associated chymotrypsin-like proteinase. J Biol 
Chem, 277(30), 27319-27327. doi:10.1074/jbc.M202842200 
Han, Y. P., Tuan, T. L., Wu, H., Hughes, M., & Garner, W. L. (2001). TNF-alpha 
stimulates activation of pro-MMP2 in human skin through NF-(kappa)B 
mediated induction of MT1-MMP. J Cell Sci, 114(Pt 1), 131-139.  




Hardie, E. M., Kolata, R. J., & Rawlings, C. A. (1983). Canine septic peritonitis: 
treatment with flunixin meglumine. Circ Shock, 11(2), 159-173.  
Harrop, J. A., Reddy, M., Dede, K., Brigham-Burke, M., Lyn, S., Tan, K. B., . . . 
Truneh, A. (1998). Antibodies to TR2 (herpesvirus entry mediator), a new 
member of the TNF receptor superfamily, block T cell proliferation, 
expression of activation markers, and production of cytokines. J Immunol, 
161(4), 1786-1794.  
Haskill, S., Beg, A. A., Tompkins, S. M., Morris, J. S., Yurochko, A. D., Sampson-
Johannes, A., . . . Baldwin, A. S., Jr. (1991). Characterization of an 
immediate-early gene induced in adherent monocytes that encodes I kappa 
B-like activity. Cell, 65(7), 1281-1289. doi:10.1016/0092-8674(91)90022-q 
Haussner, F., Chakraborty, S., Halbgebauer, R., & Huber-Lang, M. (2019). 
Challenge to the Intestinal Mucosa During Sepsis. Front Immunol, 10, 891. 
doi:10.3389/fimmu.2019.00891 
Haybaeck, J., Zeller, N., Wolf, M. J., Weber, A., Wagner, U., Kurrer, M. O., . . . 
Heikenwalder, M. (2009). A lymphotoxin-driven pathway to hepatocellular 
carcinoma. Cancer Cell, 16(4), 295-308. doi:10.1016/j.ccr.2009.08.021 
Hayden, M. S., & Ghosh, S. (2004). Signaling to NF-kappaB. Genes Dev, 18(18), 
2195-2224. doi:10.1101/gad.1228704 
Hayden, M. S., & Ghosh, S. (2008). Shared principles in NF-kappaB signaling. Cell, 
132(3), 344-362. doi:10.1016/j.cell.2008.01.020 
Hayden, M. S., West, A. P., & Ghosh, S. (2006). NF-kappaB and the immune 
response. Oncogene, 25(51), 6758-6780. doi:10.1038/sj.onc.1209943 
He, X., Semenov, M., Tamai, K., & Zeng, X. (2004). LDL receptor-related proteins 5 
and 6 in Wnt/beta-catenin signaling: arrows point the way. Development, 
131(8), 1663-1677. doi:10.1242/dev.01117 
Heeschen, C., Dimmeler, S., Hamm, C. W., van den Brand, M. J., Boersma, E., 
Zeiher, A. M., . . . Investigators, C. S. (2003). Soluble CD40 ligand in acute 
coronary syndromes. N Engl J Med, 348(12), 1104-1111. 
doi:10.1056/NEJMoa022600 
Hehner, S. P., Hofmann, T. G., Droge, W., & Schmitz, M. L. (1999). The 
antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by 
targeting the I kappa B kinase complex. J Immunol, 163(10), 5617-5623.  
Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F., & Graeve, L. (1998). 
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. 
Biochem J, 334 ( Pt 2), 297-314. doi:10.1042/bj3340297 
Heming, N., Sivanandamoorthy, S., Meng, P., Bounab, R., & Annane, D. (2018). 
Immune Effects of Corticosteroids in Sepsis. Front Immunol, 9, 1736. 
doi:10.3389/fimmu.2018.01736 
Herfarth, H. H., Bocker, U., Janardhanam, R., & Sartor, R. B. (1998). 
Subtherapeutic corticosteroids potentiate the ability of interleukin 10 to 
prevent chronic inflammation in rats. Gastroenterology, 115(4), 856-865. 
doi:10.1016/s0016-5085(98)70257-4 
Hesse, D. G., Tracey, K. J., Fong, Y., Manogue, K. R., Palladino, M. A., Jr., Cerami, 
A., . . . Lowry, S. F. (1988). Cytokine appearance in human endotoxemia 
and primate bacteremia. Surg Gynecol Obstet, 166(2), 147-153.  
Hilliard, V. C., Frey, M. R., Dempsey, P. J., Peek, R. M., Jr., & Polk, D. B. (2011). 
TNF-alpha converting enzyme-mediated ErbB4 transactivation by TNF 
promotes colonic epithelial cell survival. Am J Physiol Gastrointest Liver 
Physiol, 301(2), G338-346. doi:10.1152/ajpgi.00057.2011 
Hinkelbein, J., Feldmann, R. E., Jr., Schubert, C., Peterka, A., Schelshorn, D., 
Maurer, M. H., & Kalenka, A. (2009). Alterations in rat serum proteome and 




Hollander, D. (1999). Intestinal permeability, leaky gut, and intestinal disorders. 
Curr Gastroenterol Rep, 1(5), 410-416. doi:10.1007/s11894-999-0023-5 
Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., . . . Tschopp, 
J. (2000). Fas triggers an alternative, caspase-8-independent cell death 
pathway using the kinase RIP as effector molecule. Nat Immunol, 1(6), 489-
495. doi:10.1038/82732 
Holmes, J. L., Van Itallie, C. M., Rasmussen, J. E., & Anderson, J. M. (2006). 
Claudin profiling in the mouse during postnatal intestinal development and 
along the gastrointestinal tract reveals complex expression patterns. Gene 
Expr Patterns, 6(6), 581-588. doi:10.1016/j.modgep.2005.12.001 
Holst, J. J., Skak-Nielsen, T., Orskov, C., & Seier-Poulsen, S. (1992). Vagal control 
of the release of somatostatin, vasoactive intestinal polypeptide, gastrin-
releasing peptide, and HCl from porcine non-antral stomach. Scand J 
Gastroenterol, 27(8), 677-685. doi:10.3109/00365529209000139 
Hotchkiss, R. S., & Karl, I. E. (2003). The pathophysiology and treatment of sepsis. 
N Engl J Med, 348(2), 138-150. doi:10.1056/NEJMra021333 
Huang, M., Cai, S., & Su, J. (2019). The Pathogenesis of Sepsis and Potential 
Therapeutic Targets. Int J Mol Sci, 20(21). doi:10.3390/ijms20215376 
Huch, M., Knoblich, J. A., Lutolf, M. P., & Martinez-Arias, A. (2017). The hope and 
the hype of organoid research. Development, 144(6), 938-941. 
doi:10.1242/dev.150201 
Hynds, R. E., & Giangreco, A. (2013). Concise review: the relevance of human 
stem cell-derived organoid models for epithelial translational medicine. Stem 
Cells, 31(3), 417-422. doi:10.1002/stem.1290 
Ijiri, K., & Potten, C. S. (1983). Response of intestinal cells of differing topographical 
and hierarchical status to ten cytotoxic drugs and five sources of radiation. 
Br J Cancer, 47(2), 175-185. doi:10.1038/bjc.1983.25 
Ijiri, K., & Potten, C. S. (1987). Further studies on the response of intestinal crypt 
cells of different hierarchical status to eighteen different cytotoxic agents. Br 
J Cancer, 55(2), 113-123. doi:10.1038/bjc.1987.25 
Inoue, J., Kerr, L. D., Kakizuka, A., & Verma, I. M. (1992). I kappa B gamma, a 70 
kd protein identical to the C-terminal half of p110 NF-kappa B: a new 
member of the I kappa B family. Cell, 68(6), 1109-1120. doi:10.1016/0092-
8674(92)90082-n 
Inoue, J., Kerr, L. D., Kakizuka, A., & Verma, I. M. (1992). I kappa B gamma, a 70 
kd protein identical to the C-terminal half of p110 NF-kappa B: a new 
member of the I kappa B family. Cell, 68(6), 1109-1120. doi:10.1016/0092-
8674(92)90082-n 
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., . . . 
Tschopp, J. (1997). Inhibition of death receptor signals by cellular FLIP. 
Nature, 388(6638), 190-195. doi:10.1038/40657 
Isaacs, K. L., Sartor, R. B., & Haskill, S. (1992). Cytokine messenger RNA profiles 
in inflammatory bowel disease mucosa detected by polymerase chain 
reaction amplification. Gastroenterology, 103(5), 1587-1595. 
doi:10.1016/0016-5085(92)91182-4 
Ito, K., Barnes, P. J., & Adcock, I. M. (2000). Glucocorticoid receptor recruitment of 
histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 
acetylation on lysines 8 and 12. Mol Cell Biol, 20(18), 6891-6903. 
doi:10.1128/mcb.20.18.6891-6903.2000 
Itoh, M., Sasaki, H., Furuse, M., Ozaki, H., Kita, T., & Tsukita, S. (2001). Junctional 
adhesion molecule (JAM) binds to PAR-3: a possible mechanism for the 
recruitment of PAR-3 to tight junctions. J Cell Biol, 154(3), 491-497. 
doi:10.1083/jcb.200103047 
Iwagami, M., Yasunaga, H., Doi, K., Horiguchi, H., Fushimi, K., Matsubara, T., . . . 
Noiri, E. (2014). Postoperative polymyxin B hemoperfusion and mortality in 
275 
 
patients with abdominal septic shock: a propensity-matched analysis. Crit 
Care Med, 42(5), 1187-1193. doi:10.1097/CCM.0000000000000150 
Izumi, Y., Hirose, T., Tamai, Y., Hirai, S., Nagashima, Y., Fujimoto, T., . . . Ohno, S. 
(1998). An atypical PKC directly associates and colocalizes at the epithelial 
tight junction with ASIP, a mammalian homologue of Caenorhabditis 
elegans polarity protein PAR-3. J Cell Biol, 143(1), 95-106. 
doi:10.1083/jcb.143.1.95 
Jabati, S., Fareed, J., Liles, J., Otto, A., Hoppensteadt, D., Bontekoe, J., . . . Syed, 
M. (2018). Biomarkers of Inflammation, Thrombogenesis, and Collagen 
Turnover in Patients With Atrial Fibrillation. Clin Appl Thromb Hemost, 24(5), 
718-723. doi:10.1177/1076029618761006 
Jacob, A., Wu, R., Zhou, M., & Wang, P. (2007). Mechanism of the Anti-
inflammatory Effect of Curcumin: PPAR-gamma Activation. PPAR Res, 
2007, 89369. doi:10.1155/2007/89369 
Jacobs, M. D., & Harrison, S. C. (1998). Structure of an IkappaBalpha/NF-kappaB 
complex. Cell, 95(6), 749-758. doi:10.1016/s0092-8674(00)81698-0 
Jager, R., Lowery, R. P., Calvanese, A. V., Joy, J. M., Purpura, M., & Wilson, J. M. 
(2014). Comparative absorption of curcumin formulations. Nutr J, 13, 11. 
doi:10.1186/1475-2891-13-11 
Jakubowski, A., Ambrose, C., Parr, M., Lincecum, J. M., Wang, M. Z., Zheng, T. S., 
. . . Burkly, L. C. (2005). TWEAK induces liver progenitor cell proliferation. J 
Clin Invest, 115(9), 2330-2340. doi:10.1172/JCI23486 
Janda, C. Y., Waghray, D., Levin, A. M., Thomas, C., & Garcia, K. C. (2012). 
Structural basis of Wnt recognition by Frizzled. Science, 337(6090), 59-64. 
doi:10.1126/science.1222879 
Jang, S. W., Lim, S. G., Suk, K., & Lee, W. H. (2015). Activation of lymphotoxin-
beta receptor enhances the LPS-induced expression of IL-8 through NF-
kappaB and IRF-1. Immunol Lett, 165(2), 63-69. 
doi:10.1016/j.imlet.2015.04.001 
Jensen, S. R., Schoof, E. M., Wheeler, S. E., Hvid, H., Ahnfelt-Ronne, J., Hansen, 
B. F., . . . Brubaker, P. L. (2017). Quantitative Proteomics of Intestinal 
Mucosa From Male Mice Lacking Intestinal Epithelial Insulin Receptors. 
Endocrinology, 158(8), 2470-2485. doi:10.1210/en.2017-00194 
Jeon, M. K., Klaus, C., Kaemmerer, E., & Gassler, N. (2013). Intestinal barrier: 
Molecular pathways and modifiers. World J Gastrointest Pathophysiol, 4(4), 
94-99. doi:10.4291/wjgp.v4.i4.94 
Jin, S., Hansson, E. M., Tikka, S., Lanner, F., Sahlgren, C., Farnebo, F., . . . 
Lendahl, U. (2008). Notch signaling regulates platelet-derived growth factor 
receptor-beta expression in vascular smooth muscle cells. Circ Res, 
102(12), 1483-1491. doi:10.1161/CIRCRESAHA.107.167965 
Jin, Y. R., & Yoon, J. K. (2012). The R-spondin family of proteins: emerging 
regulators of WNT signaling. Int J Biochem Cell Biol, 44(12), 2278-2287. 
doi:10.1016/j.biocel.2012.09.006 
Johansson, M. E., Phillipson, M., Petersson, J., Velcich, A., Holm, L., & Hansson, 
G. C. (2008). The inner of the two Muc2 mucin-dependent mucus layers in 
colon is devoid of bacteria. Proc Natl Acad Sci U S A, 105(39), 15064-
15069. doi:10.1073/pnas.0803124105 
Jones, L. G., Vaida, A., Thompson, L. M., Ikuomola, F. I., Caamano, J. H., Burkitt, 
M. D., . . . Duckworth, C. A. (2019). NF-kappaB2 signalling in enteroids 
modulates enterocyte responses to secreted factors from bone marrow-
derived dendritic cells. Cell Death Dis, 10(12), 896. doi:10.1038/s41419-
019-2129-5 
Julian, M. W., Bao, S., Knoell, D. L., Fahy, R. J., Shao, G., & Crouser, E. D. (2011). 
Intestinal epithelium is more susceptible to cytopathic injury and altered 
276 
 
permeability than the lung epithelium in the context of acute sepsis. Int J 
Exp Pathol, 92(5), 366-376. doi:10.1111/j.1365-2613.2011.00783.x 
Jung, H., Leal-Ekman, J. S., Lu, Q., & Stappenbeck, T. S. (2019). Atg14 protects 
the intestinal epithelium from TNF-triggered villus atrophy. Autophagy, 
15(11), 1990-2001. doi:10.1080/15548627.2019.1596495 
Jungbeck, M., Stopfer, P., Bataille, F., Nedospasov, S. A., Mannel, D. N., & 
Hehlgans, T. (2008). Blocking lymphotoxin beta receptor signalling 
exacerbates acute DSS-induced intestinal inflammation--opposite functions 
for surface lymphotoxin expressed by T and B lymphocytes. Mol Immunol, 
45(1), 34-41. doi:10.1016/j.molimm.2007.05.007 
Junqueira, L. C. U. a., Carneiro, J., & Contopoulos, A. N. Basic histology. In A 
Concise medical library for practitioner and student (pp. 11 volumes). Los 
Altos, Calif. 
Norwalk, Conn. 
New York: Lange Medical Publications 
Appleton & Lange 
Lange Medical Books/McGraw Hill 
McGraw Hill. 
Jurgensmeier, J. M., Krajewski, S., Armstrong, R. C., Wilson, G. M., Oltersdorf, T., 
Fritz, L. C., . . . Ottilie, S. (1997). Bax- and Bak-induced cell death in the 
fission yeast Schizosaccharomyces pombe. Mol Biol Cell, 8(2), 325-339. 
doi:10.1091/mbc.8.2.325 
Kallen, K. J., zum Buschenfelde, K. H., & Rose-John, S. (1997). The therapeutic 
potential of interleukin-6 hyperagonists and antagonists. Expert Opin 
Investig Drugs, 6(3), 237-266. doi:10.1517/13543784.6.3.237 
Kang, S. J., Wang, S., Hara, H., Peterson, E. P., Namura, S., Amin-Hanjani, S., . . . 
Yuan, J. (2000). Dual role of caspase-11 in mediating activation of caspase-
1 and caspase-3 under pathological conditions. J Cell Biol, 149(3), 613-622. 
doi:10.1083/jcb.149.3.613 
Karin, M. (1998). New twists in gene regulation by glucocorticoid receptor: is DNA 
binding dispensable? Cell, 93(4), 487-490. doi:10.1016/s0092-
8674(00)81177-0 
Karin, M., Cao, Y., Greten, F. R., & Li, Z. W. (2002). NF-kappaB in cancer: from 
innocent bystander to major culprit. Nat Rev Cancer, 2(4), 301-310. 
doi:10.1038/nrc780 
Kato, A., Truong-Tran, A. Q., Scott, A. L., Matsumoto, K., & Schleimer, R. P. 
(2006). Airway epithelial cells produce B cell-activating factor of TNF family 
by an IFN-beta-dependent mechanism. J Immunol, 177(10), 7164-7172. 
doi:10.4049/jimmunol.177.10.7164 
Kattah, M. G., Shao, L., Rosli, Y. Y., Shimizu, H., Whang, M. I., Advincula, R., . . . 
Ma, A. (2018). A20 and ABIN-1 synergistically preserve intestinal epithelial 
cell survival. J Exp Med, 215(7), 1839-1852. doi:10.1084/jem.20180198 
Kaufmann, I., Briegel, J., Schliephake, F., Hoelzl, A., Chouker, A., Hummel, T., . . . 
Thiel, M. (2008). Stress doses of hydrocortisone in septic shock: beneficial 
effects on opsonization-dependent neutrophil functions. Intensive Care Med, 
34(2), 344-349. doi:10.1007/s00134-007-0868-8 
Kawai, T., & Akira, S. (2010). The role of pattern-recognition receptors in innate 
immunity: update on Toll-like receptors. Nat Immunol, 11(5), 373-384. 
doi:10.1038/ni.1863 
Kawashima, R., Kawamura, Y. I., Oshio, T., Son, A., Yamazaki, M., Hagiwara, T., . . 
. Dohi, T. (2011). Interleukin-13 damages intestinal mucosa via TWEAK and 
Fn14 in mice-a pathway associated with ulcerative colitis. Gastroenterology, 
141(6), 2119-2129 e2118. doi:10.1053/j.gastro.2011.08.040 
Keh, D., Boehnke, T., Weber-Cartens, S., Schulz, C., Ahlers, O., Bercker, S., . . . 
Gerlach, H. (2003). Immunologic and hemodynamic effects of "low-dose" 
277 
 
hydrocortisone in septic shock: a double-blind, randomized, placebo-
controlled, crossover study. Am J Respir Crit Care Med, 167(4), 512-520. 
doi:10.1164/rccm.200205-446OC 
Keh, D., Boehnke, T., Weber-Cartens, S., Schulz, C., Ahlers, O., Bercker, S., . . . 
Gerlach, H. (2003). Immunologic and hemodynamic effects of "low-dose" 
hydrocortisone in septic shock: a double-blind, randomized, placebo-
controlled, crossover study. Am J Respir Crit Care Med, 167(4), 512-520. 
doi:10.1164/rccm.200205-446OC 
Kelliher, M. A., Grimm, S., Ishida, Y., Kuo, F., Stanger, B. Z., & Leder, P. (1998). 
The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. 
Immunity, 8(3), 297-303. doi:10.1016/s1074-7613(00)80535-x 
Kelsen, J. R., Dawany, N., Conrad, M. A., Karakasheva, T. A., Maurer, K., Wei, J. 
M., . . . Hamilton, K. E. (2020). Colonoids From Patients With Pediatric 
Inflammatory Bowel Disease Exhibit Decreased Growth Associated With 
Inflammation Severity and Durable Upregulation of Antigen Presentation 
Genes. Inflamm Bowel Dis. doi:10.1093/ibd/izaa145 
Kelstrup, C. D., Bekker-Jensen, D. B., Arrey, T. N., Hogrebe, A., Harder, A., & 
Olsen, J. V. (2018). Performance Evaluation of the Q Exactive HF-X for 
Shotgun Proteomics. J Proteome Res, 17(1), 727-738. 
doi:10.1021/acs.jproteome.7b00602 
Kiesslich, R., Duckworth, C. A., Moussata, D., Gloeckner, A., Lim, L. G., Goetz, M., 
. . . Watson, A. J. (2012). Local barrier dysfunction identified by confocal 
laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut, 
61(8), 1146-1153. doi:10.1136/gutjnl-2011-300695 
Kiesslich, R., Goetz, M., Angus, E. M., Hu, Q., Guan, Y., Potten, C., . . . Watson, A. 
J. (2007). Identification of epithelial gaps in human small and large intestine 
by confocal endomicroscopy. Gastroenterology, 133(6), 1769-1778. 
doi:10.1053/j.gastro.2007.09.011 
Kim, K. A., Wagle, M., Tran, K., Zhan, X., Dixon, M. A., Liu, S., . . . Abo, A. (2008). 
R-Spondin family members regulate the Wnt pathway by a common 
mechanism. Mol Biol Cell, 19(6), 2588-2596. doi:10.1091/mbc.E08-02-0187 
Knoop, K. A., & Newberry, R. D. (2018). Goblet cells: multifaceted players in 
immunity at mucosal surfaces. Mucosal Immunol, 11(6), 1551-1557. 
doi:10.1038/s41385-018-0039-y 
Knutson, M. D. (2017). Iron transport proteins: Gateways of cellular and systemic 
iron homeostasis. J Biol Chem, 292(31), 12735-12743. 
doi:10.1074/jbc.R117.786632 
Kohn, A. D., & Moon, R. T. (2005). Wnt and calcium signaling: beta-catenin-
independent pathways. Cell Calcium, 38(3-4), 439-446. 
doi:10.1016/j.ceca.2005.06.022 
Komatsu, M., Kobayashi, D., Saito, K., Furuya, D., Yagihashi, A., Araake, H., . . . 
Watanabe, N. (2001). Tumor necrosis factor-alpha in serum of patients with 
inflammatory bowel disease as measured by a highly sensitive immuno-
PCR. Clin Chem, 47(7), 1297-1301.  
Komatsu, M., Kobayashi, D., Saito, K., Furuya, D., Yagihashi, A., Araake, H., . . . 
Watanabe, N. (2001). Tumor necrosis factor-alpha in serum of patients with 
inflammatory bowel disease as measured by a highly sensitive immuno-
PCR. Clin Chem, 47(7), 1297-1301.  
Komiya, Y., & Habas, R. (2008). Wnt signal transduction pathways. Organogenesis, 
4(2), 68-75. doi:10.4161/org.4.2.5851 
Konigsson, K., Torneke, K., Engeland, I. V., Odensvik, K., & Kindahl, H. (2003). 
Pharmacokinetics and pharmacodynamic effects of flunixin after 
intravenous, intramuscular and oral administration to dairy goats. Acta Vet 
Scand, 44(3-4), 153-159. doi:10.1186/1751-0147-44-153 
278 
 
Kontgen, F., Grumont, R. J., Strasser, A., Metcalf, D., Li, R., Tarlinton, D., & 
Gerondakis, S. (1995). Mice lacking the c-rel proto-oncogene exhibit defects 
in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. 
Genes Dev, 9(16), 1965-1977. doi:10.1101/gad.9.16.1965 
Kopan, R. (2012). Notch signaling. Cold Spring Harb Perspect Biol, 4(10). 
doi:10.1101/cshperspect.a011213 
Koss, K., Satsangi, J., Welsh, K. I., & Jewell, D. P. (2000). Is interleukin-6 important 
in inflammatory bowel disease? Genes Immun, 1(3), 207-212. 
doi:10.1038/sj.gene.6363658 
Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israel, A., Wallach, D., & 
Courtois, G. (2003). The tumour suppressor CYLD negatively regulates NF-
kappaB signalling by deubiquitination. Nature, 424(6950), 801-805. 
doi:10.1038/nature01802 
Krasnodembskaya, A., Samarani, G., Song, Y., Zhuo, H., Su, X., Lee, J. W., . . . 
Matthay, M. A. (2012). Human mesenchymal stem cells reduce mortality 
and bacteremia in gram-negative sepsis in mice in part by enhancing the 
phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol, 
302(10), L1003-1013. doi:10.1152/ajplung.00180.2011 
Krause, P., Zahner, S. P., Kim, G., Shaikh, R. B., Steinberg, M. W., & Kronenberg, 
M. (2014). The tumor necrosis factor family member TNFSF14 (LIGHT) is 
required for resolution of intestinal inflammation in mice. Gastroenterology, 
146(7), 1752-1762 e1754. doi:10.1053/j.gastro.2014.02.010 
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, 
E. H., . . . Nomenclature Committee on Cell, D. (2009). Classification of cell 
death: recommendations of the Nomenclature Committee on Cell Death 
2009. Cell Death Differ, 16(1), 3-11. doi:10.1038/cdd.2008.150 
Kucuk, C., Sozuer, E., Gursoy, S., Canoz, O., Artis, T., Akcan, A., . . . Muhtaroglu, 
S. (2006). Treatment with Met-RANTES decreases bacterial translocation in 
experimental colitis. Am J Surg, 191(1), 77-83. 
doi:10.1016/j.amjsurg.2005.10.005 
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., . . . 
Cheang, M. (2006). Duration of hypotension before initiation of effective 
antimicrobial therapy is the critical determinant of survival in human septic 
shock. Crit Care Med, 34(6), 1589-1596. 
doi:10.1097/01.CCM.0000217961.75225.E9 
Kuppen, P. J., Jonges, L. E., van de Velde, C. J., Vahrmeijer, A. L., Tollenaar, R. 
A., Borel Rinkes, I. H., & Eggermont, A. M. (1997). Liver and tumour tissue 
concentrations of TNF-alpha in cancer patients treated with TNF-alpha and 
melphalan by isolated liver perfusion. Br J Cancer, 75(10), 1497-1500. 
doi:10.1038/bjc.1997.255 
Lai, N., Min, Q., Xiong, E., Liu, J., Zhang, L., Yasuda, S., & Wang, J. Y. (2019). A 
tetrameric form of CD40 ligand with potent biological activities in both 
mouse and human primary B cells. Mol Immunol, 105, 173-180. 
doi:10.1016/j.molimm.2018.11.018 
Lal-Nag, M., & Morin, P. J. (2009). The claudins. Genome Biol, 10(8), 235. 
doi:10.1186/gb-2009-10-8-235 
Lamkanfi, M. (2011). Emerging inflammasome effector mechanisms. Nat Rev 
Immunol, 11(3), 213-220. doi:10.1038/nri2936 
Lancaster, M. A., & Knoblich, J. A. (2014). Organogenesis in a dish: modeling 
development and disease using organoid technologies. Science, 345(6194), 
1247125. doi:10.1126/science.1247125 
Lane, K., Van Valen, D., DeFelice, M. M., Macklin, D. N., Kudo, T., Jaimovich, A., . . 
. Covert, M. W. (2017). Measuring Signaling and RNA-Seq in the Same Cell 
Links Gene Expression to Dynamic Patterns of NF-kappaB Activation. Cell 
Syst, 4(4), 458-469 e455. doi:10.1016/j.cels.2017.03.010 
279 
 
Lang, I., Fullsack, S., Wyzgol, A., Fick, A., Trebing, J., Arana, J. A., . . . Wajant, H. 
(2016). Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors 
on Intact Cells. J Biol Chem, 291(10), 5022-5037. 
doi:10.1074/jbc.M115.683946 
Lapchak, P. H., Ioannou, A., Kannan, L., Rani, P., Dalle Lucca, J. J., & Tsokos, G. 
C. (2012). Platelet-associated CD40/CD154 mediates remote tissue 
damage after mesenteric ischemia/reperfusion injury. PLoS One, 7(2), 
e32260. doi:10.1371/journal.pone.0032260 
Larmonier, C. B., Laubitz, D., Thurston, R. D., Bucknam, A. L., Hill, F. M., Midura-
Kiela, M., . . . Ghishan, F. K. (2011). NHE3 modulates the severity of colitis 
in IL-10-deficient mice. Am J Physiol Gastrointest Liver Physiol, 300(6), 
G998-G1009. doi:10.1152/ajpgi.00073.2011 
Lassus, P., Opitz-Araya, X., & Lazebnik, Y. (2002). Requirement for caspase-2 in 
stress-induced apoptosis before mitochondrial permeabilization. Science, 
297(5585), 1352-1354. doi:10.1126/science.1074721 
Last, R. J., & McMinn, R. M. H. (1994). Last's anatomy, regional and applied (9th 
ed.). Edinburgh ; New York: Churchill Livingstone. 
Laubitz, D., Harrison, C. A., Midura-Kiela, M. T., Ramalingam, R., Larmonier, C. B., 
Chase, J. H., . . . Kiela, P. R. (2016). Reduced Epithelial Na+/H+ Exchange 
Drives Gut Microbial Dysbiosis and Promotes Inflammatory Response in T 
Cell-Mediated Murine Colitis. PLoS One, 11(4), e0152044. 
doi:10.1371/journal.pone.0152044 
Lee, H. J., & Zheng, J. J. (2010). PDZ domains and their binding partners: 
structure, specificity, and modification. Cell Commun Signal, 8, 8. 
doi:10.1186/1478-811X-8-8 
Lee, J. W., & Juliano, R. L. (2000). alpha5beta1 integrin protects intestinal epithelial 
cells from apoptosis through a phosphatidylinositol 3-kinase and protein 
kinase B-dependent pathway. Mol Biol Cell, 11(6), 1973-1987. 
doi:10.1091/mbc.11.6.1973 
Lee, J. W., Wang, P., Kattah, M. G., Youssef, S., Steinman, L., DeFea, K., & 
Straus, D. S. (2008). Differential regulation of chemokines by IL-17 in 
colonic epithelial cells. J Immunol, 181(9), 6536-6545. 
doi:10.4049/jimmunol.181.9.6536 
Lee, W. H., Seo, D., Lim, S. G., & Suk, K. (2019). Reverse Signaling of Tumor 
Necrosis Factor Superfamily Proteins in Macrophages and Microglia: 
Superfamily Portrait in the Neuroimmune Interface. Front Immunol, 10, 262. 
doi:10.3389/fimmu.2019.00262 
Legras, A., Giraudeau, B., Jonville-Bera, A. P., Camus, C., Francois, B., Runge, I., . 
. . Autret-Leca, E. (2009). A multicentre case-control study of nonsteroidal 
anti-inflammatory drugs as a risk factor for severe sepsis and septic shock. 
Crit Care, 13(2), R43. doi:10.1186/cc7766 
Lennernas, H., Skrtic, S., & Johannsson, G. (2008). Replacement therapy of oral 
hydrocortisone in adrenal insufficiency: the influence of gastrointestinal 
factors. Expert Opin Drug Metab Toxicol, 4(6), 749-758. 
doi:10.1517/17425255.4.6.749 
Leppkes, M., Roulis, M., Neurath, M. F., Kollias, G., & Becker, C. (2014). Pleiotropic 
functions of TNF-alpha in the regulation of the intestinal epithelial response 
to inflammation. Int Immunol, 26(9), 509-515. doi:10.1093/intimm/dxu051 
Lerebours, F., Vacher, S., Andrieu, C., Espie, M., Marty, M., Lidereau, R., & Bieche, 
I. (2008). NF-kappa B genes have a major role in inflammatory breast 
cancer. BMC Cancer, 8, 41. doi:10.1186/1471-2407-8-41 
Lesley, R., Kelly, L. M., Xu, Y., & Cyster, J. G. (2006). Naive CD4 T cells 
constitutively express CD40L and augment autoreactive B cell survival. Proc 
Natl Acad Sci U S A, 103(28), 10717-10722. doi:10.1073/pnas.0601539103 
280 
 
Ley, R. E., Peterson, D. A., & Gordon, J. I. (2006). Ecological and evolutionary 
forces shaping microbial diversity in the human intestine. Cell, 124(4), 837-
848. doi:10.1016/j.cell.2006.02.017 
Li, L. Y., Luo, X., & Wang, X. (2001). Endonuclease G is an apoptotic DNase when 
released from mitochondria. Nature, 412(6842), 95-99. 
doi:10.1038/35083620 
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & 
Wang, X. (1997). Cytochrome c and dATP-dependent formation of Apaf-
1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91(4), 
479-489. doi:10.1016/s0092-8674(00)80434-1 
Li, Q., Zhang, Q., Wang, C., Liu, X., Li, N., & Li, J. (2009). Disruption of tight 
junctions during polymicrobial sepsis in vivo. J Pathol, 218(2), 210-221. 
doi:10.1002/path.2525 
Li, X., Su, J., Cui, X., Li, Y., Barochia, A., & Eichacker, P. Q. (2009). Can we predict 
the effects of NF-kappaB inhibition in sepsis? Studies with parthenolide and 
ethyl pyruvate. Expert Opin Investig Drugs, 18(8), 1047-1060. 
doi:10.1517/13543780903018880 
Liang, S. C., Tan, X. Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., 
Collins, M., & Fouser, L. A. (2006). Interleukin (IL)-22 and IL-17 are 
coexpressed by Th17 cells and cooperatively enhance expression of 
antimicrobial peptides. J Exp Med, 203(10), 2271-2279. 
doi:10.1084/jem.20061308 
Lim, S. G., Suk, K., & Lee, W. H. (2013). Reverse signaling from LIGHT promotes 
pro-inflammatory responses in the human monocytic leukemia cell line, 
THP-1. Cell Immunol, 285(1-2), 10-17. doi:10.1016/j.cellimm.2013.08.002 
Lindon, J. C., Tranter, G. E., & Koppenaal, D. W. (2017). Encyclopedia of 
spectroscopy and spectrometry (Third edition. ed.). Amsterdam ; Boston: 
Elsevier/AP, Academic Press is an imprint of Elsevier. 
Liu, F., Bardhan, K., Yang, D., Thangaraju, M., Ganapathy, V., Waller, J. L., . . . Liu, 
K. (2012). NF-kappaB directly regulates Fas transcription to modulate Fas-
mediated apoptosis and tumor suppression. J Biol Chem, 287(30), 25530-
25540. doi:10.1074/jbc.M112.356279 
Liu, J. Z., van Sommeren, S., Huang, H., Ng, S. C., Alberts, R., Takahashi, A., . . . 
Weersma, R. K. (2015). Association analyses identify 38 susceptibility loci 
for inflammatory bowel disease and highlight shared genetic risk across 
populations. Nat Genet, 47(9), 979-986. doi:10.1038/ng.3359 
Liu, X., Zheng, X., Wang, N., Cao, H., Lu, Y., Long, Y., . . . Zheng, J. (2011). 
Kukoamine B, a novel dual inhibitor of LPS and CpG DNA, is a potential 
candidate for sepsis treatment. Br J Pharmacol, 162(6), 1274-1290. 
doi:10.1111/j.1476-5381.2010.01114.x 
Liu, Y. F., Yang, C. W., Liu, H., Sui, S. G., & Li, X. D. (2017). Efficacy and 
Therapeutic Potential of Curcumin Against Sepsis-Induced Chronic Lung 
Injury in Male Albino Rats. J Nutr Health Aging, 21(3), 307-313. 
doi:10.1007/s12603-016-0722-1 
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001). The TNF and TNF receptor 
superfamilies: integrating mammalian biology. Cell, 104(4), 487-501. 
doi:10.1016/s0092-8674(01)00237-9 
Loddo, I., & Romano, C. (2015). Inflammatory Bowel Disease: Genetics, 
Epigenetics, and Pathogenesis. Front Immunol, 6, 551. 
doi:10.3389/fimmu.2015.00551 
Lodish, H. F. (2008). Molecular cell biology (6th ed.). New York: W.H. Freeman. 
Logan, C. Y., & Nusse, R. (2004). The Wnt signaling pathway in development and 




Loh, K., Chia, J. A., Greco, S., Cozzi, S. J., Buttenshaw, R. L., Bond, C. E., . . . 
Whitehall, V. L. (2008). Bone morphogenic protein 3 inactivation is an early 
and frequent event in colorectal cancer development. Genes Chromosomes 
Cancer, 47(6), 449-460. doi:10.1002/gcc.20552 
Lorenz, J. N., Nieman, M., Sabo, J., Sanford, L. P., Hawkins, J. A., Elitsur, N., . . . 
Cohen, M. B. (2003). Uroguanylin knockout mice have increased blood 
pressure and impaired natriuretic response to enteral NaCl load. J Clin 
Invest, 112(8), 1244-1254. doi:10.1172/JCI18743 
Lu, J., Yang, Y., Guo, G., Liu, Y., Zhang, Z., Dong, S., . . . Huang, Q. (2017). IKBKE 
regulates cell proliferation and epithelial-mesenchymal transition of human 
malignant glioma via the Hippo pathway. Oncotarget, 8(30), 49502-49514. 
doi:10.18632/oncotarget.17738 
Ludwiczek, O., Kaser, A., & Tilg, H. (2003). Plasma levels of soluble CD40 ligand 
are elevated in inflammatory bowel diseases. Int J Colorectal Dis, 18(2), 
142-147. doi:10.1007/s00384-002-0425-4 
Luftig, M., Yasui, T., Soni, V., Kang, M. S., Jacobson, N., Cahir-McFarland, E., . . . 
Kieff, E. (2004). Epstein-Barr virus latent infection membrane protein 1 
TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-
kappaB activation. Proc Natl Acad Sci U S A, 101(1), 141-146. 
doi:10.1073/pnas.2237183100 
Lundell, A. C., Nordstrom, I., Andersson, K., Lundqvist, C., Telemo, E., Nava, S., . . 
. Rudin, A. (2017). IFN type I and II induce BAFF secretion from human 
decidual stromal cells. Sci Rep, 7, 39904. doi:10.1038/srep39904 
Luu, L., Matthews, Z. J., Armstrong, S. D., Powell, P. P., Wileman, T., Wastling, J. 
M., & Coombes, J. L. (2018). Proteomic Profiling of Enteroid Cultures 
Skewed toward Development of Specific Epithelial Lineages. Proteomics, 
18(16), e1800132. doi:10.1002/pmic.201800132 
Lv, S., Han, M., Yi, R., Kwon, S., Dai, C., & Wang, R. (2014). Anti-TNF-alpha 
therapy for patients with sepsis: a systematic meta-analysis. Int J Clin Pract, 
68(4), 520-528. doi:10.1111/ijcp.12382 
Lyss, G., Knorre, A., Schmidt, T. J., Pahl, H. L., & Merfort, I. (1998). The anti-
inflammatory sesquiterpene lactone helenalin inhibits the transcription factor 
NF-kappaB by directly targeting p65. J Biol Chem, 273(50), 33508-33516. 
doi:10.1074/jbc.273.50.33508 
Ma, T. Y., Boivin, M. A., Ye, D., Pedram, A., & Said, H. M. (2005). Mechanism of 
TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: 
role of myosin light-chain kinase protein expression. Am J Physiol 
Gastrointest Liver Physiol, 288(3), G422-430. doi:10.1152/ajpgi.00412.2004 
MacEwan, D. J. (2015). TWEAKing for a fight with GVHD. Blood, 126(4), 429-430. 
doi:10.1182/blood-2015-06-649517 
Mach, F., Schonbeck, U., Sukhova, G. K., Bourcier, T., Bonnefoy, J. Y., Pober, J. 
S., & Libby, P. (1997). Functional CD40 ligand is expressed on human 
vascular endothelial cells, smooth muscle cells, and macrophages: 
implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl 
Acad Sci U S A, 94(5), 1931-1936. doi:10.1073/pnas.94.5.1931 
Mackay, F., Browning, J. L., Lawton, P., Shah, S. A., Comiskey, M., Bhan, A. K., . . 
. Simpson, S. J. (1998). Both the lymphotoxin and tumor necrosis factor 
pathways are involved in experimental murine models of colitis. 
Gastroenterology, 115(6), 1464-1475. doi:10.1016/s0016-5085(98)70025-3 
Mackay, F., & Leung, H. (2006). The role of the BAFF/APRIL system on T cell 
function. Semin Immunol, 18(5), 284-289. doi:10.1016/j.smim.2006.04.005 
Macpherson, A. J., & McCoy, K. (2007). APRIL in the intestine: a good destination 




Madara, J. L. (1990). Maintenance of the macromolecular barrier at cell extrusion 
sites in intestinal epithelium: physiological rearrangement of tight junctions. 
J Membr Biol, 116(2), 177-184. doi:10.1007/BF01868675 
Madison, B. B., Braunstein, K., Kuizon, E., Portman, K., Qiao, X. T., & Gumucio, D. 
L. (2005). Epithelial hedgehog signals pattern the intestinal crypt-villus axis. 
Development, 132(2), 279-289. doi:10.1242/dev.01576 
Malmstrom, E., Kilsgard, O., Hauri, S., Smeds, E., Herwald, H., Malmstrom, L., & 
Malmstrom, J. (2016). Large-scale inference of protein tissue origin in gram-
positive sepsis plasma using quantitative targeted proteomics. Nat 
Commun, 7, 10261. doi:10.1038/ncomms10261 
Mana, P., Linares, D., Silva, D. G., Fordham, S., Scheu, S., Pfeffer, K., . . . Bertram, 
E. M. (2013). LIGHT (TNFSF14/CD258) is a decisive factor for recovery 
from experimental autoimmune encephalomyelitis. J Immunol, 191(1), 154-
163. doi:10.4049/jimmunol.1203016 
Mankertz, J., & Schulzke, J. D. (2007). Altered permeability in inflammatory bowel 
disease: pathophysiology and clinical implications. Curr Opin Gastroenterol, 
23(4), 379-383. doi:10.1097/MOG.0b013e32816aa392 
Marcelino, J., Sciortino, C. M., Romero, M. F., Ulatowski, L. M., Ballock, R. T., 
Economides, A. N., . . . Warman, M. L. (2001). Human disease-causing 
NOG missense mutations: effects on noggin secretion, dimer formation, and 
bone morphogenetic protein binding. Proc Natl Acad Sci U S A, 98(20), 
11353-11358. doi:10.1073/pnas.201367598 
Marchiando, A. M., Shen, L., Graham, W. V., Edelblum, K. L., Duckworth, C. A., 
Guan, Y., . . . Watson, A. J. (2011). The epithelial barrier is maintained by in 
vivo tight junction expansion during pathologic intestinal epithelial shedding. 
Gastroenterology, 140(4), 1208-1218 e1201-1202. 
doi:10.1053/j.gastro.2011.01.004 
Marik, P. E., Khangoora, V., Rivera, R., Hooper, M. H., & Catravas, J. (2017). 
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe 
Sepsis and Septic Shock: A Retrospective Before-After Study. Chest, 
151(6), 1229-1238. doi:10.1016/j.chest.2016.11.036 
Marik, P. E., & Taeb, A. M. (2017). SIRS, qSOFA and new sepsis definition. J 
Thorac Dis, 9(4), 943-945. doi:10.21037/jtd.2017.03.125 
Martin, L., Koczera, P., Simons, N., Zechendorf, E., Hoeger, J., Marx, G., & 
Schuerholz, T. (2016). The Human Host Defense Ribonucleases 1, 3 and 7 
Are Elevated in Patients with Sepsis after Major Surgery--A Pilot Study. Int J 
Mol Sci, 17(3), 294. doi:10.3390/ijms17030294 
Martins, T. B., Rose, J. W., Jaskowski, T. D., Wilson, A. R., Husebye, D., Seraj, H. 
S., & Hill, H. R. (2011). Analysis of proinflammatory and anti-inflammatory 
cytokine serum concentrations in patients with multiple sclerosis by using a 
multiplexed immunoassay. Am J Clin Pathol, 136(5), 696-704. 
doi:10.1309/AJCP7UBK8IBVMVNR 
Matsuda, M., Kubo, A., Furuse, M., & Tsukita, S. (2004). A peculiar internalization 
of claudins, tight junction-specific adhesion molecules, during the 
intercellular movement of epithelial cells. J Cell Sci, 117(Pt 7), 1247-1257. 
doi:10.1242/jcs.00972 
Matsumoto, H., Ogura, H., Shimizu, K., Ikeda, M., Hirose, T., Matsuura, H., . . . 
Shimazu, T. (2018). The clinical importance of a cytokine network in the 
acute phase of sepsis. Sci Rep, 8(1), 13995. doi:10.1038/s41598-018-
32275-8 
Mauri, D. N., Ebner, R., Montgomery, R. I., Kochel, K. D., Cheung, T. C., Yu, G. L., 
. . . Ware, C. F. (1998). LIGHT, a new member of the TNF superfamily, and 
lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity, 
8(1), 21-30. doi:10.1016/s1074-7613(00)80455-0 
283 
 
Mauro, C., Pacifico, F., Lavorgna, A., Mellone, S., Iannetti, A., Acquaviva, R., . . . 
Leonardi, A. (2006). ABIN-1 binds to NEMO/IKKgamma and co-operates 
with A20 in inhibiting NF-kappaB. J Biol Chem, 281(27), 18482-18488. 
doi:10.1074/jbc.M601502200 
Mayhew, T. M., Myklebust, R., Whybrow, A., & Jenkins, R. (1999). Epithelial 
integrity, cell death and cell loss in mammalian small intestine. Histol 
Histopathol, 14(1), 257-267. doi:10.14670/HH-14.257 
Mayr, F. B., Yende, S., & Angus, D. C. (2014). Epidemiology of severe sepsis. 
Virulence, 5(1), 4-11. doi:10.4161/viru.27372 
Mazor, R. L., Menendez, I. Y., Ryan, M. A., Fiedler, M. A., & Wong, H. R. (2000). 
Sesquiterpene lactones are potent inhibitors of interleukin 8 gene 
expression in cultured human respiratory epithelium. Cytokine, 12(3), 239-
245. doi:10.1006/cyto.1999.0526 
McGovern, D. P., Kugathasan, S., & Cho, J. H. (2015). Genetics of Inflammatory 
Bowel Diseases. Gastroenterology, 149(5), 1163-1176 e1162. 
doi:10.1053/j.gastro.2015.08.001 
McIlwraith, C. W., Frisbie, D. D., Kawcak, C. E., & Weeren, R. v. (2016). Joint 
disease in the horse (Second edition. ed.). St. Louis, Missouri: Elsevier. 
McKinley, E. T., Sui, Y., Al-Kofahi, Y., Millis, B. A., Tyska, M. J., Roland, J. T., . . . 
Coffey, R. J. (2017). Optimized multiplex immunofluorescence single-cell 
analysis reveals tuft cell heterogeneity. JCI Insight, 2(11). 
doi:10.1172/jci.insight.93487 
McKinley, M. P., & O'Loughlin, V. D. (2008). Human anatomy (2nd ed.). Boston: 
McGraw-Hill Higher Education. 
Medvedev, A. E., Espevik, T., Ranges, G., & Sundan, A. (1996). Distinct roles of 
the two tumor necrosis factor (TNF) receptors in modulating TNF and 
lymphotoxin alpha effects. J Biol Chem, 271(16), 9778-9784. 
doi:10.1074/jbc.271.16.9778 
Meighan-Mantha, R. L., Hsu, D. K., Guo, Y., Brown, S. A., Feng, S. L., Peifley, K. 
A., . . . Winkles, J. A. (1999). The mitogen-inducible Fn14 gene encodes a 
type I transmembrane protein that modulates fibroblast adhesion and 
migration. J Biol Chem, 274(46), 33166-33176. 
doi:10.1074/jbc.274.46.33166 
Merga, Y. J., O'Hara, A., Burkitt, M. D., Duckworth, C. A., Probert, C. S., Campbell, 
B. J., & Pritchard, D. M. (2016). Importance of the alternative NF-kappaB 
activation pathway in inflammation-associated gastrointestinal 
carcinogenesis. Am J Physiol Gastrointest Liver Physiol, 310(11), G1081-
1090. doi:10.1152/ajpgi.00026.2016 
Michel, N. A., Zirlik, A., & Wolf, D. (2017). CD40L and Its Receptors in 
Atherothrombosis-An Update. Front Cardiovasc Med, 4, 40. 
doi:10.3389/fcvm.2017.00040 
Michie, H. R., Manogue, K. R., Spriggs, D. R., Revhaug, A., O'Dwyer, S., Dinarello, 
C. A., . . . Wilmore, D. W. (1988). Detection of circulating tumor necrosis 
factor after endotoxin administration. N Engl J Med, 318(23), 1481-1486. 
doi:10.1056/NEJM198806093182301 
Michielan, A., & D'Inca, R. (2015). Intestinal Permeability in Inflammatory Bowel 
Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. 
Mediators Inflamm, 2015, 628157. doi:10.1155/2015/628157 
Middendorp, S., Schneeberger, K., Wiegerinck, C. L., Mokry, M., Akkerman, R. D., 
van Wijngaarden, S., . . . Nieuwenhuis, E. E. (2014). Adult stem cells in the 
small intestine are intrinsically programmed with their location-specific 
function. Stem Cells, 32(5), 1083-1091. doi:10.1002/stem.1655 
Mikuda, N., Schmidt-Ullrich, R., Kargel, E., Golusda, L., Wolf, J., Hopken, U. E., . . . 
Kolesnichenko, M. (2020). Deficiency in IkappaBalpha in the intestinal 
284 
 
epithelium leads to spontaneous inflammation and mediates apoptosis in 
the gut. J Pathol, 251(2), 160-174. doi:10.1002/path.5437 
Miller, H., Zhang, J., Kuolee, R., Patel, G. B., & Chen, W. (2007). Intestinal M cells: 
the fallible sentinels? World J Gastroenterol, 13(10), 1477-1486. 
doi:10.3748/wjg.v13.i10.1477 
Miller, S. C., Huang, R., Sakamuru, S., Shukla, S. J., Attene-Ramos, M. S., Shinn, 
P., . . . Xia, M. (2010). Identification of known drugs that act as inhibitors of 
NF-kappaB signaling and their mechanism of action. Biochem Pharmacol, 
79(9), 1272-1280. doi:10.1016/j.bcp.2009.12.021 
Mineta, K., Yamamoto, Y., Yamazaki, Y., Tanaka, H., Tada, Y., Saito, K., . . . 
Tsukita, S. (2011). Predicted expansion of the claudin multigene family. 
FEBS Lett, 585(4), 606-612. doi:10.1016/j.febslet.2011.01.028 
Mizoguchi, E., Mizoguchi, A., Takedatsu, H., Cario, E., de Jong, Y. P., Ooi, C. J., . . 
. Bhan, A. K. (2002). Role of tumor necrosis factor receptor 2 (TNFR2) in 
colonic epithelial hyperplasia and chronic intestinal inflammation in mice. 
Gastroenterology, 122(1), 134-144. doi:10.1053/gast.2002.30347 
Mizushima, N. (2007). Autophagy: process and function. Genes Dev, 21(22), 2861-
2873. doi:10.1101/gad.1599207 
M'Koma, A. E., Seeley, E. H., Washington, M. K., Schwartz, D. A., Muldoon, R. L., 
Herline, A. J., . . . Caprioli, R. M. (2011). Proteomic profiling of mucosal and 
submucosal colonic tissues yields protein signatures that differentiate the 
inflammatory colitides. Inflamm Bowel Dis, 17(4), 875-883. 
doi:10.1002/ibd.21442 
Moore, F., Buonocore, S., Aksoy, E., Ouled-Haddou, N., Goriely, S., Lazarova, E., . 
. . Flamand, V. (2007). An alternative pathway of NF-kappaB activation 
results in maturation and T cell priming activity of dendritic cells 
overexpressing a mutated IkappaBalpha. J Immunol, 178(3), 1301-1311. 
doi:10.4049/jimmunol.178.3.1301 
Moss, M. L., Jin, S. L., Milla, M. E., Bickett, D. M., Burkhart, W., Carter, H. L., . . . et 
al. (1997). Cloning of a disintegrin metalloproteinase that processes 
precursor tumour-necrosis factor-alpha. Nature, 385(6618), 733-736. 
doi:10.1038/385733a0 
Moulton, D. E., Crandall, W., Lakhani, R., & Lowe, M. E. (2004). Expression of a 
novel cadherin in the mouse and human intestine. Pediatr Res, 55(6), 927-
934. doi:10.1203/01.PDR.0000125260.46861.32 
Mowat, A. M., & Agace, W. W. (2014). Regional specialization within the intestinal 
immune system. Nat Rev Immunol, 14(10), 667-685. doi:10.1038/nri3738 
Mudter, J., & Neurath, M. F. (2007). Il-6 signaling in inflammatory bowel disease: 
pathophysiological role and clinical relevance. Inflamm Bowel Dis, 13(8), 
1016-1023. doi:10.1002/ibd.20148 
Murch, S. H., Braegger, C. P., Walker-Smith, J. A., & MacDonald, T. T. (1993). 
Location of tumour necrosis factor alpha by immunohistochemistry in 
chronic inflammatory bowel disease. Gut, 34(12), 1705-1709. 
doi:10.1136/gut.34.12.1705 
Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., 
. . . Dixit, V. M. (1996). FLICE, a novel FADD-homologous ICE/CED-3-like 
protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling 
complex. Cell, 85(6), 817-827. doi:10.1016/s0092-8674(00)81266-0 
Nagata, S. (2000). Apoptotic DNA fragmentation. Exp Cell Res, 256(1), 12-18. 
doi:10.1006/excr.2000.4834 
Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner, B. A., & Yuan, J. 
(2000). Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and 
cytotoxicity by amyloid-beta. Nature, 403(6765), 98-103. doi:10.1038/47513 
Nasdala, I., Wolburg-Buchholz, K., Wolburg, H., Kuhn, A., Ebnet, K., Brachtendorf, 
G., . . . Butz, S. (2002). A transmembrane tight junction protein selectively 
285 
 
expressed on endothelial cells and platelets. J Biol Chem, 277(18), 16294-
16303. doi:10.1074/jbc.M111999200 
Navale, A. M., & Paranjape, A. N. (2016). Glucose transporters: physiological and 
pathological roles. Biophys Rev, 8(1), 5-9. doi:10.1007/s12551-015-0186-2 
Nedwin, G. E., Naylor, S. L., Sakaguchi, A. Y., Smith, D., Jarrett-Nedwin, J., 
Pennica, D., . . . Gray, P. W. (1985). Human lymphotoxin and tumor 
necrosis factor genes: structure, homology and chromosomal localization. 
Nucleic Acids Res, 13(17), 6361-6373. doi:10.1093/nar/13.17.6361 
Nelson, K. M., Dahlin, J. L., Bisson, J., Graham, J., Pauli, G. F., & Walters, M. A. 
(2017). The Essential Medicinal Chemistry of Curcumin. J Med Chem, 
60(5), 1620-1637. doi:10.1021/acs.jmedchem.6b00975 
Nenci, A., Becker, C., Wullaert, A., Gareus, R., van Loo, G., Danese, S., . . . 
Pasparakis, M. (2007). Epithelial NEMO links innate immunity to chronic 
intestinal inflammation. Nature, 446(7135), 557-561. 
doi:10.1038/nature05698 
Neufert, C., Becker, C., Tureci, O., Waldner, M. J., Backert, I., Floh, K., . . . 
Neurath, M. F. (2013). Tumor fibroblast-derived epiregulin promotes growth 
of colitis-associated neoplasms through ERK. J Clin Invest, 123(4), 1428-
1443. doi:10.1172/JCI63748 
Neugut, A. I., Jacobson, J. S., Suh, S., Mukherjee, R., & Arber, N. (1998). The 
epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarkers 
Prev, 7(3), 243-251.  
Neurath, M. F., Pettersson, S., Meyer zum Buschenfelde, K. H., & Strober, W. 
(1996). Local administration of antisense phosphorothioate oligonucleotides 
to the p65 subunit of NF-kappa B abrogates established experimental colitis 
in mice. Nat Med, 2(9), 998-1004. doi:10.1038/nm0996-998 
Neutra, M. R., Mantis, N. J., & Kraehenbuhl, J. P. (2001). Collaboration of epithelial 
cells with organized mucosal lymphoid tissues. Nat Immunol, 2(11), 1004-
1009. doi:10.1038/ni1101-1004 
Newton, K., & Dixit, V. M. (2012). Signaling in innate immunity and inflammation. 
Cold Spring Harb Perspect Biol, 4(3). doi:10.1101/cshperspect.a006049 
Ng, L. G., Mackay, C. R., & Mackay, F. (2005). The BAFF/APRIL system: life 
beyond B lymphocytes. Mol Immunol, 42(7), 763-772. 
doi:10.1016/j.molimm.2004.06.041 
Ngo, V. N., Korner, H., Gunn, M. D., Schmidt, K. N., Riminton, D. S., Cooper, M. D., 
. . . Cyster, J. G. (1999). Lymphotoxin alpha/beta and tumor necrosis factor 
are required for stromal cell expression of homing chemokines in B and T 
cell areas of the spleen. J Exp Med, 189(2), 403-412. 
doi:10.1084/jem.189.2.403 
Nicholls, S., Stephens, S., Braegger, C. P., Walker-Smith, J. A., & MacDonald, T. T. 
(1993). Cytokines in stools of children with inflammatory bowel disease or 
infective diarrhoea. J Clin Pathol, 46(8), 757-760. doi:10.1136/jcp.46.8.757 
Nicholls, S., Stephens, S., Braegger, C. P., Walker-Smith, J. A., & MacDonald, T. T. 
(1993). Cytokines in stools of children with inflammatory bowel disease or 
infective diarrhoea. J Clin Pathol, 46(8), 757-760. doi:10.1136/jcp.46.8.757 
Niisato, N., & Marunaka, Y. (2001). Forskolin activation of apical Cl- channel and 
Na+/K+/2Cl- cotransporter via a PTK-dependent pathway in renal 
epithelium. Biochem Biophys Res Commun, 285(4), 880-884. 
doi:10.1006/bbrc.2001.5251 
Nijman, S. M., Luna-Vargas, M. P., Velds, A., Brummelkamp, T. R., Dirac, A. M., 
Sixma, T. K., & Bernards, R. (2005). A genomic and functional inventory of 
deubiquitinating enzymes. Cell, 123(5), 773-786. 
doi:10.1016/j.cell.2005.11.007 
Nomme, J., Fanning, A. S., Caffrey, M., Lye, M. F., Anderson, J. M., & Lavie, A. 
(2011). The Src homology 3 domain is required for junctional adhesion 
286 
 
molecule binding to the third PDZ domain of the scaffolding protein ZO-1. J 
Biol Chem, 286(50), 43352-43360. doi:10.1074/jbc.M111.304089 
Notarangelo, L. D., Duse, M., & Ugazio, A. G. (1992). Immunodeficiency with hyper-
IgM (HIM). Immunodefic Rev, 3(2), 101-121.  
Ogata, A., & Tanaka, T. (2012). Tocilizumab for the treatment of rheumatoid 
arthritis and other systemic autoimmune diseases: current perspectives and 
future directions. Int J Rheumatol, 2012, 946048. doi:10.1155/2012/946048 
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., . . . 
Cho, J. H. (2001). A frameshift mutation in NOD2 associated with 
susceptibility to Crohn's disease. Nature, 411(6837), 603-606. 
doi:10.1038/35079114 
O'Hara, A. M., & Shanahan, F. (2006). The gut flora as a forgotten organ. EMBO 
Rep, 7(7), 688-693. doi:10.1038/sj.embor.7400731 
Okumura, R., & Takeda, K. (2017). Roles of intestinal epithelial cells in the 
maintenance of gut homeostasis. Exp Mol Med, 49(5), e338. 
doi:10.1038/emm.2017.20 
Opal, S. M., Laterre, P. F., Francois, B., LaRosa, S. P., Angus, D. C., Mira, J. P., . . 
. Group, A. S. (2013). Effect of eritoran, an antagonist of MD2-TLR4, on 
mortality in patients with severe sepsis: the ACCESS randomized trial. 
JAMA, 309(11), 1154-1162. doi:10.1001/jama.2013.2194 
Ostermann, G., Weber, K. S., Zernecke, A., Schroder, A., & Weber, C. (2002). 
JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial 
migration of leukocytes. Nat Immunol, 3(2), 151-158. doi:10.1038/ni755 
Otterdal, K., Haukeland, J. W., Yndestad, A., Dahl, T. B., Holm, S., Segers, F. M., . 
. . Aukrust, P. (2015). Increased Serum Levels of LIGHT/TNFSF14 in 
Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation. 
Clin Transl Gastroenterol, 6, e95. doi:10.1038/ctg.2015.23 
Owen, R. L., & Jones, A. L. (1974). Epithelial cell specialization within human 
Peyer's patches: an ultrastructural study of intestinal lymphoid follicles. 
Gastroenterology, 66(2), 189-203.  
Ozoren, N., Inohara, N., & Nunez, G. (2009). A putative role for human BFK in DNA 
damage-induced apoptosis. Biotechnol J, 4(7), 1046-1054. 
doi:10.1002/biot.200900091 
Pahl, H. L. (1999). Activators and target genes of Rel/NF-kappaB transcription 
factors. Oncogene, 18(49), 6853-6866. doi:10.1038/sj.onc.1203239 
Palomero, T., Lim, W. K., Odom, D. T., Sulis, M. L., Real, P. J., Margolin, A., . . . 
Ferrando, A. A. (2006). NOTCH1 directly regulates c-MYC and activates a 
feed-forward-loop transcriptional network promoting leukemic cell growth. 
Proc Natl Acad Sci U S A, 103(48), 18261-18266. 
doi:10.1073/pnas.0606108103 
Papich, M. G. (2016). Saunders handbook of veterinary drugs : small and large 
animal (Fourth edition. ed.). St. Louis, Missouri: Elsevier. 
Park, E., Kim, G. H., Choi, S. C., & Han, J. K. (2006). Role of PKA as a negative 
regulator of PCP signaling pathway during Xenopus gastrulation 
movements. Dev Biol, 292(2), 344-357. doi:10.1016/j.ydbio.2006.01.011 
Park, J. S., Kwok, S. K., Lim, M. A., Oh, H. J., Kim, E. K., Jhun, J. Y., . . . Cho, M. L. 
(2013). TWEAK promotes osteoclastogenesis in rheumatoid arthritis. Am J 
Pathol, 183(3), 857-867. doi:10.1016/j.ajpath.2013.05.027 
Parween, S., DiNardo, G., Baj, F., Zhang, C., Gilardi, G., & Pandey, A. V. (2020). 
Differential effects of variations in human P450 oxidoreductase on the 
aromatase activity of CYP19A1 polymorphisms R264C and R264H. J 
Steroid Biochem Mol Biol, 196, 105507. doi:10.1016/j.jsbmb.2019.105507 
Pattison, A. M., Barton, J. R., Entezari, A. A., Zalewski, A., Rappaport, J. A., Snook, 
A. E., & Waldman, S. A. (2020). Silencing the intestinal GUCY2C tumor 
287 
 
suppressor axis requires APC loss of heterozygosity. Cancer Biol Ther, 
21(9), 799-805. doi:10.1080/15384047.2020.1779005 
Pearce, S. C., Al-Jawadi, A., Kishida, K., Yu, S., Hu, M., Fritzky, L. F., . . . Ferraris, 
R. P. (2018). Marked differences in tight junction composition and 
macromolecular permeability among different intestinal cell types. BMC Biol, 
16(1), 19. doi:10.1186/s12915-018-0481-z 
Pekalski, J., Zuk, P. J., Kochanczyk, M., Junkin, M., Kellogg, R., Tay, S., & 
Lipniacki, T. (2013). Spontaneous NF-kappaB activation by autocrine 
TNFalpha signaling: a computational analysis. PLoS One, 8(11), e78887. 
doi:10.1371/journal.pone.0078887 
Pelekanou, V., Kampa, M., Kafousi, M., Darivianaki, K., Sanidas, E., Tsiftsis, D. D., 
. . . Castanas, E. (2008). Expression of TNF-superfamily members BAFF 
and APRIL in breast cancer: immunohistochemical study in 52 invasive 
ductal breast carcinomas. BMC Cancer, 8, 76. doi:10.1186/1471-2407-8-76 
Pennica, D., Nedwin, G. E., Hayflick, J. S., Seeburg, P. H., Derynck, R., Palladino, 
M. A., . . . Goeddel, D. V. (1984). Human tumour necrosis factor: precursor 
structure, expression and homology to lymphotoxin. Nature, 312(5996), 724-
729. doi:10.1038/312724a0 
Perkins, N. D. (2007). Integrating cell-signalling pathways with NF-kappaB and IKK 
function. Nat Rev Mol Cell Biol, 8(1), 49-62. doi:10.1038/nrm2083 
Perrot-Applanat, M., Vacher, S., Toullec, A., Pelaez, I., Velasco, G., Cormier, F., . . 
. Bieche, I. (2011). Similar NF-kappaB gene signatures in TNF-alpha treated 
human endothelial cells and breast tumor biopsies. PLoS One, 6(7), 
e21589. doi:10.1371/journal.pone.0021589 
Peterson, E. J., Clements, J. L., Fang, N., & Koretzky, G. A. (1998). Adaptor 
proteins in lymphocyte antigen-receptor signaling. Curr Opin Immunol, 
10(3), 337-344. doi:10.1016/s0952-7915(98)80173-8 
Pickert, G., Neufert, C., Leppkes, M., Zheng, Y., Wittkopf, N., Warntjen, M., . . . 
Becker, C. (2009). STAT3 links IL-22 signaling in intestinal epithelial cells to 
mucosal wound healing. J Exp Med, 206(7), 1465-1472. 
doi:10.1084/jem.20082683 
Piguet, P. F., Vesin, C., Guo, J., Donati, Y., & Barazzone, C. (1998). TNF-induced 
enterocyte apoptosis in mice is mediated by the TNF receptor 1 and does 
not require p53. Eur J Immunol, 28(11), 3499-3505. doi:10.1002/(SICI)1521-
4141(199811)28:11<3499::AID-IMMU3499>3.0.CO;2-Q 
Pinto, D., Gregorieff, A., Begthel, H., & Clevers, H. (2003). Canonical Wnt signals 
are essential for homeostasis of the intestinal epithelium. Genes Dev, 
17(14), 1709-1713. doi:10.1101/gad.267103 
Piton, G., Manzon, C., Cypriani, B., Carbonnel, F., & Capellier, G. (2011). Acute 
intestinal failure in critically ill patients: is plasma citrulline the right marker? 
Intensive Care Med, 37(6), 911-917. doi:10.1007/s00134-011-2172-x 
Plevy, S. E., Landers, C. J., Prehn, J., Carramanzana, N. M., Deem, R. L., Shealy, 
D., & Targan, S. R. (1997). A role for TNF-alpha and mucosal T helper-1 
cytokines in the pathogenesis of Crohn's disease. J Immunol, 159(12), 
6276-6282.  
Plubell, D. L., Wilmarth, P. A., Zhao, Y., Fenton, A. M., Minnier, J., Reddy, A. P., . . . 
Pamir, N. (2017). Extended Multiplexing of Tandem Mass Tags (TMT) 
Labeling Reveals Age and High Fat Diet Specific Proteome Changes in 
Mouse Epididymal Adipose Tissue. Mol Cell Proteomics, 16(5), 873-890. 
doi:10.1074/mcp.M116.065524 
Portillo, J. A., Feliciano, L. M., Okenka, G., Heinzel, F., Subauste, M. C., & 
Subauste, C. S. (2012). CD40 and tumour necrosis factor-alpha co-operate 
to up-regulate inducuble nitric oxide synthase expression in macrophages. 
Immunology, 135(2), 140-150. doi:10.1111/j.1365-2567.2011.03519.x 
288 
 
Potten, C. S. (1977). Extreme sensitivity of some intestinal crypt cells to X and 
gamma irradiation. Nature, 269(5628), 518-521. doi:10.1038/269518a0 
Potten, C. S. (1990). A comprehensive study of the radiobiological response of the 
murine (BDF1) small intestine. Int J Radiat Biol, 58(6), 925-973. 
doi:10.1080/09553009014552281 
Potten, C. S., Gandara, R., Mahida, Y. R., Loeffler, M., & Wright, N. A. (2009). The 
stem cells of small intestinal crypts: where are they? Cell Prolif, 42(6), 731-
750. doi:10.1111/j.1365-2184.2009.00642.x 
Potten, C. S., & Grant, H. K. (1998). The relationship between ionizing radiation-
induced apoptosis and stem cells in the small and large intestine. Br J 
Cancer, 78(8), 993-1003. doi:10.1038/bjc.1998.618 
Potten, C. S., & Loeffler, M. (1990). Stem cells: attributes, cycles, spirals, pitfalls 
and uncertainties. Lessons for and from the crypt. Development, 110(4), 
1001-1020.  
Potten, C. S., Wilson, J. W., & Booth, C. (1997). Regulation and significance of 
apoptosis in the stem cells of the gastrointestinal epithelium. Stem Cells, 
15(2), 82-93. doi:10.1002/stem.150082 
Pourdast, A., Sanaei, M., Jafari, S., Mohammadi, M., Khalili, H., Shafiee, G., . . . 
Mohraz, M. (2017). Effect of Septimeb(TM) as a new natural extract on 
severe sepsis: A randomized clinical trial. Caspian J Intern Med, 8(1), 35-43.  
Pritchard, D. M., Watson, A. J., Potten, C. S., Jackman, A. L., & Hickman, J. A. 
(1997). Inhibition by uridine but not thymidine of p53-dependent intestinal 
apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA 
perturbation. Proc Natl Acad Sci U S A, 94(5), 1795-1799. 
doi:10.1073/pnas.94.5.1795 
Punchard, N. A., Greenfield, S. M., & Thompson, R. P. (1992). Mechanism of action 
of 5-arninosalicylic acid. Mediators Inflamm, 1(3), 151-165. 
doi:10.1155/S0962935192000243 
Qi, Z., & Chen, Y. G. (2015). Regulation of intestinal stem cell fate specification. Sci 
China Life Sci, 58(6), 570-578. doi:10.1007/s11427-015-4859-7 
Qin, C., Qiu, K., Sun, W., Jiao, N., Zhang, X., Che, L., . . . Yin, J. (2016). A 
proteomic adaptation of small intestinal mucosa in response to dietary 
protein limitation. Sci Rep, 6, 36888. doi:10.1038/srep36888 
Qiu, Z., He, Y., Ming, H., Lei, S., Leng, Y., & Xia, Z. Y. (2019). Lipopolysaccharide 
(LPS) Aggravates High Glucose- and Hypoxia/Reoxygenation-Induced 
Injury through Activating ROS-Dependent NLRP3 Inflammasome-Mediated 
Pyroptosis in H9C2 Cardiomyocytes. J Diabetes Res, 2019, 8151836. 
doi:10.1155/2019/8151836 
Qu, Y., Zhao, G., & Li, H. (2017). Forward and Reverse Signaling Mediated by 
Transmembrane Tumor Necrosis Factor-Alpha and TNF Receptor 2: 
Potential Roles in an Immunosuppressive Tumor Microenvironment. Front 
Immunol, 8, 1675. doi:10.3389/fimmu.2017.01675 
Quaglio, A. E., Castilho, A. C., & Di Stasi, L. C. (2015). Experimental evidence of 
heparanase, Hsp70 and NF-kappaB gene expression on the response of 
anti-inflammatory drugs in TNBS-induced colonic inflammation. Life Sci, 
141, 179-187. doi:10.1016/j.lfs.2015.09.023 
Raffray, M., & Cohen, G. M. (1997). Apoptosis and necrosis in toxicology: a 
continuum or distinct modes of cell death? Pharmacol Ther, 75(3), 153-177. 
doi:10.1016/s0163-7258(97)00037-5 
Rakoff-Nahoum, S., Hao, L., & Medzhitov, R. (2006). Role of toll-like receptors in 
spontaneous commensal-dependent colitis. Immunity, 25(2), 319-329. 
doi:10.1016/j.immuni.2006.06.010 
Ranganathan, P., Weaver, K. L., & Capobianco, A. J. (2011). Notch signalling in 
solid tumours: a little bit of everything but not all the time. Nat Rev Cancer, 
11(5), 338-351. doi:10.1038/nrc3035 
289 
 
Rao, P., & Kadesch, T. (2003). The intracellular form of notch blocks transforming 
growth factor beta-mediated growth arrest in Mv1Lu epithelial cells. Mol Cell 
Biol, 23(18), 6694-6701. doi:10.1128/mcb.23.18.6694-6701.2003 
Raymond, S. L., Holden, D. C., Mira, J. C., Stortz, J. A., Loftus, T. J., Mohr, A. M., . 
. . Efron, P. A. (2017). Microbial recognition and danger signals in sepsis 
and trauma. Biochim Biophys Acta Mol Basis Dis, 1863(10 Pt B), 2564-
2573. doi:10.1016/j.bbadis.2017.01.013 
Reed, J. C. (1999). Dysregulation of apoptosis in cancer. J Clin Oncol, 17(9), 2941-
2953. doi:10.1200/JCO.1999.17.9.2941 
Rees, W. D., Stahl, M., Jacobson, K., Bressler, B., Sly, L. M., Vallance, B. A., & 
Steiner, T. S. (2020). Enteroids Derived From Inflammatory Bowel Disease 
Patients Display Dysregulated Endoplasmic Reticulum Stress Pathways, 
Leading to Differential Inflammatory Responses and Dendritic Cell 
Maturation. J Crohns Colitis, 14(7), 948-961. doi:10.1093/ecco-jcc/jjz194 
Reinecker, H. C., Steffen, M., Witthoeft, T., Pflueger, I., Schreiber, S., MacDermott, 
R. P., & Raedler, A. (1993). Enhanced secretion of tumour necrosis factor-
alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from 
patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol, 94(1), 
174-181. doi:10.1111/j.1365-2249.1993.tb05997.x 
Reinhart, K., Daniels, R., Kissoon, N., Machado, F. R., Schachter, R. D., & Finfer, 
S. (2017). Recognizing Sepsis as a Global Health Priority - A WHO 
Resolution. N Engl J Med, 377(5), 414-417. doi:10.1056/NEJMp1707170 
Reinisch, W., Gasche, C., Tillinger, W., Wyatt, J., Lichtenberger, C., Willheim, M., . . 
. Lochs, H. (1999). Clinical relevance of serum interleukin-6 in Crohn's 
disease: single point measurements, therapy monitoring, and prediction of 
clinical relapse. Am J Gastroenterol, 94(8), 2156-2164. doi:10.1111/j.1572-
0241.1999.01288.x 
Rescigno, M., Urbano, M., Valzasina, B., Francolini, M., Rotta, G., Bonasio, R., . . . 
Ricciardi-Castagnoli, P. (2001). Dendritic cells express tight junction 
proteins and penetrate gut epithelial monolayers to sample bacteria. Nat 
Immunol, 2(4), 361-367. doi:10.1038/86373 
Ritsma, L., Ellenbroek, S. I. J., Zomer, A., Snippert, H. J., de Sauvage, F. J., 
Simons, B. D., . . . van Rheenen, J. (2014). Intestinal crypt homeostasis 
revealed at single-stem-cell level by in vivo live imaging. Nature, 507(7492), 
362-365. doi:10.1038/nature12972 
Rizvi, M., Pathak, D., Freedman, J. E., & Chakrabarti, S. (2008). CD40-CD40 ligand 
interactions in oxidative stress, inflammation and vascular disease. Trends 
Mol Med, 14(12), 530-538. doi:10.1016/j.molmed.2008.09.006 
Roach, D. R., Briscoe, H., Saunders, B., France, M. P., Riminton, S., & Britton, W. 
J. (2001). Secreted lymphotoxin-alpha is essential for the control of an 
intracellular bacterial infection. J Exp Med, 193(2), 239-246. 
doi:10.1084/jem.193.2.239 
Rock, K. L., & Kono, H. (2008). The inflammatory response to cell death. Annu Rev 
Pathol, 3, 99-126. doi:10.1146/annurev.pathmechdis.3.121806.151456 
Russell, R. C., Tian, Y., Yuan, H., Park, H. W., Chang, Y. Y., Kim, J., . . . Guan, K. 
L. (2013). ULK1 induces autophagy by phosphorylating Beclin-1 and 
activating VPS34 lipid kinase. Nat Cell Biol, 15(7), 741-750. 
doi:10.1038/ncb2757 
Saelens, X., Festjens, N., Vande Walle, L., van Gurp, M., van Loo, G., & 
Vandenabeele, P. (2004). Toxic proteins released from mitochondria in cell 
death. Oncogene, 23(16), 2861-2874. doi:10.1038/sj.onc.1207523 
Saha, S., Jing, X., Park, S. Y., Wang, S., Li, X., Gupta, D., & Dziarski, R. (2010). 
Peptidoglycan recognition proteins protect mice from experimental colitis by 
promoting normal gut flora and preventing induction of interferon-gamma. 
Cell Host Microbe, 8(2), 147-162. doi:10.1016/j.chom.2010.07.005 
290 
 
Saito, A., Suzuki, H. I., Horie, M., Ohshima, M., Morishita, Y., Abiko, Y., & Nagase, 
T. (2013). An integrated expression profiling reveals target genes of TGF-
beta and TNF-alpha possibly mediated by microRNAs in lung cancer cells. 
PLoS One, 8(2), e56587. doi:10.1371/journal.pone.0056587 
Sakai, J., & Akkoyunlu, M. (2017). The Role of BAFF System Molecules in Host 
Response to Pathogens. Clin Microbiol Rev, 30(4), 991-1014. 
doi:10.1128/CMR.00046-17 
Salim, S. Y., & Soderholm, J. D. (2011). Importance of disrupted intestinal barrier in 
inflammatory bowel diseases. Inflamm Bowel Dis, 17(1), 362-381. 
doi:10.1002/ibd.21403 
Sanz, A. B., Sanchez-Nino, M. D., Ramos, A. M., Moreno, J. A., Santamaria, B., 
Ruiz-Ortega, M., . . . Ortiz, A. (2010). NF-kappaB in renal inflammation. J 
Am Soc Nephrol, 21(8), 1254-1262. doi:10.1681/ASN.2010020218 
Sartor, R. B. (2004). Therapeutic manipulation of the enteric microflora in 
inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. 
Gastroenterology, 126(6), 1620-1633. doi:10.1053/j.gastro.2004.03.024 
Sasaki, N., Sachs, N., Wiebrands, K., Ellenbroek, S. I., Fumagalli, A., Lyubimova, 
A., . . . Clevers, H. (2016). Reg4+ deep crypt secretory cells function as 
epithelial niche for Lgr5+ stem cells in colon. Proc Natl Acad Sci U S A, 
113(37), E5399-5407. doi:10.1073/pnas.1607327113 
Sathawane, D., Kharat, R. S., Halder, S., Roy, S., Swami, R., Patel, R., & Saha, B. 
(2013). Monocyte CD40 expression in head and neck squamous cell 
carcinoma (HNSCC). Hum Immunol, 74(1), 1-5. 
doi:10.1016/j.humimm.2012.09.004 
Sato, T., & Clevers, H. (2013). Growing self-organizing mini-guts from a single 
intestinal stem cell: mechanism and applications. Science, 340(6137), 1190-
1194. doi:10.1126/science.1234852 
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G., Van Es, J. H., Van den Brink, S., 
. . . Clevers, H. (2011). Long-term expansion of epithelial organoids from 
human colon, adenoma, adenocarcinoma, and Barrett's epithelium. 
Gastroenterology, 141(5), 1762-1772. doi:10.1053/j.gastro.2011.07.050 
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. 
E., . . . Clevers, H. (2009). Single Lgr5 stem cells build crypt-villus structures 
in vitro without a mesenchymal niche. Nature, 459(7244), 262-265. 
doi:10.1038/nature07935 
Say, L., Chou, D., Gemmill, A., Tuncalp, O., Moller, A. B., Daniels, J., . . . Alkema, 
L. (2014). Global causes of maternal death: a WHO systematic analysis. 
Lancet Glob Health, 2(6), e323-333. doi:10.1016/S2214-109X(14)70227-X 
Schaumann, R., Schlick, T., Schaper, M., & Shah, P. M. (1997). Is TNF-alpha a 
prognostic factor in patients with sepsis? Clin Microbiol Infect, 3(1), 24-31. 
doi:10.1111/j.1469-0691.1997.tb00247.x 
Schepers, A. G., Vries, R., van den Born, M., van de Wetering, M., & Clevers, H. 
(2011). Lgr5 intestinal stem cells have high telomerase activity and 
randomly segregate their chromosomes. EMBO J, 30(6), 1104-1109. 
doi:10.1038/emboj.2011.26 
Schijvens, A. M., Ter Heine, R., de Wildt, S. N., & Schreuder, M. F. (2019). 
Pharmacology and pharmacogenetics of prednisone and prednisolone in 
patients with nephrotic syndrome. Pediatr Nephrol, 34(3), 389-403. 
doi:10.1007/s00467-018-3929-z 
Schmid-Schonbein, G. W., Penn, A., & Kistler, E. (2011). The Autodigestion 
Hypothesis in Shock and Multi-Organ Failure: Degrading Protease Activity. 
Bol Soc Port Hemorreol Microcirc, 26(3), 6-15.  
Schmitz, H., Fromm, M., Bode, H., Scholz, P., Riecken, E. O., & Schulzke, J. D. 
(1996). Tumor necrosis factor-alpha induces Cl- and K+ secretion in human 
291 
 
distal colon driven by prostaglandin E2. Am J Physiol, 271(4 Pt 1), G669-
674. doi:10.1152/ajpgi.1996.271.4.G669 
Schneeberger, E. E., & Lynch, R. D. (2004). The tight junction: a multifunctional 
complex. Am J Physiol Cell Physiol, 286(6), C1213-1228. 
doi:10.1152/ajpcell.00558.2003 
Schneider, P., MacKay, F., Steiner, V., Hofmann, K., Bodmer, J. L., Holler, N., . . . 
Tschopp, J. (1999). BAFF, a novel ligand of the tumor necrosis factor family, 
stimulates B cell growth. J Exp Med, 189(11), 1747-1756. 
doi:10.1084/jem.189.11.1747 
Schonbeck, U., & Libby, P. (2001). The CD40/CD154 receptor/ligand dyad. Cell Mol 
Life Sci, 58(1), 4-43. doi:10.1007/pl00000776 
Schonbeck, U., & Libby, P. (2001). The CD40/CD154 receptor/ligand dyad. Cell Mol 
Life Sci, 58(1), 4-43. doi:10.1007/pl00000776 
Schreiber, S., Nikolaus, S., & Hampe, J. (1998). Activation of nuclear factor kappa 
B inflammatory bowel disease. Gut, 42(4), 477-484. 
doi:10.1136/gut.42.4.477 
Schulte, G., & Bryja, V. (2007). The Frizzled family of unconventional G-protein-
coupled receptors. Trends Pharmacol Sci, 28(10), 518-525. 
doi:10.1016/j.tips.2007.09.001 
Schulzke, J. D., Ploeger, S., Amasheh, M., Fromm, A., Zeissig, S., Troeger, H., . . . 
Fromm, M. (2009). Epithelial tight junctions in intestinal inflammation. Ann N 
Y Acad Sci, 1165, 294-300. doi:10.1111/j.1749-6632.2009.04062.x 
Schwartz, N., Rubinstein, T., Burkly, L. C., Collins, C. E., Blanco, I., Su, L., . . . 
Putterman, C. (2009). Urinary TWEAK as a biomarker of lupus nephritis: a 
multicenter cohort study. Arthritis Res Ther, 11(5), R143. 
doi:10.1186/ar2816 
Schwarz, B. T., Wang, F., Shen, L., Clayburgh, D. R., Su, L., Wang, Y., . . . Turner, 
J. R. (2007). LIGHT signals directly to intestinal epithelia to cause barrier 
dysfunction via cytoskeletal and endocytic mechanisms. Gastroenterology, 
132(7), 2383-2394. doi:10.1053/j.gastro.2007.02.052 
Sellon, R. K., Tonkonogy, S., Schultz, M., Dieleman, L. A., Grenther, W., Balish, E., 
. . . Sartor, R. B. (1998). Resident enteric bacteria are necessary for 
development of spontaneous colitis and immune system activation in 
interleukin-10-deficient mice. Infect Immun, 66(11), 5224-5231. 
doi:10.1128/IAI.66.11.5224-5231.1998 
Sen, R., & Baltimore, D. (1986). Multiple nuclear factors interact with the 
immunoglobulin enhancer sequences. Cell, 46(5), 705-716. 
doi:10.1016/0092-8674(86)90346-6 
Serramito-Gomez, I., Boada-Romero, E., Slowicka, K., Vereecke, L., Van Loo, G., 
& Pimentel-Muinos, F. X. (2019). The anti-inflammatory protein 
TNFAIP3/A20 binds the WD40 domain of ATG16L1 to control the 
autophagic response, NFKB/NF-kappaB activation and intestinal 
homeostasis. Autophagy, 15(9), 1657-1659. 
doi:10.1080/15548627.2019.1628549 
Sha, T., Iizawa, Y., & Ii, M. (2011). Combination of imipenem and TAK-242, a Toll-
like receptor 4 signal transduction inhibitor, improves survival in a murine 
model of polymicrobial sepsis. Shock, 35(2), 205-209. 
doi:10.1097/SHK.0b013e3181f48942 
Sha, W. C., Liou, H. C., Tuomanen, E. I., & Baltimore, D. (1995). Targeted 
disruption of the p50 subunit of NF-kappa B leads to multifocal defects in 
immune responses. Cell, 80(2), 321-330. doi:10.1016/0092-8674(95)90415-
8 
Shao, L., Oshima, S., Duong, B., Advincula, R., Barrera, J., Malynn, B. A., & Ma, A. 
(2013). A20 restricts wnt signaling in intestinal epithelial cells and 
292 
 
suppresses colon carcinogenesis. PLoS One, 8(5), e62223. 
doi:10.1371/journal.pone.0062223 
Shao, Y., Chen, F., Chen, Y., Zhang, W., Lin, Y., Cai, Y., . . . Cui, L. (2017). 
Association between genetic polymorphisms in the autophagy-related 5 
gene promoter and the risk of sepsis. Sci Rep, 7(1), 9399. 
doi:10.1038/s41598-017-09978-5 
Sharma, N. K., & Salomao, R. (2017). Sepsis Through the Eyes of Proteomics: The 
Progress in the Last Decade. Shock, 47(1S Suppl 1), 17-25. 
doi:10.1097/SHK.0000000000000698 
Sharma, V. M., Draheim, K. M., & Kelliher, M. A. (2007). The Notch1/c-Myc 
pathway in T cell leukemia. Cell Cycle, 6(8), 927-930. 
doi:10.4161/cc.6.8.4134 
Sheehan, M., Wong, H. R., Hake, P. W., & Zingarelli, B. (2003). Parthenolide 
improves systemic hemodynamics and decreases tissue leukosequestration 
in rats with polymicrobial sepsis. Crit Care Med, 31(9), 2263-2270. 
doi:10.1097/01.CCM.0000085186.14867.F7 
Shen, L., Weber, C. R., & Turner, J. R. (2008). The tight junction protein complex 
undergoes rapid and continuous molecular remodeling at steady state. J 
Cell Biol, 181(4), 683-695. doi:10.1083/jcb.200711165 
Shen, M., Zhou, L., Zhou, P., Zhou, W., & Lin, X. (2017). Lymphotoxin beta receptor 
activation promotes mRNA expression of RelA and pro-inflammatory 
cytokines TNFalpha and IL-1beta in bladder cancer cells. Mol Med Rep, 
16(1), 937-942. doi:10.3892/mmr.2017.6676 
Shen, X. F., Cao, K., Jiang, J. P., Guan, W. X., & Du, J. F. (2017). Neutrophil 
dysregulation during sepsis: an overview and update. J Cell Mol Med, 21(9), 
1687-1697. doi:10.1111/jcmm.13112 
Shiels, H., Li, X., Schumacker, P. T., Maltepe, E., Padrid, P. A., Sperling, A., . . . 
Lindsten, T. (2000). TRAF4 deficiency leads to tracheal malformation with 
resulting alterations in air flow to the lungs. Am J Pathol, 157(2), 679-688. 
doi:10.1016/S0002-9440(10)64578-6 
Shifrin, D. A., Jr., McConnell, R. E., Nambiar, R., Higginbotham, J. N., Coffey, R. J., 
& Tyska, M. J. (2012). Enterocyte microvillus-derived vesicles detoxify 
bacterial products and regulate epithelial-microbial interactions. Curr Biol, 
22(7), 627-631. doi:10.1016/j.cub.2012.02.022 
Shin, J. H., & Seeley, R. J. (2019). Reg3 Proteins as Gut Hormones? 
Endocrinology, 160(6), 1506-1514. doi:10.1210/en.2019-00073 
Shinoda, T., Shinya, N., Ito, K., Ohsawa, N., Terada, T., Hirata, K., . . . Shirouzu, M. 
(2016). Structural basis for disruption of claudin assembly in tight junctions 
by an enterotoxin. Sci Rep, 6, 33632. doi:10.1038/srep33632 
Shirey, K. A., Lai, W., Scott, A. J., Lipsky, M., Mistry, P., Pletneva, L. M., . . . Vogel, 
S. N. (2013). The TLR4 antagonist Eritoran protects mice from lethal 
influenza infection. Nature, 497(7450), 498-502. doi:10.1038/nature12118 
Shukla, P., Rao, G. M., Pandey, G., Sharma, S., Mittapelly, N., Shegokar, R., & 
Mishra, P. R. (2014). Therapeutic interventions in sepsis: current and 
anticipated pharmacological agents. Br J Pharmacol, 171(22), 5011-5031. 
doi:10.1111/bph.12829 
Siddiqui, A. M., Cui, X., Wu, R., Dong, W., Zhou, M., Hu, M., . . . Wang, P. (2006). 
The anti-inflammatory effect of curcumin in an experimental model of sepsis 
is mediated by up-regulation of peroxisome proliferator-activated receptor-
gamma. Crit Care Med, 34(7), 1874-1882. 
doi:10.1097/01.CCM.0000221921.71300.BF 
Siegel, R. M., Chan, F. K., Chun, H. J., & Lenardo, M. J. (2000). The multifaceted 
role of Fas signaling in immune cell homeostasis and autoimmunity. Nat 
Immunol, 1(6), 469-474. doi:10.1038/82712 
293 
 
Silva, A. T., Bayston, K. F., & Cohen, J. (1990). Prophylactic and therapeutic effects 
of a monoclonal antibody to tumor necrosis factor-alpha in experimental 
gram-negative shock. J Infect Dis, 162(2), 421-427. 
doi:10.1093/infdis/162.2.421 
Silva, L. S., Catalao, C. H., Felippotti, T. T., Oliveira-Pelegrin, G. R., Petenusci, S., 
de Freitas, L. A., & Rocha, M. J. (2017). Curcumin suppresses inflammatory 
cytokines and heat shock protein 70 release and improves metabolic 
parameters during experimental sepsis. Pharm Biol, 55(1), 269-276. 
doi:10.1080/13880209.2016.1260598 
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., 
Bauer, M., . . . Angus, D. C. (2016). The Third International Consensus 
Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 315(8), 801-810. 
doi:10.1001/jama.2016.0287 
Sinnatamby, C. S., & Last, R. J. (2011). Last's anatomy : regional and applied (12th 
ed.). Edinburgh ; New York: Churchill Livingstone/Elsevier. 
Slee, E. A., Adrain, C., & Martin, S. J. (2001). Executioner caspase-3, -6, and -7 
perform distinct, non-redundant roles during the demolition phase of 
apoptosis. J Biol Chem, 276(10), 7320-7326. doi:10.1074/jbc.M008363200 
Slusarski, D. C., Yang-Snyder, J., Busa, W. B., & Moon, R. T. (1997). Modulation of 
embryonic intracellular Ca2+ signaling by Wnt-5A. Dev Biol, 182(1), 114-
120. doi:10.1006/dbio.1996.8463 
Smulski, C. R., Decossas, M., Chekkat, N., Beyrath, J., Willen, L., Guichard, G., . . . 
Fournel, S. (2017). Hetero-oligomerization between the TNF receptor 
superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling. 
Cell Death Dis, 8(2), e2601. doi:10.1038/cddis.2017.22 
Snoeck, V., Goddeeris, B., & Cox, E. (2005). The role of enterocytes in the 
intestinal barrier function and antigen uptake. Microbes Infect, 7(7-8), 997-
1004. doi:10.1016/j.micinf.2005.04.003 
Sohma, M. (1983). Ultrastructure of the absorptive cells in the small intestine of the 
rat during starvation. Anat Embryol (Berl), 168(3), 331-339. 
doi:10.1007/BF00304271 
Son, A., Oshio, T., Kawamura, Y. I., Hagiwara, T., Yamazaki, M., Inagaki-Ohara, K., 
. . . Dohi, T. (2013). TWEAK/Fn14 pathway promotes a T helper 2-type 
chronic colitis with fibrosis in mice. Mucosal Immunol, 6(6), 1131-1142. 
doi:10.1038/mi.2013.10 
Song, D., Zong, X., Zhang, H., Wang, T., Yi, H., Luan, C., & Wang, Y. (2015). 
Antimicrobial peptide Cathelicidin-BF prevents intestinal barrier dysfunction 
in a mouse model of endotoxemia. Int Immunopharmacol, 25(1), 141-147. 
doi:10.1016/j.intimp.2015.01.017 
Song, W. B., Wang, Y. Y., Meng, F. S., Zhang, Q. H., Zeng, J. Y., Xiao, L. P., . . . 
Zhang, Z. S. (2010). Curcumin protects intestinal mucosal barrier function of 
rat enteritis via activation of MKP-1 and attenuation of p38 and NF-kappaB 
activation. PLoS One, 5(9), e12969. doi:10.1371/journal.pone.0012969 
Sotillo, J., Ferreira, I., Potriquet, J., Laha, T., Navarro, S., Loukas, A., & Mulvenna, 
J. (2017). Changes in protein expression after treatment with Ancylostoma 
caninum excretory/secretory products in a mouse model of colitis. Sci Rep, 
7, 41883. doi:10.1038/srep41883 
Specian, R. D., & Neutra, M. R. (1980). Mechanism of rapid mucus secretion in 
goblet cells stimulated by acetylcholine. J Cell Biol, 85(3), 626-640. 
doi:10.1083/jcb.85.3.626 
Spit, M., Koo, B. K., & Maurice, M. M. (2018). Tales from the crypt: intestinal niche 




Spooner, C. E., Markowitz, N. P., & Saravolatz, L. D. (1992). The role of tumor 
necrosis factor in sepsis. Clin Immunol Immunopathol, 62(1 Pt 2), S11-17. 
doi:10.1016/0090-1229(92)90036-n 
Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., Litwack, G., & Alnemri, E. S. 
(1996). Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 
protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-
3/ICE-like cysteine proteases. Proc Natl Acad Sci U S A, 93(25), 14486-
14491. doi:10.1073/pnas.93.25.14486 
Stadnyk, A. W. (2002). Intestinal epithelial cells as a source of inflammatory 
cytokines and chemokines. Can J Gastroenterol, 16(4), 241-246. 
doi:10.1155/2002/941087 
Starr, A. E., Deeke, S. A., Ning, Z., Chiang, C. K., Zhang, X., Mottawea, W., . . . 
Figeys, D. (2017). Proteomic analysis of ascending colon biopsies from a 
paediatric inflammatory bowel disease inception cohort identifies protein 
biomarkers that differentiate Crohn's disease from UC. Gut, 66(9), 1573-
1583. doi:10.1136/gutjnl-2015-310705 
Stelzner, M., Helmrath, M., Dunn, J. C., Henning, S. J., Houchen, C. W., Kuo, C., . . 
. Consortium, N. I. H. I. S. C. (2012). A nomenclature for intestinal in vitro 
cultures. Am J Physiol Gastrointest Liver Physiol, 302(12), G1359-1363. 
doi:10.1152/ajpgi.00493.2011 
Steri, M., Orru, V., Idda, M. L., Pitzalis, M., Pala, M., Zara, I., . . . Cucca, F. (2017). 
Overexpression of the Cytokine BAFF and Autoimmunity Risk. N Engl J 
Med, 376(17), 1615-1626. doi:10.1056/NEJMoa1610528 
Stuber, E., Strober, W., & Neurath, M. (1996). Blocking the CD40L-CD40 
interaction in vivo specifically prevents the priming of T helper 1 cells 
through the inhibition of interleukin 12 secretion. J Exp Med, 183(2), 693-
698. doi:10.1084/jem.183.2.693 
Sun, S. C. (2011). Non-canonical NF-kappaB signaling pathway. Cell Res, 21(1), 
71-85. doi:10.1038/cr.2010.177 
Susin, S. A., Daugas, E., Ravagnan, L., Samejima, K., Zamzami, N., Loeffler, M., . . 
. Kroemer, G. (2000). Two distinct pathways leading to nuclear apoptosis. J 
Exp Med, 192(4), 571-580. doi:10.1084/jem.192.4.571 
Suzuki, Y., Imai, Y., Nakayama, H., Takahashi, K., Takio, K., & Takahashi, R. 
(2001). A serine protease, HtrA2, is released from the mitochondria and 
interacts with XIAP, inducing cell death. Mol Cell, 8(3), 613-621. 
doi:10.1016/s1097-2765(01)00341-0 
Swardfager, W., Lanctot, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. 
(2010). A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry, 
68(10), 930-941. doi:10.1016/j.biopsych.2010.06.012 
Tait, S. W., & Green, D. R. (2008). Caspase-independent cell death: leaving the set 
without the final cut. Oncogene, 27(50), 6452-6461. 
doi:10.1038/onc.2008.311 
Tak, P. P., & Firestein, G. S. (2001). NF-kappaB: a key role in inflammatory 
diseases. J Clin Invest, 107(1), 7-11. doi:10.1172/JCI11830 
Takeuchi, O., & Akira, S. (2010). Pattern recognition receptors and inflammation. 
Cell, 140(6), 805-820. doi:10.1016/j.cell.2010.01.022 
Tamada, K., Shimozaki, K., Chapoval, A. I., Zhu, G., Sica, G., Flies, D., . . . Chen, 
L. (2000). Modulation of T-cell-mediated immunity in tumor and graft-versus-
host disease models through the LIGHT co-stimulatory pathway. Nat Med, 
6(3), 283-289. doi:10.1038/73136 
Tamura, A., Kitano, Y., Hata, M., Katsuno, T., Moriwaki, K., Sasaki, H., . . . Tsukita, 
S. (2008). Megaintestine in claudin-15-deficient mice. Gastroenterology, 
134(2), 523-534. doi:10.1053/j.gastro.2007.11.040 
Tanaka, H., Takechi, M., Kiyonari, H., Shioi, G., Tamura, A., & Tsukita, S. (2015). 
Intestinal deletion of Claudin-7 enhances paracellular organic solute flux and 
295 
 
initiates colonic inflammation in mice. Gut, 64(10), 1529-1538. 
doi:10.1136/gutjnl-2014-308419 
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014). IL-6 in inflammation, immunity, 
and disease. Cold Spring Harb Perspect Biol, 6(10), a016295. 
doi:10.1101/cshperspect.a016295 
Tang, B., Zhong, Z., Qiu, Z., Wu, H. P., Hu, J. Y., Ma, J. P., & Wu, J. P. (2019). 
Serum soluble TWEAK levels in severe traumatic brain injury and its 
prognostic significance. Clin Chim Acta, 495, 227-232. 
doi:10.1016/j.cca.2019.04.070 
Tang, J., Chen, X., Tu, W., Guo, Y., Zhao, Z., Xue, Q., . . . Liu, Y. (2011). Propofol 
inhibits the activation of p38 through up-regulating the expression of annexin 
A1 to exert its anti-inflammation effect. PLoS One, 6(12), e27890. 
doi:10.1371/journal.pone.0027890 
Targan, S. R., Hanauer, S. B., van Deventer, S. J., Mayer, L., Present, D. H., 
Braakman, T., . . . Rutgeerts, P. J. (1997). A short-term study of chimeric 
monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. 
Crohn's Disease cA2 Study Group. N Engl J Med, 337(15), 1029-1035. 
doi:10.1056/NEJM199710093371502 
Taupin, D., & Podolsky, D. K. (2003). Trefoil factors: initiators of mucosal healing. 
Nat Rev Mol Cell Biol, 4(9), 721-732. doi:10.1038/nrm1203 
Tetikcok, R., Kayaoglu, H. A., Ozsoy, Z., Yenidogan, E., Ozkan, N., Celik, A., . . . 
Ersoy, O. F. (2016). The Effect of Peritoneal Prednisolone Lavage in 
Bacterial Peritonitis: An Experimental Study. Wounds, 28(10), 354-359.  
Theiss, A. L., Simmons, J. G., Jobin, C., & Lund, P. K. (2005). Tumor necrosis 
factor (TNF) alpha increases collagen accumulation and proliferation in 
intestinal myofibroblasts via TNF receptor 2. J Biol Chem, 280(43), 36099-
36109. doi:10.1074/jbc.M505291200 
Thuny, F., Textoris, J., Amara, A. B., Filali, A. E., Capo, C., Habib, G., . . . Mege, J. 
L. (2012). The gene expression analysis of blood reveals S100A11 and 
AQP9 as potential biomarkers of infective endocarditis. PLoS One, 7(2), 
e31490. doi:10.1371/journal.pone.0031490 
Tickenbrock, L., Muller-Tidow, C., Berdel, W. E., & Serve, H. (2006). Emerging Flt3 
kinase inhibitors in the treatment of leukaemia. Expert Opin Emerg Drugs, 
11(1), 153-165. doi:10.1517/14728214.11.1.153 
Tipsmark, C. K., Kiilerich, P., Nilsen, T. O., Ebbesson, L. O., Stefansson, S. O., & 
Madsen, S. S. (2008). Branchial expression patterns of claudin isoforms in 
Atlantic salmon during seawater acclimation and smoltification. Am J Physiol 
Regul Integr Comp Physiol, 294(5), R1563-1574. 
doi:10.1152/ajpregu.00915.2007 
Toden, S., Theiss, A. L., Wang, X., & Goel, A. (2017). Essential turmeric oils 
enhance anti-inflammatory efficacy of curcumin in dextran sulfate sodium-
induced colitis. Sci Rep, 7(1), 814. doi:10.1038/s41598-017-00812-6 
Tracey, K. J., Fong, Y., Hesse, D. G., Manogue, K. R., Lee, A. T., Kuo, G. C., . . . 
Cerami, A. (1987). Anti-cachectin/TNF monoclonal antibodies prevent septic 
shock during lethal bacteraemia. Nature, 330(6149), 662-664. 
doi:10.1038/330662a0 
Tran, N. L., McDonough, W. S., Donohue, P. J., Winkles, J. A., Berens, T. J., Ross, 
K. R., . . . Berens, M. E. (2003). The human Fn14 receptor gene is up-
regulated in migrating glioma cells in vitro and overexpressed in advanced 
glial tumors. Am J Pathol, 162(4), 1313-1321. doi:10.1016/S0002-
9440(10)63927-2 
Trevaskis, N. L., Kaminskas, L. M., & Porter, C. J. (2015). From sewer to saviour - 
targeting the lymphatic system to promote drug exposure and activity. Nat 
Rev Drug Discov, 14(11), 781-803. doi:10.1038/nrd4608 
296 
 
Tsertsvadze, A., Royle, P., & McCarthy, N. (2015). Community-onset sepsis and its 
public health burden: protocol of a systematic review. Syst Rev, 4, 119. 
doi:10.1186/s13643-015-0103-6 
Tsukita, S., Yamazaki, Y., Katsuno, T., Tamura, A., & Tsukita, S. (2008). Tight 
junction-based epithelial microenvironment and cell proliferation. Oncogene, 
27(55), 6930-6938. doi:10.1038/onc.2008.344 
Tumanov, A. V., Koroleva, E. P., Guo, X., Wang, Y., Kruglov, A., Nedospasov, S., & 
Fu, Y. X. (2011). Lymphotoxin controls the IL-22 protection pathway in gut 
innate lymphoid cells during mucosal pathogen challenge. Cell Host 
Microbe, 10(1), 44-53. doi:10.1016/j.chom.2011.06.002 
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & 
Gordon, J. I. (2007). The human microbiome project. Nature, 449(7164), 
804-810. doi:10.1038/nature06244 
Turner, J. R. (2009). Intestinal mucosal barrier function in health and disease. Nat 
Rev Immunol, 9(11), 799-809. doi:10.1038/nri2653 
Uchiyama, K., Naito, Y., Takagi, T., Mizushima, K., Hirai, Y., Hayashi, N., . . . 
Yoshikawa, T. (2012). Serpin B1 protects colonic epithelial cell via blockage 
of neutrophil elastase activity and its expression is enhanced in patients with 
ulcerative colitis. Am J Physiol Gastrointest Liver Physiol, 302(10), G1163-
1170. doi:10.1152/ajpgi.00292.2011 
Uhlig, H. H. (2013). Monogenic diseases associated with intestinal inflammation: 
implications for the understanding of inflammatory bowel disease. Gut, 
62(12), 1795-1805. doi:10.1136/gutjnl-2012-303956 
Ulluwishewa, D., Anderson, R. C., McNabb, W. C., Moughan, P. J., Wells, J. M., & 
Roy, N. C. (2011). Regulation of tight junction permeability by intestinal 
bacteria and dietary components. J Nutr, 141(5), 769-776. 
doi:10.3945/jn.110.135657 
Upadhyay, V., & Fu, Y. X. (2013). Lymphotoxin signalling in immune homeostasis 
and the control of microorganisms. Nat Rev Immunol, 13(4), 270-279. 
doi:10.1038/nri3406 
van Amerongen, R., Fuerer, C., Mizutani, M., & Nusse, R. (2012). Wnt5a can both 
activate and repress Wnt/beta-catenin signaling during mouse embryonic 
development. Dev Biol, 369(1), 101-114. doi:10.1016/j.ydbio.2012.06.020 
van der Bruggen, T., Nijenhuis, S., van Raaij, E., Verhoef, J., & van Asbeck, B. S. 
(1999). Lipopolysaccharide-induced tumor necrosis factor alpha production 
by human monocytes involves the raf-1/MEK1-MEK2/ERK1-ERK2 pathway. 
Infect Immun, 67(8), 3824-3829. doi:10.1128/IAI.67.8.3824-3829.1999 
van der Meulen, T., Donaldson, C. J., Caceres, E., Hunter, A. E., Cowing-Zitron, C., 
Pound, L. D., . . . Huising, M. O. (2015). Urocortin3 mediates somatostatin-
dependent negative feedback control of insulin secretion. Nat Med, 21(7), 
769-776. doi:10.1038/nm.3872 
van Es, J. H., & Clevers, H. (2005). Notch and Wnt inhibitors as potential new drugs 
for intestinal neoplastic disease. Trends Mol Med, 11(11), 496-502. 
doi:10.1016/j.molmed.2005.09.008 
van Gent, D., Sharp, P., Morgan, K., & Kalsheker, N. (2003). Serpins: structure, 
function and molecular evolution. Int J Biochem Cell Biol, 35(11), 1536-
1547. doi:10.1016/s1357-2725(03)00134-1 
van Kooten, C., & Banchereau, J. (2000). CD40-CD40 ligand. J Leukoc Biol, 67(1), 
2-17. doi:10.1002/jlb.67.1.2 
van Kuijk, A. W., Wijbrandts, C. A., Vinkenoog, M., Zheng, T. S., Reedquist, K. A., 
& Tak, P. P. (2010). TWEAK and its receptor Fn14 in the synovium of 
patients with rheumatoid arthritis compared to psoriatic arthritis and its 




Vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S., Walczak, H., & 
Vandenabeele, P. (2014). Regulated necrosis: the expanding network of 
non-apoptotic cell death pathways. Nat Rev Mol Cell Biol, 15(2), 135-147. 
doi:10.1038/nrm3737 
Vane, J. R., Botting, J. H., & Botting, R. M. (1996). Improved non-steroid anti-
inflammatory drugs COX-2 enzyme inhibitors : proceedings of a conference 
held on October 10-11, 1995, at Regent's College, London. Dordrecht ; 
Boston: Kluwer Academic Publishers. 
Vazquez-Frias, R., Gutierrez-Reyes, G., Urban-Reyes, M., Velazquez-Guadarrama, 
N., Fortoul-van der Goes, T. I., Reyes-Lopez, A., & Consuelo-Sanchez, A. 
(2015). Proinflammatory and anti-inflammatory cytokine profile in pediatric 
patients with irritable bowel syndrome. Rev Gastroenterol Mex, 80(1), 6-12. 
doi:10.1016/j.rgmx.2014.11.001 
Venet, F., & Monneret, G. (2018). Advances in the understanding and treatment of 
sepsis-induced immunosuppression. Nat Rev Nephrol, 14(2), 121-137. 
doi:10.1038/nrneph.2017.165 
Ventham, N. T., Kennedy, N. A., Nimmo, E. R., & Satsangi, J. (2013). Beyond gene 
discovery in inflammatory bowel disease: the emerging role of epigenetics. 
Gastroenterology, 145(2), 293-308. doi:10.1053/j.gastro.2013.05.050 
Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., . 
. . Vaux, D. L. (2000). Identification of DIABLO, a mammalian protein that 
promotes apoptosis by binding to and antagonizing IAP proteins. Cell, 
102(1), 43-53. doi:10.1016/s0092-8674(00)00009-x 
Verhelst, K., Gardam, S., Borghi, A., Kreike, M., Carpentier, I., & Beyaert, R. 
(2015). XEDAR activates the non-canonical NF-kappaB pathway. Biochem 
Biophys Res Commun, 465(2), 275-280. doi:10.1016/j.bbrc.2015.08.019 
Verma, I. M. (2004). Nuclear factor (NF)-kappaB proteins: therapeutic targets. Ann 
Rheum Dis, 63 Suppl 2, ii57-ii61. doi:10.1136/ard.2004.028266 
Victor, F. C., & Gottlieb, A. B. (2002). TNF-alpha and apoptosis: implications for the 
pathogenesis and treatment of psoriasis. J Drugs Dermatol, 1(3), 264-275.  
Vincent, F. B., Saulep-Easton, D., Figgett, W. A., Fairfax, K. A., & Mackay, F. 
(2013). The BAFF/APRIL system: emerging functions beyond B cell biology 
and autoimmunity. Cytokine Growth Factor Rev, 24(3), 203-215. 
doi:10.1016/j.cytogfr.2013.04.003 
Vit, O., & Petrak, J. (2017). Integral membrane proteins in proteomics. How to 
break open the black box? J Proteomics, 153, 8-20. 
doi:10.1016/j.jprot.2016.08.006 
Vlantis, K., Wullaert, A., Polykratis, A., Kondylis, V., Dannappel, M., Schwarzer, R., 
. . . Pasparakis, M. (2016). NEMO Prevents RIP Kinase 1-Mediated 
Epithelial Cell Death and Chronic Intestinal Inflammation by NF-kappaB-
Dependent and -Independent Functions. Immunity, 44(3), 553-567. 
doi:10.1016/j.immuni.2016.02.020 
Waage, A., Halstensen, A., & Espevik, T. (1987). Association between tumour 
necrosis factor in serum and fatal outcome in patients with meningococcal 
disease. Lancet, 1(8529), 355-357. doi:10.1016/s0140-6736(87)91728-4 
Wallach, T. E., & Bayrer, J. R. (2017). Intestinal Organoids: New Frontiers in the 
Study of Intestinal Disease and Physiology. J Pediatr Gastroenterol Nutr, 
64(2), 180-185. doi:10.1097/MPG.0000000000001411 
Wallin, E., & von Heijne, G. (1998). Genome-wide analysis of integral membrane 
proteins from eubacterial, archaean, and eukaryotic organisms. Protein Sci, 
7(4), 1029-1038. doi:10.1002/pro.5560070420 
Wan, F., & Lenardo, M. J. (2009). Specification of DNA binding activity of NF-




Wang, F., Graham, W. V., Wang, Y., Witkowski, E. D., Schwarz, B. T., & Turner, J. 
R. (2005). Interferon-gamma and tumor necrosis factor-alpha synergize to 
induce intestinal epithelial barrier dysfunction by up-regulating myosin light 
chain kinase expression. Am J Pathol, 166(2), 409-419. doi:10.1016/s0002-
9440(10)62264-x 
Wang, L., Bastarache, J. A., & Ware, L. B. (2008). The coagulation cascade in 
sepsis. Curr Pharm Des, 14(19), 1860-1869. 
doi:10.2174/138161208784980581 
Wang, M. J., Yang, H. Y., Zhang, H., Zhou, X., Liu, R. P., & Mi, Y. Y. (2016). 
TNFAIP3 gene rs10499194, rs13207033 polymorphisms decrease the risk 
of rheumatoid arthritis. Oncotarget, 7(50), 82933-82942. 
doi:10.18632/oncotarget.12638 
Wang, X., & Lin, Y. (2008). Tumor necrosis factor and cancer, buddies or foes? 
Acta Pharmacol Sin, 29(11), 1275-1288. doi:10.1111/j.1745-
7254.2008.00889.x 
Wang, Y., Koroleva, E. P., Kruglov, A. A., Kuprash, D. V., Nedospasov, S. A., Fu, 
Y. X., & Tumanov, A. V. (2010). Lymphotoxin beta receptor signaling in 
intestinal epithelial cells orchestrates innate immune responses against 
mucosal bacterial infection. Immunity, 32(3), 403-413. 
doi:10.1016/j.immuni.2010.02.011 
Wang, Y., Meng, A., Lang, H., Brown, S. A., Konopa, J. L., Kindy, M. S., . . . Zhou, 
D. (2004). Activation of nuclear factor kappaB In vivo selectively protects the 
murine small intestine against ionizing radiation-induced damage. Cancer 
Res, 64(17), 6240-6246. doi:10.1158/0008-5472.CAN-04-0591 
Wannemuehler, T. J., Manukyan, M. C., Brewster, B. D., Rouch, J., Poynter, J. A., 
Wang, Y., & Meldrum, D. R. (2012). Advances in mesenchymal stem cell 
research in sepsis. J Surg Res, 173(1), 113-126. 
doi:10.1016/j.jss.2011.09.053 
Ward-Kavanagh, L. K., Lin, W. W., Sedy, J. R., & Ware, C. F. (2016). The TNF 
Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. 
Immunity, 44(5), 1005-1019. doi:10.1016/j.immuni.2016.04.019 
Waters, J. P., Pober, J. S., & Bradley, J. R. (2013). Tumour necrosis factor and 
cancer. J Pathol, 230(3), 241-248. doi:10.1002/path.4188 
Watson, A. J., Duckworth, C. A., Guan, Y., & Montrose, M. H. (2009). Mechanisms 
of epithelial cell shedding in the Mammalian intestine and maintenance of 
barrier function. Ann N Y Acad Sci, 1165, 135-142. doi:10.1111/j.1749-
6632.2009.04027.x 
Watson, A. J., & Hughes, K. R. (2012). TNF-alpha-induced intestinal epithelial cell 
shedding: implications for intestinal barrier function. Ann N Y Acad Sci, 
1258, 1-8. doi:10.1111/j.1749-6632.2012.06523.x 
Wei, J., & Feng, J. (2010). Signaling pathways associated with inflammatory bowel 
disease. Recent Pat Inflamm Allergy Drug Discov, 4(2), 105-117. 
doi:10.2174/187221310791163071 
Werner, S. L., Barken, D., & Hoffmann, A. (2005). Stimulus specificity of gene 
expression programs determined by temporal control of IKK activity. 
Science, 309(5742), 1857-1861. doi:10.1126/science.1113319 
Werner, T., Sweetman, G., Savitski, M. F., Mathieson, T., Bantscheff, M., & 
Savitski, M. M. (2014). Ion coalescence of neutron encoded TMT 10-plex 
reporter ions. Anal Chem, 86(7), 3594-3601. doi:10.1021/ac500140s 
White, G. L., Archer, L. T., Beller, B. K., & Hinshaw, L. B. (1978). Increased survival 
with methylprednisolone treatment in canine endotoxin shock. J Surg Res, 
25(4), 357-364. doi:10.1016/0022-4804(78)90131-2 
Wiley, S. R., Cassiano, L., Lofton, T., Davis-Smith, T., Winkles, J. A., Lindner, V., . . 
. Fanslow, W. C. (2001). A novel TNF receptor family member binds 
299 
 
TWEAK and is implicated in angiogenesis. Immunity, 15(5), 837-846. 
doi:10.1016/s1074-7613(01)00232-1 
Wilkins, M. R., Sanchez, J. C., Gooley, A. A., Appel, R. D., Humphery-Smith, I., 
Hochstrasser, D. F., & Williams, K. L. (1996). Progress with proteome 
projects: why all proteins expressed by a genome should be identified and 
how to do it. Biotechnol Genet Eng Rev, 13, 19-50. 
doi:10.1080/02648725.1996.10647923 
Williams, J. M., Duckworth, C. A., Burkitt, M. D., Watson, A. J., Campbell, B. J., & 
Pritchard, D. M. (2015). Epithelial cell shedding and barrier function: a 
matter of life and death at the small intestinal villus tip. Vet Pathol, 52(3), 
445-455. doi:10.1177/0300985814559404 
Williams, J. M., Duckworth, C. A., Watson, A. J., Frey, M. R., Miguel, J. C., Burkitt, 
M. D., . . . Pritchard, D. M. (2013). A mouse model of pathological small 
intestinal epithelial cell apoptosis and shedding induced by systemic 
administration of lipopolysaccharide. Dis Model Mech, 6(6), 1388-1399. 
doi:10.1242/dmm.013284 
Willott, E., Balda, M. S., Fanning, A. S., Jameson, B., Van Itallie, C., & Anderson, J. 
M. (1993). The tight junction protein ZO-1 is homologous to the Drosophila 
discs-large tumor suppressor protein of septate junctions. Proc Natl Acad 
Sci U S A, 90(16), 7834-7838. doi:10.1073/pnas.90.16.7834 
Winkles, J. A. (2008). The TWEAK-Fn14 cytokine-receptor axis: discovery, biology 
and therapeutic targeting. Nat Rev Drug Discov, 7(5), 411-425. 
doi:10.1038/nrd2488 
Wodarz, A., & Nusse, R. (1998). Mechanisms of Wnt signaling in development. 
Annu Rev Cell Dev Biol, 14, 59-88. doi:10.1146/annurev.cellbio.14.1.59 
Wolczyk, D., Zaremba-Czogalla, M., Hryniewicz-Jankowska, A., Tabola, R., 
Grabowski, K., Sikorski, A. F., & Augoff, K. (2016). TNF-alpha promotes 
breast cancer cell migration and enhances the concentration of membrane-
associated proteases in lipid rafts. Cell Oncol (Dordr), 39(4), 353-363. 
doi:10.1007/s13402-016-0280-x 
Wong, V. W., Stange, D. E., Page, M. E., Buczacki, S., Wabik, A., Itami, S., . . . 
Jensen, K. B. (2012). Lrig1 controls intestinal stem-cell homeostasis by 
negative regulation of ErbB signalling. Nat Cell Biol, 14(4), 401-408. 
doi:10.1038/ncb2464 
Wullaert, A., Bonnet, M. C., & Pasparakis, M. (2011). NF-kappaB in the regulation 
of epithelial homeostasis and inflammation. Cell Res, 21(1), 146-158. 
doi:10.1038/cr.2010.175 
Xavier, R. J., & Podolsky, D. K. (2007). Unravelling the pathogenesis of 
inflammatory bowel disease. Nature, 448(7152), 427-434. 
doi:10.1038/nature06005 
Xiao, Y., Lu, Y., Wang, Y., Yan, W., & Cai, W. (2019). Deficiency in intestinal 
epithelial Reg4 ameliorates intestinal inflammation and alters the colonic 
bacterial composition. Mucosal Immunol, 12(4), 919-929. 
doi:10.1038/s41385-019-0161-5 
Xu, C., Wang, K., Ding, Y. H., Li, W. J., & Ding, L. (2019). Claudin-7 gene knockout 
causes destruction of intestinal structure and animal death in mice. World J 
Gastroenterol, 25(5), 584-599. doi:10.3748/wjg.v25.i5.584 
Xu, G., & Shi, Y. (2007). Apoptosis signaling pathways and lymphocyte 
homeostasis. Cell Res, 17(9), 759-771. doi:10.1038/cr.2007.52 
Yagami, T., Yamamoto, Y., & Koma, H. (2019). Pathophysiological Roles of 
Intracellular Proteases in Neuronal Development and Neurological 




Yamazaki, Y., Okawa, K., Yano, T., Tsukita, S., & Tsukita, S. (2008). Optimized 
proteomic analysis on gels of cell-cell adhering junctional membrane 
proteins. Biochemistry, 47(19), 5378-5386. doi:10.1021/bi8002567 
Yang, J., Andre, P., Ye, L., & Yang, Y. Z. (2015). The Hedgehog signalling pathway 
in bone formation. Int J Oral Sci, 7(2), 73-79. doi:10.1038/ijos.2015.14 
Yang, L., Liu, C., Zhao, W., He, C., Ding, J., Dai, R., . . . Meng, H. (2018). Impaired 
Autophagy in Intestinal Epithelial Cells Alters Gut Microbiota and Host 
Immune Responses. Appl Environ Microbiol, 84(18). 
doi:10.1128/AEM.00880-18 
Yang, R., Miki, K., Oksala, N., Nakao, A., Lindgren, L., Killeen, M. E., . . . 
Tenhunen, J. (2009). Bile high-mobility group box 1 contributes to gut barrier 
dysfunction in experimental endotoxemia. Am J Physiol Regul Integr Comp 
Physiol, 297(2), R362-369. doi:10.1152/ajpregu.00184.2009 
Yao, J., Mackman, N., Edgington, T. S., & Fan, S. T. (1997). Lipopolysaccharide 
induction of the tumor necrosis factor-alpha promoter in human monocytic 
cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. J 
Biol Chem, 272(28), 17795-17801. doi:10.1074/jbc.272.28.17795 
Yarmolinsky, M. B. (1995). Programmed cell death in bacterial populations. 
Science, 267(5199), 836-837. doi:10.1126/science.7846528 
Ye, D., Ma, I., & Ma, T. Y. (2006). Molecular mechanism of tumor necrosis factor-
alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol 
Gastrointest Liver Physiol, 290(3), G496-504. doi:10.1152/ajpgi.00318.2005 
Yoo, J. H., & Donowitz, M. (2019). Intestinal enteroids/organoids: A novel platform 
for drug discovery in inflammatory bowel diseases. World J Gastroenterol, 
25(30), 4125-4147. doi:10.3748/wjg.v25.i30.4125 
Yoseph, B. P., Klingensmith, N. J., Liang, Z., Breed, E. R., Burd, E. M., Mittal, R., . . 
. Coopersmith, C. M. (2016). Mechanisms of Intestinal Barrier Dysfunction in 
Sepsis. Shock, 46(1), 52-59. doi:10.1097/SHK.0000000000000565 
Yoshikawa, Y., Nakayama, T., Saito, K., Hui, P., Morita, A., Sato, N., . . . Usami, R. 
(2007). Haplotype-based case-control study of the association between the 
guanylate cyclase activator 2B (GUCA2B, Uroguanylin) gene and essential 
hypertension. Hypertens Res, 30(9), 789-796. doi:10.1291/hypres.30.789 
Young, J., Yu, X., Wolslegel, K., Nguyen, A., Kung, C., Chiang, E., . . . Grogan, J. L. 
(2010). Lymphotoxin-alphabeta heterotrimers are cleaved by 
metalloproteinases and contribute to synovitis in rheumatoid arthritis. 
Cytokine, 51(1), 78-86. doi:10.1016/j.cyto.2010.03.003 
Yu, F. S., Yin, J., Xu, K., & Huang, J. (2010). Growth factors and corneal epithelial 
wound healing. Brain Res Bull, 81(2-3), 229-235. 
doi:10.1016/j.brainresbull.2009.08.024 
Yu, K. Y., Kwon, B., Ni, J., Zhai, Y., Ebner, R., & Kwon, B. S. (1999). A newly 
identified member of tumor necrosis factor receptor superfamily (TR6) 
suppresses LIGHT-mediated apoptosis. J Biol Chem, 274(20), 13733-
13736. doi:10.1074/jbc.274.20.13733 
Yuan, J., & Horvitz, H. R. (2004). A first insight into the molecular mechanisms of 
apoptosis. Cell, 116(2 Suppl), S53-56, 51 p following S59. 
doi:10.1016/s0092-8674(04)00028-5 
Zachary, J. F., & McGavin, M. D. (2012). Pathologic basis of veterinary disease (5th 
ed.). St.Louis, Mo.: Elsevier. 
Zambrano, S., De Toma, I., Piffer, A., Bianchi, M. E., & Agresti, A. (2016). NF-
kappaB oscillations translate into functionally related patterns of gene 
expression. Elife, 5, e09100. doi:10.7554/eLife.09100 
Zhang, C., Yan, J., Xiao, Y., Shen, Y., Wang, J., Ge, W., & Chen, Y. (2017). 
Inhibition of Autophagic Degradation Process Contributes to Claudin-2 
Expression Increase and Epithelial Tight Junction Dysfunction in TNF-alpha 
Treated Cell Monolayers. Int J Mol Sci, 18(1). doi:10.3390/ijms18010157 
301 
 
Zhang, H., Nan, W., Wang, S., Zhang, T., Si, H., Wang, D., . . . Li, G. (2016). 
Epidermal growth factor promotes proliferation of dermal papilla cells via 
Notch signaling pathway. Biochimie, 127, 10-18. 
doi:10.1016/j.biochi.2016.04.015 
Zhang, J. M., & An, J. (2007). Cytokines, inflammation, and pain. Int Anesthesiol 
Clin, 45(2), 27-37. doi:10.1097/AIA.0b013e318034194e 
Zhang, L., Sun, J., Wang, B., Ren, J. C., Su, W., & Zhang, T. (2015). MicroRNA-
10b Triggers the Epithelial-Mesenchymal Transition (EMT) of Laryngeal 
Carcinoma Hep-2 Cells by Directly Targeting the E-cadherin. Appl Biochem 
Biotechnol, 176(1), 33-44. doi:10.1007/s12010-015-1505-6 
Zhang, P., Liu, X., Guo, A., Xiong, J., Fu, Y., & Zou, K. (2016). B Cell-Activating 
Factor as a New Potential Marker in Inflammatory Bowel Disease. Dig Dis 
Sci, 61(9), 2608-2618. doi:10.1007/s10620-016-4136-z 
Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., . . . Hauser, C. J. 
(2010). Circulating mitochondrial DAMPs cause inflammatory responses to 
injury. Nature, 464(7285), 104-107. doi:10.1038/nature08780 
Zhang, X., Wu, J., Ye, B., Wang, Q., Xie, X., & Shen, H. (2016). Protective effect of 
curcumin on TNBS-induced intestinal inflammation is mediated through the 
JAK/STAT pathway. BMC Complement Altern Med, 16(1), 299. 
doi:10.1186/s12906-016-1273-z 
Zhang, Y., Chen, D., Wang, F., Li, X., Xue, X., Jiang, M., . . . Liang, J. (2019). 
Comparison of the efficiency of different enemas on patients with distal 
ulcerative colitis. Cell Prolif, 52(2), e12559. doi:10.1111/cpr.12559 
Zhao, G. J., Li, D., Zhao, Q., Lian, J., Hu, T. T., Hong, G. L., . . . Lu, Z. Q. (2016). 
Prognostic Value of Plasma Tight-Junction Proteins for Sepsis in 
Emergency Department: An Observational Study. Shock, 45(3), 326-332. 
doi:10.1097/SHK.0000000000000524 
Zhou, Z., Ren, J., Liu, H., Gu, G., & Li, J. (2011). Serum proteomic analysis from 
bacteremic and leucopenic rabbits. J Surg Res, 171(2), 749-754. 
doi:10.1016/j.jss.2010.04.056 
Zhu, Y., Brannstrom, M., Janson, P. O., & Sundfeldt, K. (2006). Differences in 
expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in 
human ovarian surface epithelium as compared to epithelia in inclusion 
cysts and epithelial ovarian tumours. Int J Cancer, 118(8), 1884-1891. 
doi:10.1002/ijc.21506 
Zihni, C., Mills, C., Matter, K., & Balda, M. S. (2016). Tight junctions: from simple 
barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol, 17(9), 
564-580. doi:10.1038/nrm.2016.80 
Zou, G. M., & Hu, W. Y. (2005). LIGHT regulates CD86 expression on dendritic 
cells through NF-kappaB, but not JNK/AP-1 signal transduction pathway. J 
Cell Physiol, 205(3), 437-443. doi:10.1002/jcp.20420 
Zou, H., Li, Y., Liu, X., & Wang, X. (1999). An APAF-1.cytochrome c multimeric 
complex is a functional apoptosome that activates procaspase-9. J Biol 
Chem, 274(17), 11549-11556. doi:10.1074/jbc.274.17.11549 
Zuo, C., Sheng, X., Ma, M., Xia, M., & Ouyang, L. (2016). ISG15 in the 
tumorigenesis and treatment of cancer: An emerging role in malignancies of 
the digestive system. Oncotarget, 7(45), 74393-74409. 
doi:10.18632/oncotarget.11911 
Zwanzger, P., Domschke, K., & Bradwejn, J. (2012). Neuronal network of panic 
disorder: the role of the neuropeptide cholecystokinin. Depress Anxiety, 







Cell Death Dis. 2019 Dec; 10(12): 896.  
Published online 2019 Nov 26. doi: 10.1038/s41419-019-2129-5 
PMCID: PMC6879761 
PMID: 31772152 
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Abstract 
Alternative pathway NF-κB signalling regulates susceptibility towards developing 
inflammatory bowel disease (IBD), colitis-associated cancer and sepsis-associated 
intestinal epithelial cell apoptosis and shedding. However, the cell populations 
responsible for the perturbed alternative pathway NF-κB signalling in intestinal 
mucosal pathology remain unclear. In order to investigate the contribution of the 
epithelial compartment, we have tested whether NF-κB2 regulated transcription in 
intestinal epithelial cells controls the intestinal epithelial response to cytokines that 
are known to disrupt intestinal barrier permeability. Enteroids were generated from 
the proximal, middle and distal regions of small intestine (SI) from C57BL/6J wild-
type mice and displayed region-specific morphology that was maintained during 
sub-culture. Enteroids treated with 100 ng/mL TNF were compared with 
corresponding regions of SI from C57BL/6J mice treated systemically with 
0.33 mg/kg TNF for 1.5 h. TNF-induced apoptosis in all regions of the intestine in 
vitro and in vivo but resulted in Paneth cell degranulation only in proximal tissue-
derived SI and enteroids. TNF also resulted in increased enteroid sphericity 
(quantified as circularity from two-dimensional bright field images). This response 
was dose and time-dependent and correlated with active caspase-3 
immunopositivity. Proximal tissue-derived enteroids generated from Nfκb2−/− mice 
showed a significantly blunted circularity response following the addition of TNF, 
IFNγ, lipopolysaccharide (LPS) activated C57BL/6J-derived bone marrow-derived 
dendritic cells (BMDC) and secreted factors from LPS-activated BMDCs. However, 
Nfκb1−/− mouse-derived enteroids showed no significant changes in response to 
these stimuli. In conclusion, the selection of SI region is important when designing 
enteroid studies as region-specific identity and response to stimuli such as TNF are 
maintained in culture. Intestinal epithelial cells are at least partially responsible for 
regulating their own fate by modulating NF-κB2 signalling in response to stimuli 
known to be involved in multiple intestinal and systemic diseases. Future studies 
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Introduction 
The intestine is lined by a single layer of columnar epithelial cells that function to 
maintain a barrier between luminal contents and the body1,2. Barrier function is 
maintained by the tight regulation of intestinal epithelial cell proliferation, apoptosis 
and cell shedding rates which are themselves modulated by several factors, 
including age, genetic background, dietary components, intestinal microbiota, 
enterally and parenterally administered drugs and other environmental factors3. 
Dysregulation of these cellular processes results in the break-down of the intestinal 
barrier and this is thought to be a contributing factor to the development of multiple 
diseases. We have recently shown that defective intestinal barrier function caused 
by cell shedding in the terminal ileum predicts relapse of inflammatory bowel 
disease (IBD) in humans4. Defects in intestinal barrier function may also be involved 
in the pathogenesis of systemic conditions, such as metabolic endotoxaemia and 
sepsis5,6. 
Several pro-inflammatory cytokines are present at increased concentrations in the 
circulation, intestinal lumen and lamina propria of the intestine during active IBD, 
infectious diarrhoea, coeliac disease and sepsis7–12. Tumour necrosis factor (TNF) 
is a well characterised cytokine that is produced in these conditions and is a key 
mediator of mucosal pathology3,13. Elevated TNF concentrations in excess of 
63 ng/g stool have been documented in humans in response to Shigella flexneri 
infection11. Anti-TNF therapies are also widely used clinically to ameliorate active 
Crohn’s disease14. 
We have recently shown that the administration of lipopolysaccharide (LPS) or its 
downstream effector, TNF, by intraperitoneal injection to mice results in a massive 
induction of epithelial apoptosis and cell shedding from the SI villus tip within 
1.5 h4,15–17. This rapid onset of active caspase-3 positively stained shedding cells 
subsequently resulted in villus atrophy and was accompanied by fluid effusion into 
the SI lumen and diarrhoea, but was largely diminished at 3 h post LPS injection17. 
However, increased efflux of FITC-dextran (FD4) from the intestinal lumen into the 
circulation following LPS treatment was observed at later time-points17, suggesting 
that defects in intestinal barrier function persist once cell shedding and apoptosis 
have subsided, until complete restitution of the epithelium has been achieved. The 
regenerative capacity of the intestinal epithelium is remarkable. Cell turnover in the 
epithelium is normally around 5 days with around 1400 cells shed from a single 
mouse villus tip per day18. We would therefore anticipate that barrier function could 
take up to 5 days to be restored following extensive epithelial cell loss by apoptosis 
and cell shedding once inflammatory stimuli such as TNF and interferon γ (IFNγ) 
have been removed. Understanding the mechanisms underpinning intestinal 
epithelial cell protection from cytokine-mediated injury will enable the future 
development of therapeutics for several intestinal and systemic diseases. 
The NF-κB family of transcription factors consists of 5 members (NF-κB2 (p52), 
RelB, NF-κB1 (p50), c-Rel, and RelA (p65)) and regulate multiple cellular 
processes19. We have recently identified components of the alternative NF-κB 
signalling pathway that are important in modulating the susceptibility to IBD, colitis-
associated cancer and intestinal epithelial apoptosis and cell shedding in mice. 
Nfκb2−/− mice were resistant to dextran sulphate sodium (DSS)-induced colitis and 
azoxymethane/DSS-induced colonic adenoma formation20 and were also resistant 
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to the induction of LPS and TNF-induced SI apoptosis and cell shedding in vivo16,17. 
Infection studies have also shown that Nfκb2−/− mice have a reduced ability to clear 
the gut helminth Trichuris muris21 and the gastric pathogen Helicobacter felis, the 
latter observation being associated with reduced gastric preneoplastic pathology 
owing to a defective immune response22. The complex in vivo nature of these 
studies to date, has made it impossible to determine the importance of each cellular 
compartment (e.g., immune or epithelial) in regulating the intestinal response to 
damage-inducing stimuli. The majority of studies characterising alternative pathway 
NF-κB signalling are also focused on immune cell mechanisms which may be 
differentially regulated in other cellular compartments. Therefore, we have now 
generated a SI enteroid model to assess the interactions between the intestinal 
epithelium and specific immune cell derived cytokines that are known to be 
elevated in intestinal and systemic disease, and to determine the importance of 
epithelial cell-specific alternative pathway NF-κB signalling in regulating the 
epithelial cell response to cytokine-induced pathology. 
Dendritic cells are present throughout the lamina propria of the gut and contribute to 
innate and adaptive immunity thus regulating gut homoeostasis. Direct bidirectional 
interaction of dendritic cells with the epithelium is believed to maintain the dendritic 
cell population in a tolerogenic state and this protects the intestinal epithelium from 
inappropriate immune cell-derived attack23. Whilst dendritic cells are the most 
potent antigen presenting cell population, they are also activated by pro-
inflammatory cytokines or oxidative stress and are conditioned by their surrounding 
microenvironment24. Cytokines and chemokines released by dendritic cells along 
with other lamina propria immune cell populations can modulate intestinal barrier 
integrity, intestinal cell proliferation and cell death25. Our previous whole mouse 
global Nfκb2 knockout studies17,20,22 have limited our ability to dissect the 
importance of alternative pathway NF-κB signalling within epithelial and immune 
compartments in regulating the susceptibility of the intestinal epithelium to cytokine-
induced injury. We therefore generated a bone marrow-derived dendritic cell 
(BMDC) reconstituted intestinal organoid model to assess the role of NF-κB2 in 
regulating intestinal epithelial cell-specific responses to secreted factors from 
BMDCs. 
We hypothesise that Nfκb2 activation within intestinal epithelial cells sensitises 
them to the induction of apoptosis by pro-inflammatory cytokines that are 
upregulated in intestinal tissues and systemically during active intestinal disease 
and bacteraemia. We have therefore explored whether Nfκb2 inhibition within 
intestinal epithelia could be a potential therapeutic approach to ameliorating 
inflammation-associated intestinal disease using a novel reconstituted intestinal 
organoid co-culture model. 
Results 
Regional differences are observed in enteroid morphology 
The small intestine (SI) displays regional differences in structure and function. The 
expression of several genes is altered along the cephalocaudal axis in vivo and this 
region-specific identity has previously been shown to be maintained in enteroid 
culture26,27. We therefore generated organoids from proximal, middle and distal 
2 cm segments of murine SI from female C57BL/6J mice and assessed their 
morphological changes over 10 consecutive passages. Enteroids derived from the 
three distinct areas displayed morphological differences between regions and these 
did not alter following repeated passage. At days 3–5 post passage, proximal SI 
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derived enteroids had the longest (116 ± 3 μm) and most abundant crypt domains 
(7.22 ± 0.26/enteroid) with smooth surfaces and a polarised Paneth cell distribution 
at the base of crypts, whilst the distal SI derived enteroids had a smaller number of 
crypt domains (4.04 ± 1.02/enteroid) which were shorter (89 ± 4 μm) and displayed a 
more rounded and rugged appearance with a less polarised Paneth cell distribution 
with these differentiated cells also being found further along the crypt axes (Fig. 
(Fig.1a).1a). Middle SI derived enteroids had 5.22 ± 1.90 crypts per enteroid that 
were 91 ± 11 μm in length and showed the greatest degree of variation in crypt 




Enteroids show regional differences in morphology and respond to TNF 
similarly to native SI tissue. 
Bright field micrographs of enteroids derived from proximal, middle and distal 
sections of C57BL/6J SI (a). Proximal, middle and distal sections of SI tissue taken 
from untreated and TNF (0.33 mg/kg, 1.5 h) treated C57BL/6J mice (b) and 
enteroids generated from proximal, middle and distal regions of SI untreated or 
treated with TNF (100 ng/mL 24 h) (c) immunohistochemically stained for active 
caspase-3. Quantification of active caspase-3 positive epithelial cells from 
untreated (white) and TNF treated (black) SI epithelia (d) and enteroid culture (e). 
For animal study, quantified from n = 6 mice per group; for enteroid study n = 6, 
N = 3, *p < 0.05, **p < 0.01. Scale bars = 100 µm. 
TNF induces enteroid apoptosis and Paneth cell depletion, but does 
not modulate enteroid proliferation 
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We previously identified subtle regional differences in the murine SI in vivo in 
response to intraperitoneally administered LPS. A greater extent of villus blunting 
was observed in the proximal SI compared with other SI regions17. We therefore 
investigated the apoptotic and proliferative responses to a downstream effector of 
LPS, TNF, in region-specific enteroid cultures compared to histological sections 
taken from the same regions of the intestine in vivo. Baseline amounts of apoptosis 
in both untreated SI and in enteroid culture regardless of region were low, however, 
a small increase in the percentage of active caspase-3 positive cells was observed 
along the cephalocaudal axis in both systems (Fig. 1b–e). As expected, 
intraperitoneal injection of 0.33 mg/kg TNF-induced a significant increase in 
apoptotic cells at the villus tip after 1.5 h (Fig. 1b, d), whilst 100 ng/ml TNF-induced 
apoptosis to a similar extent in enteroids after 24 h (Fig. 1c, e). 
Paneth cells are important for maintaining the intestinal stem cell niche, although 
the exact mechanisms by which this cell population supports the proliferative 
capacity and number of neighbouring crypt base columnar cells remain unknown. 
However, TNF has previously been shown to induce Paneth cell dysfunction in 
vivo28, and this could potentially impact on the regenerative capacity of the intestinal 
epithelium. We therefore investigated whether TNF modulated Paneth cell number 
in SI tissue and in enteroids as this could impact on crypt-villus growth dynamics. 
TNF administration caused a more marked and significant reduction in Paneth cell 
number in the proximal SI and proximal tissue-derived enteroids compared with 
other SI regions (Fig. 2a, b) suggesting that TNF may modulate the intestinal stem 
cell niche in different ways within the proximal SI compared with other intestinal 
regions. Olfactomedin-4 (Olfm4) is a putative active stem cell marker that also 
labels early transit-amplifying cells. Olfm4 expression was not altered in SI tissues 
treated with TNF but due to the distribution differences in cellular location of Olfm4 
observed in enteroids, Olfm4 expressing cells were not possible to quantify reliably 
(Supplementary Fig. 1). We also wanted to test whether another abundant 
secretory cell type was affected by the addition of TNF and found that the goblet 
cell population in different regions of SI and in enteroids was not modulated by the 






TNF causes Paneth cell degranulation in proximal SI but does not change the 
rate of cell proliferation. 
Proximal SI and enteroids stained with Sirius red (a). Percentage of Sirius red 
stained Paneth cells in untreated (white) and TNF treated (black) proximal, middle 
and distal derived SI (top) and enteroids (bottom) (b). Proximal SI and enteroids 
stained with Ki67 (c). Percentage of Ki67 stained epithelial cells in untreated (white) 
and TNF treated (black) proximal, middle and distal derived SI (top) and enteroids 
(bottom) (d). For animal study quantified from n = 6 mice per group, for enteroid 
study n = 6, N = 3, *p < 0.05. Scale bars = 100 µm. 
Proliferation in the SI in vivo occurs within the transit-amplifying region of the crypt; 
a distinctly different part of the crypt-villus axis to the villus tip, which is the region 
most susceptible to apoptosis in response to systemically administered TNF. As we 
have shown that TNF causes apoptosis and Paneth cell depletion at the dose and 
time-points tested in mice in vivo and in enteroids, we wanted to determine whether 
this treatment had any impact on intestinal proliferation. Proliferation indicated by 
Ki67 positively stained nuclei was identified in the crypt domains of whole SI tissue 
and enteroids. TNF treatment had no significant effect on cellular proliferation either 
in vivo or in enteroid culture, in any of the three SI regions at the doses and time 
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points that showed an increased apoptotic response and Paneth cell depletion (Fig. 
2c, d). 
Apoptosis and resultant cell shedding into the lumen correlate 
positively with enteroid circularity 
Villus shortening occurs in vivo as a result of an increased rate of apoptosis and cell 
shedding from the villus tip with no compensatory increase in cellular proliferation 
(Figs. (Figs.11 and and22)17. Similar atrophy also occurs in enteroid cultures. As a 
result of cell loss by apoptosis with no accompanying change in cellular proliferation 
(Figs. (Figs.11 and and2),2), cells are shed into the enteroid lumen and these are 
not immediately replaced. Junctional complexes hold remaining epithelial cells 
together whilst there is likely pressure from the build-up of apoptotic bodies within 
enteroid lumens. This results in the enteroids gaining a more spherical morphology. 
We have quantified this enteroid ‘rounding’ in terms of circularity from 2-
dimensional images and have validated this as a reproducible and robust method of 
cell death analysis in enteroids following cytokine treatment (materials and 
methods). Three days post passage, untreated enteroids had circularity values of 
~0.35, however, circularity increased to ~0.65 48 h following 100 ng/mL TNF and 
~0.9 with conditioned media from LPS-activated BMDCs in C57BL/6J proximal 
tissue-derived enteroids (Fig. (Fig.3a).3a). We validated the reproducibility of the 
scoring method by assessment of intra-scorer variability where the same person 
(L.J.) scored images from the same 12 enteroids with a range of different 
circularities 1 week apart (Fig. (Fig.3b),3b), and inter-scorer variability where two 
different blinded scorers (L.J. and C.D.) assessed enteroid circularity from the same 
12 enteroid images (Fig. (Fig.3c).3c). We also determined that there was no 
correlation between enteroid area and circularity as long as organoids were above 
a critical size at the start of each experiment, which equated to 3 days post passage 




Validation of circularity assessment as a marker of TNF-induced apoptosis in 
enteroid culture. 
Light micrograph examples of proximal tissue-derived enteroids either untreated 3 
days post passage (left), 48 h following 100 ng/ml TNF (middle) and 48 h following 
treatment with CM from LPS-activated BMDCs (right) traced in yellow using Image 
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J (a). Quantification of circularity from 12 different enteroids administered with a 
range of treatments over different experiments and re-scored by the same observer 
(b) and by an independent second observer (c). Correlation between relative 
enteroid area and circularity for 130 individual enteroids at baseline (d), small 
organoids at baseline have high circularity values and need to be excluded from 
further analysis (grey box). Percentage active-caspase 3 positive cells were 
correlated with enteroid circularity from organoids selected at 0, 24 and 48 h post 
treatment with 100 ng/ml TNF (e). Change in circularity between three enteroid 
regions at baseline (white bars) and 24 h after 100 ng/ml TNF (black bars). Scale 
bars = 100 µm. 
To further validate the assessment of circularity as a reliable indicator of cytokine-
induced cell death in proximal tissue-derived enteroids, we observed a good 
positive correlation (R2 = 0.6) between enteroid circularity and active caspase-3 
immunohistochemical staining (Fig. (Fig.3e).3e). TNF activates apoptosis via 
caspase-8 and active caspase-8 is observed at the villus tip during intestinal cell 
shedding29. Active caspase-8 was not detected at later time-points during enteroid 
studies (Supplementary Fig. 3). As enteroids derived from the middle or distal 
segments of the SI displayed a more rounded appearance in culture at baseline 
(Fig. (Fig.1a),1a), they also showed a blunted response to TNF in terms of 
increased circularity compared with proximal tissue-derived enteroids (Fig. 
(Fig.3f).3f). Future studies should therefore consider the use of the circularity 
method for determining enteroid response to injury, however this method is not 
suitable for comparing responses between enteroid regions. We therefore used 
proximal tissue-derived enteroids for the remainder of this study. 
Alternative NF-κB pathway signalling in small intestinal epithelial cells 
regulates the response to cytokine-induced injury 
We have previously shown that Nfκb2−/− mice are resistant to TNF-induced villus tip 
apoptosis and cell shedding compared with their wild-type C57BL/6J counterparts17. 
However, the mechanism responsible for this resistance could not be determined 
during these in vivo studies as it was impossible to quantify the contribution of 
specific cellular compartments such as epithelial cells or immune cells. Using 
proximal tissue-derived enteroids, we have now assessed the importance of NF-
κB2 signalling specifically in the epithelial cell compartment in response to TNF and 
IFNγ stimulation. Both TNF and IFNγ caused C57BL/6J and Nfκb1−/− mouse-
derived enteroids to undergo morphological changes and round up over a 24-h 
period, with further noticeable rounding after 48 h (Fig. 4a, b). This response was 
however blunted in Nfκb2−/− enteroids (Fig. (Fig.4c).4c). A dose-dependent increase 
in circularity was observed in C57BL/6J and Nfκb1−/− enteroids from 1 to 
1000 ng/mL TNF and from 0.1 to 100 ng/mL IFNγ at both 24- and 48-h post 
treatment, however, no such increase was observed in Nfκb2−/− enteroids (Fig. 5a–
f) suggesting that alternative pathway NF-κB activation is an important modulator of 






TNF induces circularity of C57BL/6 but not Nfκb2−/− enteroids. 
TNF (100 ng/mL) induces enteroid rounding of C57BL/6J (a) and Nfκb1−/− (b) 
proximal tissue-derived enteroids but not Nfκb2−/− proximal tissue-derived enteroids 






TNF and IFNγ-induced circularity is blunted in Nfκb2−/− enteroids. 
Enteroid circularity is dose-dependently increased at 24 and 48 h time-points by 
treatment with TNF (a–c) and IFNγ (d–f) in C57BL/6J-derived enteroids (a, d) and 
Nfκb1−/− enteroids (b, e), but is blunted in Nfκb2−/− enteroids (c, f). N = 4, n = 6, 
*p < 0.05, **p < 0.01, **p < 0.001 compared with untreated of the same genotype at 
the same time point. 
LPS-activated bone marrow-derived dendritic cells induce enteroid 
rounding in a co-culture model and this is inhibited by epithelial NF-
κB2 deletion 
LPS administration to mice in vivo resulted in abundant villus tip apoptosis and cell 
shedding 1.5 h following intraperitoneal injection. We have previously shown 
Tnfr1−/− and Tlr4−/− mice to be resistant to LPS-induced cell shedding, suggesting 
that LPS acts via TLR4 on immune cells to induce ligands that bind the TNFR1 on 
epithelial cells to initiate the shedding process17. Dendritic cells have important 
functions in the innate and adaptive immune systems and are activated by LPS. We 
therefore co-cultured C57BL/6J-derived BMDCs with C57BL/6J, Nfκb1−/− or Nfκb2−/− 
enteroids and tested BMDCs that had or had not been activated by LPS. The direct 
application of 1 μg/mL LPS or unstimulated BMDCs had no morphological effect on 
any enteroid genotype (Fig. (Fig.6a)6a) and we did not observe any significant 
differences in enteroid circularity following treatment (Fig. 6b–d). Interestingly, co-
culture of C57BL/6J and Nfκb1−/− enteroids with LPS-activated BMDCs resulted in 
enteroid rounding (Fig. (Fig.6a)6a) and a significant increase in enteroid circularity 
at both 24- and 48-h post treatment (Fig. 6b, c). However, Nfκb2−/− enteroids were 
resistant to rounding and showed no significant increase in circularity in co-culture 
with LPS-activated BMDCs at 24 or 48 h (Fig. 6a, d). This suggests that NF-κB2 







Nfκb2−/− enteroids showed a blunted response to co-culture with LPS 
activated BMDCs. 
Enteroids were generated from the proximal SI of C57BL/6J, Nfκb1−/− and Nfκb2−/− 
mice and were either left untreated, treated with 1 µg/ml LPS, 5 × 104 C57BL/6J-
derived BMDC or 5 × 104 C57BL/6J-derived BMDC plus 1 µg/ml LPS and subjected 
to light microscopy at 48 h (a). Circularity assessment was conducted at 0, 24 and 
48 h time points for each stimulus in C57BL/6J (b), Nfκb1−/− (c) and Nfκb2−/− (d) 
enteroids. N = 3, n = 6, *p < 0.05, **p < 0.01 compared with untreated of the same 
enteroid genotype at the same time point. Scale bars = 100 µm. 
Secreted factors from LPS-activated bone marrow-derived dendritic 
cells are responsible for organoid injury 
We sought to determine whether the direct action of BMDC secreted factors on 
epithelial cells were responsible for the observed increase in C57BL/6J-derived 
enteroid circularity following stimulation with LPS. Conditioned media from 
unstimulated and LPS-stimulated BMDCs was placed onto C57BL/6J enteroids. 
Conditioned media from BMDCs did not induce an increase in enteroid circularity, 
however, conditioned media from LPS-activated BMDCs induced a significant 
increase in enteroid circularity at both 24- and 48-h post treatment (Fig. 7a, b). We 
assessed the cytokines that had been secreted by BMDCs into this conditioned 
media following stimulation with LPS and determined that several pro-inflammatory 
cytokines were upregulated. Initial analysis suggested that the amounts of IL-2, IL-
4, IL-5 and IL-23 produced were minimal or below the lower limit of detection, 
hence these cytokines were not considered in subsequent experiments. TNF was 
upregulated in response to LPS and reached maximal concentrations of around 
1 ng/mL (Table (Table1).1). However, this concentration was not high enough to 
stimulate an increase in enteroid circularity alone (Figs. (Figs.44 and and5).5). 
Significant increases in IL-6, IL-1β, IL-17A and IL-15 were also detected in the 
media of LPS-activated BMDCs in co-culture with enteroids and these cytokines 
may therefore have contributed to the observed increase in enteroid circularity. 
Secreted factors from dendritic cells are therefore able to modulate intestinal 






Conditioned media from LPS-activated BMDCs induced enteroid rounding. 
Enteroids derived from the proximal SI of C57BL/6J mice were untreated or treated 
with 50% conditioned media (CM) generated from 1 × 105 BMDC/ml that were 
previously either untreated or treated with 1 µg/ml LPS for 48 h (a). Circularity 
assessment of enteroids was conducted at 0, 24 and 48 h time points for each 
stimulus (b). N = 3, n = 6, **p < 0.01 compared with untreated at the same time 
point. Scale bars = 100 µm. 
Table 1 
Cytokines produced by C57BL/6J proximal tissue-derived enteroids, enteroids in 









IFN-γ 0.09 ± 0.02 0.05 ± 0.02 ND 
IL-10 ND 98.42 ± 43.94 51.18 ± 30.89 
IL-12 p70 ND 2.35 ± 2.03 320.85 ± 94.57 
IL-15 0.40 ± 0.40 10.81 ± 6.37 186.74 ± 42.01* 
IL-17A 0.01 ± 0.01 0.01 ± 0.01 1.51 ± 0.28* 
IL-1β ND 0.61 ± 0.28 42.90 ± 5.36* 
IL-33 0.60 ± 0.15 0.30 ± 0.19 4.97 ± 2.92 
IL-6 2.14 ± 0.82 31.61 ± 14.81 43967.35 ± 4220.72* 
KC/GRO 4.16 ± 0.55 5.52 ± 1.96 103.43 ± 30.89 
TNF 2.29 ± 0.51 180.37 ± 78.95 806.86 ± 335.23 
Analysis from three independent experiments in duplicate, data presented ± SEM. ND = not 




Recent advances have enabled long-term three-dimensional culture of the 
mammalian SI epithelium30–32. However, many published studies have not 
considered the differences that exist in structure and function between different 
anatomical regions of the SI in vivo. The duodenum, jejunum and ileum are each 
specialised compartments which have distinct absorptive and secretory 
functions26,33–36. Previous studies in human and mouse enteroids have indicated 
that cultures retain their region-specific identities following multiple passage, in the 
absence of mesenchymal cell signalling or other niche factors27. For instance, the 
Gata 4 transcription factor is highly expressed in all epithelial cells of the 
duodenum, but shows greatly reduced expression further down the cephalocaudal 
axis, with no expression being detected in the terminal ileum26,27. Gata 4 has been 
shown to activate jejunal-specific genes such as Clnd2 (encoding Claudin-2 protein) 
but represses ileal-specific genes such as Slc10a2 (solute carrier family 10, 
member 2) and Fabp6 (encoding fatty acid binding protein 6)26,37. Overexpression 
of Claudin-2 has been associated with inflammatory bowel disease and coeliac 
disease38 and is also upregulated in the intestine within 1 h of experimentally 
induced sepsis39. Regional differences in susceptibility occur for each of these 
pathologies and this is likely to result from differences in gene expression and 
environmental cues. 
We therefore considered SI location when establishing enteroids and have 
identified variations in growth dynamics between three different regions of the 
intestine at baseline and following TNF treatment. These differences were also 
observed in parallel in vivo studies. In particular, Paneth cell numbers were 
increased from proximal to distal SI in vivo and in enteroid culture and we noted a 
greater amount of Paneth cell degranulation in the proximal SI both in vitro and in 
vivo in response to TNF. Previous studies have indicated that there is a greater 
degree of LPS-induced SI shedding and villus atrophy in the proximal SI compared 
with other regions17, however, loss of Paneth cell function within the crypt domains 
may also contribute to an alteration in the SI stem cell niche, thus perturbing cell 
production and dynamics further along the crypt-villus axis. We did not observe 
differences in the proliferative compartment along the length of the intestine by Ki67 
immunohistochemistry (IHC), however, a large population of cells are labelled by 
Ki67 in both systems and more subtle differences in the proliferative compartment 
may be apparent by using more sensitive detection methods. It was difficult to 
compare the overall growth rate of organoids between the three regions, however, 
distal tissue-derived enteroids were more difficult to establish than those from other 
regions of the SI and displayed morphological differences that were maintained for 
greater than ten passages. Therefore, future studies should consider that following 
successive culture, proximal tissue-derived enteroids may outcompete distal tissue-
derived derived enteroids in a mixed population. 
One of the major cytokines that is responsible for the development of IBD and 
which is a major contributor to the cytokine storm and multiple organ dysfunction 
(including the gut epithelium) that occurs in sepsis is TNF4,7,17. The direct impact of 
TNF on enteroid morphology was striking. Over a period of 48 h, enteroids adopted 
a rounded appearance and many became almost spherical. This altered 
morphology was a likely result of increased apoptosis and cell shedding into the 
enteroid lumen. Analogous to bubble formation, a spherical appearance may result 
from the line of least tension across tight and adherens junctions with pressure 
build up from shed cellular debris and secretions within the enteroid lumen. The 
observed change in enteroid morphology was assessed by measuring circularity 
and this correlated linearly with active caspase-3 expression, thus validating the 
technique as a method for analysing cell death in this setting. This technique is 
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much quicker than other similarly reported methods such as the assessment of 
branching morphogenesis by assessing the number and length of crypt buds40. The 
circularity assessment method is therefore useful for determining dose and time 
points for further investigations of a mechanistic nature, but requires optimisation 
and validation for each culture media formulation and damaging stimulus. The 
mechanisms of rounding are unlikely to be the same for all stimuli, however, this 
assay is particularly useful to determining the morphological impact on intestinal 
epithelia. Active caspase-3 is relatively stable compared with other caspases and 
has a half-life of 8–11 h41 and was detectable following TNF treatment for the entire 
time-course of our experiments. We also assessed the expression of active 
caspase-8 and whilst this was observed at the villus tip at early time-points as in 
previous studies29, this caspase is much less stable, cleaved components p43 
having a half-life of 63 ± 5 min and p18 having a much shorter half-life of 7 ± 1 min42 
and was not detected over the whole time-course of our experiments in enteroids, 
thus active caspase-8 activity did not positively correlate with enteroid circularity. 
Upregulation of NF-kB2 mRNA has been observed in colitis-associated dysplasia 
and carcinoma43. Our previous in vivo studies have also demonstrated that Nfκb2−/− 
mice are less susceptible to the induction of experimental colitis, colitis-associated 
cancer and LPS-induced SI cell shedding17,20. However, the role of the intestinal 
epithelium in contributing to this protection was previously unclear as Nfκb2−/− mice 
have a perturbed immune system that could have also contributed to the altered 
phenotype44. We have now demonstrated that Nfκb2−/− proximal SI epithelium is 
resistant to TNF and IFNγ induced pathology in enteroids in the absence of 
contributions from the other cellular compartments that are present in vivo. This 
suggests that NF-κB2 signalling is an important determinant of intestinal epithelial 
cell homoeostasis. A range of concentrations of cytokines was tested in our 
experiments and alterations in circularity were noted at concentrations greater than 
10 ng/ml TNF and 0.1 ng/ml IFNγ. These concentrations are higher than those 
detected in the circulation and tissues of human patients, however, faecal 
concentrations have been noted between 1 and 100 ng/g and are in line with the 
concentrations used in this study11. Murine TNF is a known regulator of both 
classical and alternative pathway NF-κB signalling and is likely to mediate its effects 
via TNFR1 and 2 ligation. However, it was surprising to also observe a decreased 
sensitivity to IFNγ in Nfκb2−/− enteroids, though this is likely to be via an indirect 
mechanism resulting in the production of an NF-κB2 activator such as BAFF45. In 
addition to TNF and IFNγ, many cytokines contribute to the development of 
intestinal pathologies. We generated a co-culture model incorporating enteroids and 
BMDCs and showed that these cell populations could co-exist without any change 
to enteroid morphology. However, upon activation by LPS, BMDCs induced 
significant morphological changes in wild-type enteroids, whereas Nfκb2−/− 
enteroids were seemingly protected. Cytokines generated in the model included 
TNF and IFNγ but both were produced at much lower concentrations than were 
required alone to induce circularity changes in enteroids and were similar to those 
observed in patients with pathology. This suggests that other secreted factors may 
also act synergistically with TNF and IFNγ to induce enteroid rounding in this 
setting. IL-6 was produced in abundance and could therefore contribute to 
modulating epithelial cell dynamics. An in-depth investigation of the BMDC 
secretome and assessment of cytokine combinations is now warranted to 
determine how the intestinal mucosal microenvironment regulates epithelial cell 
dynamics in combination with genetic susceptibility that may modulate the threshold 
for cytokines to induce a pathological response. 
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These data suggest that the NF-κB2 signalling pathway, specifically in intestinal 
epithelial cells, may be targetable to ameliorate intestinal and systemic 
inflammation. 
Materials and methods 
Animals 
Ten- to 12-week old wild-type C57BL/6J (Charles River, Margate, UK) and NfκB1−/− 
and Nfκb2−/− mice44,46, bred on the C57BL/6J genetic background were maintained 
at the University of Liverpool under a 12:12 h light dark cycle and fed a standard 
pelleted diet. All mice were euthanized by cervical dislocation with ethical approval 
under UK Home Office legislation (Animals Scientific Procedures Act 1986) and 
local ethical approval. 
TNF treatment 
Six female C57BL/6J mice were administered 0.33 mg/kg murine recombinant TNF 
(Peprotech Ltd., London, UK) by intraperitoneal injection and euthanized 1.5 h later. 
Six untreated female C57BL/6J were used as controls, mice were randomly 
allocated to two groups prior to treatment. SIs were excised, flushed with 
phosphate-buffered saline (PBS) pH 7.4 and fixed in 10% v/v neutral buffered 
formalin maintaining orientation using previously described methods47. 
Tissue preparation and scoring 
Formalin-fixed SI was divided up into proximal, middle and distal thirds and bundled 
using methods previously described47–49. Bundles were routinely processed, 
embedded in paraffin wax in the transverse orientation and 4 µm thick tissue 
sections were stained with haematoxylin and eosin (H&E), direct red 80 (both from 
Sigma, Dorset, UK) or prepared for IHC. 
For the quantification of apoptotic and proliferative intestinal epithelial cells in 
immunostained tissue sections, individual epithelial cells were counted from the 
base of the crypt to the mid-point of the villus tip in 20 well-orientated hemi crypt-
hemi villi at 400× magnification from 6 mice per group (group sizes of 6 were 
estimated to be needed from previous studies to provide appropriate statistical 
power and the scorer was blinded to animal identifier at the time of analysis)17. For 
the quantification of apoptotic and proliferative intestinal epithelial cells in 
immunostained enteroid sections, individual cells were counted in the total 
circumference of 6 whole enteroids from at least 3 independent replicate studies at 
400× magnification. Labelled cells were counted if in continuation with the epithelial 
monolayer. Intestinal epithelial cells were categorised according to the following 
criteria: 
1. Normal if there was no or weak non-specific brown staining. 
2. Apoptotic/mitotic if there was defined positive staining confined to 
cytoplasmic or nuclear borders. 
IHC and histochemical staining 
Tissue and enteroid sections were deparaffinised and rehydrated. Standard 
histochemical techniques were used for H&E, direct red 80 (Sirius red) and alcian 
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blue staining, the latter two being counterstained with haematoxylin to identify 
nuclei for quantification. Immunohistochemically stained slides were subjected to 
1% v/v hydrogen peroxide in methanol to block endogenous peroxidases, followed 
by heat-mediated antigen retrieval in 0.01 M citrate acid buffer (pH 6) and then 
blocked with 1% w/v bovine serum albumin (Sigma, Dorset, UK). Rabbit polyclonal 
primary antibodies against active caspase-3 (AF835; R&D Systems, Abingdon, 
UK), Ki67 (AB15580; Abcam, Cambridge, UK) and olfactomedin-4 (#39141; Cell 
Signalling Technology, UK) were applied at 2.5, 2 and 0.25 μg/mL, respectively to 
sections for 2 h and visualisation was completed using an anti-rabbit Envision kit 
(Dako, Cambridge, UK) polymer followed by peroxidase substrate 3,3′-
diaminobenzidine (DAB) (Sigma, Dorset, UK) using the manufacturer’s instructions. 
Sections were counterstained with haematoxylin. 
Bone marrow-derived dendritic cell extraction and culture 
Femurs and tibias were harvested from male C57BL/6J wild-type mice and were 
mechanically cleaned to remove any surrounding tissues. Bones were transferred 
into 70% v/v ethanol for 2 min to sterilise their outsides. Bones were clipped at the 
top and bottom and a 24 G needle was used to flush out the bone marrow through a 
40 μm cell sieve. Red blood cells were lysed, cells were quantified and 
resuspended in dendritic cell differentiation solution (RPMI containing GM-CSF 
(20 ng/ml), β-mercaptoethanol (50 μM), 10% w/v FCS, 1% w/v glutamine, 1% w/v 
penicillin/streptomycin; all from Sigma, Dorset, UK) in 10 cm petri dishes at a 
concentration of 2.5 × 105/mL and plated at 20 mL/plate. Fresh media was added to 
dishes 4 days following and non-adherent BMDCs were used in experiments 7 days 
following isolation and differentiation. 
BMDC conditioned media was generated by plating BMDCs in complete RPMI 
media as described above at concentrations of 1 × 103, 1 × 104, 1 × 105 BMDC/mL. 
BMDCs were removed from culture media by centrifugation after 48 h and 
supernatants were immediately used in enteroid assays. 
Enteroid culture 
Extraction and culture of SI crypts was carried out as previously described32 with 
modifications as indicated below. Male 10-week-old C57BL/6J mice were killed and 
the SI was rapidly removed and flushed with ice-cold PBS. The most proximal, 
middle and most distal 2 cm segments were isolated separately, opened out 
longitudinally, cut into 1 cm lengths and placed into PBS. Intestinal segments were 
washed 10 times in ice-cold PBS and incubated with ice-cold chelation buffer 
(20 mL of 2 mM EDTA in PBS) at 4 oC with constant gentle agitation for 30 min. 
Chelation buffer was then replaced with 20 mL shaking buffer (43.3 mM sucrose, 
59.4 mM sorbitol; Sigma, Dorset, UK) and shaken gently for 30 s to remove the 
majority of villi. Shaking buffer was replaced with fresh shaking buffer (20 mL) and 
crypts were then detached from the basal membrane by vigorous shaking by hand 
for 2 min. The crypt-enriched supernatant was filtered through a 70 μm cell strainer 
(BD Biosciences Heidelberg, Germany) and quantified using microscopy. The 
filtered crypts were centrifuged at 200 × g (4 °C, 10 min) and resuspended at 
10,000 crypts/mL in Matrigel (BD Biosciences) containing growth factors; epidermal 
growth factor (50 ng/mL), R-spondin-1 (500 ng/mL) and Noggin (100 ng/mL) (R&D 
Systems). Approximately, 500 crypts in 50 μL Matrigel were seeded per well of a 
pre-warmed 24-well flat-bottomed plate and incubated at 37 °C for 10 min to 
polymerise the Matrigel. Finally, 500 μL of minigut culture medium was added to 
each well (advanced DMEM/F12, 1% l-glutamine, 1% Pen/Strep, 10 mM HEPES, 
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10 mM N2 supplement, 50 mM B27 supplement (Invitrogen)) and crypts were 
cultured at 37 °C in a 95% air, 5% CO2 atmosphere. 
All enteroids were passaged at least once prior to use in an experiment. Passage 
was carried out weekly at a 1:4 split ratio. Media was removed and enteroids in 
Matrigel were resuspended in PBS and mechanically dissociated into crypts by 
passing through a 27 G needle. Dissociated enteroids were then centrifuged at 
200 × g (4 oC, 10 min), resuspended in fresh Matrigel containing growth factors and 
plated as above. Culture medium was changed and replaced with new media 
containing growth factors every 4 days. 
Enteroid treatments 
C57BL/6J, Nfκb1−/− and NFκb2−/− enteroids (passage 2–12) were treated 3 days 
following passage by adding murine recombinant TNF (1–1000 ng/mL; PeproTech 
Ltd., London, UK), IFNγ (01–100 ng/mL; Peprotech Ltd.), C57BL/6J BMDCs 
(5 × 104/well) with or without 1 μg/mL LPS diluted in 50% minigut media (containing 
2× growth factors) and 50% complete BMDC media or conditioned media from 
BMDCs. High power images of 3 enteroids/well, conducted in duplicate were taken 
at 0, 24 and 48 h for circularity measurements and enteroids were harvested for 
histological analysis as described below. 
Enteroid histology 
Following treatment with TNF, media was removed and replaced with 500 µL cell 
recovery solution (Corning, New York, USA) and agitated at 4 °C until the Matrigel 
was dispersed. Enteroids were then fixed in 2% v/v neutral buffered formalin. After 
1-h fixation enteroids were centrifuged at 100×g for 1 min. The supernatant was 
discarded and 80–120 µl of pre-warmed HistogelTM (Thermo Scientific, 
Massachusetts, USA) was mixed carefully with enteroids and transferred directly 
onto a section of MicroporeTM surgical tape forming a button when set. Sections of 
tape with Histogel were transferred into embedding cassettes and routinely 
processed and embedded in paraffin wax. Sections of Histogel containing enteroids 
(4 µm thick) were stained with H&E, direct red 80, or prepared for IHC as described 
above. 
Enteroid circularity assessment 
Bright field microscopy was used to monitor enteroid development from crypt 
isolation and throughout subsequent passages and treatments. Images were taken 
using an Axiovert 25 microscope (Zeiss) and a 20× objective lens with a Hitachi 
HV-C20A camera. Enteroid morphology was assessed throughout experiments 
using 2D bright field images and a software-based formula for calculating circularity: 
4π (area)/perimeter2. Two-dimensional images of enteroids were traced (three 
representative images per well conducted in duplicate) and analysis was conducted 
by recording enteroid area, perimeter and circularity using the analyse and measure 
function in ImageJ software50. Circularity values are possible between 0 and 1, with 
a score of 1 indicating a perfect circle. The circularity scoring method was adapted 




Media was removed from enteroids and enteroids in co-culture with BMDCs with 
and without LPS treatment 48 h post culture and centrifuged to remove debris. 
Samples were immediately frozen at −80 °C until further analysis and defrosted only 
once for further usage. Samples were run in duplicate and a multiplexing capable 
analysis platform selected for simultaneous cytokine profiling (QuickPlex SQ 120, 
Meso Scale Discovery, USA). The U-plex mouse cytokine assay system was 
employed for the analysis of a panel of markers as per manufacturer’s instructions. 
Cytokines analysed were: IFNγ, TNF, KC/GRO, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, 
IL-12 p70, IL-15, IL-17, IL-23 and IL-33. Quantitative measurement of each marker 
was achieved using a four-parameter logistic regression method. 
Statistical analysis 
Student’s t tests were carried out on normally distributed data within proximal, 
middle and distal regions of the SI and for cytokine production between LPS-treated 
BMDCs and untreated BMDCs. All additional normally distributed data were 
analysed by one-way ANOVA versus control group followed by Holm–Sidak post 
hoc analysis. Statistical tests that achieved p < 0.05 were considered significant. 
Supplemental Figure legends 
Supplemental figure 1: TNF does not modulate Olfm4 expression in small 
intestine at the time-points tested.  Untreated and TNF treated proximal SI and 
enteroids stained for Olfm4 (a).  Percentage of Olfm4 stained cells in untreated 
(white) and TNF treated (black) proximal, middle and distal small intestine (b). For 
animal study quantified from n=3 mice per group.  
 
Supplemental figure 2: TNF does not reduce goblet cell number at the time-points 
tested.  Proximal SI and enteroids stained with alcian blue (a).  Percentage of alcian 
blue stained goblet cells in untreated (white) and TNF treated (black) proximal, 
middle and distal derived small intestine (top) and enteroids (bottom)(b). For animal 




Supplemental figure 3: TNF activates caspase-8 in the small intestinal epithelium 
but is short lived.  Proximal SI and enteroids stained for active caspase-8.  Arrows 
indicate active caspase-8 positive cells with shedding morphology, and arrow heads 
indicate active caspase-8 positive cells without shedding morphology (a). 
 
 
 
 
 
